
<html lang="en"     class="pb-page"  data-request-id="9433d12e-6aa7-4230-8219-a29abb7302d9"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.6b00908;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2016.59.issue-19"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease" /></meta><meta name="dc.Creator" content="Obdulia  Rabal" /></meta><meta name="dc.Creator" content="Juan A.  Sánchez-Arias" /></meta><meta name="dc.Creator" content="Mar  Cuadrado-Tejedor" /></meta><meta name="dc.Creator" content="Irene  de Miguel" /></meta><meta name="dc.Creator" content="Marta  Pérez-González" /></meta><meta name="dc.Creator" content="Carolina  García-Barroso" /></meta><meta name="dc.Creator" content="Ana  Ugarte" /></meta><meta name="dc.Creator" content="Ander  Estella-Hermoso de Mendoza" /></meta><meta name="dc.Creator" content="Elena  Sáez" /></meta><meta name="dc.Creator" content="Maria  Espelosin" /></meta><meta name="dc.Creator" content="Susana  Ursua" /></meta><meta name="dc.Creator" content="Tan  Haizhong" /></meta><meta name="dc.Creator" content="Wu  Wei" /></meta><meta name="dc.Creator" content="Xu  Musheng" /></meta><meta name="dc.Creator" content="Ana  Garcia-Osta" /></meta><meta name="dc.Creator" content="Julen  Oyarzabal" /></meta><meta name="dc.Description" content="Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). To furthe..." /></meta><meta name="Description" content="Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). To furthe..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 27, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00908" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00908" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00908" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00908" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00908" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0019.jpeg" /></meta><meta property="og:description" content="Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (&gt;1 log unit), and the ability to cross the blood–brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso,&#xA;C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.;&#xA;Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00908"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00908">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00908&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00908&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00908&amp;href=/doi/10.1021/acs.jmedchem.6b00908" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8967-9004</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00905" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00939" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Obdulia++Rabal">Obdulia Rabal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juan+A.++S%C3%A1nchez-Arias">Juan A. Sánchez-Arias</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mar++Cuadrado-Tejedor">Mar Cuadrado-Tejedor</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Irene++de+Miguel">Irene de Miguel</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marta++P%C3%A9rez-Gonz%C3%A1lez">Marta Pérez-González</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carolina++Garc%C3%ADa-Barroso">Carolina García-Barroso</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Ugarte">Ana Ugarte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ander++Estella-Hermoso+de+Mendoza">Ander Estella-Hermoso de Mendoza</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elena++S%C3%A1ez">Elena Sáez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maria++Espelosin">Maria Espelosin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susana++Ursua">Susana Ursua</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tan++Haizhong">Tan Haizhong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wu++Wei">Wu Wei</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xu++Musheng">Xu Musheng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ana++Garcia-Osta">Ana Garcia-Osta</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julen++Oyarzabal">Julen Oyarzabal</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Small Molecule Discovery Platform, Molecular Therapeutics Program, <sup>‡</sup>Neurobiology of Alzheimer’s Disease, Neurosciences Division, Center for Applied Medical Research (CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">WuXi Apptec (Tianjin) Co. Ltd., TEDA, No. 111 HuangHai Road, Fourth Avenue, Tianjin 300456, PR China</span></div><div class="corresp-info"><strong>*</strong>(A. G.-O.) Phone: +34 948 19 47 00, ext 2021. E-mail: <a href="/cdn-cgi/l/email-protection#2342444c50574263564d42550d4650"><span class="__cf_email__" data-cfemail="97f6f0f8e4e3f6d7e2f9f6e1b9f2e4">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>(J. O.) Phone: +34 948 19 47 00, ext 2044. E-mail: <a href="/cdn-cgi/l/email-protection#f79d829b9299988e96858d9695969bb782999681d99284"><span class="__cf_email__" data-cfemail="7f150a131a1110061e0d051e1d1e133f0a111e09511a0c">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00908&amp;href=/doi/10.1021%2Facs.jmedchem.6b00908" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8967–9004</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 8, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 June 2016</li><li><span class="item_label"><b>Published</b> online</span>27 September 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 October 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00908" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00908</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8967%26pageCount%3D38%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DObdulia%2BRabal%252C%2BJuan%2BA.%2BS%25C3%25A1nchez-Arias%252C%2BMar%2BCuadrado-Tejedor%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D19%26contentID%3Dacs.jmedchem.6b00908%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BFirst-in-Class%2BDual%2BActing%2BHistone%2BDeacetylases%2B%2528HDACs%2529%2Band%2BPhosphodiesterase%2B5%2B%2528PDE5%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BAlzheimer%25E2%2580%2599s%2BDisease%26numPages%3D38%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9004%26publicationDate%3DOctober%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00908"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3524</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">50</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00908" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer’s Disease&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Obdulia&quot;,&quot;last_name&quot;:&quot;Rabal&quot;},{&quot;first_name&quot;:&quot;Juan&quot;,&quot;last_name&quot;:&quot;A. Sánchez-Arias&quot;},{&quot;first_name&quot;:&quot;Mar&quot;,&quot;last_name&quot;:&quot;Cuadrado-Tejedor&quot;},{&quot;first_name&quot;:&quot;Irene&quot;,&quot;last_name&quot;:&quot;de Miguel&quot;},{&quot;first_name&quot;:&quot;Marta&quot;,&quot;last_name&quot;:&quot;Pérez-González&quot;},{&quot;first_name&quot;:&quot;Carolina&quot;,&quot;last_name&quot;:&quot;García-Barroso&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Ugarte&quot;},{&quot;first_name&quot;:&quot;Ander&quot;,&quot;last_name&quot;:&quot;Estella-Hermoso de Mendoza&quot;},{&quot;first_name&quot;:&quot;Elena&quot;,&quot;last_name&quot;:&quot;Sáez&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Espelosin&quot;},{&quot;first_name&quot;:&quot;Susana&quot;,&quot;last_name&quot;:&quot;Ursua&quot;},{&quot;first_name&quot;:&quot;Tan&quot;,&quot;last_name&quot;:&quot;Haizhong&quot;},{&quot;first_name&quot;:&quot;Wu&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Xu&quot;,&quot;last_name&quot;:&quot;Musheng&quot;},{&quot;first_name&quot;:&quot;Ana&quot;,&quot;last_name&quot;:&quot;Garcia-Osta&quot;},{&quot;first_name&quot;:&quot;Julen&quot;,&quot;last_name&quot;:&quot;Oyarzabal&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8967-9004&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00908&quot;},&quot;abstract&quot;:&quot;Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (&gt;1 log unit), and the ability to cross the blood–brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00908&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00908" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00908&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00908" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00908&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00908" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00908&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00908&amp;href=/doi/10.1021/acs.jmedchem.6b00908" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00908" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00908" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00908%26sid%3Dliteratum%253Aachs%26pmid%3D27606546%26genre%3Darticle%26aulast%3DRabal%26date%3D2016%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BFirst-in-Class%2BDual%2BActing%2BHistone%2BDeacetylases%2B%2528HDACs%2529%2Band%2BPhosphodiesterase%2B5%2B%2528PDE5%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BAlzheimer%25E2%2580%2599s%2BDisease%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D19%26spage%3D8967%26epage%3D9004%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291304" title="Organic reactions">Organic reactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/jmcmar.2016.59.issue-19/20161013/jmcmar.2016.59.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual <i>in vitro</i> inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for <i>in vivo</i> testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood–brain barrier, leading to the identification of <b>7</b> as a candidate for <i>in vivo</i> proof-of-concept testing (<contrib-group person-group-type="allauthors">Cuadrado-Tejedor, M.; Garcia-Barroso,
C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.;
Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A.</contrib-group> <cite>Neuropsychopharmacology</cite> <span class="NLM_year">2016</span>, in press, doi: 10.1038/npp.2016.163).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20051" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20051" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multitarget drugs have emerged as an innovative therapeutic approach for Alzheimer’s disease (AD) due to the complex etiology of this neurodegenerative disease and its multifactorial progression.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As observed for other conditions (e.g., complex diseases), it is becoming clear that AD therapies should focus on the simultaneous modulation of multiple targets implicated in the disease.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Among these targets, phosphodiesterases (PDEs)<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and epigenetic targets, primarily histone deacetylases (HDACs),<a onclick="showRef(event, 'ref3 ref4 ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5 ref6">(3-6)</a> have recently attracted much potential therapeutic interest to restore memory function.</div><div class="NLM_p">PDEs hydrolyze the second messengers cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) and are extensively distributed in the brain.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In fact, PDE5, a cGMP-specific phosphodiesterase, is up-regulated in the brains of AD patients compared with that in age-matched healthy control subjects.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Consequently, cGMP levels, but not cAMP levels, are significantly decreased in the cerebrospinal fluid (CSF) of AD patients when compared with that in nondemented controls.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Inhibition of phosphodiesterase-5 (PDE5), a cGMP-specific phosphodiesterase, elevates cGMP levels, which may ultimately promote gene transcription by directly and/or indirectly activating CREB.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Moreover, by favoring the inactive form of GSK3β (phosphorylated at GSK3β-Ser9), PDE5 inhibition decreases levels of phosphorylated Tau (pTau).<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Specific PDE5 inhibitors (sildenafil <b>1</b>, vardenafil <b>2</b>, and tadalafil <b>3</b>, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) approved for the treatment of erectile dysfunction and pulmonary arterial hypertension<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> have been shown to improve memory performance and/or enhance synaptic plasticity and cognitive function in different animal models of AD.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9-11)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Known PDE5 Inhibitors Shown to Improve Memory (<b>1</b>, <b>2</b>, and <b>3</b>), HDAC Inhibitors (<b>4</b>, <b>5</b>, and <b>6</b>), and the Structure of a Novel Therapeutic Tool <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Chart a</span>PDE5 IC<sub>50</sub> inhibition values were taken from ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a> for <b>1</b>, <b>2</b>, and <b>3</b>. HDAC inhibition IC<sub>50</sub> values for <b>4</b> were extracted from ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>, values for <b>5</b> extracted from ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>, and values for <b>6</b> extracted from ref <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">31</a>.</p></p></figure><div class="NLM_p">Histone deacetylases (HDACs) comprise a family of 18 genes in humans and are divided into four groups: class I (HDACs 1, 2, 3, and 8), class IIa (HDACs 4, 5, 7, and 9), class IIb (HDACs 6 and 10), and class IV (HDAC11). HDACs are epigenetic modulators that deacetylate lysine residues in histone and nonhistone substrates. Although already a proven strategy for the treatment of cancers,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> inhibition of HDACs has attracted much interest for the treatment of neurodegenerative disorders<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> in recent years, with class I HDACs and HDAC6 being implicated in AD memory-related dysfunction. Class I HDACs, particularly HDAC2, predominantly localize in the nucleus and reduce the transcription of CREB-regulated genes that are important for learning and memory,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> and HDAC1 activity may be neuroprotective.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Notably, HDAC2 and HDAC6 are overexpressed in the cortex and hippocampus of AD patients, although the cause and effect of this up-regulation remain unknown.<a onclick="showRef(event, 'ref14 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref16">(14, 16)</a> Chronic treatment with suberoylanilide hydroxamic acid <b>4</b> (SAHA; vorinostat, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), a clinically approved pan-HDAC inhibitor for the treatment of cutaneous T cell lymphoma (CTCL), enhanced memory in animal models.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> HDAC6, the major cytoplasmatic deacetylase in mammalian cells, targets α-tubulin, among other proteins. Increasing α-tubulin acetylation via HDAC6 inhibition may facilitate the amelioration of tau<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a> and amyloid pathologies<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> by promoting tau clearance and decreasing Aβ levels, respectively.</div><div class="NLM_p last">In this context, we have recently demonstrated the beneficial synergistic effects of concomitant HDAC and PDE5 inhibition in the Tg2576 murine model of AD using <b>3</b> and the pan-HDAC inhibitor <b>4</b>, thereby establishing the basis for a potential new symptomatic and disease-modifying strategy to treat AD.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> On the basis of these results and considering that (i) toxicity is associated with the strong inhibition of HDAC class I isoforms;<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> (ii) simultaneous inhibition of HDAC and PDE5 exerts a synergistic effect on histone acetylation,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and thus, strong inhibition of HDAC class I is not required; (iii) histone acetylation in conjunction with CREB activation, achieved through PDE5 inhibition, may facilitate the transcription of specific memory-related genes;<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (iv) inhibition of HDAC6 does not affect cell survival<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and may facilitate the degradation of misfolded proteins (such as Aβ and pTau);<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> (v) HDAC inhibitors show poor permeability<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> and brain availability;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and (vi) a single agent does not lead to the additive toxicity that is often observed with combination therapy,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> our next step was to obtain brain-penetrating dual inhibitors with moderate HDAC class I activity as well as potent HDAC6 and PDE5 inhibition. Thus, we set out with the goal of designing novel dual PDE5 and HDAC inhibitors with the appropriate profiles for potency, selectivity, and pharmacokinetic properties to consider for <i>in vivo</i> testing in AD mouse models. Compound <b>7</b> (CM-414, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>) fulfilled these requirements in terms of primary activities (IC<sub>50</sub> values of 60 nM, 310 nM, 490 nM, 322 nM, and 91 nM against PDE5, HDAC1, HDAC2, HDAC3, and HDAC6, respectively), crossing the blood–brain barrier (BBB), inducing AcH3K9 acetylation and CREB phosphorylation in the hippocampus and rescuing long-term potentiation (LTP) in APP/PS1 mice. With additional consideration of its adequate ADME and pharmacokinetic profiles, <b>7</b> was selected for <i>in vivo</i> proof-of-concept (PoC) testing.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In this article, we present a detailed account of the discovery of this novel first-in-class chemical series with dual acting PDE5 and HDAC inhibitory activities, from initial hits (e.g., <b>13a</b>) to lead identification (<b>7</b>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65084" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65084" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Rational Design</h3><div class="NLM_p">One interesting approach to generate multivalent ligands is to combine key structural features facilitating binding to HDAC and PDE into one molecule to obtain a new chemical entity; however, this is not a straightforward procedure, and we must identify the appropriate common features, substitution sites, and growing vectors to maintain primary activities without interference. Indeed, in this particular case, given the structures of both protein families (see below), the design process goes one step further than simply incorporating the pharmacophoric features of HDAC inhibitors (HDACi) and PDE inhibitors into one molecule as the sum of two parts to obtain a single agent with dual activity. This strategy has been particularly useful to derive bifunctional HDACi anticancer agents due to the presence of large hydrophobic patches at the HDAC surface rim.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> We envisioned using the sildenafil central core to append HDAC pharmacophores.</div><div class="NLM_p">However, before commencing any design and synthetic efforts around the sildenafil scaffold, we confirmed that the synergestic effects achieved by <b>3</b> and <b>4</b><a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> on the induction of histone 3 acetylation at lysine 9 (AcH3K9) are mechanism-of-action (MoA)-dependent; then, a combination of <b>4</b> and <b>1</b> was tested and quantified using AlphaLisa technology in the SH-SY5Y neuroblastoma cell line. After treating cells with 50 nM of <b>4</b>, AcH3K9 marks increased by 1.5-fold compared to nontreated cells (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), and this induction was significantly stronger (<i>P</i> value <0.01) when combined with concentrations of <b>1</b> higher than 400 nM (1.95-fold change over vehicle-treated cells at 400 nM of compound <b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><figure id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Detection of AcH3K9 assayed using SH-SY5Y cells and AlphaLisa technology. SH-SY5Y cells were treated with <b>4</b> and <b>1</b> for 2 h (** <i>p</i> ≤ 0.01, ***<i>p</i> ≤ 0.001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Once the synergistic effect between <b>4</b> and <b>1</b> was confirmed, our design strategy commenced. Typically, the classical pharmacophore for HDACi consists of a hydrophobic recognition capping group (also known as a surface recognition motif) that is able to interact with the rim of the catalytic tunnel, a zinc-binding group (ZBG) that is able to complex the Zn<sup>2+</sup> ion at the bottom of the catalytic cavity and a hydrophobic linker connecting the two parts along the 11-Å hydrophobic channel.<a onclick="showRef(event, 'ref12 ref33'); return false;" href="javascript:void(0);" class="ref ref12 ref33">(12, 33)</a> There are various ZBGs for HDACi, including hydroxamic acids, aminobenzamides, carboxylates (short-chain fatty acids), electrophilic ketons, thiols, mercaptoacetamides, and 3-hydroxypyridin-2-thiones.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Initially and for this proof-of-concept series, the hydroxamic moiety was chosen as a ZBG because it is one of the most well-established functionalities for chelating the zinc ion at the catalytic site of HDACs. Examination of the crystal structure of <b>1</b> bound to PDE5 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TBF">1TBF</a>,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a><a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A) suggested that linking the hydroxamic moiety to the methylpiperazine would project this ZBG substituent into the solvent region and be well tolerated from a potency perspective. From the viewpoint of HDAC inhibitory activity, the sildenafil core would serve as a cap group. As a straightforward strategy for HDACi linker design, different linker moieties contained in reported potent HDAC inhibitors were analyzed in the context of the structure of HDAC2 complexed with <b>4</b> (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a>,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>B), considering the 11-Å cavity length.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0004.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>1</b> in the PDE5 cavity (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TBF">1TBF</a><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>). The pyrazolopyrimidinone group of <b>1</b> makes bidentate H-bonds with the conserved Q817. The piperidinylsulfonamide group is solvent-oriented toward the H-loop region (residues 660–683). (B) Complex of <b>4</b> and HDAC2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>). The NH of the amide group of <b>4</b> makes an H-bond contact with the well-conserved residue Asp104 of HDAC2 (Asp99 for HDAC1 and Asp567 for HDAC6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This combination of structure-based and knowledge-based approaches, together with consideration to synthetic accessibility, enabled the rapid design of potential dual PDE5/HDAC inhibitors. We envisioned attaching the following to the piperidinylsulfonamide group of <b>1</b>: flexible alkyl linkers of varying lengths as in compound <b>4</b>, a cinnamic hydroxamic acid analogue as in <b>5</b>,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and pyrimidylhydroxamic acids as in <b>6</b>,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> resulting in novel N-4-substituted-piperazine derivatives <b>13a</b>–<b>13d</b> as potential dual PDE5/HDAC inhibitors. These compounds were synthesized from commercially available 5-(2-ethoxyphenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>8</b>) (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Selective sulfonylation at the 5′-position of the phenyl ring afforded <b>9</b>, which was converted into esters <b>10a</b>–<b>10d</b> via reactions with appropriated amines. Then, the corresponding carboxylic acids were obtained through hydrolysis and transformed into the THP-protected hydroxamic acids <b>12a</b>–<b>12d</b> by reacting with <i>O</i>-(tetrahydro-2<i>H</i>-pyran-2-yl)hydroxylamine (THPONH<sub>2</sub>) using EDC/HOBt as the coupling system. Final deprotection under acidic conditions afforded us the desired compounds <b>13a</b>–<b>13d</b>.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) ClSO<sub>3</sub>H, rt, 2 h; (ii) corresponding amine, Et<sub>3</sub>N (optional), EtOH, MW, 100 °C, 1–2 h; (iii) ethyl 3-bromopropanoate or ethyl 4-bromobutanoate, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, MW, 100 °C, 2 h; (iv) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (10:1:5), rt, overnight; (v) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (vi) HCl/1,4-dioxane (2.0 M), 1,4-dioxane or CH<sub>2</sub>Cl<sub>2</sub> (optional) rt, 3 h.</p></p></figure><div class="NLM_p">Compounds <b>13a</b>–<b>13d</b> were evaluated for their inhibition against PDE5, HDAC1, HDAC2, and HDAC6 activity (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Purified full-length recombinant human HDAC proteins were used to monitor HDAC activity (HDAC1, 2, and 6 were routinely included in our screening funnel, and HDAC3 activity was evaluated for selected compounds). As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, all of these compounds are potent PDE5 inhibitors, with IC<sub>50</sub> values in the low nanomolar range (2–3 nM), comparable to <b>1</b> (IC<sub>50</sub> is 8.5 nM<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> or 4 nM in our assay setup, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>). Moreover, these compounds exhibit HDAC inhibitory activity with different profiles for potency and isoform selectivity, validating our initial hypothesis to design dual PDE5/HDAC inhibitors. Alkyl (<b>13a</b>, <b>13b</b>) linkers resulted in low micromolar or midnanomolar inhibitors (<b>13b</b> against HDAC6). The comparison of <b>13a</b> with <b>13b</b> suggests that increasing the length of the linker may have a positive effect on the HDAC activities of the three isoforms. However, due to the size of these derivatives, this strategy was not further contemplated. The cinnamic derivative <b>13d</b> showed similar potency against HDAC1 and HDAC2 compared to alkyl derivatives but a remarkable potency against HDAC6 (IC<sub>50</sub> value of 89 nM), with >1 log units of selectivity over the class I HDACs (HDAC1 and HDAC2). Conversely, the pyrimidylhydroxamic <b>13c</b> showed excellent potency against HDAC1 (IC<sub>50</sub> of 8 nM), comparable to that of the standard compound <b>4</b> (IC<sub>50</sub> of 30 nM, <a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>), and HDAC2 (117 nM) and less potency against HDAC6 (268 nM). The suitable potency of this pyrimidylhydroxamic moiety against class I HDAC isoforms has also been previously reported for <b>6</b> and related analogues.<a onclick="showRef(event, 'ref31 ref37'); return false;" href="javascript:void(0);" class="ref ref31 ref37">(31, 37)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial Set of Potential PDE5/HDAC Inhibitors Bearing a Sulfonamide Moiety<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0013.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0014.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">*: HDAC3_NCOR2 values obtained at BPS.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Hit Explosion. Exploring the 5′-Position of the Phenyl Ring of Compound <b>1</b> (R1 at 1′) and SAR Analysis</h3><div class="NLM_p">Encouraged by these early <i>in vitro</i> results for our dual acting compounds that were initial hits, our strategy focused on identifying molecules with previously defined primary activities (moderate HDAC class I as well as potent HDAC6 and PDE5 inhibitors) that were CNS-penetrating. The physicochemical properties of compounds <b>13a</b>–<b>13d</b> are far outside the traditional range for CNS drugs, with high topological surface areas (TPSA > 90 Å<sup>2</sup>) and high molecular weights (MW > 450).<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> Thus, we sought to explore different alternatives for the piperidinylsulfonamide group of compound <b>1</b>, not only to optimize potency and examine different <i>in vitro</i> HDAC inhibitory profiles but also to obtain derivatives that demonstrated a reduced polar surface area to derisk poor blood–brain barrier (BBB) penetration.</div><div class="NLM_p">From the viewpoint of PDE5 activity, based on the crystal structure of compound <b>1</b> bound to PDE5 (<a class="ref internalNav" href="#notes-2" aria-label="Figure S1">Figure S1</a>) and the previous analysis of structure–activity relationships (SAR),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> the piperidinylsulfonamide group of compound <b>1</b> is not essential for potent PDE5 inhibition. Moreover, several published complexes of ligands <b>1</b><a onclick="showRef(event, 'ref35 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref35 ref42 ref43">(35, 42, 43)</a> and <b>2</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> with PDE5 have exhibited significantly different orientations of the methylpiperazine portion of both ligands, stressing the potential of PDE5 to accommodate different substituents at this region. Thus, our SAR strategy to effectively balance dual PDE5/HDAC potency, differential selectivity profiles versus HDACs and ADME properties focused on (i) exploring different attachment points (connecting bonds) and enabling different geometries at the 5′-position of the phenyl ring of molecule <b>1</b> (sulfonamide-, amine-, ether-, and carbon-linked substituents) as well as (ii) varying the substituents acting as HDAC linkers to occupy the catalytic channel between the ZBG and the surface recognition motif of HDACi (that corresponds to the sildenafil core, acting as a driving force for PDE binding). Moreover, in this case many analogues can be easily synthesized due to the selectivity of electrophilic attack on the 5′-position of the phenyl ring of intermediate <b>8</b>.</div><div class="NLM_p">As a first initial exploration, the sulfonamide linker was retained with variations in the piperidinyl ring designed to (i) increase its hydrophobicity by removing the positively charged nitrogen (<b>13e</b>) and (ii) increase the flexibility between the sildenafil core (capping group) and the hydrophobic linker binding in the HDAC catalytic channel by introducing a secondary sulfonamide as an attachment point (<b>13f</b>), together with increasing the planarity of the HDACi linker by removing the piperidinyl group (<b>13g</b>). The synthesis of these compounds was performed as previously described for hydroxamic acids <b>13a</b>–<b>13d</b> by coupling benzenesulfonyl chloride (<b>9</b>) with appropriated amines (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), and the <i>in vitro</i> evaluation is listed in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. These three derivatives (<b>13e</b>–<b>13g</b>) resulted in potent HDAC6 inhibitors with IC<sub>50</sub> values <100 nM. Concerning class I HDACs, derivatives <b>13e</b> and <b>13g</b> exhibited enhanced potency (with IC<sub>50</sub> values of approximately 400 nM against HDAC1) compared to that of their less-hydrophobic parent compounds <b>13a</b> and <b>13d</b> (with IC<sub>50</sub> ≥ 1300 nM against HDAC1), suggesting that a positively charged amine at this position of the class I HDAC channel is not well tolerated. Conversely, the secondary sulfonamide bearing a pyrimidylhydroxamic group <b>13f</b> was less potent against HDAC1 compared to the privileged substructure conferring potent class I HDAC activity in <b>13c</b> (57 nM versus 8 nM; 0.8 log units). As expected, all of these modifications exerted minor influences on PDE5 activity.</div><div class="NLM_p">We next examined a variety of heteroatom (nitrogen and oxygen) bonded substituents at the 5′-position of the phenyl ring of compound <b>1</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>): secondary amines (<b>21a</b>–<b>21e</b>), linear tertiary amines (<b>21f</b>), cyclic tertiary amines (<b>30a</b>–<b>30e</b>), and ethers (<b>30f</b>, <b>30g</b>, <b>37</b>). Together with the heteroatom connection, a variety of alkyl (<b>21a</b>, <b>30a</b>, <b>30b</b>)-, cycloalkyl (<b>21b</b>, <b>30f</b>)-, phenyl (<b>30g</b>)-, piperidylphenyl (<b>21c</b>)-, piperidylpyrimidine (<b>21d</b>, <b>21e</b>, <b>21f</b>)-, and nitrogen-bonded spiro substituents (<b>30c</b>, <b>30d</b>, <b>30e</b>) (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) were selected to cover a large variety of hydrophobic, electronic, and steric properties that might result in different HDAC profiles, as previously obtained for compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Heteroatom-Bonded Substituents as Dual PDE5/HDAC Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0015.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0016.gif" alt="" id="fx4" /></img><div></div></div><div class="NLM_p">Amines <b>21a</b>–<b>21f</b> were synthesized as illustrated in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Intermediate <b>8</b> was converted into amine <b>15</b> via nitration and reduction of the nitro group. Then, esters <b>18a</b>–<b>18f</b> were obtained through reductive amination (and subsequent BOC-deprotection and coupling with ethyl 2-chloropyrimidine-5-carboxylate in the case of esters <b>18d</b>, <b>18e</b>, and <b>18f</b>). These intermediates were transformed into the desired hydroxamic acids via ester hydrolysis, reaction with THPONH<sub>2</sub>, and acidic cleavage of the protecting group.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) H<sub>2</sub>SO<sub>4</sub>, KNO<sub>3</sub>, 0 °C, 20 min; (ii) Pd/C, H<sub>2</sub> (1 atm), MeOH, rt, overnight; (iii) corresponding carbonyl compound, AcOH, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (iv) 3,3-dimethoxypropanoate, TFA, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (v) paraformaldehyde, AcOH, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 60 °C, overnight; (vi) HCl/EtOAc (1.0 or 4.0 M), rt, 1–4 h; (vii) K<sub>2</sub>CO<sub>3</sub>, ethyl 2-chloropyrimidine-5-carboxylate, CH<sub>3</sub>CN, 40 °C, overnight; (viii) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2 or 3:1:1), 25–40 °C, overnight; (ix) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight.</p></p></figure><div class="NLM_p">The synthesis of tertiary amines <b>30a</b>–<b>30e</b> and ethers <b>30f</b> and <b>30g</b> was performed as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> from iodure <b>22</b>. This compound was transformed into boronic acid <b>26</b>, and then esters <b>27b</b>–<b>27g</b> were obtained through reactions with different amines or alcohols. Conversely, ester <b>27a</b> was synthesized from iodure <b>22</b> after Buchwald–Hartwig amination with 1,4-dioxa-8-azaspiro[4.5]decane, acidic deprotection, Horner–Wadsworth–Emmons reaction with methyl 2-diethoxyphosphorylacetate, and reduction of the double bond under H<sub>2</sub>. Finally, hydroxamic acids <b>30a</b>–<b>30g</b> were prepared from esters <b>27a</b>–<b>27g</b> employing the strategy previously described.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions (i) NIS, TFA, 0 °C, then rt, overnight; (ii) <i>t</i>-BuOK, Pd<sub>2</sub>(dba)<sub>3</sub>, 1,4-dioxa-8-azaspiro[4.5]decane, xantphos, toluene, 120 °C, MW, 1 h; (iii) HCl/THF (6.0 M), 70 °C, overnight; (iv) methyl 2-diethoxyphosphorylacetate, NaH, THF, 0 °C, 1 h, then <b>24</b>, rt, overnight; (v) Pd/C, MeOH, H<sub>2</sub> (1 atm), rt, 3 h; (vi) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane, PdCl<sub>2</sub>(dppf), KOAc, 1,4-dioxane, 80–100 °C, 48 h; (vii) NaIO<sub>4</sub>, NH<sub>4</sub>OAc, acetone, 25 °C, 16 h; (viii) corresponding alcohol or amine, Cu(OAc)<sub>2</sub>, Et<sub>3</sub>N, DMAP (optional), 4 Å MS, CH<sub>2</sub>Cl<sub>2</sub>, O<sub>2</sub> (1 atm), rt, 2–12 h; (ix) HCl/EtOAc (1.0, 2.0, or 4.0 M), rt, 1–2 h; (x) K<sub>2</sub>CO<sub>3</sub>, ethyl 2-chloropyrimidine-5-carboxylate, CH<sub>3</sub>CN, 60 °C, overnight; (xi) LiOH·H<sub>2</sub>O, MeOH/THF/H<sub>2</sub>O (3:1:3, 1:3:1, 3:3:2), rt, overnight; (xii) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight.</p></p></figure><div class="NLM_p">The synthetic route for ether <b>37</b> with a pyrimidyl group is outlined in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Starting from boronic ester <b>25</b>, alcohol <b>31</b> was obtained by oxidation. Then, ether <b>32</b> was prepared by the Mitsunobu reaction. Acidic removal of the BOC protecting group led us to amine <b>33</b>, which was coupled with ethyl 2-chloropyrimidine-5-carboxylate. The resulting ester, <b>34</b>, was converted into the carboxylic acid <b>35</b>, which was finally transformed in the desired hydroxamic acid <b>37</b> via the THP-protected intermediate <b>36</b>.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0009.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) NaOH (aq, 4.0 M), H<sub>2</sub>O<sub>2</sub>, H<sub>2</sub>O, rt, overnight; (ii) <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate, PPh<sub>3</sub>, DEAD, toluene, 110 °C, 1 h; (iii) HCl/1,4-dioxane (4.0 M), rt, 1–2 h; (iv) ethyl 2-chloropyrimidine-5-carboxylate, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, rt, 3 h; (v) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (10:1:3), rt, overnight; (vi) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight.</p></p></figure><div class="NLM_p">Regarding PDE5 activity, all compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> retained potent activities in the low nanomolar range (IC<sub>50</sub> < 75 nM); however, the replacement of the sulfonamide group tended to result in a slight decrease in the potency for PDE5 compared to that of <b>1</b>, particularly for compounds <b>21a</b>, <b>30a</b>, <b>30d</b>, and <b>30e</b>, which exhibited >1 log unit of decreased potency.</div><div class="NLM_p">As anticipated, diverse responses in HDAC activity were observed for the compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. This differential HDAC inhibitory profile is largely attributable to the nature of the linker groups bearing the hydroxamic acid, predictably lying deep in the hydrophobic catalytic channel of the HDACs, rather than due to the influence of the heteroatom attached to the sildenafil core, closer to the rim surface according to the proposed binding mode. Thus, differences of low significant in terms of inhibitory activity against the three isoforms (HDAC1, HDAC2, and HDAC6) are observed when comparing the secondary amines <b>21b</b> (5980 nM, > 20000 nM, and 12700 nM) and <b>21e</b> (118 nM, 712 nM, and 709 nM) with their corresponding ether-linked matched pairs <b>30f</b> (2440 nM, 9830 nM, and 2330 nM) and <b>37</b> (66 nM, 432 nM, and 373 nM), although a preference for the more liphophilic ethers can be acknowledged.</div><div class="NLM_p">Concerning the linkers entering deep into the HDAC catalytic channel, the class I HDAC potency trend toward pyrimidylhydroxamic acids was replicated in the case of nitrogen- and oxygen-bonded variants (<b>21d</b>–<b>21f</b>, <b>30e</b>, <b>37</b>). These analogues were the most potent compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> against HDAC1 and HDAC2 isoforms, with IC<sub>50</sub> values close to or below 100 nM for HDAC1 and in the midnanomolar range for HDAC2 and HDAC6, with the exception of the spiro-linked pyrimidylhydroxamic <b>30e</b>, which exhibited reduced potency against the three isoforms, likely due to conformational constraints to achieve optimal chelation geometry. The impact of this pyrimidyl group for HDAC activity is clearly recognized when replacing it (<b>21d</b>) with a phenyl group (<b>21c</b>); derivative <b>21c</b> demonstrated decreased potency against HDAC1, HDAC2, and HDAC6 by more than 2, 1.5, and 0.5 log units, respectively. The good potency of the pyrimidyl group could not be attributed to a plausible explicit hydrogen-bond contact between any nitrogen of the pyrimidine ring and HDAC residues in the catalytic pocket. Additionally, the catalytic channel of the three isoforms is highly conserved such that this class selectivity can be attributed to a particular residue. The decreased p<i>K</i><sub>a</sub> of the hydroxamic group (from 8.73 in <b>21c</b> to 7.83 in <b>21d</b>, as calculated with Pipeline Pilot<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a>) might play a role in the good class I potency of the pyrimidyl group, although it does not definitively explain the selectivity profile.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Conversely, small linear alkyl (<b>21a</b>, <b>30a</b>, <b>30b</b>) and cycloalkyl (<b>21b</b>, <b>30f</b>) derivatives were weak micromolar HDAC inhibitors or even inactive against HDAC2 (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), although increasing the flexible chain length tended to improve HDAC1 and HDAC2 potency compared to that of shorter linkers (e.g., compare <b>30b</b> with <b>30a</b>). Conformationally constrained spiros (<b>30c</b>, <b>30d</b>) exhibited no improvement in HDAC potency. Among the derivatives in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, the optimal linker for HDAC6 was the small phenyl group of <b>30g</b>, which had an IC<sub>50</sub> value of 196 nM. Replacement of the planar phenyl ring in <b>30g</b> by the cyclohexyl in derivative <b>30f</b> was detrimental for HDAC inhibitory activity, particularly for HDAC6 (IC<sub>50</sub> of <b>30f</b> of 2330 nM). This fully agrees with previous findings regarding the preference of HDAC6 isoforms for aromatic groups over alkyl groups<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and inspired us to guide the rational design of HDAC6 selective inhibitors (manuscript in preparation). The hydrophobic nature of the tunnel channel, flanked by Phe150 in HDAC1 (Phe155 and Phe620 for HDAC2 and HDAC6, respectively) and Phe205 in HDAC1 (Phe210 and Phe680 for HDAC2 and HDAC6, respectively) as well as the different conformation of the hydroxamic acid group for optimal bidentate coordination with Zn metal might explain the preference for phenyl over cyclohexyl linkers. In summary, despite their reduced polar surface area, compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> showed no clear HDAC improvement <i>in vitro</i> compared to that of compounds in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_p">The next stage of our SAR exploration focused on carbon-linked substituents at the 5′-position of the phenyl ring (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>) covering both linear alkyl chains (<b>48a</b>, <b>48b</b>) and methylene-homologated rings (<b>7</b>, <b>48c</b>–<b>48m</b>, <b>52a</b>, <b>52b</b>) as well as more rigid derivatives with carbon-bonded rings at the 5′ position (<b>48n</b>–<b>48o</b>, <b>52c</b>–<b>52f</b>). Additionally, the hydroxamic moiety was directly attached to the phenyl ring of sildenafil (<b>42</b>), resulting in an inactive derivative against HDAC2 and HDAC6 and low affinity for HDAC1 (IC<sub>50</sub> of 6420 nM, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). According to our modeling studies, the ethoxyphenyl ring and sildenafil core causes steric clashes that prevent optimal positioning of the ZBG within the HDAC cavity. This compound, <b>42</b>, was prepared from bromide <b>38</b> via reaction with Pd(dppf)<sub>2</sub>Cl<sub>2</sub> and Et<sub>3</sub>N in EtOH under a CO atmosphere, ester hydrolysis, treatment with THPONH<sub>2</sub>, and acidic removal of the THP-protecting group (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of Carbon-Linked Dual PDE5/HDAC Inhibitors</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0017.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0018.gif" alt="" id="fx6" /></img><div></div></div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) Br<sub>2</sub>, AcOH, rt, overnight; (ii) Pd(dppf)Cl<sub>2</sub>, Et<sub>3</sub>N, EtOH, CO (atm), 80 °C, overnight; (iii) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:1:1), 40 °C, overnight; (iv) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (v) HCl/EtOAc (4.0 M), rt, 1 h.</p></p></figure><div class="NLM_p">Hydroxamic acids <b>48a</b>–<b>48o</b> and <b>7</b> were synthesized as illustrated in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. In this case, bromine <b>38</b> and iodine <b>22</b> were employed as starting materials to prepare esters <b>43a</b>–<b>43m</b> and <b>43o</b>–<b>43p</b>. Esters <b>43a</b> and <b>43d</b>–<b>43g</b> were obtained from bromide <b>38</b> through a Negishi reaction or Suzuki coupling. Intermediates <b>43b</b>, <b>43h</b>–<b>43k</b>, and <b>43p</b> were prepared from iodide <b>22</b> by different methods. The key intermediate <b>22</b> was also transformed into aldehyde <b>45</b>, and then ester <b>43c</b> could be synthesized. Esters <b>43l</b>, <b>43m</b>, and <b>43o</b> were also prepared from aldehyde <b>45</b>, in this case via reductive amination, aldolic condensation, and cyclopropanation, respectively. Then, carboxylic acids <b>46a</b>–<b>46m</b> and <b>46o</b>–<b>46p</b> were isolated as previously described after reaction with LiOH. Conversely, carboxylic acid <b>46n</b> was directly obtained from iodide <b>22</b> after reaction with ethyl 2-formylcyclopropanecarboxylate and reduction with Et<sub>3</sub>SiH. Finally, the desired hydroxamic acids <b>48a</b>–<b>48o</b> and <b>7</b> were achieved through a THP-protected intermediate or by direct reaction with NH<sub>2</sub>OH hydrochloride.</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) bromo-(2-ethoxy-2-oxo-ethyl)zinc, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, THF, 80 °C, overnight; (ii) corresponding borane reagent, xantphos, Na<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (10:1, 6:1 or 5:1), reflux, overnight; (iii) HCl/EtOAc (0.2, 1.0, 2.0, or 4.0 M), 0–25 °C, 1–3 h; (iv) corresponding chloride, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 40–100 °C, overnight; (v) CAN, ethyl prop-2-enoate, DIEA, 80 °C, overnight; (vi) (4-methoxycarbonylphenyl)boronic acid, Cu(OAc)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, O<sub>2</sub> (1 atm), rt, overnight; (vii) ethyl acrylate, POT, Et<sub>3</sub>N, DMF, 100 °C, overnight; (viii) Pd/C, H<sub>2</sub> (1 atm), MeOH, rt, overnight; (ix) <i>n</i>-BuLi, THF, −70 °C, 10 min, then −40 °C, 1 h, then ethyl 2-formylcyclopropanecarboxylate, rt, 15 h; (x) TFA, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then rt, 10 h; (xi) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 °C, overnight; (xii) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then rt, overnight; (xiii) <i>tert</i>-butyl piperazine-1-carboxylate, Ti[OCH(CH<sub>3</sub>)<sub>2</sub>]<sub>4</sub>, toluene, rt, 90 min, then NaBH(OAc)<sub>3</sub>, rt, overnight; (xiv) corresponding amine, AcOH, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (xv) ethyl 2-diethoxyphosphorylacetate, NaH, THF, 0 °C, 1 h, then <b>45</b>, rt, overnight; (xvi) trimethyloxosulfonium iodide, NaH, DMSO, 40 °C, 12 h; (xvii) LiOH·H<sub>2</sub>O, MeOH/THF/H<sub>2</sub>O (1:3:1 or 3:3:2), rt or 40 °C, overnight; (xviii) <i>n</i>-BuLi, THF, −70 °C, then −40 °C, 1 h, then <i>tert</i>-butyl 3-oxocyclobutanecarboxylate, rt, 15 h; (xix) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (xx) BOP, DIEA, NH<sub>2</sub>OH·HCl, DMF, 80 °C, overnight; (xxi) SFC separation.</p></p></figure><div class="NLM_p">Hydroxamic acids <b>48i1</b> and <b>48i2</b> (trans and cis isomers) were obtained directly after preparative HPLC purification of the crude reaction mixture. Conversely, hydroxamic acids <b>7a</b> and <b>7b</b> (cis and trans isomers too) could be isolated after supercritical fluid chromatography (SFC), although the stereochemistry of these two pairs of isomers could not be confirmed and was randomly assigned.</div><div class="NLM_p">A similar synthetic route was used to prepare compounds <b>52a</b>–<b>52f</b>. As shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>, ester functionality was conferred via the reaction of boronic ester <b>25</b> with the appropriated bromide, chloride, or triflate and subsequent hydrogenation in the case of ester <b>49f</b>. Then, a three-step protocol (hydrolysis, reaction with THPONH<sub>2</sub> and acidic deprotection) led us to the desired hydroxamic acids <b>52a</b>–<b>52f</b>.</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0012.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) corresponding bromide, chloride or triflate, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (5:2) or 1,4-dioxane, 85 °C, MW, 1 h, or conventional heating, 80 °C, overnight; (ii) Pd/C, H<sub>2</sub> (1 atm), MeOH, rt, 1 h; (iii) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2 or 3:1:1), rt, overnight; (iv) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (v) HCl/EtOAc (2.0 or 4.0 M) or HCl/1,4-dioxane (4.0 M), rt, 1 h.</p></p></figure><div class="NLM_p">As with previous attachment points and connections at the 5′ position, reported in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>, short linear alkyl chains (<b>48a</b>, <b>48b</b>) and homologated arylalkyl chains (<b>52a</b>, <b>52b</b>) resulted in weak micromolar (HDAC1 and HDAC6) and even inactive HDAC2 compounds. Strikingly, the methylene-linked cinnamic derivative <b>52b</b> was far less potent against HDAC6 (IC<sub>50</sub> of 1790 nM) than the corresponding sulfonamide-linked derivatives <b>13d</b> and <b>13g</b> as shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> (with HDAC6 IC<sub>50</sub> values of 89 and 84 nM, respectively), likely as a result of the different positioning of the sildenafil capping group on the surface area due to the different geometries of the connecting bonds.</div><div class="NLM_p">Once again, the influence of the pyrimidylhydroxamic moiety on class I activity was clearly recognized for compounds <b>48c</b> and <b>48d</b> (IC<sub>50</sub> values of 14 and 63 nM for HDAC1 and 89 and 335 nM for HDAC2, respectively). Regarding the nitrogen-linked pair (<b>21d</b> versus <b>21c</b>), replacement of the pyrimidine ring (<b>48d</b>) by pyridine (<b>48e</b>) and phenyl (<b>48f</b>) progressively decreased HDAC activity against the three isoforms, in agreement with a trend toward increased basicity of the p<i>K</i><sub>a</sub> of the hydroxamic acid group (7.85 <b>48d</b> > 8.29 <b>48e</b> > 8.73 <b>48f</b>). The role of the heteroatom connecting the ethoxyphenyl ring of sildenafil to the linker moiety exerted a minor influence; derivatives <b>21d</b> (−NH−), <b>37</b> (-O−), and <b>48d</b> (−CH<sub>2</sub>−) exhibited similar potencies (<0.3 log units difference) against HDAC1 (<100 nM) and HDAC2 (300–500 nM). For HDAC6, the replacement of the heteroatoms with carbon (<b>48d</b>) caused a drop in inhibitory activity (1250 nM), which confirmed this compound as one of the most selective class I inhibitors over HDAC6 over the course of this study (absolute pIC<sub>50</sub> difference of 1.4 log units between HDAC1 and HDAC6).</div><div class="NLM_p">The <i>cis</i>-cyclohexylmethyl derivative <b>48i2</b> (stereochemistry not confirmed and randomly assigned as cis- in comparison with <i>trans-</i><b>48i1</b>) was found to be one of the most potent HDAC6 inhibitors in our exploration (HDAC6 IC<sub>50</sub> of 57 nM), with a greatly reduced molecular weight and polar surface area (MW = 467.56 Da and TPSA = 118 Å<sup>2</sup>) compared to those of other compounds with similar HDAC6 potency in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, such as <b>13d</b> (MW = 635.74 Da and TPSA = 167 Å<sup>2</sup>) or <b>13g</b> (MW = 552.60 and TPSA = 172 Å<sup>2</sup>). Thus, given its good HDAC potency and improved physicochemical properties, we decided to systematically reduce the ring size of the cycloalkyl (<b>48j</b>, <b>7</b>, <b>48k</b>). It was not possible to observe a shared ring size SAR between the three HDAC isoforms, but the cyclobutylmethyl <b>7</b> achieved the best compromise in terms of HDAC activity as a midnanomolar pan-HDAC inhibitor with potent inhibition of HDAC6, although exhibiting reduced potency against PDE5 compared to that of compound <b>1</b> (IC<sub>50</sub> of 60 nM). On the basis of its potency, the corresponding cis- and trans- forms of <b>7</b> were separated by SFC. As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, no significant differences in HDAC potency against HDAC1, HDAC2, and HDAC6 (<0.4 log units difference) were observed between the racemic <b>7</b> and the <i>cis-</i><b>7a</b> and <i>trans-</i><b>7b</b> forms. Thus, given its simpler accessibility, the parent derivative <b>7</b> was selected for further studies.</div><div class="NLM_p">Replacement of the two best 4 (<b>7</b>)- and 6-membered (<b>48i2</b>) cycloalkyl rings with azetidine (<b>48m</b>) and piperidine (<b>48l</b>) caused a dramatic lost of potency against all HDACs (micromolar range or inactive compounds) as well as PDE5 (midnanomolar range) (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). These data suggest that positively charged groups entering deep into the channel of the HDAC catalytic center are disfavored. Additionally, direct connection of the cycloalkyl rings to the 5′-position of the phenyl ring tended to reduce HDAC potency compared to that of the pair-matched set of methylene-homologated derivatives: <b>48n</b> versus <b>7</b>, <b>48o</b> versus <b>48k</b>, and <b>52c</b> versus <b>48h</b>.</div><div class="NLM_p">Finally, we carried out a small investigation of heteroaryl rings directly bonded at the 5′ position: 2-pyridine (<b>52d</b>), 3-pyridine (<b>52e</b>), and 2-furan (<b>52f</b>). As shown in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, these derivatives recovered PDE5 inhibitory activity comparable to that of <b>1</b> (in the 1–10 nM range), although achieving variable results in terms of HDAC activity: while the 2-pyridine <b>52d</b> exhibited good (<100 nM at HDAC6) and modest (HDAC1, HDAC2) potency, the furane <b>52f</b> was a weak micromolar (HDAC6) or inactive (HDAC1, HDAC2) inhibitor.</div><div class="NLM_p last">Concerning HDAC isoform selectivity, the most remarkable trend among these compounds was observed for the pyrimidylhydroxamic derivatives (<b>13c</b>, <b>21d</b>, <b>21e</b>, <b>21f</b>, <b>30e</b>, <b>37</b>, <b>48c</b>, <b>48d</b>), which exhibited >0.6 log units of selectivity for HDAC1 over HDAC6, with some compounds (<b>13c</b>, <b>21f</b>, <b>48c</b>, <b>48d</b>) possessing more than 1 log unit of preference for the HDAC1 isoform. Interestingly, similar HDAC1 and HDAC6 activities (IC<sub>50</sub> values of 57 nM and 59 nM, respectively) were found for the secondary sulfonamide <b>13f</b> bearing this pyrimidylhydroxamic moiety. Conversely, a certain trend for HDAC6 preference over HDAC1 was observed for the carbon-linked aliphatic rings in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, with derivatives <b>48h</b>, <b>48i2</b>, <b>48j</b>, and <b>48n</b> demonstrating an absolute pIC<sub>50</sub> difference of more than 0.6 log units between HDAC6 and HDAC1. Our efforts to develop dual PDE5-HDAC6 selective inhibitors and examine analogues, focusing on this type of linker substituent, will be reported in due course (manuscript in preparation).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Cytotoxicity and Cellular Functional Response: Effects on Histone Acetylation and CREB Phosphorylation</h3><div class="NLM_p">Compounds were selected to be assayed in a cellular context based on a well-balanced compromise between favorable PDE inhibition (IC<sub>50</sub>< 100 nM), HDAC potency against at least one isoform (preferably with IC<sub>50</sub> ≤ 500 nM) and structural diversity (e.g., <b>30a</b>, <b>52e</b>).</div><div class="NLM_p">Unlike HDAC6 inhibition,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> inhibition of HDAC class I isoforms is associated with toxicity,<a onclick="showRef(event, 'ref22 ref48'); return false;" href="javascript:void(0);" class="ref ref22 ref48">(22, 48)</a> and this was a major concern when investigating this novel therapeutic approach for neurodegenerative disorders. Thus, we routinely screened the cytotoxicity of selected compounds in the healthy hepatic cell line THLE-2 (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>) after 72 h of incubation, and for those compounds demonstrating LC<sub>50</sub> values higher than 5000 nM in THLE-2 cells, their cytotoxicity was also evaluated in primary neuronal cultures of glia cells (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). This threshold was established on the basis of the LC<sub>50</sub> values exhibited by the standard compound <b>4</b> (3590 nM, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), which was our initial reference compound to study the synergistic effects induced by inhibiting both PDE5 and HDACs.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> With the exception of the 3-pyrido derivative <b>52e</b> (LC<sub>50</sub> of 161 nM) and the pyrimidylhydroxamic acid <b>48c</b> (LC<sub>50</sub> of 422 nM), all compounds exhibited middling (1000–5000 nM) or low (>5000 nM) THLE-2 cytotoxicity. In general, a certain correlation exists between THLE-2 cytotoxicity and potent HDAC1 inhibition, as observed for the potent HDAC1 pyrimidylhydroxamic derivatives (<b>13f</b> < <b>21d</b> < <b>37</b> < <b>48d</b> < <b>13c</b> < <b>48c</b> in order of compounds exhibiting less to more THLE-2 cytotoxicity). Obviously, differences not only in primary biochemical activities (e.g., HDAC1 inhibition) but also in permeability may play a major role in the cytotoxicity observed as well as in the corresponding functional responses. Thus, the passive membrane permeability (<i>P</i><sub>e</sub>) of these molecules was measured <i>in vitro</i> in a parallel artificial membrane permeation assay (PAMPA) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). PAMPA was performed using a brain polar lipid (BPL) membrane, which is particularly suited for predicting brain permeability; therefore, providing an additional value to our priorization process: identification of compounds with higher probability to cross the BBB. In general, our compounds demonstrated low (<i>P</i><sub>e</sub> < 10 nm/s) or moderate (10 < <i>P</i><sub>e</sub> < 30 nm/s) permeability comparable to that of <b>1</b> (<i>P</i><sub>e</sub> = 27.5 nm/s), a well-characterized CNS-penetrating drug.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> These ranges to classify poor (<i>P</i><sub>e</sub> < 10 nm/s), moderate (10 < <i>P</i><sub>e</sub> < 30 nm/s), and good (30 nm/s) cellular permeation were established on the basis of the permeability values determined for known commercial drugs with either high or low brain penetration<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> and corrected based on internally tested permeability values. Compound <b>4</b> exhibited low permeation (<i>P</i><sub>e</sub> is 2.3 nm/s), in agreement with its established permeability classification (class IV) according to the Biopharmaceutical Classification System<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> and supportive of its poor brain availability<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> despite its demonstrated effect in improving cognitive function and rescuing memory function.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> As anticipated, compounds with the highest TPSA values (<b>13c</b>, <b>13f</b>, and <b>13g</b> with TPSA values of 193, 201, and 172 Å<sup>2</sup>, respectively) demonstrated the poorest cellular permeation (<i>P</i><sub>e</sub> < 10 nm/s). Other derivatives with TPSA attributes similar to that of <b>1</b> (117 Å<sup>2</sup>) and increased lipophilicity (calculated LogD at pH 7.4<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> > 3.5 but less than 5), such as <b>30g</b>, <b>48h</b>, and <b>48i1</b>, exhibited excellent permeability (<i>P</i><sub>e</sub> > 30 nm/s), in agreement with findings by GSK for molecules containing an ionizable group.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In general, the increased lipophilicity of our dual inhibitors compared to that of compound <b>4</b> (LogD of 2), enabled moderate to good permeability. For example, the lead compound <b>7</b> (<i>P</i><sub>e</sub> = 15.7 nm/s; TPSA of 118 Å<sup>2</sup> and LogD of 3.4) exhibited improved PAMPA results over <b>4</b>, although the results were slightly worse than those for sildenafil (<i>P</i><sub>e</sub> is 27.5 nm/s), which lacks the ionizable hydroxamic acid group.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Functional Cellular Profile of the Initial Set of PDE5/HDAC Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Cpd</th><th class="colsep0 rowsep0" align="center">THLE-2 LC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">primary neurons LC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">AcH3K9 levels (fold-change over basal (1)) 100 nM, 500 nM, 1000 nM</th><th class="colsep0 rowsep0" align="center">AcTub levels (fold-change over basal (1)) 100 nM, 500 nM, 1000 nM</th><th class="colsep0 rowsep0" align="center">pCREB levels (fold-change over basal (1)) at 500 nM, 30 min, 2 h</th><th class="colsep0 rowsep0" align="center">PAMPA P<sub>e</sub> (nm/s)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">>100000</td><td class="colsep0 rowsep0" rowspan="2" align="left">N.D.<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">N.D.</td><td class="colsep0 rowsep0" rowspan="2" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" rowspan="2" align="left">27.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left"><b>3</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">60300</td><td class="colsep0 rowsep0" rowspan="2" align="left">110000</td><td class="colsep0 rowsep0" rowspan="2" align="left">N.D.</td><td class="colsep0 rowsep0" rowspan="2" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" rowspan="2" align="left">26.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>4</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">3590</td><td class="colsep0 rowsep0" rowspan="3" align="left">4910</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" rowspan="3" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12.5</td><td class="colsep0 rowsep0" align="left">11.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13.9</td><td class="colsep0 rowsep0" align="left">27.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>13c</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">1460</td><td class="colsep0 rowsep0" rowspan="3" align="left">2150</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" rowspan="3" align="left">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" rowspan="2" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>13f</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">11900</td><td class="colsep0 rowsep0" rowspan="3" align="left">4950</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" rowspan="3" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>13g</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">27400</td><td class="colsep0 rowsep0" rowspan="3" align="left">30300</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" rowspan="3" align="left">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>21d</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">2570</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" rowspan="3" align="left">13.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" rowspan="2" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5.1</td><td class="colsep0 rowsep0" align="left">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>30a</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">88700</td><td class="colsep0 rowsep0" rowspan="3" align="left">>100000</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" rowspan="3" align="left">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" rowspan="2" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">3.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>30g</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">13400</td><td class="colsep0 rowsep0" rowspan="3" align="left">15100</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" rowspan="3" align="left">36.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.7</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>37</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">2210</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" rowspan="3" align="left">30.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13.0</td><td class="colsep0 rowsep0" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>48c</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">422</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">14.4</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" rowspan="3" align="left">8.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">21.1</td><td class="colsep0 rowsep0" align="left">2.8</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">45.6</td><td class="colsep0 rowsep0" align="left">6.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>48d</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">1830</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">2.1</td><td class="colsep0 rowsep0" rowspan="3" align="left">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8.1</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">18.9</td><td class="colsep0 rowsep0" align="left">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>48h</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">17000</td><td class="colsep0 rowsep0" rowspan="3" align="left">38300</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" rowspan="3" align="left">31.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>48i1</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">9280</td><td class="colsep0 rowsep0" rowspan="3" align="left">9020</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" rowspan="3" align="left">35.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" rowspan="2" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.8</td><td class="colsep0 rowsep0" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48i2</b></td><td class="colsep0 rowsep0" align="left">2650</td><td class="colsep0 rowsep0" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">N.D.</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>7</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">7200</td><td class="colsep0 rowsep0" rowspan="3" align="left">17700</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" rowspan="3" align="left">15.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7.4</td><td class="colsep0 rowsep0" align="left">12.7</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">19.9</td><td class="colsep0 rowsep0" align="left">17.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>48n</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">13500</td><td class="colsep0 rowsep0" rowspan="3" align="left">15300</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" rowspan="3" align="left">13.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">6.4</td><td class="colsep0 rowsep0" rowspan="2" align="left">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">10.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>52d</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">3690</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">16.9</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" rowspan="3" align="left">9.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">16.6</td><td class="colsep0 rowsep0" rowspan="2" align="left">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">21.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>52e</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">161</td><td class="colsep0 rowsep0" rowspan="3" align="left">N.D.</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" rowspan="3" align="left">15.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" rowspan="2" align="left">2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">0.9</td><td class="colsep0 rowsep0" align="left">11.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">N.D. = not determined.</p></div></div></div><div class="NLM_p">Considering both the moderate permeability and the weak potency of compound <b>52e</b> against class I HDACs (HDAC1 IC<sub>50</sub> of 2360 nM and inactive against HDAC2), there is no clear explanation for the idiosyncratically high cytotoxicity observed for this compound, particularly when it is compared with its closest analogue <b>52d</b> (IC<sub>50</sub> of 354 nM and 1870 nM against HDAC1 and HDAC2, respectively), which has similar permeation and an improved HDAC profile; <b>52e</b> is 1.3 log units less cytotoxic than <b>52d</b> in THLE-2 cells. A good correlation was observed between THLE-2 cytotoxicity and cytotoxicity in neurons and glia cells from WT mice, with absolute pLC<sub>50</sub> difference values between both cell lines <0.40 for all tested compounds. Thus, THLE-2 cytotoxicity can be used as a good marker of neuronal cytotoxicity, reducing the need to screen all compounds against a primary culture. The cytotoxicity of compound <b>7</b> was also evaluated after 24 and 48 h of incubation, and no effect was detected (LC<sub>50</sub> > 100 μM). Taken alone, these data suggest that there is potential to obtain HDAC inhibitors with moderate to low cytotoxicity, thus demonstrating an acceptable therapeutic window (see below).</div><div class="NLM_p">To test the functional responses of these molecules, the cellular activity of selected compounds was assessed; we then measured their ability to induce histone and α-tubulin acetylation in SH-SY5Y neuroblastoma cells and evaluated the functional consequence of cellular class I HDAC and HDAC6 inhibition, respectively (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Compounds were incubated at three different concentrations (100, 500, and 1000 nM) for 2 h, and Western blotting assays were carried out to quantify the levels of acetylated histone 3 at Lys 9 (AcH3K9), which has been implicated in cognition enhancement,<a onclick="showRef(event, 'ref13 ref21'); return false;" href="javascript:void(0);" class="ref ref13 ref21">(13, 21)</a> and acetylated α-tubulin at Lys 40 (AcTub) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In each case, the data were normalized to total histone 3 (H3, for AcH3K9) or actin (for AcTub) and expressed as the mean fold change versus control vehicle-treated cultures, with values greater than 1 indicating the induction of acetylation. In general, compounds in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> induced histone and tubulin acetylation in a concentration-dependent manner, with minor variations for those compounds demonstrating a weak effect on cellular acetylation (values ∼1-fold change). However, there were also exceptional cases in which this dose–response behavior was not observed (e.g., the drop in α-tubulin acetylation of compound <b>30g</b> from a 4.6- to 2.9-fold change at 500 nM and 1000 nM, respectively). We attribute these observations to the selected incubation time (after several trials, all functional responses were measured after 2 h of incubation), as we have observed a strong impact of this parameter on the induction of acetylation marks (data not shown), which may ultimately reflect the influence of the association and dissociation kinetic rates (<i>k</i><sub>on</sub>/<i>k</i><sub>off</sub>) of the HDAC inhibitors on their corresponding targets.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><div class="NLM_p">One of the desirable characteristics for our final tool compound was to possess an acceptable therapeutic window, i.e., a high toxicity/function ratio. Given that some of our compounds exhibited low cytotoxicity in the 5–10 μM range, optimal compounds were required to elicit significant functional responses on cellular acetylation at a dose of 500 nM to enable a minimal therapeutic window of 1 log unit for this cell line. Relative to the standard compound <b>4</b> (12.5- and 11.9-fold induction of AcH3K9 and AcTub at 500 nM), compound <b>7</b> was optimal among all compounds presented in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, with a well-balanced profile against both marks (7.4- and 12.7-fold change at this concentration). When comparing alpha technology and Western blotting assays, compound <b>7</b> achieved a 2.4-fold increase in H3K9 acetylation at 400 nM over nontreated cells with alpha technology; in fact, the significant induction of AcH3K9 was obtained from 64 nM.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Other compounds, such as the potent class I compounds with a pyrimidylhydroxamic acid moiety, demonstrated even greater potency when increasing the histone acetylation of neurons (<b>48c</b> and <b>48d</b>, with 21.1 and 8.1-fold values) but had only a minor influence on the tubulin marker (2.8 and 2.0-fold change, respectively) and demonstrated a reduced therapeutic window (above all <b>48c</b>) than inhibitor <b>7</b>. Conversely, the potent HDAC6 inhibitor <b>52d</b> exhibited an interesting cellular profile in terms of tubulin acetylation (increased 16.6-fold) but exerted a minor effect on histone acetylation (likely due to its decreased class I HDAC activity compared to <b>7</b>). At this step in the project, a cellular functional response for both marks, as achieved with <b>4</b>, which has demonstrated <i>in vivo</i> efficacy,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> was required to progress to <i>in vivo</i> efficacy studies.</div><div class="NLM_p">As seen in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, a weak correlation was observed between <i>in vitro</i> HDAC6 potency and the induction of α-tubulin acetylation. Compounds demonstrating IC<sub>50</sub> values against HDAC6 close to or below 100 nM (<b>52d</b>, <b>7</b>, <b>48n</b>) produced >6-fold induction of tubulin acetylation at 500 nM (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), with the exception of the derivatives <b>13f</b> and <b>13g</b>, which, despite being potent HDAC6 inhibitors, exerted weak cellular effects attributable to the fact that these two compounds are those possessing the poorest permeability (<i>P</i><sub>e</sub> < 5 nm/s) in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Derivative <b>48i2</b>, with an HDAC6 IC<sub>50</sub> of 57 nM, was not tested because its cytotoxicity (LC<sub>50</sub> of 2650 nM) was not acceptable, and its corresponding pseudoenantiomer <b>48i1</b> (with similar class I HDAC profile) showed no potent induction of histone acetylation. Conversely, this trend between <i>in vitro</i> potency and cellular AcH3K9 was not detected for either HDAC1 or HDAC2. Not all potent pyrimidilhydroxamic acid-bearing compounds (with IC<sub>50</sub> HDAC1 and HDAC2 < 100 and <500 nM, respectively), such as <b>13c</b>, <b>13f</b>, and <b>21d</b>, were able to achieve a histone acetylation change similar to that of <b>48c</b>, <b>48d</b>, and <b>37</b>. For some compounds, permeability plays a role (<b>13f</b>, <b>13g</b>), but this is clearly not the only factor involved, as highlighted for the pairwise comparison between the secondary amine-linked <b>21d</b> and the carbon-linked <b>48d</b> pyrimidyl hydroxamic compounds, with similar class I HDAC biochemical profiles (<a class="ref internalNav" href="#tbl2" aria-label="Tables 2">Tables 2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>) and reduced permeability of <b>48d</b> versus <b>21d</b> (4.1 versus 13.4 nm/s). Additionally, compared to lead compound <b>7,</b> the reduced cellular response of the more permeable and more HDAC1-potent oxygen-linked pyrimidylhydroxamic derivative <b>37</b> (7.4- versus 4.6-fold change in histone acetylation at 500 nM) is striking, although other permeability-related factors, such as active transport (P-gp efflux), which we identified for <b>7</b>, might also play a role. Conversely, this differential functional response may also mirror the impact of the different kinetic binding rates of our compounds, a characteristic that we have recently started to explore (as reported for <b>7</b>, residence time<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a>). Moreover, the nonspecific contribution of each HDAC to H3K9 deacetylation complicates the analysis of the functional responses determined for these compounds.</div><div class="NLM_p">To further validate the PDE5 inhibitory activity of these compounds and to determine whether this activity translates to a functional cell-based response, the effects of the compounds at 500 nM on pCREB-Ser133 in SH-SY5Y neuroblastoma cells were also examined after 30 min and 2 h of incubation (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). As a reference, the equipotent low nanomolar PDE5 inhibitors <b>1</b> and <b>3</b> enhanced pCREB 1.9 times (30 min) and 1.4 times (2 h) over vehicle controls. As expected, compound <b>4</b> had no effect. Compared to the notable alterations in epigenetic marks, the effects observed on pCREB had a narrower window for improvement and were also highly affected by the chosen incubation time. Thus, we targeted a minimal fold change of 1.4 (as observed with <b>3</b>) at any incubation time. This response was achieved by most tested compounds in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> (with the exception of <b>13c</b>, <b>48i1</b>, and <b>52d</b>). However, two compounds that demonstrated strong stimulation of CREB phosphorylation (<b>21d</b>, <b>52e</b>) did not progress based on their poor induction of acetylation hallmarks and their cytotoxicity.</div><div class="NLM_p last">To further characterize the translational potential of the compounds reported in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>, which had good potency in cell-based assays and an acceptable therapeutic window (<b>7</b> and <b>37</b>), we examined their effect on wild type (WT) neurons exposed to different concentrations of compounds for 2 h. As previously reported, our lead compound <b>7</b> led to a 190% increase in AcH3K9 at 10 nM,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> whereas compound <b>37</b> reached its maximum effect at 100 nM (170% increase). Thus, there is consistency between the acetylation responses observed for this pair of compounds in SH-SY5Y neuroblastoma and WT neurons.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> ADME Profiling of Compounds <b>37</b> and Therapeutic Tool <b>7</b></h3><div class="NLM_p last">On the basis of its good cellular response for the induction of epigenetic hallmarks with an acceptable therapeutic window (approximately 1 log unit), we determined the <i>in vivo</i> CNS penetration of compounds <b>7</b> and <b>37</b> in mice after intraperitoneal administration at a dose of 40 mg/kg by determining the logBB, where BB is the ratio of the brain to plasma concentration. Both compounds exhibited poor central access with logBB values at each corresponding time to reach maximum plasma concentrations (<i>T</i><sub>max</sub>) of −1.87 (<b>7</b>, at <i>T</i><sub>max</sub> =10 min)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and −1.43 (<b>37</b>, at <i>T</i><sub>max</sub> =15 min). The average total brain concentrations of compounds <b>7</b> and <b>37</b> were 248<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and 71 nmol/kg, respectively. Functional responses in the CNS were explored at different time points. In the case of compound <b>37</b>, the maximum functional response in the hippocampus (40% increase in AcH3K9 and 110% increase in pCREB-Ser133 phosphorylation relative to the controls) was observed 1 h after administration, while for the lead compound, there was a 98% increase in AcH3K9 and a 148% increase in pCREB-Ser133 phosphorylation relative to the controls 30 min after administration.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, taking into account that other phosphodiesterase isoforms such as PDE9 and PDE6 also hydrolyze cGMP, the effects of <b>7</b> and <b>37</b> on these two targets were assessed. In fact, <b>7</b> does not inhibit PDE9 (IC<sub>50</sub> > 10 μM);<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> but, its activity vs PDE6 is quite potent (IC<sub>50</sub> is 2.6 nM). Compound <b>37</b> is an even better inhibitor of PDE6 than <b>7</b> (>1 log unit); its IC<sub>50</sub> is 0.13 nM, and it shows moderate acitivity against PDE9 (its IC<sub>50</sub> is 4.8 μM). Additionally, considering that PDE3A is a phosphodiesterase isoform that hydrolyses cAMP and cGMP and is involved in cardiac contractility<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> (its inhibition may lead to unwanted cardiac side-effects), thus important from cardiovascular safety perpective, we also tested these two selected molecules <b>7</b> and <b>37</b> vs PDE3A. Compound <b>7</b> shows a moderate inhibition against PDE3A (IC<sub>50</sub> is 1.8 μM) to be improved; however, <b>37</b> inhibits PDE3A at midnanomolar range (IC<sub>50</sub> is 750 nM). Given the low concentration reached by <b>37</b> in the brain, its cytotoxicity (2210 nM in THLE-2) and worse off-target selectivity profiling than <b>7</b>, this compound did not progress further. The low brain permeation of compound <b>7</b> may be attributable to its still relatively high TPSA (118 Å<sup>2</sup>), as its molecular weight (439.51 Da) and lipophilicity (predicted LogD at pH = 7.4 is 3.37) are in line with commonly accepted ranges for CNS penetration (MW < 450 Da and a LogD<sub>7.4</sub> ranging between 1 and 3 are commonly recommended).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Note that the TPSA of our compounds is biased by the explored sildenafil core (<b>1′</b> substructure, unmodified), which is close to surpassing the commonly accepted values for CNS-penetrating drugs,<a onclick="showRef(event, 'ref39 ref53'); return false;" href="javascript:void(0);" class="ref ref39 ref53">(39, 53)</a> and the mandatory ZBG; thus, further exploration of the substituents of the pyrazolopyrimidinone core will also be required to optimize BBB penetration (this exploration is currently ongoing). Conversely, in addition to the moderate passive diffusion of <b>7</b> (<i>P</i><sub>e</sub>, in PAMPA, is 15.7 nm/s), a Caco-2 permeability assay revealed a low <i>P</i><sub>e</sub> value of 0.46 ( × 10<sup>–6</sup> cm/s) and clear evidence of active transport: the efflux ratio is 41.3.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Therefore, together with an improvement in passive permeability, the optimization process will require overcoming the P-gp efflux.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07366" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07366" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">On the basis of structural information as well as the available structure–activity relationship data for HDAC and PDE5 inhibitors, we designed a novel first-in-class chemical series of dual inhibitors (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0005.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Description of the proposed binding modes, represented by the selected chemical probe <b>7</b>, and key interacting features according to each target binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SAR analyses around the growing vector (R1) borne by the initially explored structure <b>1′</b> led us to evolve from initial hit compounds (e.g., <b>13b</b> and <b>13c</b>) and achieve a lead molecule, <b>7</b>, through an iterative multifactorial optimization process. We have demonstrated that significant acetylation of histone 3 is achieved through moderate HDAC class I but potent PDE5 inhibition, attributable to the synergistic effects between HDAC class I and PDE5; thus, the toxicity associated with HDAC class I inhibition is minimized.</div><div class="NLM_p">Despite its nonoptimal logBB value (←1),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> compound <b>7</b> was shown to achieve corresponding functional responses <i>in vivo</i> (i.p.; 40 mg/kg): these included the induction of AcH3K9 (98% increase over nontreated mice) and increased pCREB (148% increase over nontreated mice) in the hippocampus.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Then, considering primary activities (moderate HDAC class I and potent HDAC6 as well as PDE5 inhibition), <i>in vitro</i> and <i>in vivo</i> functional responses, ADME properties, CNS penetration, pharmacokinetics profiles, and therapeutic windows,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>7</b> was identified as a lead compound for <i>in vivo</i> PoC.</div><div class="NLM_p">As previously reported,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> treatment with <b>7</b> rescued the memory impairment exhibited by Tg2575 mice, prevented disruptions in synaptic plasticity, and induced memory-related genes; in addition, <b>7</b> provokes a significant reduction in amyloid and tau pathology as well as a reversion of the reduced dendritic spine density.</div><div class="NLM_p last">In summary, we have described the discovery of a first-in-class chemical series of dual inhibitors and identified <b>7</b> as a lead compound. This molecule was utilized as a therapeutic tool compound and validated our systems therapeutics approach, targeting two independent but synergistic enzymatic activities, as a potential new symptomatic- and disease-modifying strategy to treat AD.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Chronic treatment of Tg2576 mice with <b>7</b> diminished brain Aβ and pTau levels, increased the inactive form of GSK3β, reverted the decrease in dendritic spine density on hippocampal neurons, and it reversed their cognitive deficits, at least in part by inducing the expression of genes related to synaptic transmission; in fact, <b>7</b> rescued <i>ex-vivo</i> the impaired long-term potentiation evident in hippocampal slices from APP/PS1 mice.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, <b>7</b> can be used as a chemical probe to further elucidate the mechanisms of its targets (HDACs and PDE) in AD and represents an adequate starting point to launch an AD drug discovery program aimed at identifying optimized molecules with the target compound profile described herein.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64637" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64637" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry. General Procedure</h3><div class="NLM_p">Unless otherwise noted, all reagents and solvents were of the highest commercial quality and used without further purification. All experiments dealing with moisture sensitive compounds were conducted under N<sub>2</sub>. The reactions were monitored by thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) using reagent grade solvents. Flash column chromatography was performed on silica gel, particle size 60 Å, mesh = 230–400 (Merck) under standard techniques. Automated flash column chromatography was performed using ready-to-connect cartridges from Varian, on irregular silica gel, particle size 15–40 μm (normal phase disposable flash columns) on a Biotage SPX flash purification system. Microwave-assisted reactions were performed in a Biotage Smith Synthesis microwave reactor. Melting points were monitored with an Olympus PH2 microscope connected to a Mettler FP80 hot stage and an FP80 central processor. The NMR spectroscopic data were recorded on a Bruker AV400 or VARIAN 400MR spectrometer with standard pulse sequences, operating at 400 MHz. Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane (TMS), which was used as the internal standard. The abbreviations used to explain multiplicities are s = singlet, d = doublet, t = triplet, and m = multiplet. Coupling constants (<i>J</i>) are in hertz. HPLC-analysis was performed using a Shimadzu LC-20AB or LC-20AD with a Luna-C18(2), 5 μm, 2.0 × 50 mm column at 40 °C and UV detection at 215, 220, and 254 nm. Flow from the column was split to a MS spectrometer. The MS detector (Agilent 1200, 6110MS or Agilent 1200, 6120MS Quadropole) was configured with an electrospray source or API/APCI. N<sub>2</sub> was used as the nebulizer gas. The source temperature was maintained at 50 °C. Data acquisition was accomplished with ChemStation LC/MSD quad software. All tested compounds possessed a purity of at least 95% established by HPLC, unless otherwise noted. Reported yields were not optimized, the emphasis being on the purity of the product rather than quantity.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclobutanecarbohydroxamic Acid (<b>7</b>)</h4><div class="NLM_p last">To a solution of compound <b>46p</b> (1.1 g, 2.6 mmol) in DMF (60 mL) were added BOP (2.3 g, 5.2 mmol), DIEA (4.5 g, 35 mmol), and NH<sub>2</sub>OH·HCl (1.8 g, 26 mmol), and the mixture was stirred at 80 °C overnight. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>7</b> (530 mg, 46%) as a yellow solid; m.p., 118–119 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.75–7.74 (m, 1H), 7.35–7.33 (m, 1H), 7.11–7.09 (m, 1H), 4.25–4.21 (m, 5H), 2.93–2.89 (m, 2H), 2.81–2.74 (m, 3H), 2.54–2.52 (m, 1H), 2.36–2.34 (m, 1H), 2.20–2.18 (m, 1H), 2.02–1.99 (m, 2H), 1.87–1.82 (m, 2H), 1.48–1.45 (m, 3H), 1.05–1.01 (m, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 14.7 (CH<sub>3</sub>), 15.4 (CH<sub>3</sub>), 22.6, 28.00, 30.0, 31.4, 33.0, 33.4, 38.7 (NCH<sub>3</sub>), 41.8, 64.9 (CH<sub>2</sub>O), 113.6, 123.1, 123.2, 125.0, 130.8, 132.4, 138.8, 145.6, 150.5 (CO), 154.5, 155.5, 171.5 (CONHOH). ESI-MS <i>m</i>/<i>z</i> 440.2 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclobutanecarbohydroxamic acid (<b>7a</b>)</h4><div class="NLM_p last">From <b>7</b> (530 mg), pure isomer <b>7a</b> (9.8 mg, 1.8%) was obtained by SFC (see protocol in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) as a yellow solid; m.p.: 148–149 °C. According to SFC purification method, Rt is 3.28. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 440.2 calc. for C23H29N5O4. Purity is 96.51% according to HPLC analytical method (described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>); where Rt is 2.80. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.74 (d, <i>J</i> = 2 Hz, 1H), 7.33–7.31 (m, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 1H), 4.23–4.17 (m, 5H), 3.01–2.99 (m, 1H), 2.90–2.87 (m, 2H), 2.81–2.79 (m, 2H), 2.76–2.72 (m, 1H), 2.35–2.33 (m, 2H), 1.98–1.97 (m, 2H), 1.85–1.79 (m, 2H), 1.45 (t, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclobutanecarbohydroxamic acid (<b>7b</b>)</h4><div class="NLM_p last">From <b>7</b> (530 mg), pure isomer <b>7b</b> (113 mg, 21%) was obtained by SFC (see protocol in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) as a white solid; m.p.: 178–179 °C. According to SFC purification method, Rt is 3.03. ESI-MS <i>m</i>/<i>z</i> [M + H]<sup>+</sup>: 440.2 calc. for C23H29N5O4. Purity is 98.18% according to HPLC analytical method (described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>); where Rt is 2.63. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.73 (s, 1H), 7.32–7.29 (m, 1H), 7.07 (d, <i>J</i> = 8.4 Hz, 1H), 4.22–4.17 (m, 5H), 2.90–2.86 (m, 2H), 2.81–2.79 (m, 1H), 2.74–2.72 (m, 2H), 2.52 (m, 1H), 2.18–2.17 (m, 2H), 2.02–1.99 (m, 2H), 1.85–1.79 (m, 2H), 1.45 (t, <i>J</i> = 6.8 Hz, 3H), 1.01 (d, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)benzenesulfonyl chloride (<b>9</b>)</h4><div class="NLM_p last">Commercially available 5-(2-ethoxyphenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>8</b>) (2.5 g, 8.0 mmol) was added into ClSO<sub>3</sub>H (10 mL) at ice–water and stirred at room temperature for 2 h. The reaction mixture was quenched with water, and then filtrated. The filtrate cake was collected and dried under vacuum to give the desired product <b>9</b> (2.0 g, 61%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.94–7.92 (dd, <i>J</i> = 1.6 Hz, 7.6 Hz, 1H), 7.52 (m, 1H), 7.11–7.09 (d, <i>J</i> = 8.8 Hz 1H), 4.25 (m, 5H), 2.89 (t, 2H), 1.85 (m, 2H), 1.50 (t, 3H), 0.99 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 411 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>19</sub>ClN<sub>4</sub>O<sub>4</sub>S</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Ethyl 3-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]propanoate (<b>10a</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.41 g, 1 mmol) in EtOH (273 mL) was added piperazine (0.256 g, 2.9 mmol) and the mixture was stirred at 100 °C under MW for 1 h. Then, the reaction mixture was concentrated to give the desired intermediate 5-(2-ethoxy-5-piperazin-1-ylsulfonyl-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (0.4 g, 87%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.18–8.17 (d, <i>J</i> = 2.4 Hz, 1H), 8.00 (dd, <i>J</i> = 2.8 Hz, 9.2 Hz, 1H), 7.40–7.38 (d, <i>J</i> = 8.8 Hz, 1H) 4.32 (q, 2H), 4.27 (s, 3H), 3.40 (s, 8H), 2.87 (t, 2H), 1.81 (m, 2H), 1.45 (t, 3H), 0.99 (t, 3H). MS <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup> calc. for C<sub>21</sub>H<sub>28</sub>N<sub>6</sub>O<sub>4</sub>S. To a solution of this intermediate (300 mg, 0.651 mmol) in CH<sub>3</sub>CN (10 mL) were added K<sub>2</sub>CO<sub>3</sub> (271 mg, 1.95 mmol) and ethyl 3-bromopropanoate (177 mg, 0.976 mmol). Then the mixture was stirred at 100 °C for 2 h under MW and concentrated to give compound <b>10a</b> (260 mg, 71%). ESI-MS <i>m</i>/<i>z</i> 561 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>36</sub>N<sub>6</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Ethyl 4-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]butanoate (<b>10b</b>)</h4><div class="NLM_p last">To intermediate 5-(2-ethoxy-5-piperazin-1-ylsulfonyl-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (described before in <b>10a</b> synthesis) (500 mg, 1.09 mmol) dissolved in CH<sub>3</sub>CN (10 mL) were added K<sub>2</sub>CO<sub>3</sub> (453 mg, 3.28 mmol) and ethyl 4-bromobutanoate (320 mg, 1.64 mmol) and the mixture was stirred at 100 °C for 2 h under MW. Then, the reaction mixture was concentrated to give compound <b>10b</b> (300 mg, 48%). ESI-MS <i>m</i>/<i>z</i> 575 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>38</sub>N<sub>6</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Ethyl 2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]pyrimidine-5-carboxylate (<b>10c</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.41 g, 1 mmol) in EtOH (273 mL) were added ethyl 2-piperazin-1-ylpyrimidine-5-carboxylate (<b>Int. 1</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (0.472 g, 2 mmol) and Et<sub>3</sub>N (303 mg, 3 mmol). The mixture was stirred at 100 °C under MW for 2 h. Then, the reaction mixture was concentrated under vacuum to give compound <b>10c</b> (0.4 g, 65%). ESI-MS <i>m</i>/<i>z</i> 611 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>34</sub>N<sub>8</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Ethyl (<i>E</i>)-3-[4-[[4-[4-ethoxy-3-(3-ethyl-1-methyl-7-oxo-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]methyl]phenyl]prop-2-enoate (<b>10d</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.41 g, 1 mmol) in EtOH (273 mL) were added ethyl (<i>E</i>)-3-[4-(piperazin-1-ylmethyl)phenyl]prop-2-enoate (<b>Int. 2</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> (0.548 g, 2 mmol) and Et<sub>3</sub>N (303 mg, 3 mmol) and the reaction mixture was stirred at 100 °C under MW for 2 h. Then, the reaction mixture was concentrated under vacuum to give the desired compound <b>10d</b> (0.35 g, 55%). ESI-MS <i>m</i>/<i>z</i> 635 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>38</sub>N<sub>6</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Methyl 3-[1-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonyl-4-piperidyl]propanoate (<b>10e</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.41 g, 1 mmol) in EtOH (10 mL) was added methyl 3-(4-piperidyl)propanoate (<b>Int. 3</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (0.185 g, 1 mmol), and the mixture was stirred at 100 °C under MW for an hour. Then, the reaction mixture was concentrated under vacuum to give compound <b>10e</b> (0.4 g, 71%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.16–8.15 (d, J = 2.4 Hz, 1H), 7.92–7.86 (m, 1H), 7.39–7.33 (d, J = 8.6 Hz, 1H), 4.32 (q, 2H), 4.24 (s, 3H), 3.78–3.72 (m, 2H), 3.62 (s, 3H), 2.93–2.85 (t, 2H), 2.37–2.27 (m, 4H), 1.87–1.75 (m, 4H), 1.58–1.52 (m, 2H), 1.47 (t, 3H), 1.24–1.21 (m, 3H), 1.04–0.96 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 546 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O<sub>6</sub>S</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Ethyl 2-[4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]-1-piperidyl]pyrimidine-5-carboxylate (<b>10f</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.41 g, 1 mmol) in EtOH (273 mL) were added ethyl 2-(4-amino-1-piperidyl)pyrimidine-5-carboxylate (<b>Int. 4</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (0.510 g, 2 mmol) and Et<sub>3</sub>N (303 mg, 3 mmol). Then the reaction mixture was stirred at 100 °C under MW for 2 h and concentrated under vacuum to give the desired compound <b>10f</b> (0.41 g, 65%). ESI-MS <i>m</i>/<i>z</i> 625 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>36</sub>N<sub>8</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> Ethyl (<i>E</i>)-3-[4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]phenyl]prop-2-enoate (<b>10g</b>)</h4><div class="NLM_p last">To a solution of <b>9</b> (0.41 g, 1 mmol) in EtOH (10 mL) were added ethyl (<i>E</i>)-3-(4-aminophenyl)prop-2-enoate (<b>Int. 5</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (0.191 g, 1 mmol) and Et<sub>3</sub>N (303 mg, 3 mmol) and the reaction mixture was stirred at 100 °C under MW for 1 h. Then the solution was concentrated under vacuum to give compound <b>10g</b> (0.3 g, 54%). ESI-MS <i>m</i>/<i>z</i> 566 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>31</sub>N<sub>5</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 3-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]propanoic acid (<b>11a</b>)</h4><div class="NLM_p last">To a solution of compound <b>10a</b> (1.0 g, 1.78 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (374 mg, 8.91 mmol). The resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extracted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11a</b> (600 mg, 63%). ESI-MS <i>m</i>/<i>z</i> 533 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>32</sub>N<sub>6</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 4-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]butanoic acid (<b>11b</b>)</h4><div class="NLM_p last">To a solution of compound <b>10b</b> (200 mg, 0.35 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (73.2 mg, 1.7 mmol) and the resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extract with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11b</b> (130 mg, 68%). ESI-MS <i>m</i>/<i>z</i> 547 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]pyrimidine-5-carboxylic acid (<b>11c</b>)</h4><div class="NLM_p last">To a solution of compound <b>10c</b> (500 mg, 0.82 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (168 mg, 4.1 mmol). The resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extracted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11c</b> (300 mg, 63%). ESI-MS <i>m</i>/<i>z</i> 583 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>30</sub>N<sub>8</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>E</i>)-3-[4-[[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]methyl]phenyl]prop-2-enoic acid (<b>11d</b>)</h4><div class="NLM_p last">To a solution of compound <b>10d</b> (300 mg, 0.473 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (94.6 mg, 2.36 mmol). The resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extracted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11d</b> (150 mg, 51%). ESI-MS <i>m</i>/<i>z</i> 621 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>36</sub>N<sub>6</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonyl-4-piperidyl]propanoic acid (<b>11e</b>)</h4><div class="NLM_p last">To a solution of compound <b>10e</b> (250 mg, 0.44 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (92 mg, 2.2 mmol). The resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extracted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11e</b> (200 mg, 86%). ESI-MS <i>m</i>/<i>z</i> 532 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]-1-piperidyl]pyrimidine-5-carboxylic acid (<b>11f</b>)</h4><div class="NLM_p last">To a solution of compound <b>10f</b> (400 mg, 0.64 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (132 mg, 3.2 mmol). The resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extracted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11f</b> (300 mg, 79%). ESI-MS <i>m</i>/<i>z</i> 597 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>32</sub>N<sub>8</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]phenyl]prop-2-enoic acid (<b>11g</b>)</h4><div class="NLM_p last">To a solution of compound <b>10g</b> (200 mg, 0.354 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:5, 16 mL) was added LiOH·H<sub>2</sub>O (50.3 mg, 1.2 mmol). The resulting mixture was stirred at room temperature overnight. After TLC showed that most of the staring materials were consumed completely, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The mixture was extract with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>11g</b> (120 mg, 63%). ESI-MS <i>m</i>/<i>z</i> 538 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>27</sub>N<sub>5</sub>O<sub>6</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>12a</b>)</h4><div class="NLM_p last">To a solution of compound <b>11a</b> (100 mg, 0.19 mmol) in DMF (10 mL) were added EDC·HCl (48 mg, 0.25 mmol), HOBt (33.5 mg, 0.25 mmol), THPONH<sub>2</sub> (48 mg, 0.41 mmol) and NMM (84.8 mg, 0.84 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>12a</b> (100 mg, 84%). ESI-MS <i>m</i>/<i>z</i> 632 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>41</sub>N<sub>7</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]-<i>N</i>-tetrahydropyran-2-yloxy-butanamide (<b>12b</b>)</h4><div class="NLM_p last">To a solution of compound <b>11b</b> (300 mg, 0.548 mmol) in DMF (10 mL) were added EDC·HCl (126 mg, 0.658 mmol), HOBt (88 mg, 0.658 mmol), THPONH<sub>2</sub> (125 mg, 1.07 mmol) and NMM (221 mg, 2.192 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>12b</b> (200 mg, 57%). ESI-MS <i>m</i>/<i>z</i> 646 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>43</sub>N<sub>7</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>12c</b>)</h4><div class="NLM_p last">To a solution of compound <b>11c</b> (582 mg, 1 mmol) in DMF (10 mL) were added EDC·HCl (230 mg, 1.2 mmol), HOBt (162 mg, 1.2 mmol), THPONH<sub>2</sub> (229 mg, 1.9 mmol) and NMM (303 mg, 3 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>12c</b> (300 mg, 44%). ESI-MS <i>m</i>/<i>z</i> 682 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>39</sub>N<sub>9</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>E</i>)-3-[4-[[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]methyl]phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-prop-2-enamide (<b>12d</b>)</h4><div class="NLM_p last">To a solution of compound <b>11d</b> (100 mg, 0.161 mmol) in DMF (10 mL) were added EDC·HCl (69 mg, 0.36 mmol), HOBt (48.6 mg, 0.36 mmol), THPONH<sub>2</sub>(42 mg, 0.36 mmol) and NMM (40.4 mg, 0.4 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>12d</b> (70 mg, 61%). ESI-MS <i>m</i>/<i>z</i> 720 [M + H]<sup>+</sup> calc. for C<sub>36</sub>H<sub>45</sub>N<sub>7</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3-[1-[4-Ethoxy-3-(3-ethyl-1-methyl-7-oxo-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonyl-4-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>12e</b>)</h4><div class="NLM_p last">To a solution of compound <b>11e</b> (100 mg, 0.18 mmol) in DMF (10 mL) were added EDC·HCl (43.3 mg, 0.22 mmol), HOBt (30.5 mg, 0.22 mmol), THPONH<sub>2</sub> (32 mg, 0.27 mmol) and NMM (57 mg, 0.56 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>12e</b> (100 mg, 90%). ESI-MS <i>m</i>/<i>z</i> 617 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>40</sub>N<sub>6</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>12f</b>)</h4><div class="NLM_p last">To a solution of compound <b>11f</b> (597 mg, 1 mmol) in DMF (10 mL) were added EDC·HCl (230 mg, 1.2 mmol), HOBt (162 mg, 1.2 mmol), THPONH<sub>2</sub> (229 mg, 1.9 mmol) and NMM (303 mg, 3 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>12f</b> (300 mg, 44%). ESI-MS <i>m</i>/<i>z</i> 696 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>41</sub>N<sub>9</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-prop-2-enamide (<b>12g</b>)</h4><div class="NLM_p last">To a solution of compound <b>11g</b> (120 mg, 0.223 mmol) in DMF (10 mL) were added EDC·HCl (69 mg, 0.36 mmol), HOBt (48.6 mg, 0.36 mmol), THPONH<sub>2</sub> (42 mg, 0.36 mmol) and NMM (50 mg, 0.5 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with EtOAc, washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>12g</b> (100 mg, 70%). ESI-MS <i>m</i>/<i>z</i> 637 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>36</sub>N<sub>6</sub>O<sub>7</sub>S. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 3-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]propanehydroxamic acid (<b>13a</b>)</h4><div class="NLM_p last">A solution of compound <b>12a</b> (100 mg, 0.15 mmol) in HCl/1,4-dioxane (2.0 M, 10 mL) was stirred at room temperature for 3 h. Then, the reaction mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give desired compound <b>13a</b> (62.5 mg, 76%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.18–8.17 (d, <i>J</i> = 2.4 Hz, 1H), 8.00 (dd, <i>J</i> = 2.8 Hz, 9.2 Hz, 1H), 7.40–7.38 (d, <i>J</i> = 8.8 Hz, 1H) 4.32 (q, 2H), 4.27 (s, 3H), 3.91–3.30 (m, 10H), 2.87 (t, 2H), 2.53 (m, 2H), 1.81 (m, 2H), 1.45 (t, 3H), 0.99 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 548.3 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>33</sub>N<sub>7</sub>O<sub>6</sub>S</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]butanehydroxamic acid (<b>13b</b>)</h4><div class="NLM_p last">To a solution of compound <b>12b</b> (100 mg, 0.155 mmol) in 1,4-dioxane (10 mL) was added HCl/1,4-dioxane (2.0 M, 3 mL) and the solution was stirred at room temperature for 3 h. Then, the mixture was concentrated to give the crude product which was purified through preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give the desired compound <b>13b</b> (80 mg, 92%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.18–8.17 (d, <i>J</i> = 2.4 Hz, 1H), 8.00 (dd, <i>J</i> = 2.8 Hz, 9.2 Hz, 1H), 7.40–7.38 (d, <i>J</i> = 8.8 Hz, 1H), 4.32 (q, 2H), 4.27 (s, 3H), 4.10–3.30 (m, 6H), 3.15 (t, 3H), 2.85 (t, 3H), 2.31 (m, 2H), 1.98 (m, 2H), 1.85–1.75 (m, 2H), 1.45 (t, 3H), 0.99 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 562.1 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>35</sub>N<sub>7</sub>O<sub>6</sub>S</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]pyrimidine-5-carbohydroxamic acid (<b>13c</b>)</h4><div class="NLM_p last">To a solution of compound <b>12c</b> (200 mg, 0.293 mmol) in 1,4-dioxane (10 mL) was added HCl/1,4-dioxane (2.0 M, 10 mL) and the mixture was stirred at room temperature for 3 h. Then, the reaction mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give compound <b>13c</b> (62.5 mg, 36%). <sup>1</sup>H NMR (DMSO, 400 MHz): δ 12.16 (s, 1H), 11.08 (s, 1H), 9.03 (s, 1H), 8.65 (s, 2H), 7.85 (m, 2H), 7.36–7.34 (d, <i>J</i> = 8.8 Hz, 1H), 4.22 (q, 2H), 4.15 (s, 3H), 3.92 (s, 4H), 3.00 (s, 4H), 2.75 (t, 2H), 1.75 (m, 2H), 1.25 (t, 3H), 0.95 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 598.1 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>31</sub>N<sub>9</sub>O<sub>6</sub>S</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>E</i>)-3-[4-[[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylpiperazin-1-yl]methyl]phenyl]prop-2-enehydroxamic acid (<b>13d</b>)</h4><div class="NLM_p last">A solution of compound <b>12d</b> (50 mg, 0.069 mmol) in HCl/1,4-dioxane (2.0 M, 10 mL) was stirred at room temperature for 3 h. Then, the reaction mixture was concentrated to give the crude product which was purified through preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give compound <b>13d</b> (20 mg, 45%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.19 (s, 1H), 7.95 (m, 1H), 7.75–7.32 (m, 6H), 6.53–6.49 (d, <i>J</i> = 15.6 Hz, 1H), 4.42–4.21 (m, 7H), 3.95–3.32 (m, 7H), 3.19–3.02 (m, 1H), 2.92–2.75 (m, 2H), 1.85–1.72 (m, 2H), 1.48 (t, 3H), 0.93 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 636.1 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>37</sub>N<sub>7</sub>O<sub>6</sub>S</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 3-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonyl-4-piperidyl]propanehydroxamic acid (<b>13e</b>)</h4><div class="NLM_p last">A solution of compound <b>12e</b> (100 mg, 0.162 mmol) in HCl/1,4-dioxane (2.0 M, 10 mL) was stirred at room temperature for 3 h. Then, the reaction mixture was concentrated to give the crude product which was purified through preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give the desired compound <b>13e</b> (40 mg, 46%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.18–8.17 (d, <i>J</i> = 2.4 Hz, 1H), 8.00 (dd, <i>J</i> = 2.8 Hz, 9.2 Hz, 1H), 7.40–7.38 (d, <i>J</i> = 8.8 Hz, 1H), 4.32 (q, 2H), 4.27 (s, 3H), 3.75 (m, 2H), 2.87 (t, 2H), 2.31 (m, 2H), 2.15 (m, 2H), 1.81 (m, 4H), 1.53 (m, 2H), 1.45 (t, 3H), 1.31–1.21 (m, 3H), 0.99 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 547.1 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>34</sub>N<sub>6</sub>O<sub>6</sub>S</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]-1-piperidyl]pyrimidine-5-carbohydroxamic acid (<b>13f</b>)</h4><div class="NLM_p last">To a solution of compound <b>12f</b> (200 mg, 0.288 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added HCl/1,4-dioxane (2.0 M, 5 mL) and the solution was stirred at room temperature for 3 h. Then, the reaction mixture was concentrated to give the crude product which was purified through preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give compound <b>13f</b> (50 mg, 30%). <sup>1</sup>H NMR (DMSO, 400 MHz): δ 12.21 (s, 1H), 11.06 (s, 1H), 8.64 (s, 2H), 8.02 (s, 1H), 7.94–7.91 (d, <i>J</i> = 8.4 Hz, 1H), 7.85–7.83 (d, <i>J</i> = 6.8 Hz, 1H), 7.35–7.33 (d, <i>J</i> = 8.4 Hz, 1H), 4.45 (m, 2H), 4.22 (q, 2H), 4.15 (s, 3H), 3.35 (m, 1H), 3.15 (m, 2H), 2.75 (t, 2H), 1.75 (m, 4H), 1.45 (m, 5H), 0.93 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 612.1 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>33</sub>N<sub>9</sub>O<sub>6</sub>S</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]sulfonylamino]phenyl]prop-2-enehydroxamic acid (<b>13g</b>)</h4><div class="NLM_p last">A solution of compound <b>12g</b> (100 mg, 0.16 mmol) in HCl/1,4-dioxane (2.0 M, 10 mL) was stirred at room temperature for 3 h. Then, the reaction mixture was concentrated and purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give compound <b>13g</b> (47 mg, 53%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.25 (s, 1H), 7.91–7.88 (d, <i>J</i> = 10.8 Hz, 1H), 7.49–7.39 (m, 3H), 7.29–7.18 (m, 3H), 6.32–6.25 (d, <i>J</i> = 15.6 Hz, 1H), 4.22 (q, 2H), 4.15 (s, 3H), 2.85 (t, 2H), 1.85 (m, 2H), 1.45 (t, 3H), 0.96 (t, 3H). ESI-MS <i>m</i>/<i>z</i> 553.0 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>28</sub>N<sub>6</sub>O<sub>6</sub>S</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-(2-Ethoxy-5-nitro-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>14</b>)</h4><div class="NLM_p last">To a solution of compound <b>8</b> (1.0 g, 3.21 mmol) in concentrated sulfuric acid (5 mL) was added KNO<sub>3</sub> (324 mg, 3.21 mmol) in portions at 0 °C, then the reaction mixture was stirred at 0 °C for 20 min. Then the mixture was poured into ice water and extracted with EtOAc. The organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>14</b> (1.10 g, 96%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub> 400 MHz): δ 10.78 (s, 1H), 9.34 (s, 1H), 8.36–8.33 (m, 1H), 7.17–7.14 (d, <i>J</i> = 9.2 Hz, 1H), 4.45–4.40 (m, 2H), 4.29 (s, 3H), 2.98–2.95 (m, 2H), 1.93–1.86 (m, 2H), 1.69–1.59 (m, 3H), 1.07–1.04 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 358 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>O<sub>4</sub></div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-(5-Amino-2-ethoxy-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>15</b>)</h4><div class="NLM_p last">To a solution of compound <b>14</b> (700 mg, 1.961 mmol) in MeOH (20 mL) was added Pd/C (0.5 g) at H<sub>2</sub> atmosphere (1 atm) and the mixture was stirred at room temperature overnight. Then the mixture was filtered and the filtrate was concentrated to give the crude compound <b>15</b> (605 mg, 94%) as a white solid which was used for the next step directly. <sup>1</sup>H NMR (MeOD 400 MHz): δ 7.47 (s, 1H), 6.98–6.96 (m, 1H), 6.91–6.88 (m, 1H), 4.23 (s, 3H), 4.16–4.11 (m, 2H), 2.89–2.85 (m, 2H), 1.86–1.77 (m, 2H), 1.45–1.41 (m, 3H), 1.02–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 328 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub></div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>Tert</i>-butyl 4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]piperidine-1-carboxylate (<b>16a</b>)</h4><div class="NLM_p last">To a solution of <b>15</b> (200 mg, 0.61 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added <i>tert</i>-butyl 4-oxopiperidine-1-carboxylate (145 mg, 0.73 mmol), AcOH (cat) and NaBH(OAc)<sub>3</sub> (259 mg, 1.22 mmol), and the mixture was stirred at room temperature overnight. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to give pure compound <b>16a</b> (300 mg, 96%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 511 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>38</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>Tert</i>-butyl 4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]methyl]piperidine-1-carboxylate (<b>16b</b>)</h4><div class="NLM_p last">To a solution of compound <b>15</b> (400 mg, 1.22 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added <i>tert</i>-butyl 4-formylpiperidine-1-carboxylate (311 mg, 1.46 mmol), AcOH (cat) and NaBH(OAc)<sub>3</sub> (519 mg, 2.44 mmol), and the mixture was stirred at room temperature overnight. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to give pure compound <b>16b</b> (450 mg, 70%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 525 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>40</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>Tert</i>-butyl 4-[4-ethoxy-<i>N</i>-methyl-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]piperidine-1-carboxylate (<b>16c</b>)</h4><div class="NLM_p last">Compound <b>16a</b> (500 mg, 0.98 mmol) was dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL) and paraformaldehyde (132 mg, 1.471 mmol), AcOH (cat) and NaBH(OAc)<sub>3</sub> (416 mg, 1.960 mmol) were sequentlialy added. Then, the mixture was stirred at 60 °C overnight and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to give pure compound <b>16c</b> (288 mg, 56%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i> 525 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>40</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 5-[2-Ethoxy-5-(4-piperidylamino)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>17a</b>)</h4><div class="NLM_p last">A solution of compound <b>16a</b> (300 mg, 0.59 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h and then concentrated to give compound <b>17a</b> (240 mg, 99%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 411 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 5-[2-Ethoxy-5-(4-piperidylmethylamino)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>17b</b>)</h4><div class="NLM_p last">A solution of compound <b>16b</b> (450 mg, 0.86 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the reaction mixture was concentrated to give the crude compound <b>17b</b> (350 mg, 96%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 425 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 5-[2-Ethoxy-5-[methyl(4-piperidyl)amino]phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>17c</b>)</h4><div class="NLM_p last">A solution of compound <b>16c</b> (288 mg, 0.55 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h and then concentrated to give compound <b>17c</b> (220 mg, 94%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 425 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>32</sub>N<sub>6</sub>O<sub>2</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Methyl 3-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]propanoate (<b>18a</b>)</h4><div class="NLM_p last">To a solution of compound <b>15</b> (500 mg, 1.53 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (16 mL) under N<sub>2</sub> were added methyl 3,3-dimethoxypropanoate (274 mg, 1.85 mmol), TFA (8 mL) and Et<sub>3</sub>SiH (534 mg, 4.6 mmol) and the reaction mixture was stirred at room temperature overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 7 with aqueous NaHCO<sub>3</sub>. The solution was then extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>18a</b> (620 mg, 98%). ESI-MS <i>m</i>/<i>z</i> 414 [M + H]<sup>+</sup> calc. for C<sub>21</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Ethyl 4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]cyclohexanecarboxylate (<b>18b</b>)</h4><div class="NLM_p last">To a solution of compound <b>15</b> (350 mg, 1.07 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added ethyl 4-oxocyclohexanecarboxylate (218 mg, 1.28 mmol), AcOH (cat) and NaBH(OAc)<sub>3</sub> (454 mg, 2.14 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>,filtered and concentrated to give the crude compound which was purified by preparative TLC to give pure compound <b>18b</b> (400 mg, 78%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i> 482 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Methyl 4-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]benzoate (<b>18c</b>)</h4><div class="NLM_p last">To a solution methyl 4-(4-oxo-1-piperidyl)benzoate (<b>Int. 6</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (250 mg, 1.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added <b>15</b> (150 mg, 0.45 mmol) and AcOH (2 drop), and the solution was stirred at room temperature for 2 h. Then, NaBH(OAc)<sub>3</sub> (391 mg, 1.85 mmol) was added to the solution and the mixture was stirred at room temperature overnight. The mixture was quenched with aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>18c</b> (80 mg, 32%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 545.2 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> Ethyl 2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]pyrimidine-5-carboxylate (<b>18d</b>)</h4><div class="NLM_p last">To a solution of compound <b>17a</b> (240 mg, 0.58 mmol) in CH<sub>3</sub>CN (20 mL) were added K<sub>2</sub>CO<sub>3</sub> (161 mg, 1.17 mmol) and ethyl 2-chloropyrimidine-5-carboxylate (109 mg, 0.58 mmol), then the mixture was stirred at 40 °C overnight. After LC-MS showed the starting material was consumed completely, the mixture was extracted with EtOAc and washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>18d</b> (263 mg, 80%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i> 561 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>36</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Ethyl 2-[4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]methyl]-1-piperidyl]pyrimidine-5-carboxylate (<b>18e</b>)</h4><div class="NLM_p last">To a solution of compound <b>17b</b> (350 mg, 0.82 mmol) in CH<sub>3</sub>CN (20 mL) were added K<sub>2</sub>CO<sub>3</sub> (228 mg, 1.65 mmol) and ethyl 2-chloropyrimidine-5-carboxylate (154 mg, 0.82 mmol) and the mixture was stirred at 40 °C overnight. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>18e</b> (392 mg, 83%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 575 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>38</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Ethyl 2-[4-[4-ethoxy-<i>N</i>-methyl-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]pyrimidine-5-carboxylate (<b>18f</b>)</h4><div class="NLM_p last">To a solution of compound <b>17c</b> (220 mg, 0.52 mmol) in CH<sub>3</sub>CN (20 mL) were added K<sub>2</sub>CO<sub>3</sub> (143 mg, 1.03 mmol) and ethyl 2-chloropyrimidine-5-carboxylate (97 mg, 0.52 mmol) and the mixture was stirred at 40 °C overnight. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>18f</b> (250 mg, 84%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 575 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>38</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]propanoic acid (<b>19a</b>)</h4><div class="NLM_p last">To a solution of compound <b>18a</b> (620 mg, 1.5 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 32 mL) was added LiOH·H<sub>2</sub>O (645 mg, 15 mmol). The resulting mixture was stirred at room temperature overnight. Then the mixture was diluted with water and the pH adjusted to 3–4 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>19a</b> (580 mg, 96%) as a pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 400 [M + H]<sup>+</sup> calc. for C<sub>20</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]cyclohexanecarboxylic acid (<b>19b</b>)</h4><div class="NLM_p last">To a solution of compound <b>18b</b> (400 mg, 0.832 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (349 mg, 8.32 mmol) and the reaction mixture was stirred at 40 °C overnight. Then, the solution was concentrated and the residue was diluted with H<sub>2</sub>O and the pH adjusted to 1–2 with 1 N HCl. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>19b</b> (380 mg, 99% crude) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 454 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 4-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]benzoic acid (<b>19c</b>)</h4><div class="NLM_p last">To a solution of <b>18c</b> (80 mg, 0.15 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 8 mL) was added LiOH·H<sub>2</sub>O (63 mg, 1.5 mmol) and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>19c</b> (70 mg, 90%). ESI-MS <i>m</i>/<i>z</i> 531.2 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>34</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]pyrimidine-5-carboxylic acid (<b>19d</b>)</h4><div class="NLM_p last">To a solution of compound <b>18d</b> (263 mg, 0.47 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (197 mg, 4.70 mmol) and the reaction mixture was stirred at 40 °C overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 1–2 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>19d</b> (230 mg, 92%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 533 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>32</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]methyl]-1-piperidyl]pyrimidine-5-carboxylic acid (<b>19e</b>)</h4><div class="NLM_p last">To a solution of compound <b>18e</b> (392 mg, 0.68 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (287 mg, 6.83 mmol) and the reaction mixture was stirred at 40 °C overnight. Then, the reaction mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 1–2 with 1 N HCl. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>19e</b> (350 mg, 94%) as a red solid. ESI-MS <i>m</i>/<i>z</i> 547 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>34</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 2-[4-[4-Ethoxy-<i>N</i>-methyl-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]pyrimidine-5-carboxylic acid (<b>19f</b>)</h4><div class="NLM_p last">To a solution of compound <b>18f</b> (250 mg, 0.43 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (193 mg, 4.60 mmol) and the reaction mixture was stirred at 40 °C overnight until LC-MS showed the starting material was consumed completely. Then, the solution was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>19f</b> (220 mg, 93%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 547 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>34</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>20a</b>)</h4><div class="NLM_p last">To a solution of <b>19a</b> (580 mg, 1.45 mmol) in DMF (40 mL) were added EDC·HCl (560 mg, 2.9 mmol), HOBt (392 mg, 2.9 mmol), THPONH<sub>2</sub> (340 mg, 2.9 mmol) and NMM (505 mg, 5.0 mmol). The mixture was stirred at room temperature overnight, then quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give pure compound <b>20a</b> (630 mg, 87%) as pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 499 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>34</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-<i>N</i>-tetrahydropyran-2-yloxy-cyclohexanecarboxamide (<b>20b</b>)</h4><div class="NLM_p last">To a solution of compound <b>19b</b> (380 mg, 0.84 mmol) in DMF (10 mL) were added EDC·HCl (322 mg, 1.68 mmol), HOBt (226 mg, 1.68 mmol), THPONH<sub>2</sub> (196 mg, 1.68 mmol) and NMM (254 mg, 2.51 mmol), and the mixture was stirred at room temperature overnight. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>20b</b> (120 mg, 26%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i> 553 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>40</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-benzamide (<b>20c</b>)</h4><div class="NLM_p last">To a solution of <b>19c</b> (70 mg, 0.13 mmol) in DMF (10 mL) were added EDC·HCl (50 mg, 0.26 mmol), HOBt (35 mg, 0.26 mmol), THPONH<sub>2</sub> (31 mg, 0.26 mmol) and NMM (41 mg, 0.4 mmol) and the mixture was stirred at room temperature overnight. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>20c</b> (50 mg, 61%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 630.3 [M + H]<sup>+</sup> calc. for C<sub>34</sub>H<sub>43</sub>N<sub>7</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>20d</b>)</h4><div class="NLM_p last">To a solution of <b>19d</b> (230 mg, 0.43 mmol) in DMF (10 mL) were added EDC·HCl (166 mg, 0.86 mmol), HOBt (117 mg, 0.86 mmol), THPONH<sub>2</sub> (102 mg, 0.86 mmol) and NMM (131 mg, 1.30 mmol) and the mixture was stirred at room temperature overnight. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>20d</b> (102 mg, 37%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 632 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>41</sub>N<sub>9</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]methyl]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>20e</b>)</h4><div class="NLM_p last">To a solution of compound <b>19e</b> (350 mg, 0.64 mmol) in DMF (10 mL) were added EDC·HCl (246 mg, 1.28 mmol), HOBt (173 mg, 1.28 mmol), THPONH<sub>2</sub> (150 mg, 1.28 mmol) and NMM (194 mg, 1.92 mmol) and the mixture was stirred at room temperature. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>20e</b> (350 mg, 85%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i> 646 [M + H]<sup>+</sup> calc. for C<sub>33</sub>H<sub>43</sub>N<sub>9</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 2-[4-[4-Ethoxy-<i>N</i>-methyl-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>20f</b>)</h4><div class="NLM_p last">To a solution of compound <b>19f</b> (220 mg, 0.40 mmol) in DMF (10 mL) were added EDC·HCl (155 mg, 0.80 mmol), HOBt (109 mg, 0.80 mmol), THPONH<sub>2</sub> (95 mg, 0.80 mmol) and NMM (122 mg, 1.20 mmol), and the mixture was stirred at room temperature overnight until LC-MS showed the starting material was consumed completely. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>20f</b> (220 mg, 85%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 646 [M + H]<sup>+</sup> calc. for C<sub>33</sub>H<sub>43</sub>N<sub>9</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]propanehydroxamic acid (<b>21a</b>)</h4><div class="NLM_p last">A solution of compound <b>20a</b> (300 mg, 0.6 mmol) in HCl/EtOAc (1.0 M, 40 mL) was stirred at room temperature for 4 h, then concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21a</b> (41.2 mg, 16%) as white solid; ; m.p.: 150–151 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.75 (d, <i>J</i> = 2.8 Hz, 1H), 7.34–7.31 (m, 1H), 7.22 (d, <i>J</i> = 8.8 Hz, 1H), 4.28–4.20 (m, 5H), 3.65–3.59 (m, 2H), 2.90–2.86 (m, 2H), 2.52–2.49 (m, 2H), 1.86–1.77 (m, 2H), 1.49–1.44 (m, 3H), 1.00 (t, <i>J</i> = 8 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> 415.1 [M + H]<sup>+</sup> calc. for C<sub>20</sub>H<sub>26</sub>N<sub>6</sub>O<sub>4</sub></div></div><div id="sec4_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]cyclohexanecarbohydroxamic acid (<b>21b</b>)</h4><div class="NLM_p last">A solution of compound <b>20b</b> (120 mg, 0.217 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21b</b> (30 mg, 29%) as a white solid; m.p.: 131.5–132.5 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.94 (s, 1H), 7.51–7.48 (m, 1H), 7.33–7.31 (d, <i>J</i> = 8.8 Hz, 1H), 4.30–4.26 (m, 2H), 4.24 (s, 3H), 3.63–3.58 (m, 1H), 2.90–2.86 (m, 2H), 2.40–2.39 (m, 1H), 2.05–2.00 (m, 4H), 1.86–1.83 (m, 4H), 1.81–1.79 (m, 2H), 1.50–1.47 (m, 3H), 1.02–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 469.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub></div></div><div id="sec4_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 4-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]benzenecarbohydroxamic acid (<b>21c</b>)</h4><div class="NLM_p last">A solution of compound <b>20c</b> (50 mg, 0.08 mmol) in HCl/EtOAc (1.0 M, 10 mL) was stirred at room temperature for 1 h. Then the mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21c</b> (14.6 mg, 32%) as a white solid; m.p.: 196–197 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.86 (s, 1H), 10.92 (s, 1H), 8.90–8.60 (m, 1H), 7.64–7.61 (m, 2H), 7.20–7.10 (m, 1H), 7.10–6.90 (m, 3H), 6.90–6.70 (m, 1H), 4.14 (s, 3H), 4.10–4.00 (m, 2H), 3.90–3.75 (m, 2H), 3.00–2.85 (m, 2H), 2.80–2.70 (m, 2H), 2.52–2.40 (m, 1H), 2.05–1.90 (m, 2H), 1.80–1.70 (m, 2H), 1.50–1.35 (m, 2H), 1.35–1.20 (m, 3H), 0.95–0.85 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 546.2 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>35</sub>N<sub>7</sub>O<sub>4</sub></div></div><div id="sec4_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]pyrimidine-5-carbohydroxamic acid (<b>21d</b>)</h4><div class="NLM_p last">A solution of compound <b>20d</b> (102 mg, 0.16 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h, then concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21d</b> (50 mg, 57%) as a white solid; m.p.: 131–132 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.67 (s, 2H), 7.94 (s, 1H), 7.51–7.49 (d, <i>J</i> = 8.4 Hz, 1H), 7.33–7.31 (d, <i>J</i> = 9.2 Hz, 1H), 4.98–4.95 (m, 2H), 4.30–4.26 (m, 2H), 4.23 (s, 3H), 3.86–3.80 (m, 1H), 3.09–3.03 (m, 2H), 2.89–2.86 (m, 2H), 2.13–2.10 (m, 2H), 1.84–1.79 (m, 2H), 1.63–1.61 (m, 2H), 1.50–1.47 (m, 3H), 1.01–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 548.1 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>33</sub>N<sub>9</sub>O<sub>4</sub></div></div><div id="sec4_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]methyl]-1-piperidyl]pyrimidine-5-carbohydroxamic acid (<b>21e</b>)</h4><div class="NLM_p last">A solution of compound <b>20e</b> (350 mg, 0.54 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then the solution was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21e</b> (190 mg, 62%) as a yellow solid; m.p.: 158–159 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.65 (s, 2H), 7.95 (s, 1H), 7.50–7.48 (d, <i>J</i> = 8.4 Hz, 1H), 7.30–7.27 (d, <i>J</i> = 9.2 Hz, 1H), 4.92–4.88 (m, 2H), 4.28–4.25 (m, 2H), 4.23 (s, 3H), 3.32–3.31 (m, 2H), 3.03–2.97 (m, 2H), 2.89–2.85 (m, 2H), 2.13 (s, 1H), 1.96–1.93 (m, 2H), 1.84–1.79 (m, 2H), 1.50–1.48 (m, 3H), 1.34–1.32 (m, 2H), 1.01–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 562.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>35</sub>N<sub>9</sub>O<sub>4</sub></div></div><div id="sec4_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 2-[4-[4-Ethoxy-<i>N</i>-methyl-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)anilino]-1-piperidyl]pyrimidine-5-carbohydroxamic acid (<b>21f</b>)</h4><div class="NLM_p last">A solution of compound <b>20f</b> (220 mg, 0.34 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>21f</b> (94 mg, 49%) as a red solid; m.p.: 101–102 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.66 (s, 2H), 8.11 (s, 1H), 7.77–7.74 (m, 1H), 7.41–7.39 (d, <i>J</i> = 9.2 Hz, 1H), 5.05–5.01 (m, 2H), 4.32–4.27 (m, 2H), 4.24 (s, 3H), 4.08–4.01 (m, 1H), 3.37 (s, 3H), 3.31–2.96 (m, 2H), 2.89–2.85 (m, 2H), 2.16–2.13 (m, 2H), 1.83–1.78 (m, 2H), 1.64–1.61 (m, 2H), 1.50–1.47 (m, 3H), 1.01–0.97 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 562.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>35</sub>N<sub>9</sub>O<sub>4</sub></div></div><div id="sec4_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 5-(2-Ethoxy-5-iodo-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>22</b>)</h4><div class="NLM_p last">To a solution of <b>8</b> (10 g, 32 mmol) in TFA (50 mL) was added NIS (8.6 g, 38.4 mmol) at 0 °C and the solution was stirred at room temperature overnight. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>22</b> (11 g, 79%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.66–8.40 (m, 1H), 7.73–7.70 (m, 1H), 6.81–6.70 (m, 1H), 4.40–4.10 (m, 5H), 3.00–2.85 (m, 2H), 1.95–1.75 (m, 2H), 1.60–1.50 (m, 3H), 1.10–1.00 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 439.1 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>19</sub>IN<sub>4</sub>O<sub>2</sub></div></div><div id="sec4_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 5-[5-(1,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-2-ethoxy-phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>23</b>)</h4><div class="NLM_p last">To a solution of compound <b>22</b> (1.7 g, 3.87 mmol) in toluene (10 mL) were added <i>t</i>-BuOK (7.74 mL, 1.0 M, 7.74 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (355 mg, 0.387 mmol), 1,4-dioxa-8-azaspiro[4.5]decane (1.1 g, 7.74 mmol) and xantphos (671 mg, 1.16 mmol), and the solution was heated to 120 °C for 1 h with a microwave reactor. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>23</b> (1.4 g, 80%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.09–8.07 (m, 1H), 7.15–7.05 (m, 1H), 7.00–6.90 (m, 1H), 4.27 (s, 3H), 4.26–4.20 (m, 2H), 4.05–3.95 (m, 4H), 2.40–2.25 (m, 4H), 3.00–2.90 (m, 2H), 1.95–1.80 (m, 6H), 1.70–1.65 (m, 1H), 1.60–1.50 (m, 3H), 1.10–1.00 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 454.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub></div></div><div id="sec4_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 5-[2-Ethoxy-5-(4-oxo-1-piperidyl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>24</b>)</h4><div class="NLM_p last">A solution of compound <b>23</b> (1.4 g, 3.1 mmol) in HCl (6.0 M in THF, 10 mL) was stirred at 70 °C overnight. Then, the solution was concentrated to give the crude product which was purified by column chromatography to obtain pure compound <b>24</b> (1.1 g, 85%) as white solid. ESI-MS <i>m</i>/<i>z</i> 410.2 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 5-[2-Ethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>25</b>)</h4><div class="NLM_p last">A mixture of compound <b>22</b> (10 g, 22.82 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (8.69 g, 34.23 mmol), KOAc (6.72 g, 68.46 mmol) and Pd(dppf)Cl<sub>2</sub> (3.34 g, 4.56 mmol, 0.20 equiv) in 1,4-dioxane (150 mL) was degassed and purged with N<sub>2</sub> for 3 times. Then, the mixture was stirred at 80–100 °C for 48 h under N<sub>2</sub> atmosphere. Then, the mixture was extracted with EtOAc and the organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The crude product was purified by column chromatography to give compound <b>25</b> (9 g, 90%) as a purple solid. ESI-MS <i>m</i>/<i>z</i> 439.2 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>31</sub>BN<sub>4</sub>O<sub>2.</sub> This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> [4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]boronic acid (<b>26</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (6.00 g, 13.7 mmol) in acetone (60 mL) was added NaIO<sub>4</sub> (3.51 g, 16.4 mmol) and NH<sub>4</sub>OAc (3.69 g, 47.9 mmol) and the mixture was stirred at 25 °C for 16 h. Then, the mixture was concentrated in vacuum and filtered through a Glass funnel. The filtrate was concentrated to give compound <b>26</b> (3.50 g, 9.83 mmol, 71%) gray solid. ESI-MS <i>m</i>/<i>z</i> 357.7 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>21</sub>BN<sub>4</sub>O<sub>2.</sub> This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Ethyl 2-[1-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]acetate (<b>27a</b>)</h4><div class="NLM_p last">To a solution of methyl 2-diethoxyphosphorylacetate (279 mg, 1.34 mmol) in THF (20 mL) was added NaH (54 mg, 60% in mineral oil, 1.34 mmol) at 0 °C and the mixture was stirred at 0 °C for 1 h. Then a solution of <b>24</b> (500 mg, 1.22 mmol) in THF (5 mL) was added at 0 °C and the reaction was stirred at room temperature overnight. The mixture was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by the column chromatography to give intermediate ethyl 2-[1-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidylidene]acetate (260 mg, 45%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.07–8.06 (m, 1H), 7.09–7.05 (m, 1H), 7.05–6.95 (m, 1H), 5.75 (s, 1H), 4.40–4.10 (m, 7H), 3.40–3.25 (m, 4H), 3.25–3.15 (m, 2H), 3.00–2.90 (m, 2H), 2.55–2.50 (m, 2H), 1.95–1.70 (m, 2H), 1.60–1.50 (m, 4H), 1.35–1.20 (m, 3H), 1.10–1.00 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 480.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4.</sub> To a solution of this intermediate (140 mg, 0.29 mmol) in MeOH (40 mL) was added Pd/C (0.3 g) and the solution was stirred at room temperature for 3 h under H<sub>2</sub> atmosphere (1 atm). Then, the solution was filtered and the filtrate was concentrated to give compound <b>27a</b> (100 mg, 71%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.06–8.05 (m, 1H), 7.08–7.06 (m, 1H), 6.97–6.95 (m, 1H), 4.23–4.14 (m, 7H), 3.64–3.61 (m, 2H), 2.96–2.93 (m, 2H), 2.79–2.76 (m, 2H), 1.91–1.86 (m, 5H), 1.64–1.54 (m, 5H), 1.30–1.27 (m, 5H), 1.06–1.03 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 482.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub></div></div><div id="sec4_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Ethyl 3-[1-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]propanoate (<b>27b</b>)</h4><div class="NLM_p last">To a solution of <b>26</b> (120 mg, 0.34 mmol), Cu(OAc)<sub>2</sub> (127 mg, 0.7 mmol), Et<sub>3</sub>N (101 mg, 1.0 mmol) and 4 Å molecular sieves (400 mg) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added ethyl 3-(4-piperidyl)propanoate (75 mg, 0.4 mmol) under O<sub>2</sub> condition. Then, the mixture was stirred at room temperature for 2 h. Then the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give pure compound <b>27b</b> (15 mg, 9%). ESI-MS <i>m</i>/<i>z</i> 496.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>37</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Ethyl 8-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-8-azaspiro[4.5]decane-3-carboxylate (<b>27c</b>)</h4><div class="NLM_p last">To a solution of compound <b>26</b> (200 mg, 0.56 mmol), Cu(OAc)<sub>2</sub> (217 mg, 1.2 mmol), Et<sub>3</sub>N (152 mg, 1.5 mmol) and 4 Å molecular sieves (800 mg) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (65 mL) was added ethyl 8-azaspiro[4.5]decane-3-carboxylate (144 mg, 0.68 mmol) under O<sub>2</sub> condition. Then, the mixture was stirred at room temperature for 3.5 h. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>27c</b> (135 mg, 46%). ESI-MS <i>m</i>/<i>z</i> 522.1 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>39</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Methyl 2-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2-azaspiro[5.5]undecane-9-carboxylate (<b>27d</b>)</h4><div class="NLM_p last">To a solution of compound <b>26</b> (200 mg, 0.56 mmol), Cu(OAc)<sub>2</sub> (127 mg, 0.7 mmol), Et<sub>3</sub>N (152 mg, 1.5 mmol) and 4 Å molecular sieves (200 mg) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (40 mL) was added methyl 2-azaspiro[5.5]undecane-9-carboxylate (<b>Int. 7</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (120 mg, 0.57 mmol) under O<sub>2</sub> condition. Then, the mixture was stirred at room temperature for 2 h. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give pure compound <b>27d</b> (62 mg, 21%). ESI-MS <i>m</i>/<i>z</i> 522.2 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>39</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Ethyl 2-[2-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2,8-diazaspiro[4.5]decan-8-yl]pyrimidine-5-carboxylate (<b>27e</b>)</h4><div class="NLM_p last">To a solution of compound <b>26</b> (356 mg, 1.0 mmol), Cu(OAc)<sub>2</sub> (217 mg, 1.2 mmol), Et<sub>3</sub>N (152 mg, 1.5 mmol) and 4 Å molecular sieves (600 mg) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (60 mL) was added <i>tert</i>-butyl 2,8-diazaspiro[4.5]decane-8-carboxylate (270 mg, 1.1 mmol) under O<sub>2</sub> condition and then the mixture was stirred at room temperature for 1.5 h. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give pure intermediate <i>tert</i>-butyl 2-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2,8-diazaspiro[4.5]decane-8-carboxylate (310 mg, 56%). ESI-MS <i>m</i>/<i>z</i> 551.3 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>42</sub>N<sub>6</sub>O<sub>4</sub>. Then, a solution of this intermediate (310 mg, 0.56 mmol) in HCl/EtOAc (1.0 M, 40 mL) was stirred at room temperature for 2 h and concentrated. Finally, the residue was dissolved in CH<sub>3</sub>CN (60 mL) and K<sub>2</sub>CO<sub>3</sub> (194 mg, 1.4 mmol) was added. Then, ethyl 2-chloropyrimidine-5-carboxylate (120 mg, 0.64 mmol) was added and the reaction mixture was stirred at 60 °C overnight. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>27e</b> (130 mg, 39%, 2 steps). ESI-MS <i>m</i>/<i>z</i> 601.2 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Ethyl 4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]cyclohexanecarboxylate (<b>27f</b>)</h4><div class="NLM_p last">To a solution of compound <b>26</b> (1.0 g, 2.81 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (50 mL) were added ethyl 4-hydroxycyclohexanecarboxylate (<b>Int. 8</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (500 mg, 2.91 mmol), Cu(OAc)<sub>2</sub> (632 mg, 3.49 mmol), DMAP (71 mg, 0.58 mmol), Et<sub>3</sub>N (1.18 g, 11.6 mmol) and 4 Å molecular sieves (2.5 g), and the mixture was stirred at room temperature for 3 h under O<sub>2</sub> atmosphere. Then, the reaction was quenched with water and filtered; the resulting mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give pure compound <b>27f</b> (440 mg, 31%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 483 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>34</sub>N<sub>4</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Ethyl 4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]benzoate (<b>27g</b>)</h4><div class="NLM_p last">To a solution of compound <b>26</b> (250 mg, 0.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL) were added ethyl 4-hydroxybenzoate (83 mg, 0.5 mmol), Cu(OAc)<sub>2</sub> (127 mg, 0.7 mmol), Et<sub>3</sub>N (253 mg, 2.5 mmol) and 4 Å molecular sieves (0.5 g). Then, the mixture was stirred at room temperature overnight under O<sub>2</sub> protection. Then, the reaction mixture was filtered and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>27g</b> (115 mg, 48%) as yellow solid. ESI-MS <i>m</i>/<i>z</i> 477.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>28</sub>N<sub>4</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]acetic acid (<b>28a</b>)</h4><div class="NLM_p last">To a solution of compound <b>27a</b> (100 mg, 0.21 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 8 mL) was added LiOH·H<sub>2</sub>O (88 mg, 2.1 mmol) and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford compound <b>28a</b> (90 mg, 95%). ESI-MS <i>m</i>/<i>z</i> 454.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 3-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]propanoic acid (<b>28b</b>)</h4><div class="NLM_p last">To a solution of compound <b>27b</b> (15 mg, 0.03 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (22 mg, 0.5 mmol) and the reaction mixture was stirred at room temperature overnight. Then, the reaction mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 3 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>28b</b> (15 mg, 99% crude). ESI-MS <i>m</i>/<i>z</i> 468.3 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 8-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-8-azaspiro[4.5]decane-3-carboxylic acid (<b>28c</b>)</h4><div class="NLM_p last">To a solution of compound <b>27c</b> (135 mg, 0.26 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 30 mL) was added LiOH·H<sub>2</sub>O (130 mg, 3 mmol) and the reaction mixture was stirred at room temperature overnight. Then, the reaction mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 3–4 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>28c</b> (120 mg, 93%). ESI-MS <i>m</i>/<i>z</i> 494.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2-azaspiro[5.5]undecane-9-carboxylic acid (<b>28d</b>)</h4><div class="NLM_p last">To a solution of compound <b>27d</b> (62 mg, 0.12 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (86 mg, 2 mmol) and the reaction mixture was stirred at room temperature overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 3 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>28d</b> (48 mg, 79%). ESI-MS <i>m</i>/<i>z</i> 508.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>37</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 2-[2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2,8-diazaspiro[4.5]decan-8-yl]pyrimidine-5-carboxylic acid (<b>28e</b>)</h4><div class="NLM_p last">To a solution of compound <b>27e</b> (130 mg, 0.22 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (95 mg, 2.2 mmol) and the reaction mixture was stirred at room temperature overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 3 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound <b>28e</b> (95 mg, 77%). ESI-MS <i>m</i>/<i>z</i> 573.2 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>36</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]cyclohexanecarboxylic acid (<b>28f</b>)</h4><div class="NLM_p last">To a solution of compound <b>27f</b> (440 mg, 0.91 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (384 mg, 9.13 mmol) and the reaction mixture was stirred at room temperature overnight until LC-MS showed the starting material was consumed completely. Then, the reaction mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 1–2 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>28f</b> (400 mg, 96%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 455 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]benzoic acid (<b>28g</b>)</h4><div class="NLM_p last">To a solution of compound <b>27g</b> (115 mg, 0.24 mmol) in MeOH/THF/H<sub>2</sub>O (3:1:3, 15 mL) was added LiOH·H<sub>2</sub>O (102 mg, 2.42 mmol) and the reaction mixture was stirred at room temperature overnight until LC-MS showed the starting material was consumed completely. Then, the reaction mixture was concentrated, diluted with H<sub>2</sub>O and the pH adjusted to 1–2 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>28g</b> (100 mg, 93%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 449 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>24</sub>N<sub>4</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 2-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-acetamide (<b>29a</b>)</h4><div class="NLM_p last">To a solution of compound <b>28a</b> (90 mg, 0.2 mmol) in DMF (10 mL) were added EDC·HCl (77 mg, 0.4 mmol), HOBt (54 mg, 0.4 mmol), THPONH<sub>2</sub> (47 mg, 0.4 mmol) and NMM (62 mg, 0.6 mmol) and the mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>29a</b> (70 mg, 64%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 553.3 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>40</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 3-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>29b</b>)</h4><div class="NLM_p last">To a solution of compound <b>28b</b> (15 mg, 0.03 mmol) in DMF (15 mL) were added EDC·HCl (20 mg, 0.1 mmol), HOBt (14 mg, 0.1 mmol), THPONH<sub>2</sub> (12 mg, 0.1 mmol) and NMM (16 mg, 0.15 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>29b</b> (22 mg, 99% crude). ESI-MS <i>m</i>/<i>z</i> 567.2 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>42</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 8-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-8-azaspiro[4.5]decane-3-carboxamide (<b>29c</b>)</h4><div class="NLM_p last">To a solution of compound <b>28c</b> (120 mg, 0.24 mmol) in DMF (20 mL) were added EDC·HCl (93 mg, 0.48 mmol), HOBt (65 mg, 0.48 mmol), THPONH<sub>2</sub> (56 mg, 0.48 mmol) and NMM (62 mg, 0.6 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>29c</b> (142 mg, 99%). ESI-MS <i>m</i>/<i>z</i> 593.2 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>44</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-2-azaspiro[5.5]undecane-9-carboxamide (<b>29d</b>)</h4><div class="NLM_p last">To a solution of compound <b>28d</b> (48 mg, 0.095 mmol) in DMF (15 mL) were added EDC·HCl (39 mg, 0.2 mmol), HOBt (27 mg, 0.2 mmol), THPONH<sub>2</sub> (24 mg, 0.2 mmol) and NMM (40 mg, 0.4 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>29d</b> (52 mg, 90%). ESI-MS <i>m</i>/<i>z</i> 607.5 [M + H]<sup>+</sup> calc. for C<sub>33</sub>H<sub>46</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 2-[2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2,8-diazaspiro[4.5]decan-8-yl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>29e</b>)</h4><div class="NLM_p last">To a solution of compound <b>28e</b> (95 mg, 0.17 mmol) in DMF (30 mL) were added EDC·HCl (68 mg, 0.35 mmol), HOBt (48 mg, 0.35 mmol), THPONH<sub>2</sub> (41 mg, 0.35 mmol) and NMM (61 mg, 0.6 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>29e</b> (100 mg, 87%). ESI-MS <i>m</i>/<i>z</i> 672.2 [M + H]<sup>+</sup> calc. for C<sub>35</sub>H<sub>45</sub>N<sub>9</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]-<i>N</i>-tetrahydropyran-2-yloxy-cyclohexanecarboxamide (<b>29f</b>)</h4><div class="NLM_p last">To a solution of compound <b>28f</b> (400 mg, 0.88 mmol) in DMF (10 mL) were added EDC·HCl (338 mg, 1.76 mmol), HOBt (238 mg, 1.76 mmol), THPONH<sub>2</sub> (206 mg, 1.76 mmol) and NMM (267 mg, 2.64 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>29f</b> (400 mg, 82%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 554 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>39</sub>N<sub>5</sub>O<sub>6</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]-<i>N</i>-tetrahydropyran-2-yloxy-benzamide (<b>29g</b>)</h4><div class="NLM_p last">To a solution of compound <b>28g</b> (100 mg, 0.22 mmol) in DMF (10 mL) were added EDC·HCl (86 mg, 0.45 mmol), HOBt (60 mg, 0.45 mmol), THPONH<sub>2</sub> (52 mg, 0.45 mmol) and NMM (68 mg, 0.67 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>29g</b> (82 mg, 67%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 548 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>33</sub>N<sub>5</sub>O<sub>6</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 2-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]ethanehydroxamic acid (<b>30a</b>)</h4><div class="NLM_p last">A solution of compound <b>29a</b> (70 mg, 0.13 mmol) in HCl/EtOAc (2.0 M, 10 mL) was stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30a</b> (22.9 mg, 35%) as a white solid; m.p.: 196–197 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.19–8.17 (m, 1H), 7.84–7.80 (m, 1H), 7.40–7.36 (m, 1H), 4.35–4.15 (m, 5H), 3.75–3.65 (m, 4H), 2.90–2.80 (m, 2H), 2.35–2.05 (m, 5H), 1.80–1.70 (m, 4H), 1.50–1.40 (m, 3H), 1.05–0.95 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 469.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>.</div></div><div id="sec4_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 3-[1-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-4-piperidyl]propanehydroxamic acid (<b>30b</b>)</h4><div class="NLM_p last">A solution of compound <b>29b</b> (22 mg, 0.04 mmol) in HCl/EtOAc (1.0 M, 10 mL) was stirred at room temperature for 1 h and then concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30b</b> (5.6 mg, 29%) as a white solid; m.p.: 168–169 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.15 (s, 1H), 7.78 (d, <i>J</i> = 8.4 Hz, 1H), 7.36 (d, <i>J</i> = 9.2 Hz, 1H), 4.31–4.25 (m, 2H), 4.24 (s, 3H), 3.73–3.70 (m, 2H), 3.63–3.57 (m, 2H), 2.90–2.86 (m, 2H), 2.22–2.18 (m, 4H), 1.82–1.79 (m, 2H), 1.72–1.67 (m, 5H), 1.50–1.46 (m, 3H), 1.02–0.95 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 483.2 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>34</sub>N<sub>6</sub>O<sub>4</sub></div></div><div id="sec4_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 8-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-8-azaspiro[4.5]decane-3-carbohydroxamic acid (<b>30c</b>)</h4><div class="NLM_p last">A solution of compound <b>29c</b> (142 mg, 0.24 mmol) in HCl/EtOAc (1.0 M, 25 mL) was stirred at room temperature for 1 h and then concentrated to give crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30c</b> (44.8 mg, 37%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.18 (d, <i>J</i> = 2.4 Hz, 1H), 7.86–7.83 (m, 1H), 7.37 (d, <i>J</i> = 8.8 Hz, 1H), 4.31–4.26 (m, 2H), 4.23 (s, 3H), 3.67–3.65 (m, 4H), 2.90–2.86 (m, 2H), 2.80–2.74 (m, 1H), 2.00–1.80 (m, 12H), 1.50–1.46 (m, 3H), 1.02–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 509.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub>. Purity 98.56%.</div></div><div id="sec4_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2-azaspiro[5.5]undecane-9-carbohydroxamic acid (<b>30d</b>)</h4><div class="NLM_p last">A solution of compound <b>29d</b> (52 mg, 0.086 mmol) in HCl/EtOAc (1.0 M, 20 mL) was stirred at room temperature for 1 h. Then, the reaction mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30d</b> (7.8 mg, 17%) as a white solid; m.p.: 117–118 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.05 (s, 1H), 7.71 (d, <i>J</i> = 7.6 Hz, 1H), 7.32 (d, <i>J</i> = 9.2 Hz, 1H), 4.29–4.24 (m, 5H), 3.58–3.51 (m, 4H), 2.91–2.87 (m, 2H), 2.14–1.83 (m, 5H), 1.81–1.79 (m, 2H), 1.69–1.66 (m, 4H), 1.57–1.56 (m, 2H), 1.49–1.46 (m, 5H), 1.00 (t, <i>J</i> = 7.2 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> 523.3 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>38</sub>N<sub>6</sub>O<sub>4</sub></div></div><div id="sec4_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 2-[2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-2,8-diazaspiro[4.5]decan-8-yl]pyrimidine-5-carbohydroxamic acid (<b>30e</b>)</h4><div class="NLM_p last">A solution of compound <b>29e</b> (100 mg, 0.15 mmol) in HCl/EtOAc (1.0 M, 20 mL) was stirred at room temperature for 2 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30e</b> (15.4 mg, 17%) as yellow solid; m.p.: 198–199 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.66 (s, 2H), 7.30 (m, 1H), 7.10 (m, 1H), 6.90 (m, 1H), 4.23–4.14 (m, 5H), 3.97 (m, 4H), 3.49 (m, 2H), 3.45–3.35 (m, 2H), 2.89 (m, 2H), 2.05 (m, 2H), 1.82–1.72 (m, 6H), 1.42 (m, 3H), 1.01 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 588.3 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>37</sub>N<sub>9</sub>O<sub>4</sub>. Purity 94.60%.</div></div><div id="sec4_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]cyclohexanecarbohydroxamic acid (<b>30f</b>)</h4><div class="NLM_p last">A solution of compound <b>29f</b> (200 mg, 0.36 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h and then the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30f</b> (57.3 mg, 34%) as a white solid; m.p.: 181–182 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.60–7.58 (m, 1H), 7.14–7.09 (m, 2H), 4.57 (s, 2H), 4.22 (s, 3H), 4.19–4.16 (m, 2H), 2.91–2.87 (m, 2H), 2.24–1.60 (m, 10H), 1.47–1.44 (m, 3H), 1.03–0.99 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 470.3 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub></div></div><div id="sec4_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]benzenecarbohydroxamic acid (<b>30g</b>)</h4><div class="NLM_p last">A solution of compound <b>29g</b> (82 mg, 0.15 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to obtain pure compound <b>30g</b> (35 mg, 50%) as a white solid; m.p.: 163.5–164.5 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.76–7.74 (d, <i>J</i> = 8.4 Hz, 2H), 7.69 (s, 1H), 7.23 (s, 2H), 7.04–7.02 (d, <i>J</i> = 8.4 Hz, 2H), 4.28–4.24 (m, 2H), 4.21 (s, 3H), 2.85–2.81 (m, 2H), 1.79–1.72 (m, 2H), 1.51–1.47 (m, 3H), 0.97–0.93 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 464.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>5</sub></div></div><div id="sec4_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 5-(2-Ethoxy-5-hydroxy-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>31</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (4.39 g, 10 mmol) in H<sub>2</sub>O (50 mL) were added aqueous NaOH (4.0 M, 13 mmol) and H<sub>2</sub>O<sub>2</sub> (494 mg, 13 mmol). The reaction mixture was stirred at room temperature overnight. Then, Na<sub>2</sub>SO<sub>3</sub> solution was added and the mixture was stirred for 2 h. Then, the reaction mixture was extracted with EtOAc. The organic phase was dried by Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated to give compound <b>31</b> (2.0 g, 61%). ESI-MS <i>m</i>/<i>z</i> 329 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> <i>Tert</i>-butyl 4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]piperidine-1-carboxylate (<b>32</b>)</h4><div class="NLM_p last">To a solution of compound <b>31</b> (328 mg, 1 mmol) in anhydrous toluene (15 mL) were added <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate (<b>Int. 9</b>, synthesis described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) (230 mg, 1.1 mmol), PPh<sub>3</sub> (316 mg, 1.2 mmol) and DEAD (225 mg, 1.2 mmol) and the reaction mixture was stirred at 110 °C for 1 h. Then, the reaction mixture was concentrated under vacuum and purified by column chromatography to give the desired compound <b>32</b> (300 mg, 59%). ESI-MS <i>m</i>/<i>z</i> 512 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>37</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 5-[2-Ethoxy-5-(4-piperidyloxy)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>33</b>)</h4><div class="NLM_p last">To a solution of compound <b>32</b> (205 mg, 0.4 mmol) in 1,4-dioxane (15 mL) was added HCl/1,4-dioxane (4.0 M, 10 mL). The reaction mixture was stirred at room temperature for 2 h. Then the reaction mixture was concentrated to give compound <b>33</b> (150 mg 91%). ESI-MS <i>m</i>/<i>z</i> 412 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Ethyl 2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]-1-piperidyl]pyrimidine-5-carboxylate (<b>34</b>)</h4><div class="NLM_p last">To a solution of compound <b>33</b> (120 mg, 0.3 mmol) in CH<sub>3</sub>CN (15 mL) were added K<sub>2</sub>CO<sub>3</sub> (138 mg, 1 mmol) and ethyl 2-chloropyrimidine-5-carboxylate (88 mg, 0.45 mmol). The solution was stirred at room temperature for 3 h. Then, the mixture was concentrated and purified by column chromatography to give compound <b>34</b> (150 mg, 90%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 562 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>35</sub>N<sub>7</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]-1-piperidyl]pyrimidine-5-carboxylic acid (<b>35</b>)</h4><div class="NLM_p last">To a solution of compound <b>34</b> (281 mg, 0.5 mmol) in THF/MeOH/H<sub>2</sub>O (10:1:3 mL) was added LiOH·H<sub>2</sub>O (107 mg, 2.5 mmol) and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 2–3 with 1 N HCl. The solution was extracted with EtOAC and the combined organic phase was concentrated to give compound <b>35</b> (150 mg, 56%). ESI-MS <i>m</i>/<i>z</i> 534 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>31</sub>N<sub>7</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>36</b>)</h4><div class="NLM_p last">To a solution of compound <b>35</b> (200 mg, 0.37 mmol) in DMF (15 mL) were added EDC·HCl (124 mg, 0.61 mmol), HOBt (82.2 mg, 0.61 mmol), THPONH<sub>2</sub> (63.2 mg, 0.54 mmol) and NMM (251 mg, 2.5 mmol), and the mixture was stirred at room temperature overnight. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative HPLC (method 2 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give compound <b>36</b> (150 mg, 64%). ESI-MS <i>m</i>/<i>z</i> 633 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>40</sub>N<sub>8</sub>O<sub>6</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenoxy]-1-piperidyl]pyrimidine-5-carbohydroxamic acid (<b>37</b>)</h4><div class="NLM_p last">A solution of compound <b>36</b> (100 mg, 0.16 mmol) in HCl/1,4-dioxane (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the reaction mixture was concentrated to give the desired crude product which was purified by preparative HPLC (method 3 described in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>) to give compound <b>37</b> (40 mg, 46%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.58 (s, 2H), 7.62 (s, 1H), 7.14 (m, 2H), 4.65 (m, 1H), 4.21 (m, 7H), 3.84 (m, 2H), 2.88 (m, 2H), 2.05 (m, 2H), 1.82 (m, 4H), 1.47 (t, 3H), 0.99 (t, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 14.7 (CH<sub>3</sub>), 15.5 (CH<sub>3</sub>), 22.6, 28.0, 31.1, 38.7 (NCH<sub>3</sub>), 48.2, 65.5 (CH2O), 73.7, 115.3, 119.0, 124.3, 125.1, 138.7, 145.7, 150.0 (CO), 151.3, 154.5, 158.0, 162.1, 182.8 (CONHOH). ESI-MS <i>m</i>/<i>z</i> 549.3 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>32</sub>N<sub>8</sub>O<sub>5</sub></div></div><div id="sec4_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 5-(5-Bromo-2-ethoxy-phenyl)-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (<b>38</b>)</h4><div class="NLM_p last">To a solution of compound <b>8</b> (2 g, 6.41 mmol) in AcOH (30 mL) was added Br<sub>2</sub> (1.25 g, 7.69 mmol) slowly, and the reaction mixture was stirred at room temperature overnight. Then, Na<sub>2</sub>SO<sub>3</sub> (378 mg, 3 mmol) and water were added into the reaction, and the mixture was stirred at room temperature for 2 h. Then, the solution was concentrated under vacuum and extracted with EtOAc. The organic layer was washed with water, dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>38</b> (2 g, 80%). ESI-MS <i>m</i>/<i>z</i> 391 [M + H]<sup>+</sup> calc. for C<sub>17</sub>H<sub>19</sub>BrN<sub>4</sub>O<sub>2</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Ethyl 4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)benzoate (<b>39</b>)</h4><div class="NLM_p last">To a solution of compound <b>38</b> (350 mg, 0.897 mmol) in EtOH (30 mL) were added Et<sub>3</sub>N (227 mg, 2.243 mmol) and Pd(dppf)Cl<sub>2</sub> (146 mg, 0.199 mmol) at CO atmosphere, then the mixture was stirred at 80 °C overnight under CO protection. Then, the mixture was filtered and concentrated, and the residue was extracted with EtOAc. The organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the pure compound <b>39</b> (254 mg, 74%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 385 [M + H]<sup>+</sup> calc. for C<sub>20</sub>H<sub>24</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)benzoic Acid (<b>40</b>)</h4><div class="NLM_p last">To a solution of compound <b>39</b> (254 mg, 0.661 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (278 mg, 6.61 mmol), and the reaction mixture was stirred at 40 °C overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>40</b> (220 mg, 94%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 357 [M + H]<sup>+</sup> calc. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)-<i>N</i>-tetrahydropyran-2-yloxy-benzamide (<b>41</b>)</h4><div class="NLM_p last">To a solution of compound <b>40</b> (220 mg, 0.618 mmol) in DMF (10 mL) was added EDC·HCl (237 mg, 1.236 mmol), HOBt (167 mg, 1.236 mmol), THPONH<sub>2</sub> (145 mg, 1.236 mmol), and NMM (187 mg, 1.854 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>41</b> (140 mg, 50%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 456 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)benzenecarbohydroxamic Acid (<b>42</b>)</h4><div class="NLM_p last">A solution of compound <b>41</b> (140 mg, 0.308 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>42</b> (85 mg, 74%) as a white solid; m.p., 204.5–205.5 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 8.99 (s, 1H), 8.01 (s, 1H), 7.90–7.87 (m, 1H), 7.21–7.19 (d, <i>J</i> = 8.8 Hz, 1H), 4.19–4.13 (m, 2H), 4.16 (s, 3H), 2.80–2.76 (m, 2H), 1.79–1.70 (m, 2H), 1.34–1.31 (m, 3H), 0.96–0.92 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 372.1 [M + H]<sup>+</sup> calc. for C<sub>18</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> Ethyl 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]acetate (<b>43a</b>)</h4><div class="NLM_p last">To a solution of compound <b>38</b> (500 mg, 1.28 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (118 mg, 0.12 mmol) and xantphos (147 mg, 0.25 mmol) in anhydrous THF (30 mL) was added bromo-(2-ethoxy-2-oxo-ethyl)zinc (<b>Int. 10</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (58.6 mmol in 20 mL of THF) under N<sub>2</sub> protection, and the mixture was stirred at 80 °C overnight. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>43a</b> (270 mg, 53%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 11.10 (s, 1H), 8.35 (s, 1H), 7.41–7.38 (m, 1H), 7.02–7.00 (d, <i>J</i> = 8.4 Hz, 1H), 4.32–4.26 (m, 5H), 4.21–4.16 (m, 2H), 2.96–2.92 (m, 2H), 1.89–1.85 (m, 2H), 1.67–1.58 (m, 5H), 1.30–1.27 (m, 3H), 1.06–1.02 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 399 [M + H]<sup>+</sup> calc. for C<sub>21</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>.</div></div><div id="sec4_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Ethyl 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]propanoate (<b>43b</b>)</h4><div class="NLM_p last">A mixture of compound <b>22</b> (100 mg, 0.23 mmol), ethyl acrylate (71 mg, 0.71 mmol), tri-o-tolylphosphine (28 mg, 0.091 mmol), and Et<sub>3</sub>N (81 mg, 0.80 mmol) was heated in a heavy-walled Pyrex tube at 100 °C overnight under N<sub>2</sub> protection. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to give pure intermediate ethyl (<i>E</i>)-3-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enoate (85 mg, 90%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 10.97 (s, 1H), 8.56 (s, 1H), 7.72–7.68 (d, <i>J</i> = 16.0 Hz, 1H), 7.61–7.59 (d, <i>J</i> = 8.8 Hz, 1H), 7.04–7.02 (d, <i>J</i> = 8.8 Hz, 1H), 6.43–6.39 (d, <i>J</i> = 16.4 Hz, 1H), 4.32–4.26 (m, 4H), 4.25 (s, 3H), 3.46 (s, 2H), 1.90–1.84 (m, 2H), 1.60–1.57 (m, 3H), 1.36–1.32 (m, 3H), 1.06–1.02 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 411 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>. This compound (85 mg, 0.21 mmol) was then dissolved in MeOH (10 mL), and Pd/C (30 mg) was added under H<sub>2</sub> atmosphere (1 atm). Then, the mixture was stirred at room temperature overnight. Then, the mixture was filtered, and the filtrate was concentrated to give the desired compound <b>43b</b> (81 mg, 93%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 413 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Ethyl 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperazin-1-yl]pyrimidine-5-carboxylate (<b>43c</b>)</h4><div class="NLM_p last">To a solution of compound <b>45</b> (400 mg, 1.176 mmol) in anhydrous toluene (20 mL) were added <i>tert</i>-butyl piperazine-1-carboxylate (325 mg, 1.764 mmol) and Ti[OCH(CH<sub>3</sub>)<sub>2</sub>]<sub>4</sub> (500 mg, 1.764 mmol), and the mixture was stirred at room temperature for 90 min under N<sub>2</sub> protection. Then, NaBH(OAc)<sub>3</sub> (499 mg, 2.352 mmol) was added, and the mixture was stirred at room temperature overnight. Then, the mixture was extracted with EtOAc three times, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to obtain pure intermediate <i>tert</i>-butyl 4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperazine-1-carboxylate (450 mg, 75%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 511 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>38</sub>N<sub>6</sub>O<sub>4</sub>. Then, a solution of this intermediate (450 mg, 0.882 mmol) in HCl/EtOAc (4.0 M, 10 mL) was stirred at room temperature for 1 h. The mixture was concentrated to give intermediate 5-[2-ethoxy-5-(piperazin-1-ylmethyl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (340 mg, 94%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 411 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>30</sub>N<sub>6</sub>O<sub>2</sub>. Finally, to a solution of this compound (125 mg, 0.307 mmol) in CH<sub>3</sub>CN (20 mL) were added K<sub>2</sub>CO<sub>3</sub> (85 mg, 0.614 mmol) and ethyl 2-chloropyrimidine-5-carboxylate (57 mg, 0.307 mmol), and the mixture was stirred at 60 °C overnight. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to obtain pure compound <b>43c</b> (150 mg, 87%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 561 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>36</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Ethyl 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]pyrimidine-5-carboxylate (<b>43d</b>)</h4><div class="NLM_p last">To a solution of compound <b>38</b> (10.14 g, 26 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (733 mg, 0.8 mmol), xantphos (926 mg, 1.6 mmol), and Na<sub>2</sub>CO<sub>3</sub> (6.4 g, 60 mmol) in 1,4-dioxane/H<sub>2</sub>O (6:1, 70 mL) was added freshly prepared <i>tert</i>-butyl 4-(9-borabicyclo[3.3.1]nonan-9-ylmethyl)piperidine-1-carboxylate (<b>Int. 9</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (31 mmol in 62 mL of THF), and the mixture was heated at reflux overnight. Then, the mixture was filtered and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to obtain pure intermediate <i>tert</i>-butyl 4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperidine-1-carboxylate (7.1 g, 53%) as a pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 454.1 [M-55] calc. for C<sub>28</sub>H<sub>39</sub>N<sub>5</sub>O<sub>4</sub>. Then, a solution of this intermediate (500 mg, 0.982 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give intermedaiate 5-[2-ethoxy-5-(4-piperidylmethyl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (400 mg, 99%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 410 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub>. Finally, to a solution of this compound (400 mg, 0.978 mmol) in CH<sub>3</sub>CN (20 mL) was added K<sub>2</sub>CO<sub>3</sub> (270 mg, 1.956 mmol) and ethyl 2-chloropyrimidine-5-carboxylate (182 mg, 0.978 mmol), and the mixture was stirred at 40 °C overnight. Then, the mixture was extracted with EtOAc, and the organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>43d</b> (450 mg, 82%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 560 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>37</sub>N<sub>7</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Methyl 6-[4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]pyridine-3-carboxylate (<b>43e</b>)</h4><div class="NLM_p last">To a solution of intermediate 5-[2-ethoxy-5-(4-piperidylmethyl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (synthesis described in <b>43d</b>) (200 mg, 0.489 mmol) in CH<sub>3</sub>CN (20 mL) was added K<sub>2</sub>CO<sub>3</sub> (135 mg, 0.978 mmol) and methyl 6-chloronicotinate (100 mg, 0.587 mmol), and the mixture was stirred at 100 °C overnight. Then, the mixture was extracted with EtOAc, and the organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to obtain pure compound <b>43e</b> (150 mg, 56%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 545 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Methyl 4-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]benzoate (<b>43f</b>)</h4><div class="NLM_p last">To a solution of intermediate 5-[2-ethoxy-5-(4-piperidylmethyl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (synthesis described in <b>43d</b>) (200 mg, 0.49 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added (4-methoxycarbonylphenyl)boronic acid (180 mg, 1 mmol), Cu(OAc)<sub>2</sub> (90 mg, 0.5 mmol), and Et<sub>3</sub>N (260 mg, 2.5 mmol), and the mixture was stirred at room temperature overnight under O<sub>2</sub>. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to obtain pure compound <b>43f</b> (100 mg, 38%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 544.2 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>37</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> Ethyl 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]propanoate (<b>43g</b>)</h4><div class="NLM_p last">Freshly prepared <i>tert</i>-butyl 4-(9-borabicyclo[3.3.1]nonan-9-ylmethyl)piperidine-1-carboxylate (<b>Int. 12</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (31 mmol in 62 mL of THF) was added to a mixture of <b>38</b> (10.14 g, 26 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (733 mg, 0.8 mmol), xantphos (926 mg, 1.6 mmol), and Na<sub>2</sub>CO<sub>3</sub> (6.4 g, 60 mmol) in 1,4-dioxane/H<sub>2</sub>O (6:1, 70 mL). The resulting mixture was stirred at reflux overnight. Then, the solution was filtered and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give intermediate <i>tert</i>-butyl 4-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperidine-1-carboxylate (7.1 g, 45%) as a pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 454.1 [M+H–C(CH<sub>3</sub>)<sub>3</sub>]<sup>+</sup> calc. for C<sub>28</sub>H<sub>39</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate (500 mg, 0.98 mmol) was dissolved in HCl/EtOAc (4.0 M, 5 mL) and stirred at room temperature for 1 h. Then, the mixture was concentrated to give corresponding deprotected amine 5-[2-ethoxy-5-(4-piperidylmethyl)phenyl]-1-methyl-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-7-one (400 mg, 99%) as a white solid. MS <i>m</i>/<i>z</i> 410 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>. Finally, this intermediate (240 mg, 0.59 mmol) was dissolved in CAN (15 mL), and ethyl prop-2-enoate (180 mg, 1.8 mmol) and DIEA (290 mg, 2.24 mmol) were added. The mixture was stirred at 80 °C overnight. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>43g</b> (100 mg, 34%) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.14–8.13 (m, 1H), 7.18–7.15 (m, 1H), 6.93–6.90 (m, 1H), 4.26–4.10 (m, 6H), 3.64 (s, 3H), 3.40 (s, 1H), 3.20–3.05 (m, 2H), 2.95–2.80 (m, 4H), 2.75–2.60 (m, 2H), 2.60–2.50 (m, 2H), 2.35–2.15 (m, 2H), 1.90–1.50 (m, 10H), 1.05–0.95 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 510.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>39</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Ethyl 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexyl]acetate (<b>43h</b>)</h4><div class="NLM_p last">Freshly prepared ethyl 2-[4-(9-borabicyclo[3.3.1]nonan-9-ylmethyl)cyclohexyl]acetate (<b>Int. 13</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (2.74 mmol in 10 mL of THF) was added into a mixture of <b>22</b> (1.2 g, 2.74 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (275 mg, 0.3 mmol), xantphos (122 mg, 0.21 mmol), and Na<sub>2</sub>CO<sub>3</sub> (583 mg, 5.5 mmol) in 1,4-dioxane/H<sub>2</sub>O (5:1, 24 mL). The resulting mixture was stirred at reflux overnight. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure compound <b>43h</b> (300 mg, 23%) as a pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 495.3 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>38</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Ethyl 4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexanecarboxylate (<b>43i</b>)</h4><div class="NLM_p last">Freshly prepared ethyl 4-(9-borabicyclo[3.3.1]nonan-9-ylmethyl)cyclohexanecarboxylate (<b>Int. 14</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (3 mmol in 10 mL of THF) was added into a mixture of <b>22</b> (1 g, 2.3 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (80 mg, 0.1 mmol), xantphos (122 mg, 0.2 mmol), and Na<sub>2</sub>CO<sub>3</sub> (668 mg, 6.3 mmol) in 1,4-dioxane/H<sub>2</sub>O (5:1, 24 mL), and the resulting mixture was stirred at reflux overnight. Then, the reaction mixture was filtered and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure compound <b>43i</b> (400 mg, 36%) as a pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 481.3 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>36</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_119" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> Methyl 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclopentanecarboxylate (<b>43j</b>)</h4><div class="NLM_p last">Freshly prepared methyl 3-(9-borabicyclo[3.3.1]nonan-9-ylmethyl)cyclopentanecarboxylate (<b>Int. 15</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (5 mmol in 10 mL of THF) was added into a mixture of <b>22</b> (2.2 g, 5 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (400 mg, 0.4 mmol), xantphos (600 mg, 1.0 mmol), and Na<sub>2</sub>CO<sub>3</sub> (2.1 g, 19 mmol) in 1,4-dioxane/H<sub>2</sub>O (10:1, 44 mL). The resulting mixture was stirred at reflux overnight. Then, the solution was filtered and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to afford pure compound <b>43j</b> (600 mg, 27%) as a pale yellow oil. ESI-MS <i>m</i>/<i>z</i> 453.3 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_120" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> Ethyl 2-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclopropanecarboxylate (<b>43k</b>)</h4><div class="NLM_p last"><i>n</i>-BuLi (1.1 mL, 2.7 mmol, 2.5 M) was added to a stirred suspension of <b>22</b> (1.1 g, 2.5 mmol) in THF (40 mL) at −70 °C over a period of 10 min under N<sub>2</sub>. The resulting solution was stirred at −40 °C for 1 h, and then ethyl 2-formylcyclopropanecarboxylate (375 mg, 2.64 mmol, predominantly trans) in THF (10 mL) was added over a period of 5 min under N<sub>2</sub>. The resulting solution was stirred at room temperature for 15 h. Then, the reaction was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The combined organic phase was washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated <i>in vacuo</i>. The residue was purified by column chromatography to give intermediate alcohol ethyl 2-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-hydroxy-methyl]cyclopropanecarboxylate (210 mg, 19%). ESI-MS <i>m</i>/<i>z</i> 455.1 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O<sub>5</sub>. Then, this compound (210 mg, 0.46 mmol) was dissolved in TFA (8 mL), and a solution of Et<sub>3</sub>SiH (8 mL) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) was added dropwise at 0 °C. The reaction mixture was stirred at room temperature for another 10 h. Then, the solution was quenched by aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phase was washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>43k</b> (135 mg, 67%). ESI-MS <i>m</i>/<i>z</i> 439.1 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_121" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Ethyl 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperidine-4-carboxylate (<b>43l</b>)</h4><div class="NLM_p last">To a solution of compound <b>45</b> (250 mg, 0.736 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (30 mL) were added ethylpiperidine-4-carboxylate (97 mg, 0.62 mmol), AcOH (cat) and NaBH(OAc)<sub>3</sub> (260 mg, 1.22 mmol), and the mixture was stirred at room temperature overnight. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound, which was purified by preparative TLC to give pure compound <b>43l</b> (150 mg, 42%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 482 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_122" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> Methyl 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]azetidine-3-carboxylate (<b>43m</b>)</h4><div class="NLM_p last">To a solution of compound <b>45</b> (1 g, 2.9 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (50 mL) were added methyl azetidine-3-carboxylate (677 mg, 5.9 mmol), AcOH (cat), and NaBH(OAc)<sub>3</sub> (1 g, 4.7 mmol), and the mixture was stirred at room temperature overnight until LC-MS showed the starting material was consumed completely. Then, the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic layer was washed with aqueous NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to give pure compound <b>43m</b> (0.8 g, 63%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 440 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_123" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> Ethyl 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclopropanecarboxylate (<b>43o</b>)</h4><div class="NLM_p last">To a solution of ethyl 2-diethoxyphosphorylacetate (2.1 g, 9.5 mmol) in THF (60 mL) was added NaH (0.48 g 60% in mineral oil, 12 mmol) at 0 °C, and the solution was stirred at 0 °C for 1 h. Then, a solution of compound <b>45</b> (3.2 g, 9.4 mmol) in THF (10 mL) was added at 0 °C, and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with aqueous NH<sub>4</sub>Cl and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give intermediate ethyl (<i>E</i>)-3-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enoate (3.1 g, 80%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 411.2 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>. Then, trimethyloxosulphonium iodide (1.85 g, 8.4 mmol) was added to a stirred suspension of NaH (340 mg 60% in mineral oil, 8.4 mmol) in DMSO (50 mL) at 40 °C over a period of 15 min under N<sub>2</sub>. The resulting solution was stirred at 40 °C for 1 h, and then intermediate ethyl (<i>E</i>)-3-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]prop-2-enoate (2.3 g, 5.6 mmol) in DMSO (10 mL) was added over a period of 10 min under N<sub>2</sub>. The reaction mixture was stirred at 40 °C for another 12 h. Then, the reaction was quenched by ice slowly and extracted with EtOAc. The combined organic phase was washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuum. The residue was purified by column chromatography to give pure compound <b>43o</b> (1.82 g, 77%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.26–8.22 (m, 1H), 7.17–7.14 (m, 1H), 6.97–6.94 (m, 1H), 4.32–4.17 (m, 7H), 2.97–2.93 (m, 2H), 2.60–2.56 (m, 1H), 1.92–1.86 (m, 3H), 1.60–1.56 (m, 4H), 1.30–1.26 (m, 4H), 1.07–1.04 (m, 3H), 0.88 (m, 1H). ESI-MS <i>m</i>/<i>z</i> 425.1 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>.</div></div><div id="sec4_1_124" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> Ethyl 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclobutanecarboxylate (<b>43p</b>)</h4><div class="NLM_p last">Freshly prepared ethyl 3-(9-borabicyclo[3.3.1]nonan-9-ylmethyl)cyclobutanecarboxylate (<b>Int. 17</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (21.4 mmol in 40 mL of THF) was added to a mixture of <b>22</b> (7.82 g, 17.8 mmol), xantphos (2.55 g, 4.40 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (1.63 g,1.78 mmol), and Na<sub>2</sub>CO<sub>3</sub> (5.67 g, 53.5 mmol) in 1,4-dioxane/H<sub>2</sub>O (10:1, 44 mL). The resulting mixture was stirred at reflux overnight. Then, the reaction mixture was filtered and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure compound <b>43p</b> (4.5 g, 56%) as a pale yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 11.13 (s, 1H), 8.22 (s, 1H), 7.23–7.21 (m, 1H), 6.96–6.94 (m, 1H), 4.28 (s, 3H), 4.15–4.10 (m, 3H), 2.98–2.94 (m, 2H), 2.82–2.75 (m, 2H), 2.55–2.53 (m, 1H), 2.37–2.32 (m, 2H), 1.90–1.87 (m, 2H), 1.60–1.57 (m, 5H), 1.28–1.25 (m, 5H), 1.07–1.04 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 453.3 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>.</div></div><div id="sec4_1_125" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)benzonitrile (<b>44</b>)</h4><div class="NLM_p last">To a solution of compound <b>22</b> (20.0 g, 46 mmol) in DMF (100 mL) were added Zn(CN)<sub>2</sub> (10.6 g, 92 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (5.1 g, 4.6 mmol), and the mixture was stirred at 80 °C overnight under N<sub>2</sub> protection. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure compound <b>44</b> (10 g, 67%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 338 [M + H]<sup>+</sup> calc. for C<sub>18</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_126" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> 4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)benzaldehyde (<b>45</b>)</h4><div class="NLM_p last">To a solution of compound <b>44</b> (10 g, 29.6 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (120 mL) was added DIBAL-H (34.8 mL, 1.0 M in toluene, 34.8 mmol) slowly at 0 °C; then, the mixture was stirred at room temperature overnight under N<sub>2</sub> protection until HPLC showed the starting material was consumed completely. Then, the mixture was poured into 2 N HCl, extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure compound <b>45</b> (1 g, 10%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 341 [M + H]<sup>+</sup> calc. for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_127" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]acetic Acid (<b>46a</b>)</h4><div class="NLM_p last">To a solution of compound <b>43a</b> (270 mg, 0.68 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (285 mg, 6.78 mmol), and the reaction mixture was stirred at room temperature overnight. Then, the solution was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46a</b> (230 mg, 92%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 371 [M + H]<sup>+</sup> calc. for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_128" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]propanoic Acid (<b>46b</b>)</h4><div class="NLM_p last">To a solution of <b>43b</b> (81 mg, 0.20 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (84 mg, 2.0 mmol), and the mixture was stirred at 40 °C overnight. Then, the solution was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46b</b> (60 mg, 78%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 385 [M + H]<sup>+</sup> calc. for C<sub>20</sub>H<sub>24</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_129" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperazin-1-yl]pyrimidine-5-carboxylic Acid (<b>46c</b>)</h4><div class="NLM_p last">To a solution of compound <b>43c</b> (150 mg, 0.268 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (112 mg, 2.68 mmol), and the reaction mixture was stirred at room temperature overnight until LC-MS showed the starting material was consumed completely. Then, the mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46c</b> (130 mg, 91%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 533 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>32</sub>N<sub>8</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_130" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]pyrimidine-5-carboxylic Acid (<b>46d</b>)</h4><div class="NLM_p last">To a solution of compound <b>43d</b> (450 mg, 0.805 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (338 mg, 8.05 mmol), and the reaction mixture was stirred at 40 °C overnight until LC-MS showed the starting material was consumed completely. Then, the mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. Then, the solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46d</b> (400 mg, 94%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 532 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>33</sub>N<sub>7</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_131" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> 6-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]pyridine-3-carboxylic Acid (<b>46e</b>)</h4><div class="NLM_p last">To a solution of compound <b>43e</b> (150 mg, 0.276 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (116 mg, 2.76 mmol), and the reaction mixture was stirred at room temperature overnight until LC-MS showed the starting material was consumed completely. Then, the mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46e</b> (130 mg, 89%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 531 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>34</sub>N<sub>6</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_132" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> 4-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]benzoic Acid (<b>46f</b>)</h4><div class="NLM_p last">To a solution of compound <b>43f</b> (100 mg, 0.18 mmol) in THF/MeOH/H<sub>2</sub>O (1:3:1, 8 mL) was added LiOH·H<sub>2</sub>O (76 mg, 1.8 mmol), and the mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>46f</b> (80 mg, 84%). ESI-MS <i>m</i>/<i>z</i> 530.2 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_133" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]propanoic Acid (<b>46g</b>)</h4><div class="NLM_p last">To a solution of compound <b>43g</b> (100 mg, 0.2 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 8 mL) was added LiOH·H<sub>2</sub>O (88 mg, 2 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The mixture was extracted with EtOAc, and the organic phase was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>46g</b> (100 mg, 99%). ESI-MS <i>m</i>/<i>z</i> 482.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_134" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexyl]acetic Acid (<b>46h</b>)</h4><div class="NLM_p last">To a solution of compound <b>43h</b> (300 mg, 0.61 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (260 mg, 6.1 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>46h</b> (260 mg, 91%). ESI-MS <i>m</i>/<i>z</i> 467.3 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_135" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> 4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexanecarboxylic Acid (<b>46i</b>)</h4><div class="NLM_p last">To a solution of <b>43i</b> (400 mg, 0.84 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (361 mg, 8.6 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 3–4 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered concentrated, and purified by preparative TLC to afford the desired compound <b>46i</b> (350 mg, 93%). ESI-MS <i>m</i>/<i>z</i> 453.3 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_136" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclopentanecarboxylic Acid (<b>46j</b>)</h4><div class="NLM_p last">To a solution of compound <b>43j</b> (600 mg, 1.33 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (560 mg, 13.3 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 3–4 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by preparative TLC to afford the desired product <b>46j</b> (500 mg, 86%). ESI-MS <i>m</i>/<i>z</i> 439.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_137" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> 2-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclopropanecarboxylic Acid (<b>46k</b>)</h4><div class="NLM_p last">To a solution of compound <b>43k</b> (135 mg, 0.31 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (130 mg, 3 mmol), and the reaction mixture was stirred at room temperature overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 3–4 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46k</b> (125 mg, 98%). ESI-MS <i>m</i>/<i>z</i> 411.1 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_138" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperidine-4-carboxylic Acid (<b>46l</b>)</h4><div class="NLM_p last">To a solution of compound <b>43l</b> (150 mg, 0.31 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (131 mg, 3.12 mmol), and the reaction mixture was stirred at room temperature overnight. Then, the solution was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46l</b> (130 mg, 92%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 454 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_139" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]azetidine-3-carboxylic Acid (<b>46m</b>)</h4><div class="NLM_p last">To a solution of compound <b>43m</b> (800 mg, 1.8 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (763 mg, 18 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46m</b> (800 mg, 99% crude) as a white solid. ESI-MS <i>m</i>/<i>z</i> 426 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_140" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclobutanecarboxylic Acid (<b>46n</b>)</h4><div class="NLM_p last"><i>n</i>-BuLi (2.6 mL, 6.5 mmol, 2.5 M) was added to a stirred suspension of compound <b>22</b> (2.63 g, 6.0 mmol) in THF (60 mL) at −70 °C over a period of 5 min under N<sub>2</sub>. The resulting solution was stirred at −40 °C for 1 h, and then <i>tert</i>-butyl 3-oxocyclobutanecarboxylate (<b>Int. 16</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (1.1 g, 6.5 mmol) in THF (10 mL) was added over a period of 5 min under N<sub>2</sub>. The resulting solution was stirred at room temperature for 15 h. The reaction was quenched with aqueous NH<sub>4</sub>Cl and then extracted with EtOAc. The combined organic phase was washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuum. The residue was purified by column chromatography to give pure intermediate <i>tert</i>-butyl 3-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>h</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-3-hydroxy-cyclobutanecarboxylate (830 mg, 29%). ESI-MS <i>m</i>/<i>z</i> 483.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>34</sub>N<sub>4</sub>O<sub>5</sub>. To a solution of this intermediate (700 mg, 1.45 mmol) in TFA (8 mL) was added a solution of Et<sub>3</sub>SiH (8 mL) in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature for another 10 h. Then, the reaction was quenched with aqueous NaHCO<sub>3</sub> slowly and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The combined organic phase was washed with saturated brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46n</b> (512 mg, 86%). ESI-MS <i>m</i>/<i>z</i> 411.1 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_141" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclopropanecarboxylic Acid (<b>46o</b>)</h4><div class="NLM_p last">To a solution of compound <b>43o</b> (1.82 g, 4.3 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 60 mL) was added LiOH·H<sub>2</sub>O (2.2 g, 52 mmol), and the reaction mixture was stirred at room temperature overnight. Then, the mixture was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 3–4 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>46o</b> (1.62 g, 95%). ESI-MS <i>m</i>/<i>z</i> 397.3 [M + H]<sup>+</sup> calc. for C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_142" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclobutanecarboxylic Acid (<b>46p</b>)</h4><div class="NLM_p last">To a solution of compound <b>43p</b> (4.5 g, 9.94 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 60 mL) was added LiOH·H<sub>2</sub>O (4.17 g, 99.4 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 3–4 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford compound <b>46p</b> (3.8 g, 90%) ESI-MS <i>m</i>/<i>z</i> 425.3 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_143" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-acetamide (<b>47a</b>)</h4><div class="NLM_p last">To a solution of compound <b>46a</b> (115 mg, 0.31 mmol) in DMF (10 mL) were added EDC·HCl (119 mg, 0.62 mmol), HOBt (84 mg, 0.62 mmol), THPONH<sub>2</sub> (73 mg, 0.62 mmol), and NMM (94 mg, 0.93 mmol), and the mixture was stirred at room temperature overnight. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the desired <b>47a</b> (116 mg, 79%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 470 calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_144" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>47b</b>)</h4><div class="NLM_p last">To a solution of compound <b>46b</b> (60 mg, 0.156 mmol) in DMF (10 mL) were added EDC·HCl (60 mg, 0.31 mmol), HOBt (42 mg, 0.31 mmol), THPONH<sub>2</sub> (36 mg, 0.31 mmol), and NMM (48 mg, 0.47 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the corresponding <b>47b</b> (60 mg, 80%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 484 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_145" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperazin-1-yl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>47c</b>)</h4><div class="NLM_p last">To a solution of compound <b>46c</b> (130 mg, 0.244 mmol) in DMF (10 mL) was added EDC·HCl (94 mg, 0.488 mmol), HOBt (66 mg, 0.488 mmol), THPONH<sub>2</sub> (57 mg, 0.488 mmol), and NMM (74 mg, 0.732 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to obtain pure compound <b>47c</b> (120 mg, 78%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 632 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>41</sub>N<sub>9</sub>O<sub>5</sub>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 11.10 (s, 1H), 9.19 (s, 1H), 8.69 (s, 2H), 8.34 (s, 1H), 7.50–7.48 (d, <i>J</i> = 6.8 Hz, 1H), 7.03–7.01 (d, <i>J</i> = 8.4 Hz, 1H), 5.03 (s, 1H), 4.31–4.29 (m, 2H), 4.26 (s, 3H), 3.98–3.90 (m, 4H), 3.61 (s, 2H), 3.47 (s, 2H), 2.93–2.91 (m, 2H), 2.60–2.52 (m, 4H), 2.00–1.84 (m, 8H), 1.60–1.57 (m, 3H), 1.04–1.00 (m, 3H).</div></div><div id="sec4_1_146" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyrimidine-5-carboxamide (<b>47d</b>)</h4><div class="NLM_p last">To a solution of compound <b>46d</b> (400 mg, 0.753 mmol) in DMF (10 mL) was added EDC·HCl (289 mg, 1.507 mmol), HOBt (203 mg, 1.507 mmol), THPONH<sub>2</sub> (176 mg, 1.507 mmol), and NMM (228 mg, 2.259 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to obtain pure compound <b>47d</b> (400 mg, 84%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 631 [M + H]<sup>+</sup> calc. for C<sub>33</sub>H<sub>42</sub>N<sub>8</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_147" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> 6-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyridine-3-carboxamide (<b>47e</b>)</h4><div class="NLM_p last">To a solution of compound <b>46e</b> (130 mg, 0.245 mmol) in DMF (10 mL) was added EDC·HCl (94 mg, 0.490 mmol), HOBt (66 mg, 0.490 mmol), THPONH<sub>2</sub> (58 mg, 0.490 mmol), and NMM (74 mg, 0.735 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to obtain pure compound <b>47e</b> (100 mg, 65%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 630 [M + H]<sup>+</sup> calc. for C<sub>34</sub>H<sub>43</sub>N<sub>7</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_148" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> 4-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-benzamide (<b>47f</b>)</h4><div class="NLM_p last">To a solution of compound <b>46f</b> (80 mg, 0.15 mmol) in DMF (10 mL) was added EDC·HCl (60 mg, 0.3 mmol), HOBt (40 mg, 0.3 mmol), THPONH<sub>2</sub> (30 mg, 0.3 mmol), and NMM (50 mg, 0.45 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to obtain pure compound <b>47f</b> (60 mg, 64%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 629.2 [M + H]<sup>+</sup> calc. for C<sub>35</sub>H<sub>44</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_149" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>47g</b>)</h4><div class="NLM_p last">To a solution of compound <b>46g</b> (100 mg, 0.2 mmol) in DMF (10 mL) were added EDC·HCl (77 mg, 0.4 mmol), HOBt (54 mg, 0.4 mmol), THPONH<sub>2</sub> (47 mg, 0.4 mmol), and NMM (62 mg, 0.6 mmol), and the mixture was stirred at room temperature overnight. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the desired <b>47g</b> (80 mg, 69%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 581.3 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>44</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_150" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexyl]-<i>N</i>-tetrahydropyran-2-yloxy-acetamide (<b>47h</b>)</h4><div class="NLM_p last">To a solution of compound <b>46h</b> (260 mg, 0.56 mmol) in DMF (20 mL) were added EDC·HCl (215 mg, 1.12 mmol), HOBt (151 mg, 1.12 mmol), THPONH<sub>2</sub> (131 mg, 1.12 mmol), and NMM (170 mg, 1.68 mmol), and the mixture was stirred at room temperature overnight. Then, the mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the desired <b>47h</b> (200 mg, 62%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 566.3 [M + H]<sup>+</sup> calc. for C<sub>31</sub>H<sub>43</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_151" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> 4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-<i>N</i>-tetrahydropyran-2-yloxy-cyclohexanecarboxamide (<b>47i</b>)</h4><div class="NLM_p last">To a solution of compound <b>46i</b> (350 mg, 0.77 mmol) in DMF (20 mL) were added EDC·HCl (292 mg, 1.54 mmol), HOBt (207 mg, 1.54 mmol), THPONH<sub>2</sub> (180 mg, 1.54 mmol), and NMM (170 mg, 1.68 mmol), and the mixture was stirred at room temperature overnight. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the desired <b>47i</b> (200 mg, 47%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 552.3 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>41</sub>N<sub>5</sub>O<sub>5</sub>.</div></div><div id="sec4_1_152" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-N-tetrahydropyran-2-yloxy-cyclopentanecarboxamide (<b>47j</b>)</h4><div class="NLM_p last">To a solution of compound <b>46j</b> (500 mg, 1.14 mmol) in DMF (30 mL) were added EDC·HCl (438 mg, 2.3 mmol), HOBt (310 mg, 2.3 mmol), THPONH<sub>2</sub> (269 mg, 2.3 mmol), and NMM (345 mg, 3.4 mmol), and the mixture was stirred at room temperature overnight. Then, the solution was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the desired <b>47j</b> (300 mg, 50%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 538.3 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>39</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_153" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> 2-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-<i>N</i>-tetrahydropyran-2-yloxy-cyclopropanecarboxamide (<b>47k</b>)</h4><div class="NLM_p last">To a solution of compound <b>46k</b> (125 mg, 0.3 mmol) in DMF (20 mL) were added EDC·HCl (97 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), THPONH<sub>2</sub> (59 mg, 0.5 mmol), and NMM (101 mg, 1.0 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the desired <b>47k</b> (93 mg, 61%). ESI-MS <i>m</i>/<i>z</i> 510.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>35</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further purification.</div></div><div id="sec4_1_154" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-<i>N</i>-tetrahydropyran-2-yloxy-piperidine-4-carboxamide (<b>47l</b>)</h4><div class="NLM_p last">To a solution of compound <b>46l</b> (130 mg, 0.287 mmol) in DMF (10 mL) were added EDC·HCl (110 mg, 0.57 mmol), HOBt (77 mg, 0.57 mmol), THPONH<sub>2</sub> (67 mg, 0.57 mmol), and NMM (87 mg, 0.86 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give the compound <b>47l</b> (110 mg, 70%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 553 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>40</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_155" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-<i>N</i>-tetrahydropyran-2-yloxy-azetidine-3-carboxamide (<b>47m</b>)</h4><div class="NLM_p last">To a solution of compound <b>46m</b> (400 mg, 0.94 mmol) in DMF (20 mL) were added EDC·HCl (360 mg, 1.88 mmol), HOBt (254 mg, 1.88 mmol), THPONH<sub>2</sub> (220 mg, 1.88 mmol), and NMM (300 mg, 2.97 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>47m</b> (300 mg, 60%) as a yellow solid. ESI-MS <i>m</i>/<i>z</i> 525.3 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>36</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_156" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-cyclopropanecarboxamide (<b>47o</b>)</h4><div class="NLM_p last">To a solution of compound <b>46o</b> (1.62 g, 4.0 mmol) in DMF (60 mL) were added EDC·HCl (1.54 g, 8 mmol), HOBt (1.08 g, 8 mmol), THPONH<sub>2</sub> (940 mg, 8 mmol), and NMM (1.2 g, 12 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>47o</b> (1.75 g, 88%). ESI-MS <i>m</i>/<i>z</i> 496.3 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>33</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_157" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]ethanehydroxamic Acid (<b>48a</b>)</h4><div class="NLM_p last">Compound <b>47a</b> (116 mg, 0.25 mmol) was dissolved in HCl/EtOAc (4.0 M, 5 mL) and stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48a</b> (12.2 mg, 13%) as a white solid; m.p., 159–160 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.84 (s, 1H), 7.46–7.43 (m, 1H), 7.13–7.10 (d, <i>J</i> = 8.4 Hz, 1H), 4.22–4.18 (m, 5H), 3.43 (s, 2H), 2.89–2.85 (m, 2H), 1.85–1.76 (m, 2H), 1.46–1.43 (m, 3H), 1.02–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 386.2 [M + H]<sup>+</sup> calc. for C<sub>19</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub></div></div><div id="sec4_1_158" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]propanehydroxamic Acid (<b>48b</b>)</h4><div class="NLM_p last">Compound <b>47b</b> (60 mg, 0.124 mmol) was dissolved in HCl/EtOAc (4.0 M, 5 mL) and stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48b</b> (20 mg, 40%) as a red solid; m.p., 166–167 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.75 (s, 1H), 7.37–7.36 (d, <i>J</i> = 6.8 Hz, 1H), 7.10–7.08 (d, <i>J</i> = 8.8 Hz, 1H), 4.23 (s, 3H), 4.20–4.17 (m, 2H), 2.96–2.87 (m, 4H), 2.42–2.39 (m, 2H), 1.86–1.77 (m, 2H), 1.46–1.42 (m, 3H), 1.03–0.99 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 400.1 [M + H]<sup>+</sup> calc. for C<sub>20</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_159" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperazin-1-yl]pyrimidine-5-carbohydroxamic Acid (<b>48c</b>)</h4><div class="NLM_p last">A solution of compound <b>47c</b> (120 mg, 0.19 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (Method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48c</b> (26.2 mg, 25%) as a white solid; m.p., 173–174 °C. ESI-MS <i>m</i>/<i>z</i> 548.3 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>33</sub>N<sub>9</sub>O<sub>4</sub>. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.74 (s, 2H), 8.03 (s, 1H), 7.68–7.66 (d, <i>J</i> = 8.4 Hz, 1H), 7.31–7.29 (d, <i>J</i> = 8.8 Hz, 1H), 5.05–4.91 (m, 4H), 4.42 (s, 2H), 4.30–4.27 (m, 2H), 4.24 (s, 3H), 3.39–3.35 (m, 4H), 2.90–2.86 (m, 2H), 1.86–1.77 (m, 2H), 1.49–1.46 (m, 3H), 1.02–0.98 (m, 3H).</div></div><div id="sec4_1_160" class="NLM_sec NLM_sec_level_3"><div id="ac_i174" class="anchor-spacer"></div><h4 class="article-section__title" id="_i174"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]pyrimidine-5-carbohydroxamic Acid (<b>48d</b>)</h4><div class="NLM_p last">A solution of compound <b>47d</b> (400 mg, 0.635 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48d</b> (150 mg, 43%) as a white solid; m.p., 185.5–186.5 °C. ESI-MS <i>m</i>/<i>z</i> 547.4 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>34</sub>N<sub>8</sub>O<sub>4</sub>. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.93 (s, 1H), 11.06 (s, 1H), 8.63 (s, 2H), 7.46 (s, 1H), 7.28–7.26 (d, <i>J</i> = 8.4 Hz, 1H), 7.07–7.05 (d, <i>J</i> = 8.0 Hz, 1H), 4.70–4.67 (m, 2H), 4.14 (s, 3H), 4.11–4.08 (m, 2H), 2.90–2.87 (m, 2H), 2.78–2.74 (m, 2H), 2.53–2.50 (m, 2H), 1.74–1.65 (m, 5H), 1.32–1.29 (m, 3H), 1.12–1.00 (m, 2H), 0.94–0.91 (m, 3H).</div></div><div id="sec4_1_161" class="NLM_sec NLM_sec_level_3"><div id="ac_i175" class="anchor-spacer"></div><h4 class="article-section__title" id="_i175"> 6-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]pyridine-3-carbohydroxamic Acid (<b>48e</b>)</h4><div class="NLM_p last">A solution of compound <b>47e</b> (100 mg, 0.159 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48e</b> (22.2 mg, 25%) as a white solid; m.p., 156.5–157.5 °C. ESI-MS <i>m</i>/<i>z</i> 546.3 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>35</sub>N<sub>7</sub>O<sub>4</sub>. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.34 (s, 1H), 8.08–8.06 (d, <i>J</i> = 9.2 Hz, 1H), 7.74 (s, 1H), 7.35–7.34 (d, <i>J</i> = 6.8 Hz, 1H), 7.21–7.18 (d, <i>J</i> = 9.6 Hz, 1H), 7.12–7.10 (d, <i>J</i> = 8.8 Hz, 1H), 4.32–4.28 (m, 2H), 4.23 (s, 3H), 4.22–4.18 (m, 2H), 3.18–3.12 (m, 2H), 2.91–2.87 (m, 2H), 2.65–2.63 (m, 2H), 2.13–1.79 (m, 5H), 1.47–1.44 (m, 3H), 1.40–1.35 (m, 2H), 1.02–0.99 (m, 3H).</div></div><div id="sec4_1_162" class="NLM_sec NLM_sec_level_3"><div id="ac_i176" class="anchor-spacer"></div><h4 class="article-section__title" id="_i176"> 4-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]benzenecarbohydroxamic Acid (<b>48f</b>)</h4><div class="NLM_p last">A solution of compound <b>47f</b> (60 mg, 0.09 mmol) in HCl/EtOAc (2.0 M, 10 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48f</b> (8.3 mg, 17%) as a white solid; m.p., 203–204 °C. ESI-MS <i>m</i>/<i>z</i> 545.2 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub>. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.80–7.50 (m, 1H), 7.50–7.45 (m, 2H), 7.40–7.30 (m, 1H), 7.15–7.00 (m, 3H), 4.30–4.15 (m, 5H), 3.90–3.75 (m, 2H), 2.95–2.85 (m, 4H), 2.65–2.55 (m, 2H), 1.90–1.70 (m, 5H), 1.50–1.30 (m, 5H), 1.05–0.95 (m, 3H).</div></div><div id="sec4_1_163" class="NLM_sec NLM_sec_level_3"><div id="ac_i177" class="anchor-spacer"></div><h4 class="article-section__title" id="_i177"> 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]-1-piperidyl]propanehydroxamic Acid (<b>48g</b>)</h4><div class="NLM_p last">Compound <b>47g</b> (80 mg, 0.13 mmol) was dissolved in HCl/EtOAc (2.0 M, 10 mL) and stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48g</b> (36.1 mg, 56%) as a yellow solid; m.p., 144–145 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.75–7.70 (m, 1H), 7.40–7.30 (m, 1H), 7.15–7.05 (m, 1H), 4.35–4.15 (m, 5H), 3.60–3.45 (m, 2H), 3.40–3.30 (m, 2H), 3.00–2.75 (m, 4H), 2.65–2.50 (m, 4H), 1.95–1.65 (m, 5H), 1.60–1.40 (m, 5H), 1.05–0.95 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 497.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>36</sub>N<sub>6</sub>O<sub>4</sub></div></div><div id="sec4_1_164" class="NLM_sec NLM_sec_level_3"><div id="ac_i178" class="anchor-spacer"></div><h4 class="article-section__title" id="_i178"> 2-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexyl]ethanehydroxamic Acid (<b>48h</b>)</h4><div class="NLM_p last">Compound <b>47h</b> (200 mg, 0.35 mmol) was dissolved in HCl/EtOAc (2.0 M, 10 mL), and the mixture was stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48h</b> (45 mg, 27%) as a white solid; m.p., 165–166 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.15–8.14 (m, 1H), 7.25–7.15 (m, 1H), 6.95–6.91 (m, 1H), 4.35–4.15 (m, 5H), 3.05–2.85 (m, 2H), 2.63–2.55 (m, 1H), 2.55–2.48 (m, 2H), 2.30–2.20 (m, 1H), 2.20–1.95 (m, 2H), 1.95–1.80 (m, 2H), 1.80–1.65 (m, 4H), 1.60–1.35 (m, 6H), 1.35–1.20 (m, 1H), 1.10–0.85 (m, 6H). ESI-MS <i>m</i>/<i>z</i> 482.2 [M + H]<sup>+</sup> calc. for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_165" class="NLM_sec NLM_sec_level_3"><div id="ac_i179" class="anchor-spacer"></div><h4 class="article-section__title" id="_i179"> 4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclohexanecarbohydroxamic Acid (<b>48i1</b> and <b>48i2</b>)</h4><div class="NLM_p last">Compound <b>47i</b> (100 mg, 0.18 mmol) was dissolved in HCl/EtOAc (2.0 M, 10 mL) and stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compounds <b>48i1</b> (5.1 mg, 6.2%) and <b>48i2</b> (10.2 mg, 12%) as a white solids; m.p., 176.5–177.5 °C and 209–210 °C. <b>48i1</b>: <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.92 (s, 1H), 10.33 (s, 1H), 8.60 (s, 1H), 7.44–7.43 (m, 1H), 7.28–7.25 (m, 1H), 7.07–7.05 (m, 1H), 4.15 (s, 3H), 4.10–4.08 (m, 2H), 2.80–2.70 (m, 2H), 2.60–2.50 (m, 3H), 1.80–1.60 (m, 5H), 1.50–1.30 (m, 6H), 1.30–1.20 (m, 3H), 1.00–0.80 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 468.2 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>. Purity: 99.40%. <b>48i2</b>: <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.92 (s, 1H), 10.33 (s, 1H), 8.60 (s, 1H), 7.44–7.43 (m, 1H), 7.28–7.25 (m, 1H), 7.07–7.05 (m, 1H), 4.15 (s, 3H), 4.10–4.08 (m, 2H), 2.80–2.70 (m, 2H), 2.50–2.40 (m, 3H), 1.80–1.55 (m, 6H), 1.55–1.40 (m, 2H), 1.40–1.25 (m, 4H), 1.00–0.85 (m, 5H). ESI-MS <i>m</i>/<i>z</i> 468.2 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>. Purity: 95.47%.</div></div><div id="sec4_1_166" class="NLM_sec NLM_sec_level_3"><div id="ac_i180" class="anchor-spacer"></div><h4 class="article-section__title" id="_i180"> 3-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclopentanecarbohydroxamic Acid (<b>48j</b>)</h4><div class="NLM_p last">Compound <b>47j</b> (300 mg, 0.56 mmol) was dissolved in HCl/EtOAc (2.0 M, 10 mL) and stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48j</b> (16.4 mg, 7%) as a white solid; m.p., 102–103 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.95 (s, 1H), 10.36 (s, 1H), 7.45–7.43 (m, 1H), 7.30–7.28 (m, 1H), 7.06–7.04 (m, 1H), 4.10–4.08 (m, 5H), 3.51–3.41 (m, 2H), 3.36–3.35 (m, 1H), 2.79–2.75 (m, 2H), 2.60–2.50 (m, 2H), 1.76–1.71 (m, 6H), 1.33–1.29 (m, 4H), 0.95–0.91 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 454.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>. Purity 98.89%.</div></div><div id="sec4_1_167" class="NLM_sec NLM_sec_level_3"><div id="ac_i181" class="anchor-spacer"></div><h4 class="article-section__title" id="_i181"> 2-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]cyclopropanecarbohydroxamic Acid (<b>48k</b>)</h4><div class="NLM_p last">Compound <b>47k</b> (93 mg, 0.183 mmol) was dissolved in HCl/EtOAc (1.0 M, 20 mL) and stirred at room temperature for 2 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain the desired compound <b>48k</b> (32 mg, 41%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.74 (s, 1H), 7.40 (d, <i>J</i> = 8.4 Hz, 1H), 7.11 (d, <i>J</i> = 8.8 Hz, 1H), 4.23–4.17 (m, 5H), 2.91–2.87 (m, 2H), 2.71–2.65 (m, 2H), 1.84–1.79 (m, 2H), 1.65 (m, 1H), 1.46–1.43 (m, 3H), 1.40–1.38 (m, 1H), 1.14 (m, 1H), 1.03–0.99 (m, 3H), 0.81 (m, 1H). ESI-MS <i>m</i>/<i>z</i> 426.2 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub></div></div><div id="sec4_1_168" class="NLM_sec NLM_sec_level_3"><div id="ac_i182" class="anchor-spacer"></div><h4 class="article-section__title" id="_i182"> 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]piperidine-4-carbohydroxamic Acid (<b>48l</b>)</h4><div class="NLM_p last">A solution of compound <b>47l</b> (110 mg, 0.199 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48l</b> (26.7 mg, 29%) as a white solid; m.p., 167–168 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 8.04 (s, 1H), 7.66–7.64 (d, <i>J</i> = 8.0 Hz, 1H), 7.29–7.27 (d, <i>J</i> = 9.2 Hz, 1H), 4.35 (s, 2H), 4.29–4.26 (m, 2H), 4.23 (s, 3H), 3.69–3.57 (m, 2H), 3.06 (s, 2H), 2.89–2.80 (m, 2H), 2.42 (s, 1H), 2.00–1.94 (m, 4H), 1.85–1.76 (m, 2H), 1.49–1.45 (m, 3H), 1.02–0.98 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 469.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>.</div></div><div id="sec4_1_169" class="NLM_sec NLM_sec_level_3"><div id="ac_i183" class="anchor-spacer"></div><h4 class="article-section__title" id="_i183"> 1-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]azetidine-3-carbohydroxamic Acid (<b>48m</b>)</h4><div class="NLM_p last">A solution of compound <b>47m</b> (300 mg, 0.57 mmol) in HCl/EtOAc (4.0 M, 15 mL) was stirred at room temperature for 1 h. Then, the reaction mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48m</b> (14.3 mg, 6%) as a white solid; m.p., 132.5–133.5 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 12.07 (s, 1H), 10.81 (s, 1H), 10.54–10.40 (m, 1H), 7.73–7.61 (m, 1H), 7.60–7.58 (m, 1H), 7.22–7.20 (m, 1H), 4.39–4.14 (m, 2H), 4.14–4.01 (m, 9H), 3.41–3.37 (m, 1H), 2.79–2.75 (m, 2H), 1.77–1.70 (m, 2H), 1.33–1.30 (m, 3H), 0.96–0.92 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 441.2 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>O<sub>4</sub></div></div><div id="sec4_1_170" class="NLM_sec NLM_sec_level_3"><div id="ac_i184" class="anchor-spacer"></div><h4 class="article-section__title" id="_i184"> 3-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclobutanecarbohydroxamic Acid (<b>48n</b>)</h4><div class="NLM_p last">To a solution of compound <b>46n</b> (512 mg, 1.25 mmol) in DMF (40 mL) were added BOP (995 mg, 2.25 mmol), DIEA (413 mg, 3.2 mmol), and NH<sub>2</sub>OH·HCl (152 mg, 2.2 mmol), and the resulting mixture was stirred at 80 °C overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48n</b> (320 mg, 60%) as a yellow solid; m.p., 152.5–153.5 °C. <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.81–7.77 (m, 1H), 7.48–7.43 (m, 1H), 7.15–7.12 (m, 1H), 4.23–4.18 (m, 5H), 3.80–3.48 (m, 1H), 3.02–2.96 (m, 1H), 2.91–2.87 (m, 2H), 2.50–2.44 (m, 2H), 2.41–2.39 (m, 2H), 1.85–1.79 (m, 2H), 1.47–1.42 (m, 3H), 1.03–0.99 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 426.2 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_171" class="NLM_sec NLM_sec_level_3"><div id="ac_i185" class="anchor-spacer"></div><h4 class="article-section__title" id="_i185"> 2-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclopropanecarbohydroxamic Acid (<b>48o</b>)</h4><div class="NLM_p last">A solution of compound <b>47o</b> (1.35 g, 2.7 mmol) in HCl/EtOAc (0.2 N, 50 mL) was stirred at 0 °C for 3 h. Then, the solution was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>48o</b> (400 mg, 36%). <sup>1</sup>H NMR (MeOD, 400 MHz): δ 7.63 (s, 1H), 7.30 (d, <i>J</i> =  8.4 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 1H), 4.23–4.16 (m, 5H), 2.89 (t, <i>J</i> = 7.6 Hz, 2H), 2.44 (m, 1H), 1.84–1.79 (m, 2H), 1.72–1.70 (m, 1H), 1.51 (m, 1H), 1.46–1.42 (m, 3H), 1.29 (m, 1H), 1.01 (t, <i>J</i> = 7.2 Hz, 3H). ESI-MS <i>m</i>/<i>z</i> 412.1 [M + H]<sup>+</sup> calc. for C<sub>21</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_172" class="NLM_sec NLM_sec_level_3"><div id="ac_i186" class="anchor-spacer"></div><h4 class="article-section__title" id="_i186"> Ethyl 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]propanoate (<b>49a</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (1.20 g, 2.74 mmol) in 1,4-dioxane (30 mL) were added ethyl 3-[4-(bromomethyl)phenyl]propanoate (<b>Int. 18</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (670 mg, 2.48 mmol), K<sub>2</sub>CO<sub>3</sub> (1.13 g, 8.18 mmol in 2.0 mL water), and Pd(PPh<sub>3</sub>)<sub>4</sub> (287 mg, 0.25 mmol), and the mixture was stirred at 80 °C overnight under N<sub>2</sub> protection. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure compound <b>49a</b> (830 mg, 67%) as a yellow oil. ESI-MS <i>m</i>/<i>z</i> 503 [M + H]<sup>+</sup> calc. for C<sub>29</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_173" class="NLM_sec NLM_sec_level_3"><div id="ac_i187" class="anchor-spacer"></div><h4 class="article-section__title" id="_i187"> Methyl (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]prop-2-enoate (<b>49b</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (300 mg, 0.685 mmol) in 1,4-dioxane/H<sub>2</sub>O (5:2, 28 mL) were added methyl (<i>E</i>)-3-[4-(bromomethyl)phenyl]prop-2-enoate (190 mg, 0.75 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (79 mg, 0.067 mmol), and K<sub>2</sub>CO<sub>3</sub> (284 mg, 2.06 mmol), and the mixture was stirred at 85 °C for 1 h under MW. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>49b</b> (200 mg, 60%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 487.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_174" class="NLM_sec NLM_sec_level_3"><div id="ac_i188" class="anchor-spacer"></div><h4 class="article-section__title" id="_i188"> Ethyl 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclohexyl]acetate (<b>49c</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (500 mg, 1.14 mmol) in 1,4-dioxane (20 mL) were added ethyl 2-[4-(trifluoromethylsulfonyloxy)cyclohex-3-en-1-yl]acetate (<b>Int. 19</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (384 mg, 1.25 mmol), K<sub>2</sub>CO<sub>3</sub> (473 mg, 3.42 mmol in 2 mL water), and Pd(PPh<sub>3</sub>)<sub>4</sub> (132 mg, 0.11 mmol), and the mixture was stirred at 80 °C overnight under N<sub>2</sub> protection. Then, the reaction mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude compound which was purified by column chromatography to give pure intermediate ethyl 2-[4-[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclohex-3-en-1-yl]acetate (385 mg, 70%) as a white solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 11.09 (s, 1H), 8.44 (s, 1H), 7.47–7.45 (d, <i>J</i> = 8.8 Hz, 1H), 6.99–6.97 (d, <i>J</i> = 8.8 Hz, 1H), 6.10 (s, 1H), 4.29–4.15 (m, 7H), 2.98–2.94 (m, 3H), 2.52 (s, 2H), 2.36–2.35 (d, <i>J</i> = 7.2 Hz, 1H), 2.23–2.14 (m, 1H), 2.01–1.82 (m, 5H), 1.61–1.57 (m, 3H), 1.31–1.27 (m, 3H), 1.07–1.03 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 479 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>34</sub>N<sub>4</sub>O<sub>4</sub>. To a solution of this intermediate (245 mg, 0.513 mmol) in MeOH (20 mL) was added Pd/C (150 mg) at H<sub>2</sub> atmosphere (1 atm), and the mixture was stirred at room temperature for 1 h until LC-MS showed the starting material was consumed completely. Then the reaction mixture was filtered, and the filtrate was concentrated to give compound <b>49c</b> (150 mg, 61%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 481 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>36</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_175" class="NLM_sec NLM_sec_level_3"><div id="ac_i189" class="anchor-spacer"></div><h4 class="article-section__title" id="_i189"> Methyl 6-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]pyridine-3-carboxylate (<b>49d</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (300 mg, 0.68 mmol) in 1,4-dioxane/H<sub>2</sub>O (5:2, 28 mL) were added methyl 6-chloropyridine-3-carboxylate (129 mg, 0.75 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (79 mg, 0.068 mmol), and K<sub>2</sub>CO<sub>3</sub> (284 mg, 2.06 mmol), and the solution was stirred at 85 °C for 1 h under MW. Then, the reaction mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>49d</b> (150 mg, 49%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 448.2 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_176" class="NLM_sec NLM_sec_level_3"><div id="ac_i190" class="anchor-spacer"></div><h4 class="article-section__title" id="_i190"> Methyl 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]pyridine-2-carboxylate (<b>49e</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (300 mg, 0.68 mmol) in 1,4-dioxane/H<sub>2</sub>O (5:2, 28 mL) were added methyl 5-bromopyridine-2-carboxylate (162 mg, 0.75 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (79 mg, 0.068 mmol) and K<sub>2</sub>CO<sub>3</sub> (284 mg, 2.06 mmol) and the mixture was stirred at 85 °C for 1 h under MW. Then the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>49e</b> (170 mg, 56%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 448 [M + H]<sup>+</sup> calc. for C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_177" class="NLM_sec NLM_sec_level_3"><div id="ac_i191" class="anchor-spacer"></div><h4 class="article-section__title" id="_i191"> Methyl 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]furan-2-carboxylate (<b>49f</b>)</h4><div class="NLM_p last">To a solution of compound <b>25</b> (300 mg, 0.68 mmol) in 1,4-dioxane/H<sub>2</sub>O (5:2, 28 mL) were added methyl 5-bromofuran-2-carboxylate (<b>Int. 20</b>, synthesis described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) (153 mg, 0.75 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (79 mg, 0.068 mmol), and K<sub>2</sub>CO<sub>3</sub> (284 mg, 2.06 mmol), and the mixture was stirred at 85 °C for 1 h under MW. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by column chromatography to give compound <b>49f</b> (140 mg, 48%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 437.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_178" class="NLM_sec NLM_sec_level_3"><div id="ac_i192" class="anchor-spacer"></div><h4 class="article-section__title" id="_i192"> 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]propanoic Acid (<b>50a</b>)</h4><div class="NLM_p last">To a solution of compound <b>49a</b> (830 mg, 1.65 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (694 mg, 16.54 mmol), and the reaction mixture was stirred at 40 °C overnight until LC-MS showed the starting material was consumed completely. Then, the solution was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>50a</b> (780 mg, 99%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 475 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>30</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_179" class="NLM_sec NLM_sec_level_3"><div id="ac_i193" class="anchor-spacer"></div><h4 class="article-section__title" id="_i193"> (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]prop-2-enoic Acid (<b>50b</b>)</h4><div class="NLM_p last">To a solution of compound <b>49b</b> (200 mg, 0.41 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (172 mg, 4.1 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>50b</b> (180 mg, 93%). ESI-MS <i>m</i>/<i>z</i> 473.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>28</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_180" class="NLM_sec NLM_sec_level_3"><div id="ac_i194" class="anchor-spacer"></div><h4 class="article-section__title" id="_i194"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclohexyl]acetic Acid (<b>50c</b>)</h4><div class="NLM_p last">To a solution of compound <b>49c</b> (150 mg, 0.31 mmol) in MeOH/THF/H<sub>2</sub>O (1:3:1, 15 mL) was added LiOH·H<sub>2</sub>O (130 mg, 3.10 mmol), and the reaction mixture was stirred at room temperature overnight. Then, the solution was concentrated, diluted with H<sub>2</sub>O, and the pH adjusted to 1–2 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give compound <b>50c</b> (130 mg, 92%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 453 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>32</sub>N<sub>4</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_181" class="NLM_sec NLM_sec_level_3"><div id="ac_i195" class="anchor-spacer"></div><h4 class="article-section__title" id="_i195"> 6-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]pyridine-3-carboxylic Acid (<b>50d</b>)</h4><div class="NLM_p last">To a solution of compound <b>49d</b> (150 mg, 0.34 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (143 mg, 3.4 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>50d</b> (110 mg, 75%). ESI-MS <i>m</i>/<i>z</i> 434.2 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_182" class="NLM_sec NLM_sec_level_3"><div id="ac_i196" class="anchor-spacer"></div><h4 class="article-section__title" id="_i196"> 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]pyridine-2-carboxylic Acid (<b>50e</b>)</h4><div class="NLM_p last">To a solution of compound <b>49e</b> (170 mg, 0.38 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (160 mg, 3.8 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the mixture was diluted with water and the pH adjusted to 6–7 with 1 N HCl. The solution was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>50e</b> (120 mg, 72%). ESI-MS <i>m</i>/<i>z</i> 434.2 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_183" class="NLM_sec NLM_sec_level_3"><div id="ac_i197" class="anchor-spacer"></div><h4 class="article-section__title" id="_i197"> 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]furan-2-carboxylic Acid (<b>50f</b>)</h4><div class="NLM_p last">To a solution of compound <b>49f</b> (140 mg, 0.32 mmol) in THF/MeOH/H<sub>2</sub>O (3:3:2, 16 mL) was added LiOH·H<sub>2</sub>O (134 mg, 3.2 mmol), and the resulting mixture was stirred at room temperature overnight. Then, the solution was diluted with water and the pH adjusted to 6–7 with 1 N HCl. Then, the mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford the desired product <b>50f</b> (100 mg, 74%). ESI-MS <i>m</i>/<i>z</i> 423.2 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>22</sub>N<sub>4</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_184" class="NLM_sec NLM_sec_level_3"><div id="ac_i198" class="anchor-spacer"></div><h4 class="article-section__title" id="_i198"> 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-propanamide (<b>51a</b>)</h4><div class="NLM_p last">To a solution of compound <b>50a</b> (780 mg, 1.64 mmol) in DMF (10 mL) were added EDC·HCl (634 mg, 3.30 mmol), HOBt (446 mg, 3.30 mmol), THPONH<sub>2</sub> (385 mg, 3.30 mmol), and NMM (500 mg, 4.95 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>51a</b> (350 mg, 37%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 574 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>39</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_185" class="NLM_sec NLM_sec_level_3"><div id="ac_i199" class="anchor-spacer"></div><h4 class="article-section__title" id="_i199"> (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-prop-2-enamide (<b>51b</b>)</h4><div class="NLM_p last">To a solution of compound <b>50b</b> (180 mg, 0.38 mmol) in DMF (20 mL) were added EDC·HCl (150 mg, 0.76 mmol), HOBt (100 mg, 0.76 mmol), THPONH<sub>2</sub> (95 mg, 0.81 mmol), and NMM (120 mg, 1.18 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>51b</b> (120 mg, 55%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 572.2 [M + H]<sup>+</sup> calc. for C<sub>32</sub>H<sub>37</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_186" class="NLM_sec NLM_sec_level_3"><div id="ac_i200" class="anchor-spacer"></div><h4 class="article-section__title" id="_i200"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclohexyl]-<i>N</i>-tetrahydropyran-2-yloxy-acetamide (<b>51c</b>)</h4><div class="NLM_p last">To a solution of compound <b>50c</b> (130 mg, 0.288 mmol) in DMF (10 mL) were added EDC·HCl (110 mg, 0.57 mmol), HOBt (78 mg, 0.57 mmol), THPONH<sub>2</sub> (68 mg, 0.57 mmol), and NMM (87 mg, 0.86 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give pure compound <b>51c</b> (141 mg, 89%) as a white solid. ESI-MS <i>m</i>/<i>z</i> 552 [M + H]<sup>+</sup> calc. for C<sub>30</sub>H<sub>41</sub>N<sub>5</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_187" class="NLM_sec NLM_sec_level_3"><div id="ac_i201" class="anchor-spacer"></div><h4 class="article-section__title" id="_i201"> 6-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyridine-3-carboxamide (<b>51d</b>)</h4><div class="NLM_p last">To a solution of compound <b>50d</b> (110 mg, 0.25 mmol) in DMF (20 mL) were added EDC·HCl (96 mg, 0.5 mmol), HOBt (68 mg, 0.5 mmol), THPONH<sub>2</sub> (60 mg, 0.5 mmol), and NMM (80 mg, 0.79 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>51d</b> (100 mg, 75%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 533.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_188" class="NLM_sec NLM_sec_level_3"><div id="ac_i202" class="anchor-spacer"></div><h4 class="article-section__title" id="_i202"> 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-pyridine-2-carboxamide (<b>51e</b>)</h4><div class="NLM_p last">To a solution of compound <b>50e</b> (120 mg, 0.28 mmol) in DMF (20 mL) were added EDC·HCl (107 mg, 0.56 mmol), HOBt (76 mg, 0.56 mmol), THPONH<sub>2</sub> (66 mg, 0.56 mmol), and NMM (85 mg, 0.84 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>51e</b> (100 mg, 68%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 533.2 [M + H]<sup>+</sup> calc. for C<sub>28</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_189" class="NLM_sec NLM_sec_level_3"><div id="ac_i203" class="anchor-spacer"></div><h4 class="article-section__title" id="_i203"> 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]-<i>N</i>-tetrahydropyran-2-yloxy-furan-2-carboxamide (<b>51f</b>)</h4><div class="NLM_p last">To a solution of compound <b>50f</b> (100 mg, 0.24 mmol) in DMF (20 mL) were added EDC·HCl (92 mg, 0.48 mmol), HOBt (65 mg, 0.48 mmol), THPONH<sub>2</sub> (56 mg, 0.48 mmol), and NMM (73 mg, 0.72 mmol), and the mixture was stirred at room temperature overnight. Then, the reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to give the crude product which was purified by preparative TLC to give compound <b>51f</b> (80 mg, 64%) as a pale yellow solid. ESI-MS <i>m</i>/<i>z</i> 522.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>31</sub>N<sub>5</sub>O<sub>6</sub>. This intermediate was used in the next step without further characterization.</div></div><div id="sec4_1_190" class="NLM_sec NLM_sec_level_3"><div id="ac_i204" class="anchor-spacer"></div><h4 class="article-section__title" id="_i204"> 3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]propanehydroxamic Acid (<b>52a</b>)</h4><div class="NLM_p last">A solution of compound <b>51a</b> (350 mg, 0.61 mmol) in HCl/1,4-dioxane (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>52a</b> (88 mg, 29%) as a white solid; m.p., 190–191 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.94 (s, 1H), 10.36 (s, 1H), 8.69 (s, 1H), 7.48 (s, 1H), 7.30–7.29 (m, 1H), 7.16–7.07 (m, 5H), 4.14 (s, 3H), 4.08–4.06 (d, 2H), 3.89 (s, 2H), 2.77–2.74 (m, 4H), 2.23–2.20 (m, 2H), 1.75–1.70 (m, 2H), 1.31–1.28 (m, 3H), 0.95–0.91 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 490.2 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>31</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_191" class="NLM_sec NLM_sec_level_3"><div id="ac_i205" class="anchor-spacer"></div><h4 class="article-section__title" id="_i205"> (<i>E</i>)-3-[4-[[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]methyl]phenyl]prop-2-enehydroxamic Acid (<b>52b</b>)</h4><div class="NLM_p last">A solution of compound <b>51b</b> (120 mg, 0.21 mmol) in HCl/EtOAc (2.0 M, 10 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>52b</b> (24.3 mg, 23%) as a white solid; m.p., 185–186 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.92 (s, 1H), 10.71 (s, 1H), 8.99 (s, 1H), 7.51–7.49 (m, 3H), 7.49–7.47 (m, 1H), 7.47–7.28 (m, 3H), 7.09–7.07 (m, 1H), 6.42–6.38 (m, 1H), 4.14–4.06 (m, 5H), 3.97 (s, 2H), 2.77–2.74 (m, 2H), 1.75–1.70 (m, 2H), 1.32–1.29 (m, 3H), 0.94–0.90 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 488.1 [M + H]<sup>+</sup> calc. for C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>4</sub>.</div></div><div id="sec4_1_192" class="NLM_sec NLM_sec_level_3"><div id="ac_i206" class="anchor-spacer"></div><h4 class="article-section__title" id="_i206"> 2-[4-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]cyclohexyl]ethanehydroxamic Acid (<b>52c</b>)</h4><div class="NLM_p last">A solution of compound <b>51c</b> (141 mg, 0.256 mmol) in HCl/EtOAc (4.0 M, 5 mL) was stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude compound which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>52c</b> (11.0 mg, 9%) as a red solid; m.p., 156–157 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 11.94 (s, 1H), 10.38 (s, 1H), 7.49 (s, 1H), 7.35 (m, 1H), 7.08 (m, 1H), 4.15–4.00 (m, 6H), 3.47 (m, 1H), 2.77 (m, 2H), 2.15–2.00 (m, 2H), 1.75–1.50 (m, 10H), 1.30 (m, 3H), 0.94 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 468.3 [M + H]<sup>+</sup> calc. for C<sub>25</sub>H<sub>33</sub>N<sub>5</sub>O<sub>4</sub>. Purity 98.64%.</div></div><div id="sec4_1_193" class="NLM_sec NLM_sec_level_3"><div id="ac_i207" class="anchor-spacer"></div><h4 class="article-section__title" id="_i207"> 6-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]pyridine-3-carbohydroxamic Acid (<b>52d</b>)</h4><div class="NLM_p last">A solution of compound <b>51d</b> (100 mg, 0.19 mmol) in HCl/EtOAc (2.0 M, 10 mL) was stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>52d</b> (11.1 mg, 13%) as a white solid; m.p., 210–211 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 12.16 (s, 1H), 11.41 (s, 1H), 8.97 (s, 1H), 8.36–8.06 (m, 4H), 7.29–7.27 (m, 1H), 4.22–4.17 (m, 5H), 2.81–2.77 (m, 2H), 1.78–1.72 (m, 2H), 1.36–1.32 (m, 3H), 0.96–0.92 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>24</sub>N<sub>6</sub>O<sub>4</sub>.</div></div><div id="sec4_1_194" class="NLM_sec NLM_sec_level_3"><div id="ac_i208" class="anchor-spacer"></div><h4 class="article-section__title" id="_i208"> 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]pyridine-2-carbohydroxamic Acid (<b>52e</b>)</h4><div class="NLM_p last">A solution of compound <b>51e</b> (100 mg, 0.19 mmol) in HCl/EtOAc (2.0 M, 10 mL) was stirred at room temperature for 1 h. Then, the solution was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>52e</b> (14 mg, 16%) as a white solid; m.p., 182–183 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 12.18 (s, 1H), 11.45 (s, 1H), 9.10 (s, 1H), 8.90 (s, 1H), 8.28–8.25 (m, 1H), 8.05–7.92 (m, 3H), 7.32–7.30 (m, 1H), 4.22–4.17 (m, 5H), 2.80–2.77 (m, 2H), 1.78–1.72 (m, 2H), 1.36–1.32 (m, 3H), 0.96–0.92 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup> calc. for C<sub>23</sub>H<sub>24</sub>N<sub>6</sub>O<sub>4</sub>. Purity 94.62%.</div></div><div id="sec4_1_195" class="NLM_sec NLM_sec_level_3"><div id="ac_i209" class="anchor-spacer"></div><h4 class="article-section__title" id="_i209"> 5-[4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6<i>H</i>-pyrazolo[4,3-<i>d</i>]pyrimidin-5-yl)phenyl]furan-2-carbohydroxamic Acid (<b>52f</b>)</h4><div class="NLM_p last">A solution of compound <b>51f</b> (80 mg, 0.15 mmol) in HCl/EtOAc (2.0 M, 10 mL) was stirred at room temperature for 1 h. Then, the mixture was concentrated to give the crude product which was purified by preparative HPLC (method 1 described in <a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">Supporting Information</a>) to obtain pure compound <b>52f</b> (13 mg, 20%) as a white solid; m.p., 126–127 °C. <sup>1</sup>H NMR (DMSO, 400 MHz): δ 12.20 (s, 1H), 11.27 (s, 1H), 9.12 (s, 1H), 8.03–7.97 (m, 2H), 7.25–7.01 (m, 3H), 4.17–4.13 (m, 5H), 2.81–2.77 (m, 2H), 1.77–1.71 (m, 2H), 1.32–1.29 (m, 3H), 0.96–0.92 (m, 3H). ESI-MS <i>m</i>/<i>z</i> 438.1 [M + H]<sup>+</sup> calc. for C<sub>22</sub>H<sub>23</sub>N<sub>5</sub>O<sub>5</sub>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i210" class="anchor-spacer"></div><h3 class="article-section__title" id="_i210"> Biological Test Methods. <i>In-Vitro</i> Studies</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i211" class="anchor-spacer"></div><h4 class="article-section__title" id="_i211"> Acetyl-Histone H3 Lysine 9 (H3K9ac) Cellular Detection Assay (AlphaLisa Technology)</h4><div class="NLM_p last">Briefly, 2000 cells (SH-SY5Y) were plated in a poly-<span class="smallcaps smallerCapital">d</span>-lysine-treated 384-well plate. Cells were incubated with different concentrations of compounds <b>4</b> and <b>1</b> during 2 h. After incubation, the medium was removed, and cells were lysed, histones were extracted, and histone carrying the acetylation mark was detected following the manufacturer’s instructions (PerkinElmer; Cat number AL714 A/C kit assay). Signal of acetylation mark was obtained after 18 h of dark incubation at room temperature and was normalized by the unmodified histone signal and calculated as folds over basal levels, considered as those obtained in the absence of assayed compounds.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i212" class="anchor-spacer"></div><h3 class="article-section__title" id="_i212"> HDACs and PDEs Enzyme Activity Assays</h3><div class="NLM_p">HDAC enzyme activities were measured with a specific fluorescence-labeled substrate (BPS Biosciences, Cat # 50037) after its deacetylation by HDACs. The fluorogenic substrate, containing an acetylated lysine side chain, can be deacetylated and then sensitized to subsequent treatment with the lysine developer, which produces a fluorophore that can be measured with a fluorescence plate reader. Human HDAC1 (GenBank Accession No. <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NM_004964">NM_004964</a>), full length, with the C-terminal His-tag and C-terminal Flag-tag, was obtained from BPS Biosciences (Cat. # 50051). Human HDAC2 (GenBank Accession No. <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NM_001527">NM_001527</a>), full length, with the C-terminal His-tag was obtained from BPS Biosciences (Cat. # 50002). Human HDAC3 (GenBank Accession No. <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NM_003883">NM_003883</a>), full length, with the C-terminal His-tag and human NCOR2, N-terminal GST-tag was obtained from BPS Biosciences (Cat. # 50003). Human HDAC6 (GenBank Accession No. <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=BC069243">BC069243</a>), full length, with the N-terminal GST tag was obtained from BPS Biosciences (Cat. # 50006). Five microliters of vehicle or tested compound 10× concentrated prepared in assay buffer (BPS Biosciences, Cat # 50031) was added in black 96 well plates (final volume of 100 μL). The final percentage of DMSO was 1%. Five microliters of HDAC1 (4 μg/mL), HDAC2 (15 μg/mL), HDAC3 (10 μg/mL), or HDAC6 (36 μg/mL) enzyme in assay buffer was added (final HDAC1, HDAC2, HDAC3, and HDAC6 concentration of 0.4 μg/mL, 1.5 μg/mL, 0.1 μg/mL, and 3.6 μg/mL, respectively), and the reaction was started by the addition of 40 μL of reaction mixture containing 0.125 mg/mL BSA (final concentration of 0.1 mg/mL) and 12.5 μM fluorogenic HDAC substrate (final concentration of 10 μM). The reaction was incubated for 30 min at 37 °C. After incubation, the reaction was stopped with 50 μL of lysine assay developer (BPS Biosciences, Cat # 50030). After incubation during 20 min at room temperature, the fluorescence of each well was measured at 355 nm excitation and 460 nm emission in a Mithras plate reader (Berthold). Positive control was obtained in the presence of the vehicle of the compounds. Negative control was obtained in the absence of HDAC enzyme activity. A best fit curve was fitted using GraphPad Prism 5 to derive the half maximal inhibitory concentration (IC<sub>50</sub>) from this curve.</div><div class="NLM_p">PDE5A and PDE9A enzyme activity was measured with the HTRF cGMP assay kit from CisBio (CisBio, Cat.#62GM2PEB), which determines the amount of cGMP present in the reaction. Human PDE5A1 (GenBank Accession No. <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NM_001083">NM_001083</a>) or human PDE9A isoform b (GenBank Accession No. <a href="https://www.ncbi.nlm.nih.gov/gquery?Term=NM_001083">NM_001083</a>), full length, with the N-terminal GST tag was obtained from BPS Biosciences (Cat. # 60050 or # 60090). 2.5 μL of vehicle or tested compound 4× concentrated prepared in assay buffer (50 mM Tris-HCl and 6 mM MgCl<sub>2</sub>, pH 7.4) was added in 384 well plates (final volume of 20 μL). The final percentage of DMSO was 0.5%; 2.5 μL of PDE5A (7 μg/mL) or PDE9A (0.2 μg/mL) enzyme in assay buffer was added (final PDE5A concentration of 1.75 μg/mL or final PDE9A concentration of 0.05 μg/mL), and the reaction was started by the addition of 5 μL of substrate cGMP (4× concentrated) to a final concentration of 100 nM cGMP. The reaction was incubated for 30 min at 37 °C. After incubation, the reaction was stopped with 5 μL of cGMP-D2 (cGMP labeled with the dye D2) and 5 μL of Mab anti-cGMP labeled with cryptate (cGMP-cryptate). After incubation during 1 h at room temperature, the fluorescence of each well was measured at 665 nm excitation and 620 nm emission in an Envision plate reader (PerkinElmer), and the results were expressed as the 665 nm/620 nm ratio. Positive control was obtained in the presence of the vehicle of the compounds. Negative control was obtained in the absence of cGMP and labeled cGMP-D2 cyclic nucleotide. A best fit curve was fitted using GraphPad Prism 5 to derive the half maximal inhibitory concentration (IC<sub>50</sub>) from this curve.</div><div class="NLM_p last">PDE3A and PDE6C enzyme activity assays were carried out at BPS Bioscience (<a href="https://bpsbioscience.com/" class="extLink">https://bpsbioscience.com/</a>).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i213" class="anchor-spacer"></div><h3 class="article-section__title" id="_i213"> Cytotoxicity in THLE-2 Cells</h3><div class="NLM_p last">Cytotoxic effects of assayed compounds were tested using the immortalized human liver cell line THLE-2 (ATCC CRL-2706), cultured in BEGM medium (Clonetics #CC-4175). The medium was completed by adding 0.7 μg/mL phosphoethanolamine, 0.5 ng/mL epidermal growth factor, antibiotics (penicillin and streptomycin), and 10% fetal bovine serum (FBS). Cells were plated in 96-well black microplates at 10,000 cells/well and incubated at 37 °C (5% CO<sub>2</sub>, 95% humidity) for 24 h. Test compounds were solubilized in 100% DMSO and then diluted with cell culture medium containing 10% DMSO. The final concentrations of the test compounds (1% DMSO) ranged from 0 to 100 μM in a final volume of 200 μL. After 72 h, cell viability in each well was determined by measuring the concentration of cellular adenosine triphosphate (ATP) using the VialightTM Plus Cell Proliferation/Cytotoxicity Kit as described by the manufacturer (Cambrex, East Rutherford, NJ). After the addition of cell lysis buffer, the test plate was incubated for 45 min at room temperature (orbital shaker). ATP monitoring solution was added and ATP concentration determined by reading luminescence using an Envision plate reader (PerkinElmer). The percentage of viable cells relative to the nondrug treated controls was determined for each well, and LC<sub>50</sub> values were calculated as concentrations projected to kill 50% of the cells following a 72 h exposure.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i214" class="anchor-spacer"></div><h3 class="article-section__title" id="_i214"> Cytotoxicity in Neurons Glia Cells</h3><div class="NLM_p last">Cytotoxic effects of assayed compounds were tested using primary cultures of mice brain embryo tissue. Cell growth in 96-well black microplates were incubated at 37 °C (5% CO<sub>2</sub>, 95% humidity) for 5 days to permit neuron formation. After that, 100 μL/well of medium and studied compounds was added. Test compounds were solubilized in 100% DMSO at a concentration curve way and then diluted with cell culture medium containing 10% DMSO. The final concentrations of the test compounds (1% DMSO) ranged from 0 to 100 μM in a final volume of 200 μL. Microplates were maintained at 37 °C (5% CO<sub>2</sub>, 95% humidity) during 3 days. Following this 72 h exposure to test compounds, cell viability in each well was determined by measuring the concentration of cellular adenosine triphosphate (ATP) using the ATP1Step Kit as described by the manufacturer (PerkinElmer). In a typical procedure, 50 μL of cell reagent is added to all wells of each test plate followed by incubation for 10 min at room temperature on an orbital shaker. ATP concentration was determined by reading chemical luminescence using the Envision plate reader (PerkinElmer). The percentage of viable cells relative to the nondrug treated controls was determined for each well, and LC<sub>50</sub> values were calculated as concentrations projected to kill 50% of the cells following a 72 h exposure.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i215" class="anchor-spacer"></div><h3 class="article-section__title" id="_i215"> PAMPA Permeability</h3><div class="NLM_p last">The permeability of compounds was evaluated with the parallel artificial membrane permeation assay (PAMPA) as an in vitro model of passive diffusion. Donor solutions of test compounds (180 μL. 50 μM in PBS/ETOH 70:30) were added to each well of the donor plate, whose PVDF membrane was precoated with 4 μL of a 20 mg × mL<sup>–1</sup> PBL/dodecane mixture. PBS/EtOH (180 μL) was added to each well of the PTFE acceptor plate. The donor and acceptor plates were combined together and incubated for 18 h at 20 °C without shaking. In each plate, compounds and controls were tested in duplicate. Drug concentration in the acceptor, the donor, and the reference wells was determined using the UV plate reader with 130 μL of acceptor and donor samples. Permeability rates (<i>P</i><sub>e</sub> in nm s<sup>–1</sup>) were calculated with <a class="ref internalNav" href="#eq1" aria-label="eq 1">eq 1</a>. The permeability rate of each compound is the averaged value of three independent measurements.<span class="NLM_disp-formula" id="eq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/jm-2016-009085_m001.gif" alt="" /></img><span class="labelSpan">(1)</span></span>where <span class="NLM_inline-formula"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/jm-2016-009085_m002.gif" alt="" /></img></span> ; <i>V</i><sub>D</sub> = 0.18 mL; <i>V</i><sub>A</sub> = 0.18 mL; area = 0.32 cm<sup>2</sup>; time = 64800 s; <i>D</i><sub>F</sub> = 180/130; [drug]<sub>equilibrium</sub> = ([drug]<sub>donor</sub> × <i>V</i><sub>D</sub> + [drug]<sub>acceptor</sub> × <i>V</i><sub>A</sub>)/(<i>V</i><sub>D</sub> + <i>V</i><sub>A</sub>); [drug]<sub>donor</sub> = (<i>A</i><sub>a</sub>/<i>A</i><sub>i</sub>·<i>D</i><sub>F</sub>)<sub>donor</sub>; [drug]<sub>acceptor</sub> = (<i>A</i><sub>a</sub>/<i>A</i><sub>i</sub>·<i>D</i><sub>F</sub>)<sub>acceptor</sub>; <i>A</i><sub>a donor</sub> = <i>Abs</i><sub>donor</sub> – <i>Abs</i><sub>vehicle</sub>; <i>A</i><sub>a acceptor</sub> = <i>Abs</i><sub>acceptor</sub> – <i>Abs</i><sub>vehicle</sub>, <i>Ai</i> = <i>Abs</i><sub>withoutPBL</sub> – <i>Abs</i><sub>vehicle</sub>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i216" class="anchor-spacer"></div><h3 class="article-section__title" id="_i216"> PDE and HDAC Functional Response <i>in Vitro</i></h3><div class="NLM_p last">To analyze the functional activity of the different compounds, we used primary neuronal cultures and the human neuroblastoma SH-SY5Y cell line. Primary neuronal cultures were obtained from the hippocampus and cortex of embryonic day 16 (E16) wild type (WT) mice and used at 15 days <i>in vitro</i> (DIV).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Cells were incubated with the different compounds, and after incubation (30 min or 2h), the medium was removed, and the cells were lysed in a buffer containing 10 mM Tris HCl, 1 mM NaF, 0.1 mM NaVO<sub>4</sub>, 2% sodium dodecyl sulfate (SDS), and protease inhibitors.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i217" class="anchor-spacer"></div><h3 class="article-section__title" id="_i217"> Biological Test Methods. <i>In-Vivo</i> Studies</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i218" class="anchor-spacer"></div><h4 class="article-section__title" id="_i218"> Determination of Brain to Plasma Concentration Ratio</h4><div class="NLM_p">Compound <b>37</b> was measured in plasma and brain samples using an Acquity UPLC system (Waters, Manchester, UK) coupled to a Xevo-TQ MS triple quadrupole mass spectrometer with an electrospray ionization (ESI) source. Plasma and brain samples were collected at different times (0.25, 0.5, and 1 h). Compound <b>37</b> was injected (40 mg/kg, i.p.) to mice (<i>n</i> = 3 per time point). Three control mice were sacrificed 15 min after the administration of vehicle solution. Compound solutions were prepared by dissolving the solid in DMSO, and this solution was diluted with a mixture of Tween 20 and 0.9% NaCl up to a final composition of 1:1:8 (v/v/v, DMSO/Tween 20/saline). Blood was collected at the different time points in EDTA-coated tubes and centrifuged at 2500 rpm for 5 min at 4 °C to obtain the plasma. The brain was removed following whole body perfusion with saline. All plasma and brain samples were stored at −80 °C until further analysis.</div><div class="NLM_p">Chromatographic separation was performed by gradient elution at 0.45 mL/min using an Acquity UPLC BEH C18 column (50 × 2.1 mm, 1.7 μm; Waters). The mobile phase consisted of A, water with 0.1% formic acid; B, methanol with 0.1% formic acid. The autosampler temperature was set at 10 °C and column temperature at 40 °C. For detection and quantification, the electrospray ionization operated in the positive mode was set up for multiple reaction monitoring (MRM). The collision gas used was ultrapure argon at a flow rate of 0.15 mL min<sup>–1</sup>.</div><div class="NLM_p last">At the time of analysis, frozen plasma samples were thawed at room temperature and vortex-mixed thoroughly, and 50 μL was subjected to the sample preparation procedure described below. Brain samples were thawed unassisted at room temperature and homogenized using a Branson 250 ultrasonic probe sonicator (Branson, Danbury, Connecticut, USA), and 75 mg of the homogenate was subjected to the sample preparation procedure described below. Quantification was achieved by external calibration using matrix-matched standards. Concentrations were calculated using a weighted least-squares linear regression (<i>W</i> = 1/<i>x</i>). Calibration standards were prepared by adding the appropriate volume of diluted solutions of the compound (made in a mixture of methanol and water, 50:50, v/v) to either aliquots of 50 μL of blank plasma or 75 mg of the blank brain homogenate. The calibration standard and sample preparation are as follows: 450 μL of 2% formic acid in acetonitrile was added to precipitate the proteins (approximately vol. ratio 1:10). The mixture was then vortex-mixed for 5 min and centrifuged at 13200 rpm for 10 min at 4 °C. The resulting supernatants were transferred to an Ostro plate (Waters, Manchester, UK), designed to remove phospholipids. The resulting eluents were evaporated at 37 °C under a stream of nitrogen. Plasma and brain residues were dissolved in 100 μL of a mixture of methanol and water with 0.1% formic acid (50:50, v/v). A 10 μL aliquot of the resulting solution was injected into the LC-MS/MS system for analysis.</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i219" class="anchor-spacer"></div><h4 class="article-section__title" id="_i219"> PDE and HDAC Functional Response <i>in Vivo</i></h4><div class="NLM_p last">To confirm the ability of <b>37</b> to inhibit HDAC and PDE in the brain, the compound (40 mg/kg) was administered to WT mice (<i>n</i> = 3). One hour later, mice were sacrificed, and their hippocampus was quickly dissected from the brains. Total tissue homogenates were obtained by homogenizing the hippocampus in a lysis buffer containing 10 mM Tris HCl, 1 mM NaF, 0.1 mM NaVO<sub>4</sub>, 2% sodium dodecyl sulfate (SDS), and protease inhibitors. Western blot was carried out to analyze AcH3K9 and pCREB-Ser133.</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i220" class="anchor-spacer"></div><h4 class="article-section__title" id="_i220"> Western Blot Analysis of Brain Samples</h4><div class="NLM_p last">For Western blot analysis of histones, pCREB, and tubulin, protein samples were mixed with 6X Laemmli sample buffer and resolved onto SDS–polyacrylamide gels and transferred to nitrocellulose membranes. In all cases, the membranes were blocked with 5% milk, 0.05% Tween-20 in Tris-buffered saline (TBS), followed by overnight incubation with the following primary antibodies: rabbit monoclonal antiacetylated H3 (Lys9), rabbit monoclonal anti-pCREB (Ser133), mouse monoclonal antiactin, and mouse monoclonal antiacetylated-tubulin (1:20 000, Sigma-Aldrich, St. Louis, MO, USA) in the corresponding buffer. Following two washes in PBS/Tween-20 or TBS/Tween-20 and one PBS or TBS alone, immunolabeled protein bands were detected by using HRP-conjugated antirabbit or antimouse antibody (1:5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) or antigoat (1:1500, Dako) antibody following an enhanced chemiluminescence system (ECL, GE Healthcare Bioscience, Buckinghamshire, UK) and autoradiographic exposure to Hyperfilm ECL (GE Healthcare Bioscience). Quantity One software v.4.6.3 (Bio-Rad, Hercules, CA, USA) was used for quantification.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i221"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00908">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16542" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16542" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00908" class="ext-link">10.1021/acs.jmedchem.6b00908</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Details about purification methods, SFC methods, synthesis of intermediates, purities, HRMS data and HPLC traces for final compounds, superposition of PDE5 inhibitors extracted from crystal complexes as well as biochemical activities as pIC<sub>50</sub> values (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf">jm6b00908_si_001.pdf (2.29 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_002.csv">jm6b00908_si_002.csv (4.45 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00908" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13583" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13583" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Garcia-Osta</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cdacaaa2beb9ac8db8a3acbbe3a8be"><span class="__cf_email__" data-cfemail="3b5a5c54484f5a7b4e555a4d155e48">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julen Oyarzabal</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9df7e8f1f8f3f2e4fcefe7fcfffcf1dde8f3fcebb3f8ee"><span class="__cf_email__" data-cfemail="2b415e474e4544524a59514a494a476b5e454a5d054e58">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Obdulia Rabal</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juan A. Sánchez-Arias</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mar Cuadrado-Tejedor</span> - <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irene de Miguel</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marta Pérez-González</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolina García-Barroso</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ana Ugarte</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ander Estella-Hermoso de Mendoza</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elena Sáez</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Espelosin</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susana Ursua</span> - <span class="hlFld-Affiliation affiliation">†Small Molecule Discovery
Platform, Molecular Therapeutics Program, ‡Neurobiology of Alzheimer’s
Disease, Neurosciences Division, Center for Applied Medical Research
(CIMA), University of Navarra, Avenida Pio XII 55, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">Anatomy Department, School of Medicine, University of Navarra, Irunlarrea 1, E-31008 Pamplona, Spain</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tan Haizhong</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wu Wei</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xu Musheng</span> - <span class="hlFld-Affiliation affiliation">WuXi Apptec (Tianjin) Co. Ltd.,
TEDA, No. 111 HuangHai Road, Fourth
Avenue, Tianjin 300456, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>O.R., J.A.S.-A., and M.C.-T. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d434e16046-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i223">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08832" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08832" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the Foundation for Applied Medical Research (FIMA), University of Navarra (Pamplona, Spain) as well as Fundación Fuentes Dutor for financial support. This work has been partially supported through Ministerio de Economía y Competitividad (FIS PI12/00710) and FSE (Inncorpora-Torres Quevedo grant) PTQ-12-05641 (A.U.). This work was supported by grants from FIS projects (11/02861 and 14/01244)</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i224" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i224"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i225" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i225"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">THP</td><td class="NLM_def"><p class="first last">tetrahydropyranyl</p></td></tr><tr><td class="NLM_term">PAMPA</td><td class="NLM_def"><p class="first last">parallel artificial membrane permeability assay</p></td></tr><tr><td class="NLM_term">BPL</td><td class="NLM_def"><p class="first last">brain polar lipid</p></td></tr><tr><td class="NLM_term">BOC</td><td class="NLM_def"><p class="first last"><i>tert</i>-butoxycarbonyl</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">Et<sub>3</sub>N</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TLC</td><td class="NLM_def"><p class="first last">thin layer chromatography</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">Rt</td><td class="NLM_def"><p class="first last">retention time</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">EDC·HCl</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">THPONH<sub>2</sub></td><td class="NLM_def"><p class="first last"><i>N</i>-(tetrahydro-2<i>H</i>-pyran-2-yloxy)amine</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">NMM</td><td class="NLM_def"><p class="first last"><i>N</i>-methylmorpholine</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">AcOH</td><td class="NLM_def"><p class="first last">acetic acid</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(<i>N</i>,<i>N</i>-dimethylamino)pyridine</p></td></tr><tr><td class="NLM_term">DEAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">xantphos</td><td class="NLM_def"><p class="first last">4,5-bis(diphenylphosphino)-9,9-dimethylxanthene</p></td></tr><tr><td class="NLM_term">m.p.</td><td class="NLM_def"><p class="first last">melting point</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NIS</td><td class="NLM_def"><p class="first last"><i>N</i>-iodosuccinimide</p></td></tr><tr><td class="NLM_term">NBS</td><td class="NLM_def"><p class="first last"><i>N</i>-bromosuccinimide</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last">diethanolamine</p></td></tr><tr><td class="NLM_term">BOP</td><td class="NLM_def"><p class="first last">(benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">CAN</td><td class="NLM_def"><p class="first last">ceric ammonium nitrate</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">LHMDS</td><td class="NLM_def"><p class="first last">lithium bis(trimethylsilyl)amide</p></td></tr><tr><td class="NLM_term">TMSCl</td><td class="NLM_def"><p class="first last">trimethylsilyl chloride</p></td></tr><tr><td class="NLM_term">9-BBN-H</td><td class="NLM_def"><p class="first last">9-borabicyclo[3.3.1]nonane</p></td></tr><tr><td class="NLM_term">POT</td><td class="NLM_def"><p class="first last">tri-<i>o</i>-tolylphosphine</p></td></tr><tr><td class="NLM_term">ESI-MS</td><td class="NLM_def"><p class="first last">electrospray ionization mass spectrometry</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term"><i>t</i>BuOK</td><td class="NLM_def"><p class="first last">potassium <i>tert</i>-butoxide</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">DIBAL-H</td><td class="NLM_def"><p class="first last">diisobutylaluminum hydride</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i226">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81227" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81227" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 54 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M.</span><span> </span><span class="NLM_article-title">New Approaches to Treating Alzheimer’s Disease</span> <span class="citation_source-journal">Perspect. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.4137/PMC.S13210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.4137%2FPMC.S13210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25733799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BC2MngsF2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=1-8&author=H.+Zhengauthor=M.+Fridkinauthor=M.+Youdim&title=New+Approaches+to+Treating+Alzheimer%E2%80%99s+Disease&doi=10.4137%2FPMC.S13210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches to treating Alzheimer's disease</span></div><div class="casAuthors">Zheng Hailin; Fridkin Mati; Youdim Moussa</div><div class="citationInfo"><span class="NLM_cas:title">Perspectives in medicinal chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To date, no truly efficacious drugs for Alzheimer's disease (AD) have been developed; moreover, all new anti-AD drugs developed since 2003 have failed.  To succeed where previous ones have failed in drug development, new approaches for AD therapy are needed.  Here we discuss the potential application of network medicine as a new approach to AD treatment.  Unlike traditional approaches focused on a single target/pathway, network medicine targets and restores disease-disrupted networks through simultaneous modulation of numerous proteins (targets)/pathways involved in AD pathogenesis.  We consider several drug candidates under development for AD therapy, including Keap1-Nrf2 regulators, endogenous neurogenic agents, and hypoxia-inducible factor 1 (HIF-1) activators.  These drug candidates are multi-target ligands with the potential to further develop as network medicines, since they act as master regulators to initiate a broad range of cellular defense mechanisms/cytoprotective genes that exert their efficacy in a holistic way.  We also explore their diverse mechanisms of action and potential disease-modifying effects, which may have profound implications for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ124YrbIuB24YPsCkJIw00fW6udTcc2eao9yUgTyQDF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MngsF2ntA%253D%253D&md5=d6641b1444233a80e69dfe0c74515da0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.4137%2FPMC.S13210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FPMC.S13210%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%26atitle%3DNew%2520Approaches%2520to%2520Treating%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DPerspect.%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D1%26epage%3D8%26doi%3D10.4137%2FPMC.S13210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzábal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Phosphodiesterases as Therapeutic Targets for Alzheimer’s Disease</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1021/cn3000907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn3000907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=832-844&author=A.+Garc%C3%ADa-Ostaauthor=M.+Cuadrado-Tejedorauthor=C.+Garc%C3%ADa-Barrosoauthor=J.+Oyarz%C3%A1balauthor=R.+Franco&title=Phosphodiesterases+as+Therapeutic+Targets+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fcn3000907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease</span></div><div class="casAuthors">Garcia-Osta, Ana; Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Oyarzabal, Julen; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">832-844</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common form of dementia among the elderly.  In AD patients, memory loss is accompanied by the formation of beta-amyloid plaques and the appearance of tau in a pathol. form.  Given the lack of effective treatments for AD, the development of new management strategies for these patients is crit.  The continued failure to find effective therapies using mols. aimed at addressing the anti-beta amyloid pathol. has led researchers to focus on other non-amyloid-based approaches to restore memory function.  Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compd. found to effectively restore cognitive deficits in animal models of AD.  More recently, PDE5 inhibitors have also been shown to effectively restore memory function.  Accordingly, inhibitors of other members of the PDE family may also improve memory performance in AD and non-AD animal models.  Hence, in this review, we will summarize the data supporting the use of PDE inhibitors as cognitive enhancers and we will discuss the possible mechanisms of action underlying these effects.  We shall also adopt a medicinal chem. perspective that leads us to propose the most promising PDE candidates on the basis of inhibitor selectivity, brain distribution, and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppeOP4NskdvrVg90H21EOLACvtfcHk0lgQJtVoMV2fdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK&md5=53c6dfed22bb240b17132672b13fdcf1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fcn3000907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn3000907%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DOyarz%25C3%25A1bal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPhosphodiesterases%2520as%2520Therapeutic%2520Targets%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D832%26epage%3D844%26doi%3D10.1021%2Fcn3000907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Epigenetic Drugs in Alzheimer’s Disease</span> <span class="citation_source-journal">Biomol. Concepts</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span><span class="refDoi"> DOI: 10.1515/bmc-2013-0012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1515%2Fbmc-2013-0012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25436752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=433-445&author=M.+Cuadrado-Tejedorauthor=J.+Oyarzabalauthor=M.+P.+Lucasauthor=R.+Francoauthor=A.+Garc%C3%ADa-Osta&title=Epigenetic+Drugs+in+Alzheimer%E2%80%99s+Disease&doi=10.1515%2Fbmc-2013-0012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic drugs in Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, Mar; Oyarzabal, Julen; Lucas, Maria Pascual; Franco, Rafael; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">433-445</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Epigenetic processes, such as DNA methylation and histone acetylation, regulate the genome-environment interactions that may play important roles in a wide range of brain disorders, including Alzheimer's disease (AD).  Indeed, the role of epigenetic machinery in learning and memory processes is well documented.  In this review, we will focus on the most recent literature on tools that target epigenetic mechanisms, particularly on histone acetylation, and we will discuss the use of chem. probes to validate these targets in therapeutic strategies for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IfwPOTWKkbVg90H21EOLACvtfcHk0lgQJtVoMV2fdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVWltrw%253D&md5=8e337544ac4fbd673b7086254fc07fb1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1515%2Fbmc-2013-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fbmc-2013-0012%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BP.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DEpigenetic%2520Drugs%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiomol.%2520Concepts%26date%3D2013%26volume%3D4%26spage%3D433%26epage%3D445%26doi%3D10.1515%2Fbmc-2013-0012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Gräff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">The Potential of HDAC Inhibitors as Cognitive Enhancers</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1146/annurev-pharmtox-011112-140216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1146%2Fannurev-pharmtox-011112-140216" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=311-330&author=J.+Gr%C3%A4ffauthor=L.-H.+Tsai&title=The+Potential+of+HDAC+Inhibitors+as+Cognitive+Enhancers&doi=10.1146%2Fannurev-pharmtox-011112-140216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-011112-140216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-011112-140216%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A4ff%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DThe%2520Potential%2520of%2520HDAC%2520Inhibitors%2520as%2520Cognitive%2520Enhancers%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D53%26spage%3D311%26epage%3D330%26doi%3D10.1146%2Fannurev-pharmtox-011112-140216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Benito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbanke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awasthi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capece, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro-Sala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütz, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnsen, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lührmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, A.</span><span> </span><span class="NLM_article-title">HDAC Inhibitor-Dependent Transcriptome and Memory Reinstatement in Cognitive Decline Models</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">3572</span><span class="NLM_x">–</span> <span class="NLM_lpage">3584</span><span class="refDoi"> DOI: 10.1172/JCI79942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1172%2FJCI79942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26280576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3572-3584&author=E.+Benitoauthor=H.+Urbankeauthor=B.+Ramachandranauthor=J.+Barthauthor=R.+Halderauthor=A.+Awasthiauthor=G.+Jainauthor=V.+Capeceauthor=S.+Burkhardtauthor=M.+Navarro-Salaauthor=S.+Nagarajanauthor=A.-L.+Sch%C3%BCtzauthor=S.+A.+Johnsenauthor=S.+Bonnauthor=R.+L%C3%BChrmannauthor=C.+Deanauthor=A.+Fischer&title=HDAC+Inhibitor-Dependent+Transcriptome+and+Memory+Reinstatement+in+Cognitive+Decline+Models&doi=10.1172%2FJCI79942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models</span></div><div class="casAuthors">Benito Eva; Urbanke Hendrik; Ramachandran Binu; Barth Jonas; Halder Rashi; Awasthi Ankit; Jain Gaurav; Capece Vincenzo; Burkhardt Susanne; Navarro-Sala Magdalena; Nagarajan Sankari; Schutz Anna-Lena; Johnsen Steven A; Bonn Stefan; Luhrmann Reinhardt; Dean Camin; Fischer Andre</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3572-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aging and increased amyloid burden are major risk factors for cognitive diseases such as Alzheimer's disease (AD).  Effective therapies for these diseases are lacking.  Here, we evaluated mouse models of age-associated memory impairment and amyloid deposition to study transcriptome and cell type-specific epigenome plasticity in the brain and peripheral organs.  We determined that aging and amyloid pathology are associated with inflammation and impaired synaptic function in the hippocampal CA1 region as the result of epigenetic-dependent alterations in gene expression.  In both amyloid and aging models, inflammation was associated with increased gene expression linked to a subset of transcription factors, while plasticity gene deregulation was differentially mediated.  Amyloid pathology impaired histone acetylation and decreased expression of plasticity genes, while aging altered H4K12 acetylation-linked differential splicing at the intron-exon junction in neurons, but not nonneuronal cells.  Furthermore, oral administration of the clinically approved histone deacetylase inhibitor vorinostat not only restored spatial memory, but also exerted antiinflammatory action and reinstated epigenetic balance and transcriptional homeostasis at the level of gene expression and exon usage.  This study provides a systems-level investigation of transcriptome plasticity in the hippocampal CA1 region in aging and AD models and suggests that histone deacetylase inhibitors should be further explored as a cost-effective therapeutic strategy against age-associated cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaDMtpB5WPpwyMywPm6HgQfW6udTcc2eawSY24na_ay7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D&md5=e30caf3ba1aaddf0a149c514d23640b8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI79942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI79942%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DE.%26aulast%3DUrbanke%26aufirst%3DH.%26aulast%3DRamachandran%26aufirst%3DB.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DHalder%26aufirst%3DR.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DG.%26aulast%3DCapece%26aufirst%3DV.%26aulast%3DBurkhardt%26aufirst%3DS.%26aulast%3DNavarro-Sala%26aufirst%3DM.%26aulast%3DNagarajan%26aufirst%3DS.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DA.-L.%26aulast%3DJohnsen%26aufirst%3DS.%2BA.%26aulast%3DBonn%26aufirst%3DS.%26aulast%3DL%25C3%25BChrmann%26aufirst%3DR.%26aulast%3DDean%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DA.%26atitle%3DHDAC%2520Inhibitor-Dependent%2520Transcriptome%2520and%2520Memory%2520Reinstatement%2520in%2520Cognitive%2520Decline%2520Models%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3572%26epage%3D3584%26doi%3D10.1172%2FJCI79942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kilgore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fass, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennig, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweatt, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumbaugh, G.</span><span> </span><span class="NLM_article-title">Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">870</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span><span class="refDoi"> DOI: 10.1038/npp.2009.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnpp.2009.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=20010553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=870-880&author=M.+Kilgoreauthor=C.+A.+Millerauthor=D.+M.+Fassauthor=K.+M.+Hennigauthor=S.+J.+Haggartyauthor=J.+D.+Sweattauthor=G.+Rumbaugh&title=Inhibitors+of+Class+1+Histone+Deacetylases+Reverse+Contextual+Memory+Deficits+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fnpp.2009.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Kilgore, Mark; Miller, Courtney A.; Fass, Daniel M.; Hennig, Krista M.; Haggarty, Stephen J.; Sweatt, J. David; Rumbaugh, Gavin</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">870-880</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder characterized clin. by cognitive impairments that progress to dementia and death.  The earliest symptoms of AD present as a relatively pure deficit in memory retrieval.  Therefore, drug treatments that intervene in the early stages of AD by rescuing memory deficits could be promising therapies to slow, or even reverse progression of the disease.  In this study, we tested the potential of systemic histone deacetylase inhibitor (HDACi) treatment to rescue cognitive deficits in a mouse model of AD.  APPswe/PS1dE9 mice showed pronounced contextual memory impairments beginning at 6 mo of age.  Chronic HDACi injections (2-3 wk) did not alter contextual memory formation in normal mice, but had profound effects in transgenic animals.  Injections of sodium valproate, sodium butyrate, or vorinostat (suberoylanilide hydroxamic acid; Zolinza) completely restored contextual memory in these mutant mice.  Further behavioral testing of the HDACi-treated transgenic mice showed that the newly consolidated memories were stably maintained over a 2-wk period.  Measurement of the HDAC isoform selectivity profile of sodium valproate, sodium butyrate, and vorinostat revealed the common inhibition of class I HDACs (HDAC1, 2, 3, 8) with little effect on the class IIa HDAC family members (HDAC4, 5, 7, 9) and inhibition of HDAC6 only by vorinostat.  These preclin. results indicate that targeted inhibition of class I HDAC isoforms is a promising avenue for treating the cognitive deficits assocd. with early stage AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRmqbpy-Ssz7Vg90H21EOLACvtfcHk0lgKkBQOghokHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslOisrk%253D&md5=d1054975a9a53f305d1ea257b92a62ec</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2009.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2009.197%26sid%3Dliteratum%253Aachs%26aulast%3DKilgore%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DC.%2BA.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DSweatt%26aufirst%3DJ.%2BD.%26aulast%3DRumbaugh%26aufirst%3DG.%26atitle%3DInhibitors%2520of%2520Class%25201%2520Histone%2520Deacetylases%2520Reverse%2520Contextual%2520Memory%2520Deficits%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeuropsychopharmacology%26date%3D2010%26volume%3D35%26spage%3D870%26epage%3D880%26doi%3D10.1038%2Fnpp.2009.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Maurice, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manganiello, V. C.</span><span> </span><span class="NLM_article-title">Advances in Targeting Cyclic Nucleotide Phosphodiesterases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span><span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+Targeting+Cyclic+Nucleotide+Phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0lgKkBQOghokHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520Targeting%2520Cyclic%2520Nucleotide%2520Phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil-Bea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cedazo-Minguez, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramírez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span> </span><span class="NLM_article-title">Decreased Levels of Guanosine 3′, 5′-monophosphate (cGMP) in Cerebrospinal Fluid (CSF) Are Associated with Cognitive Decline and Amyloid Pathology in Alzheimer’s Disease</span> <span class="citation_source-journal">Neuropathol. Appl. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1111/nan.12203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fnan.12203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25488891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2015&pages=471-482&author=A.+Ugarteauthor=F.+Gil-Beaauthor=C.+Garc%C3%ADa-Barrosoauthor=%C3%81.+Cedazo-Minguezauthor=M.+J.+Ram%C3%ADrezauthor=R.+Francoauthor=A.+Garc%C3%ADa-Ostaauthor=J.+Oyarzabalauthor=M.+Cuadrado-Tejedor&title=Decreased+Levels+of+Guanosine+3%E2%80%B2%2C+5%E2%80%B2-monophosphate+%28cGMP%29+in+Cerebrospinal+Fluid+%28CSF%29+Are+Associated+with+Cognitive+Decline+and+Amyloid+Pathology+in+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fnan.12203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease</span></div><div class="casAuthors">Ugarte, Ana; Gil-Bea, Francisco; Garcia-Barroso, Carolina; Cedazo-Minguez, Angel; Ramirez, M. Javier; Franco, Rafael; Garcia-Osta, Ana; Oyarzabal, Julen; Cuadrado-Tejedor, Mar</div><div class="citationInfo"><span class="NLM_cas:title">Neuropathology and Applied Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">NANEDL</span>;
        ISSN:<span class="NLM_cas:issn">0305-1846</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Levels of the cyclic nucleotides guanosine 3', 5'-monophosphate (cGMP) or adenosine 3', 5'-monophosphate (cAMP) that play important roles in memory processes are not characterized in Alzheimer's disease (AD).  The aim of this study was to analyze the levels of these nucleotides in cerebrospinal fluid (CSF) samples from patients diagnosed with clin. and prodromal stages of AD and study the expression level of the enzymes that hydrolyzed them [phosphodiesterases (PDEs)] in the brain of AD patients vs. controls.  Methods : For cGMP and cAMP CSF anal., the cohort (n = 79) included cognitively normal participants (subjective cognitive impairment), individuals with stable mild cognitive impairment or AD converters (sMCI and cMCI), and mild AD patients.  A high throughput liq. chromatog.-tandem mass spectrometry method was used.  Interactions between CSF cGMP or cAMP with mini-mental state examn. (MMSE) score, CSF Aβ(1-42) and CSF p-tau were analyzed.  For PDE4, 5, 9 and 10 expression anal., brains of AD patients vs. controls (n = 7 and n = 8) were used.  Results : cGMP, and not cAMP levels, were significantly lower in the CSF of patients diagnosed with mild AD when compared with nondemented controls.  CSF levels of cGMP showed a significant assocn. with MMSE-diagnosed clin. dementia and with CSF biomarker Aβ42 in AD patients.  Significant increase in PDE5 expression was detected in temporal cortex of AD patients compared with that of age-matched healthy control subjects.  No changes in the expression of others PDEs were detected.  Conclusions : These results support the potential involvement of cGMP in the pathol. and clin. development of AD.  The cGMP redn. in early stages of AD might participate in the aggravation of amyloid pathol. and cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDfphh1a73krVg90H21EOLACvtfcHk0lgCB2xA4NgFSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D&md5=4aabb42e396d12b9a74e64bd42abb064</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fnan.12203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnan.12203%26sid%3Dliteratum%253Aachs%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DGil-Bea%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DCedazo-Minguez%26aufirst%3D%25C3%2581.%26aulast%3DRam%25C3%25ADrez%26aufirst%3DM.%2BJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26atitle%3DDecreased%2520Levels%2520of%2520Guanosine%25203%25E2%2580%25B2%252C%25205%25E2%2580%25B2-monophosphate%2520%2528cGMP%2529%2520in%2520Cerebrospinal%2520Fluid%2520%2528CSF%2529%2520Are%2520Associated%2520with%2520Cognitive%2520Decline%2520and%2520Amyloid%2520Pathology%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeuropathol.%2520Appl.%2520Neurobiol.%26date%3D2015%26volume%3D41%26spage%3D471%26epage%3D482%26doi%3D10.1111%2Fnan.12203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hervias, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puerta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Roldán, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Sildenafil Restores Cognitive Function without Affecting β-Amyloid Burden in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">2029</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01517.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fj.1476-5381.2011.01517.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=21627640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=2029-2041&author=M.+Cuadrado-Tejedorauthor=I.+Herviasauthor=A.+Ricobarazaauthor=E.+Puertaauthor=J.+M.+P%C3%A9rez-Rold%C3%A1nauthor=C.+Garc%C3%ADa-Barrosoauthor=R.+Francoauthor=N.+Aguirreauthor=A.+Garc%C3%ADa-Osta&title=Sildenafil+Restores+Cognitive+Function+without+Affecting+%CE%B2-Amyloid+Burden+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fj.1476-5381.2011.01517.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, M.; Hervias, I.; Ricobaraza, A.; Puerta, E.; Perez-Roldan, J. M.; Garcia-Barroso, C.; Franco, R.; Aguirre, N.; Garcia-Osta, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2029-2041</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Inhibitors of phosphodiesterase 5 (PDE5) affect signalling pathways by elevating cGMP, which is a second messenger involved in processes of neuroplasticity.  In the present study, the effects of the PDE5 inhibitor, sildenafil, on the pathol. features of Alzheimer's disease and on memory-related behavior were investigated.  Exptl. Approach Sildenafil was administered to the Tg2576 transgenic mouse model of Alzheimer's disease and to age-matched neg. littermates (controls).  Memory function was analyzed using the Morris water maze test and fear conditioning tasks.  Biochem. analyses were performed in brain lysates from animals treated with saline or with sildenafil.  Key Results Treatment of aged Tg2576 animals with sildenafil completely reversed their cognitive impairment.  Such changes were accompanied in the hippocampus by a redn. of tau hyperphosphorylation and a decrease in the activity of glycogen synthase kinase 3β (GSK3β) and of cyclin-dependent kinase 5 (CDK5) (p25/p35 ratio).  Moreover, sildenafil also increased levels of brain-derived neurotrophic factor (BDNF) and the activity-regulated cytoskeletal-assocd. protein (Arc) in the hippocampus without any detectable modification of brain amyloid burden.  Conclusions and Implications Sildenafil improved cognitive functions in Tg2576 mice and the effect was not related to changes in the amyloid burden.  These data further strengthen the potential of sildenafil as a therapeutic agent for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSIHZg2HFLZbVg90H21EOLACvtfcHk0lgCB2xA4NgFSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsL3F&md5=5bda5d02186b430428a2d7ce8c354696</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01517.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01517.x%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DHervias%26aufirst%3DI.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DPuerta%26aufirst%3DE.%26aulast%3DP%25C3%25A9rez-Rold%25C3%25A1n%26aufirst%3DJ.%2BM.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DAguirre%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DSildenafil%2520Restores%2520Cognitive%2520Function%2520without%2520Affecting%2520%25CE%25B2-Amyloid%2520Burden%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D2029%26epage%3D2041%26doi%3D10.1111%2Fj.1476-5381.2011.01517.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unceta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rico, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goicolea, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Tadalafil Crosses the Blood-Brain Barrier and Reverses Cognitive Dysfunction in a Mouse Model of AD</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">123</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.neuropharm.2012.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22776546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=114-123&author=C.+Garc%C3%ADa-Barrosoauthor=A.+Ricobarazaauthor=M.+Pascual-Lucasauthor=N.+Uncetaauthor=A.+J.+Ricoauthor=M.+A.+Goicoleaauthor=J.+Sall%C3%A9sauthor=J.+L.+Lanciegoauthor=J.+Oyarzabalauthor=R.+Francoauthor=M.+Cuadrado-Tejedorauthor=A.+Garc%C3%ADa-Osta&title=Tadalafil+Crosses+the+Blood-Brain+Barrier+and+Reverses+Cognitive+Dysfunction+in+a+Mouse+Model+of+AD&doi=10.1016%2Fj.neuropharm.2012.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD</span></div><div class="casAuthors">Garcia-Barroso, Carolina; Ricobaraza, Ana; Pascual-Lucas, Maria; Unceta, Nora; Rico, Alberto J.; Goicolea, Maria Aranzazu; Salles, Joan; Lanciego, Jose Luis; Oyarzabal, Julen; Franco, Rafael; Cuadrado-Tejedor, Mar; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-123</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil, a specific PDE5 inhibitor (Puzzo et al., 2009; Cuadrado-Tejedor et al.).  Another very potent PDE5 inhibitor with a longer half-life and safe in chronic treatments, tadalafil, may represent a better alternative candidate for AD therapy.  However, tadalafil was proven unable to achieve similar benefits than those of sildenafil in AD animal models (Puzzo et al., 2009).  The lack of efficacy was attributed to inability to cross the blood-brain barrier (BBB).  In this paper we first measured the blood and brain levels of tadalafil to prove that the compd. crosses BBB and that chronic treatment leads to accumulation in the brain of the J20 transgenic mouse model of AD.  We demonstrated the presence of PDE5 mRNA in the brain of the mice and also in the human brain.  After a 10 wk treatment with either of these PDE5 inhibitors, the performance of the J20 mice in the Morris water maze test improved when compared with the transgenic mice that received vehicle.  Biochem. anal. revealed that neither sildenafil nor tadalafil altered the amyloid burden, although both compds. reduced Tau phosphorylation in the mouse hippocampus.  This study provides evidence of the potential benefits of a chronic tadalafil treatment in AD therapy.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkrxYqIGt7LVg90H21EOLACvtfcHk0lgCB2xA4NgFSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O&md5=aafb7dacec3ffd9d8ef4abc38c08e0f6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DPascual-Lucas%26aufirst%3DM.%26aulast%3DUnceta%26aufirst%3DN.%26aulast%3DRico%26aufirst%3DA.%2BJ.%26aulast%3DGoicolea%26aufirst%3DM.%2BA.%26aulast%3DSall%25C3%25A9s%26aufirst%3DJ.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DTadalafil%2520Crosses%2520the%2520Blood-Brain%2520Barrier%2520and%2520Reverses%2520Cognitive%2520Dysfunction%2520in%2520a%2520Mouse%2520Model%2520of%2520AD%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D114%26epage%3D123%26doi%3D10.1016%2Fj.neuropharm.2012.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Reneerkens, O. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akkerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Type 5 (PDE5) Inhibition Improves Object Recognition Memory: Indications for Central and Peripheral Mechanisms</span> <span class="citation_source-journal">Neurobiol. Learn. Mem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1016/j.nlm.2012.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.nlm.2012.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22426465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt12lt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=370-379&author=O.+A.+H.+Reneerkensauthor=K.+Ruttenauthor=S.+Akkermanauthor=A.+Bloklandauthor=C.+L.+Shafferauthor=F.+S.+Mennitiauthor=H.+W.+M.+Steinbuschauthor=J.+Prickaerts&title=Phosphodiesterase+Type+5+%28PDE5%29+Inhibition+Improves+Object+Recognition+Memory%3A+Indications+for+Central+and+Peripheral+Mechanisms&doi=10.1016%2Fj.nlm.2012.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms</span></div><div class="casAuthors">Reneerkens, Olga A. H.; Rutten, Kris; Akkerman, Sven; Blokland, Arjan; Shaffer, Christopher L.; Menniti, Frank S.; Steinbusch, Harry W. M.; Prickaerts, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">370-379</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A promising target for memory improvement is phosphodiesterase type 5 (PDE5), which selectively hydrolyzes cyclic guanosine monophosphate (cGMP).  In rodents, PDE5 inhibitors (PDE5-Is) have been shown to improve memory performance in many behavioral paradigms.  However, it is questioned whether the pos. effects in animal studies result from PDE5 inhibition in the central nervous system or the periphery.  Therefore, we studied the effects of PDE5 inhibition on memory and detd. whether compd. penetration of the blood-brain barrier (BBB) is required for this activity.  Two selective PDE5-Is, vardenafil and UK-343,664, were tested in the object recognition task (ORT) in both a MK-801- and scopolamine-induced memory deficit model, and a time-delay model without pharmacol. intervention.  Compds. were dosed 30 min before the learning trial of the task.  To det. if the PDE5-Is crossed the BBB, their concns. were detd. in plasma and brain tissue collected 30 min after oral administration.  Vardenafil improved object recognition memory in all three variants of the ORT.  UK-343,664 was ineffective at either preventing MK-801-induced memory disruption or time-dependent memory decay.  However, UK-343,664 attenuated the memory impairment of scopolamine.  Vardenafil crossed the BBB whereas UK-343,664 did not.  Further, co-administration of UK-343,664 and scopolamine did not alter the brain partitioning of either mol.  This suggests that the pos. effect of UK-343,664 on scopolamine-induced memory decay might arise from peripheral PDE5 inhibition.  The results herein suggest that there may be multiple mechanisms that mediate the efficacy of PDE5 inhibition to improve memory performance in tasks such as the ORT and that these involve PDE5 located both within and outside of the brain.  To further elucidate the underlying mechanisms, the cellular and subcellular localization of PDE5 needs to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHK-AKR-M6bVg90H21EOLACvtfcHk0lgvNgfWf7yElQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt12lt7s%253D&md5=b57ecbaeb7529e71b4edc10aa2f78956</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2012.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2012.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DReneerkens%26aufirst%3DO.%2BA.%2BH.%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DAkkerman%26aufirst%3DS.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DPhosphodiesterase%2520Type%25205%2520%2528PDE5%2529%2520Inhibition%2520Improves%2520Object%2520Recognition%2520Memory%253A%2520Indications%2520for%2520Central%2520and%2520Peripheral%2520Mechanisms%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2012%26volume%3D97%26spage%3D370%26epage%3D379%26doi%3D10.1016%2Fj.nlm.2012.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Falkenberg, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span><span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lgvNgfWf7yElQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Guan, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacometti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dannenberg, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieland, T. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinho, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenisch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">HDAC2 Negatively Regulates Memory Formation and Synaptic Plasticity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">459</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1038/nature07925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnature07925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19424149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2009&pages=55-60&author=J.-S.+Guanauthor=S.+J.+Haggartyauthor=E.+Giacomettiauthor=J.-H.+Dannenbergauthor=N.+Josephauthor=J.+Gaoauthor=T.+J.+F.+Nielandauthor=Y.+Zhouauthor=X.+Wangauthor=R.+Mazitschekauthor=J.+E.+Bradnerauthor=R.+A.+DePinhoauthor=R.+Jaenischauthor=L.-H.+Tsai&title=HDAC2+Negatively+Regulates+Memory+Formation+and+Synaptic+Plasticity&doi=10.1038%2Fnature07925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC2 negatively regulates memory formation and synaptic plasticity</span></div><div class="casAuthors">Guan, Ji-Song; Haggarty, Stephen J.; Giacometti, Emanuela; Dannenberg, Jan-Hermen; Joseph, Nadine; Gao, Jun; Nieland, Thomas J. F.; Zhou, Ying; Wang, Xinyu; Mazitschek, Ralph; Bradner, James E.; DePinho, Ronald A.; Jaenisch, Rudolf; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">7243</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chromatin modifications, esp. histone-tail acetylation, have been implicated in memory formation.  Increased histone-tail acetylation induced by histone deacetylases inhibitors (HDACis) facilitates learning and memory in wild-type mice as well as in mouse models of neurodegeneration.  Harnessing the therapeutic potential of HDACis requires knowledge of the specific HDAC family member(s) linked to cognitive enhancement.  Here, the authors show that neuron-specific overexpression of HDAC2, but not that of HDAC1, decreased dendritic spine d., synapse no., synaptic plasticity and memory formation.  Conversely, gene Hdac2 deficiency resulted in increased synapse no. and memory facilitation, similar to chronic treatment with HDACis in mice.  Notably, reduced synapse no. and learning impairment of HDAC2-overexpressing mice were ameliorated by chronic treatment with HDACis.  Correspondingly, treatment with HDACis failed to further facilitate memory formation in gene Hdac2-deficient mice.  Furthermore, anal. of promoter occupancy revealed an assocn. of HDAC2 with the promoters of genes implicated in synaptic plasticity and memory formation.  Taken together, these results suggest that HDAC2 functions in modulating synaptic plasticity and long-lasting changes of neural circuits, which in turn neg. regulates learning and memory.  These observations encourage the development and testing of HDAC2-selective inhibitors for human diseases assocd. with memory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0MzAlmmDwLLVg90H21EOLACvtfcHk0lgvNgfWf7yElQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D&md5=bbd00accb8b6992f9c109114e8818388</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature07925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07925%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.-S.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DGiacometti%26aufirst%3DE.%26aulast%3DDannenberg%26aufirst%3DJ.-H.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DNieland%26aufirst%3DT.%2BJ.%2BF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DJaenisch%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DHDAC2%2520Negatively%2520Regulates%2520Memory%2520Formation%2520and%2520Synaptic%2520Plasticity%26jtitle%3DNature%26date%3D2009%26volume%3D459%26spage%3D55%26epage%3D60%26doi%3D10.1038%2Fnature07925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Gräff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennig, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieland, T. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fass, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samiei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delalle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">An Epigenetic Blockade of Cognitive Functions in the Neurodegenerating Brain</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">483</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1038/nature10849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnature10849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22388814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BC383ptlCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=222-226&author=J.+Gr%C3%A4ffauthor=D.+Reiauthor=J.-S.+Guanauthor=W.-Y.+Wangauthor=J.+Seoauthor=K.+M.+Hennigauthor=T.+J.+F.+Nielandauthor=D.+M.+Fassauthor=P.+F.+Kaoauthor=M.+Kahnauthor=S.+C.+Suauthor=A.+Samieiauthor=N.+Josephauthor=S.+J.+Haggartyauthor=I.+Delalleauthor=L.-H.+Tsai&title=An+Epigenetic+Blockade+of+Cognitive+Functions+in+the+Neurodegenerating+Brain&doi=10.1038%2Fnature10849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">An epigenetic blockade of cognitive functions in the neurodegenerating brain</span></div><div class="casAuthors">Graff Johannes; Rei Damien; Guan Ji-Song; Wang Wen-Yuan; Seo Jinsoo; Hennig Krista M; Nieland Thomas J F; Fass Daniel M; Kao Patricia F; Kahn Martin; Su Susan C; Samiei Alireza; Joseph Nadine; Haggarty Stephen J; Delalle Ivana; Tsai Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">483</span>
        (<span class="NLM_cas:issue">7388</span>),
    <span class="NLM_cas:pages">222-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cognitive decline is a debilitating feature of most neurodegenerative diseases of the central nervous system, including Alzheimer's disease.  The causes leading to such impairment are only poorly understood and effective treatments are slow to emerge.  Here we show that cognitive capacities in the neurodegenerating brain are constrained by an epigenetic blockade of gene transcription that is potentially reversible.  This blockade is mediated by histone deacetylase 2, which is increased by Alzheimer's-disease-related neurotoxic insults in vitro, in two mouse models of neurodegeneration and in patients with Alzheimer's disease.  Histone deacetylase 2 associates with and reduces the histone acetylation of genes important for learning and memory, which show a concomitant decrease in expression.  Importantly, reversing the build-up of histone deacetylase 2 by short-hairpin-RNA-mediated knockdown unlocks the repression of these genes, reinstates structural and synaptic plasticity, and abolishes neurodegeneration-associated memory impairments.  These findings advocate for the development of selective inhibitors of histone deacetylase 2 and suggest that cognitive capacities following neurodegeneration are not entirely lost, but merely impaired by this epigenetic blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_TBTrhihJh3WEEzDrymxmfW6udTcc2eZNglFFd6tIE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ptlCjtw%253D%253D&md5=6e567f82c587972acbdf75fbb06d2954</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature10849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10849%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A4ff%26aufirst%3DJ.%26aulast%3DRei%26aufirst%3DD.%26aulast%3DGuan%26aufirst%3DJ.-S.%26aulast%3DWang%26aufirst%3DW.-Y.%26aulast%3DSeo%26aufirst%3DJ.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DNieland%26aufirst%3DT.%2BJ.%2BF.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DKao%26aufirst%3DP.%2BF.%26aulast%3DKahn%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%2BC.%26aulast%3DSamiei%26aufirst%3DA.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DDelalle%26aufirst%3DI.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DAn%2520Epigenetic%2520Blockade%2520of%2520Cognitive%2520Functions%2520in%2520the%2520Neurodegenerating%2520Brain%26jtitle%3DNature%26date%3D2012%26volume%3D483%26spage%3D222%26epage%3D226%26doi%3D10.1038%2Fnature10849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsunemoto, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giusti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broodie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delalle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">Deregulation of HDAC1 by p25/Cdk5 in Neurotoxicity</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">803</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1016/j.neuron.2008.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.neuron.2008.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19081376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFahs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=803-817&author=D.+Kimauthor=C.+L.+Frankauthor=M.+M.+Dobbinauthor=R.+K.+Tsunemotoauthor=W.+Tuauthor=P.+L.+Pengauthor=J.-S.+Guanauthor=B.-H.+Leeauthor=L.+Y.+Moyauthor=P.+Giustiauthor=N.+Broodieauthor=R.+Mazitschekauthor=I.+Delalleauthor=S.+J.+Haggartyauthor=R.+L.+Neveauthor=Y.+Luauthor=L.-H.+Tsai&title=Deregulation+of+HDAC1+by+p25%2FCdk5+in+Neurotoxicity&doi=10.1016%2Fj.neuron.2008.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity</span></div><div class="casAuthors">Kim, Dohoon; Frank, Christopher L.; Dobbin, Matthew M.; Tsunemoto, Rachel K.; Tu, Weihong; Peng, Peter L.; Guan, Ji-Song; Lee, Byung-Hoon; Moy, Lily Y.; Giusti, Paola; Broodie, Nisha; Mazitschek, Ralph; Delalle, Ivanna; Haggarty, Stephen J.; Neve, Rachael L.; Lu, YouMing; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">803-817</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Aberrant cell-cycle activity and DNA damage are emerging as important pathol. components in various neurodegenerative conditions.  However, their underlying mechanisms are poorly understood.  Here, it is shown that deregulation of histone deacetylase 1 (HDAC1) activity by p25/Cdk5 induces aberrant cell-cycle activity and double-strand DNA breaks leading to neurotoxicity.  In a transgenic model for neurodegeneration, p25/Cdk5 activity elicited cell-cycle activity and double-strand DNA breaks that preceded neuronal death.  Inhibition of HDAC1 activity by p25/Cdk5 was identified as an underlying mechanism for these events, and HDAC1 gain of function provided potent protection against DNA damage and neurotoxicity in cultured neurons and an in vivo model for ischemia.  These findings outline a pathol. signaling pathway illustrating the importance of maintaining HDAC1 activity in the adult neuron.  This pathway constitutes a mol. link between aberrant cell-cycle activity and DNA damage and is a potential target for therapeutics against diseases and conditions involving neuronal death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFpYueKsA8XbVg90H21EOLACvtfcHk0lgXEazlmf00uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFahs7rE&md5=12d9ecc3fe53ea6fcee61f149e5ffae3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2008.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2008.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DFrank%26aufirst%3DC.%2BL.%26aulast%3DDobbin%26aufirst%3DM.%2BM.%26aulast%3DTsunemoto%26aufirst%3DR.%2BK.%26aulast%3DTu%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DP.%2BL.%26aulast%3DGuan%26aufirst%3DJ.-S.%26aulast%3DLee%26aufirst%3DB.-H.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DGiusti%26aufirst%3DP.%26aulast%3DBroodie%26aufirst%3DN.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DDelalle%26aufirst%3DI.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DNeve%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DDeregulation%2520of%2520HDAC1%2520by%2520p25%252FCdk5%2520in%2520Neurotoxicity%26jtitle%3DNeuron%26date%3D2008%26volume%3D60%26spage%3D803%26epage%3D817%26doi%3D10.1016%2Fj.neuron.2008.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolan, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, G. V. W.</span><span> </span><span class="NLM_article-title">Histone Deacetylase 6 Interacts with the Microtubule-Associated Protein Tau</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">2119</span><span class="NLM_x">–</span> <span class="NLM_lpage">2130</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05564.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fj.1471-4159.2008.05564.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=18636984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2008&pages=2119-2130&author=H.+Dingauthor=P.+J.+Dolanauthor=G.+V.+W.+Johnson&title=Histone+Deacetylase+6+Interacts+with+the+Microtubule-Associated+Protein+Tau&doi=10.1111%2Fj.1471-4159.2008.05564.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 interacts with the microtubule-associated protein tau</span></div><div class="casAuthors">Ding, Huiping; Dolan, Philip J.; Johnson, Gail V. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2130</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a unique cytoplasmic deacetylase, likely plays a role in neurodegeneration by coordinating cell responses to abnormal protein aggregation.  Here, we provide in vitro and in vivo evidence that HDAC6 interacts with tau, a microtubule-assocd. protein that forms neurofibrillary tangles in Alzheimer's disease.  This interaction is mediated by the microtubule-binding domain on tau and the Ser/Glu tetradecapeptide domain on HDAC6.  Treatment with tubacin, a selective inhibitor of tubulin deacetylation activity of HDAC6, did not disrupt HDAC6-tau interaction.  Nonetheless tubacin treatment attenuated site-specific tau phosphorylation, as did shRNA-mediated knockdown of HDAC6.  Proteasome inhibition potentiated HDAC6-tau interactions and facilitated the concn. and co-localization of HDAC6 and tau in a perinuclear aggresome-like compartment, independent of HDAC6 tubulin deacetylase activity.  Furthermore, we obsd. that in Alzheimer's disease brains the protein level of HDAC6 was significantly increased.  These findings establish HDAC6 as a tau-interacting protein and as a potential modulator of tau phosphorylation and accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OtxbhpBU9LVg90H21EOLACvtfcHk0lgXEazlmf00uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM&md5=cf63da19f8f887459227b620d9a0898b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05564.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05564.x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DDolan%26aufirst%3DP.%2BJ.%26aulast%3DJohnson%26aufirst%3DG.%2BV.%2BW.%26atitle%3DHistone%2520Deacetylase%25206%2520Interacts%2520with%2520the%2520Microtubule-Associated%2520Protein%2520Tau%26jtitle%3DJ.%2520Neurochem.%26date%3D2008%26volume%3D106%26spage%3D2119%26epage%3D2130%26doi%3D10.1111%2Fj.1471-4159.2008.05564.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Selenica, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housley, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manchec, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, D.</span><span> </span><span class="NLM_article-title">Histone Deacetylase 6 Inhibition Improves Memory and Reduces Total Tau Levels in a Mouse Model of Tau Deposition</span> <span class="citation_source-journal">Alzheimer's Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="refDoi"> DOI: 10.1186/alzrt241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1186%2Falzrt241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24576665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=12&author=M.-L.+Selenicaauthor=L.+Bennerauthor=S.+B.+Housleyauthor=B.+Manchecauthor=D.+C.+Leeauthor=K.+R.+Nashauthor=J.+Kalinauthor=J.+A.+Bergmanauthor=A.+Kozikowskiauthor=M.+N.+Gordonauthor=D.+Morgan&title=Histone+Deacetylase+6+Inhibition+Improves+Memory+and+Reduces+Total+Tau+Levels+in+a+Mouse+Model+of+Tau+Deposition&doi=10.1186%2Falzrt241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition</span></div><div class="casAuthors">Selenica, Maj-Linda; Benner, Leif; Housley, Steven B.; Manchec, Barbara; Lee, Daniel C.; Nash, Kevin R.; Kalin, Jay; Bergman, Joel A.; Kozikowski, Alan; Gordon, Marcia N.; Morgan, Dave</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12/1-12/12, 12</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Tau pathol. is assocd. with a no. of age-related neurodegenerative disorders.  Few treatments have been demonstrated to diminish the impact of tau pathol. in mouse models and none are yet effective in humans.  Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather than nuclear histones.  Its substrates include tubulin, heat shock protein 90 and cortactin.  Tubastatin A is a selective inhibitor of HDAC6.  Modification of tau pathol. by specific inhibition of HDAC6 presents a potential therapeutic approach in tauopathy.  Methods: We treated rTg4510 mouse models of tau deposition and non-transgenic mice with tubastatin (25 mg/kg) or saline (0.9%) from 5 to 7 mo of age.  Cognitive behavior anal., histol. and biochem. anal. were applied to access the effect of tubastatin on memory, tau pathol. and neurodegeneration (hippocampal vol.).  Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed a hyperactivity phenotype.  We further found that tubastatin reduced the levels of total tau, both histol. and by western anal.  Redn. in total tau levels was pos. correlated with memory improvement in these mice.  However, there was no impact on phosphorylated forms of tau, either by histol. or western anal., nor was there an impact on silver pos. inclusions histol.  Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include stabilization of microtubules secondary to increased tubulin acetylation, increased degrdn. of tau secondary to increased acetylation of HSP90 or both.  These data support the use of HDAC6 inhibitors as potential therapeutic agents against tau pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYGE6Rou8uVrVg90H21EOLACvtfcHk0lilNjtcymj3OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVyms78%253D&md5=d0e234d073b768649c60284711685155</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Falzrt241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Falzrt241%26sid%3Dliteratum%253Aachs%26aulast%3DSelenica%26aufirst%3DM.-L.%26aulast%3DBenner%26aufirst%3DL.%26aulast%3DHousley%26aufirst%3DS.%2BB.%26aulast%3DManchec%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DD.%2BC.%26aulast%3DNash%26aufirst%3DK.%2BR.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DM.%2BN.%26aulast%3DMorgan%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylase%25206%2520Inhibition%2520Improves%2520Memory%2520and%2520Reduces%2520Total%2520Tau%2520Levels%2520in%2520a%2520Mouse%2520Model%2520of%2520Tau%2520Deposition%26jtitle%3DAlzheimer%2527s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D12%26doi%3D10.1186%2Falzrt241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Q.</span><span> </span><span class="NLM_article-title">HDAC6Mutations Rescue Human Tau-Induced Microtubule Defects in Drosophila</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">4604</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span><span class="refDoi"> DOI: 10.1073/pnas.1207586110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1073%2Fpnas.1207586110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=4604-4609&author=Y.+Xiongauthor=K.+Zhaoauthor=J.+Wuauthor=Z.+Xuauthor=S.+Jinauthor=Y.+Q.+Zhang&title=HDAC6Mutations+Rescue+Human+Tau-Induced+Microtubule+Defects+in+Drosophila&doi=10.1073%2Fpnas.1207586110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207586110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207586110%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%2BQ.%26atitle%3DHDAC6Mutations%2520Rescue%2520Human%2520Tau-Induced%2520Microtubule%2520Defects%2520in%2520Drosophila%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D4604%26epage%3D4609%26doi%3D10.1073%2Fpnas.1207586110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sung, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiBattista, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoe, H.-S.</span><span> </span><span class="NLM_article-title">Mercaptoacetamide-Based Class II HDAC Inhibitor Lowers Aβ Levels and Improves Learning and Memory in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Exp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">239</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1016/j.expneurol.2012.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.expneurol.2012.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=23063601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2013&pages=192-201&author=Y.+M.+Sungauthor=T.+Leeauthor=H.+Yoonauthor=A.+M.+DiBattistaauthor=J.+M.+Songauthor=Y.+Sohnauthor=E.+I.+Moffatauthor=R.+S.+Turnerauthor=M.+Jungauthor=J.+Kimauthor=H.-S.+Hoe&title=Mercaptoacetamide-Based+Class+II+HDAC+Inhibitor+Lowers+A%CE%B2+Levels+and+Improves+Learning+and+Memory+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.expneurol.2012.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Sung, You Me; Lee, Taehee; Yoon, Hyejin; DiBattista, Amanda Marie; Song, Jung Min; Sohn, Yoojin; Moffat, Emily Isabella; Turner, R. Scott; Jung, Mira; Kim, Jungsu; Hoe, Hyang-Sook</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-201</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) alter gene expression epigenetically by interfering with the normal functions of HDAC.  Given their ability to decrease Aβ levels, HDACIs are a potential treatment for Alzheimer's disease (AD).  However, it is unclear how HDACIs alter Aβ levels.  We developed two novel HDAC inhibitors with improved pharmacol. properties, such as a longer half-life and greater penetration of the blood-brain barrier: mercaptoacetamide-based class II HDACI (coded as W2) and hydroxamide-based class I and IIHDACI (coded as I2) and investigated how they affect Aβ levels and cognition.  HDACI W2 decreased Aβ40 and Aβ42 in vitro.  HDACI I2 also decreased Aβ40, but not Aβ42.  We systematically examd. the mol. mechanisms by which HDACIs W2 and I2 can decrease Aβ levels.  HDACI W2 decreased gene expression of γ-secretase components and increased the Aβ degrdn. enzyme Mmp2.  Similarly, HDACI I2 decreased expression of β- and γ-secretase components and increased mRNA levels of Aβ degrdn. enzymes.  HDACI W2 also significantly decreased Aβ levels and rescued learning and memory deficits in aged hAPP 3xTg AD mice.  Furthermore, we found that the novel HDACI W2 decreased tau phosphorylation at Thr181, an effect previously unknown for HDACIs.  Collectively, these data suggest that class II HDACls may serve as a novel therapeutic strategy for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgE2jeS-UuA7Vg90H21EOLACvtfcHk0lilNjtcymj3OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWisw%253D%253D&md5=11db4f9ac4e0f6f541b2441e4316b6e8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2012.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2012.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DDiBattista%26aufirst%3DA.%2BM.%26aulast%3DSong%26aufirst%3DJ.%2BM.%26aulast%3DSohn%26aufirst%3DY.%26aulast%3DMoffat%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DR.%2BS.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHoe%26aufirst%3DH.-S.%26atitle%3DMercaptoacetamide-Based%2520Class%2520II%2520HDAC%2520Inhibitor%2520Lowers%2520A%25CE%25B2%2520Levels%2520and%2520Improves%2520Learning%2520and%2520Memory%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExp.%2520Neurol.%26date%3D2013%26volume%3D239%26spage%3D192%26epage%3D201%26doi%3D10.1016%2Fj.expneurol.2012.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, X.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, C.</span><span> </span><span class="NLM_article-title">Tubastatin A/ACY-1215 Improves Cognition in Alzheimer’s Disease Transgenic Mice</span> <span class="citation_source-journal">J. Alzheimer’s Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1193</span><span class="NLM_x">–</span> <span class="NLM_lpage">1205</span><span class="refDoi"> DOI: 10.3233/JAD-140066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.3233%2FJAD-140066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24844691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wisb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=1193-1205&author=L.+Zhangauthor=C.+Liuauthor=J.+Wuauthor=J.-J.+Taoauthor=X.-L.+Suiauthor=Z.-G.+Yaoauthor=Y.-F.+Xuauthor=L.+Huangauthor=H.+Zhuauthor=S.-L.+Shengauthor=C.+Qin&title=Tubastatin+A%2FACY-1215+Improves+Cognition+in+Alzheimer%E2%80%99s+Disease+Transgenic+Mice&doi=10.3233%2FJAD-140066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice</span></div><div class="casAuthors">Zhang, Ling; Liu, Cui; Wu, Jie; Tao, Jing-jing; Sui, Xiao-long; Yao, Zhi-gang; Xu, Yan-feng; Huang, Lan; Zhu, Hua; Sheng, Shu-li; Qin, Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1193-1205</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is currently being discussed as a promising therapeutic target for the treatment of Alzheimer's disease (AD).  Mounting evidence indicates that increased HDAC6 expression may contribute to AD-assocd. neurodegeneration, although beneficial effects have also been identified.  In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD.  We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects.  Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced prodn. and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.  Further, the decreased hyperphosphorylated tau and increased tubulin acetylation may account for the improved microtubule stability in AD mice after tubastatin A/ACY-1215 treatment.  These preclin. results support the detrimental role of HDAC6 in AD, and offer prospective approaches for using tubastatin A/ACY-1215 as potential therapeutic strategy for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMqSzA-9TiiLVg90H21EOLACvtfcHk0lilNjtcymj3OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wisb3N&md5=4bd700182b457a81cfc688511aead426</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3233%2FJAD-140066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-140066%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DJ.-J.%26aulast%3DSui%26aufirst%3DX.-L.%26aulast%3DYao%26aufirst%3DZ.-G.%26aulast%3DXu%26aufirst%3DY.-F.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSheng%26aufirst%3DS.-L.%26aulast%3DQin%26aufirst%3DC.%26atitle%3DTubastatin%2520A%252FACY-1215%2520Improves%2520Cognition%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Transgenic%2520Mice%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2014%26volume%3D41%26spage%3D1193%26epage%3D1205%26doi%3D10.3233%2FJAD-140066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanzhez-Arias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mederos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Osta, A.</span><span> </span><span class="NLM_article-title">Concomitant Histone Deacetylase and Phosphodiesterase 5 Inhibition Synergistically Prevents the Disruption in Synaptic Plasticity and It Reverses Cognitive Impairment in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="refDoi"> DOI: 10.1186/s13148-015-0142-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1186%2Fs13148-015-0142-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26457123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVOksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=108&author=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+Sanzhez-Ariasauthor=S.+Mederosauthor=O.+Rabalauthor=A.+Ugarteauthor=R.+Francoauthor=M.+Pascual-Lucasauthor=V.+Seguraauthor=G.+Pereaauthor=J.+Oyarzabalauthor=A.+Garcia-Osta&title=Concomitant+Histone+Deacetylase+and+Phosphodiesterase+5+Inhibition+Synergistically+Prevents+the+Disruption+in+Synaptic+Plasticity+and+It+Reverses+Cognitive+Impairment+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1186%2Fs13148-015-0142-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sanzhez-Arias, J.; Mederos, S.; Rabal, O.; Ugarte, A.; Franco, R.; Pascual-Lucas, M.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108/1-108/11</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Given the implication of histone acetylation in memory processes, histone deacetylase inhibitors (HDACIs) have been postulated as potential modulators of cognitive impairment in Alzheimer's disease (AD).  However, dose-dependent side effects have been described in patients with the currently available broad-spectrum HDACIs, explaining why their therapeutic potential has not been realized for chronic diseases.  Here, by simultaneously targeting two independent enzyme activities, histone deacetylase (HDAC) and phosphodiesterase-5 (PDE5), we propose a novel mode of inhibitory action that might increase the therapeutic specificity of HDACIs.  Results: The combination of vorinostat, a pan-HDACI, and tadalafil, a PDE5 inhibitor, rescued the long-term potentiation impaired in slices from APP/PS1 mice.  When administered in vivo, the combination of these drugs alleviated the cognitive deficits in AD mice, as well as the amyloid and tau pathol., and it reversed the reduced dendritic spine d. on hippocampal neurons.  Significantly, the combination of vorinostat and tadalafil was more effective than each drug alone, both against the symptoms and in terms of disease modification, and importantly, these effects persisted after a 4-wk washout period.  Conclusions: The results highlight the pharmacol. potential of a combination of mols. that inhibit HDAC and PDE5 as a therapeutic approach for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMSYuXPnR9SLVg90H21EOLACvtfcHk0lgnGTIMVANmuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVOksbw%253D&md5=bb0f0702afbc1ac3fe7867bd037ca09e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs13148-015-0142-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-015-0142-9%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DSanzhez-Arias%26aufirst%3DJ.%26aulast%3DMederos%26aufirst%3DS.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DPascual-Lucas%26aufirst%3DM.%26aulast%3DSegura%26aufirst%3DV.%26aulast%3DPerea%26aufirst%3DG.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DConcomitant%2520Histone%2520Deacetylase%2520and%2520Phosphodiesterase%25205%2520Inhibition%2520Synergistically%2520Prevents%2520the%2520Disruption%2520in%2520Synaptic%2520Plasticity%2520and%2520It%2520Reverses%2520Cognitive%2520Impairment%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DClin.%2520Epigenet.%26date%3D2015%26volume%3D7%26spage%3D108%26doi%3D10.1186%2Fs13148-015-0142-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Robers, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dart, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodroofe, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimprich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkland, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupcho, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartnett, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niles, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohana, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slater, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, K. V.</span><span> </span><span class="NLM_article-title">Target Engagement and Drug Residence Time Can Be Observed in Living Cells with BRET</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">10091</span><span class="refDoi"> DOI: 10.1038/ncomms10091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fncomms10091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26631872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10091&author=M.+B.+Robersauthor=M.+L.+Dartauthor=C.+C.+Woodroofeauthor=C.+A.+Zimprichauthor=T.+A.+Kirklandauthor=T.+Machleidtauthor=K.+R.+Kupchoauthor=S.+Levinauthor=J.+R.+Hartnettauthor=K.+Zimmermanauthor=A.+L.+Nilesauthor=R.+F.+Ohanaauthor=D.+L.+Danielsauthor=M.+Slaterauthor=M.+G.+Woodauthor=M.+Congauthor=Y.-Q.+Chengauthor=K.+V.+Wood&title=Target+Engagement+and+Drug+Residence+Time+Can+Be+Observed+in+Living+Cells+with+BRET&doi=10.1038%2Fncomms10091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement and drug residence time can be observed in living cells with BRET</span></div><div class="casAuthors">Robers, Matthew B.; Dart, Melanie L.; Woodroofe, Carolyn C.; Zimprich, Chad A.; Kirkland, Thomas A.; Machleidt, Thomas; Kupcho, Kevin R.; Levin, Sergiy; Hartnett, James R.; Zimmerman, Kristopher; Niles, Andrew L.; Ohana, Rachel Friedman; Daniels, Danette L.; Slater, Michael; Wood, Monika G.; Cong, Mei; Cheng, Yi-Qiang; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10091</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic action of drugs is predicated on their phys. engagement with cellular targets.  Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells.  Cell-permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement with the target proteins fused to Nanoluc luciferase.  The approach enabled us to profile isoenzyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors.  Our anal. was directed particularly to the clin. approved prodrug FK228 (Istodax/Romidepsin) because of its unique and largely unexplained mechanism of sustained intracellular action.  Anal. of the binding kinetics by BRET revealed remarkably long intracellular residence times for FK228 at HDAC1, explaining the protracted intracellular behavior of this prodrug.  Our results demonstrate a novel application of BRET for assessing target engagement within the complex milieu of the intracellular environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRFFk0LNiL_LVg90H21EOLACvtfcHk0lgnGTIMVANmuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO&md5=723cc5dd7d229b1115da4c2c9d75c913</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fncomms10091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10091%26sid%3Dliteratum%253Aachs%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DDart%26aufirst%3DM.%2BL.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKupcho%26aufirst%3DK.%2BR.%26aulast%3DLevin%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DNiles%26aufirst%3DA.%2BL.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.-Q.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DTarget%2520Engagement%2520and%2520Drug%2520Residence%2520Time%2520Can%2520Be%2520Observed%2520in%2520Living%2520Cells%2520with%2520BRET%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10091%26doi%3D10.1038%2Fncomms10091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez-Arias, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mederos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Osta, A.</span><span> </span><span class="NLM_article-title">A First-in-Class Small-Molecule That Acts as a Dual Inhibitor of HDAC and PDE5, and That Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1038/npp.2016.163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnpp.2016.163" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+A.+S%C3%A1nchez-Ariasauthor=O.+Rabalauthor=S.+Mederosauthor=A.+Ugarteauthor=R.+Francoauthor=V.+Seguraauthor=G.+Pereaauthor=J.+Oyarzabalauthor=A.+Garcia-Osta&title=A+First-in-Class+Small-Molecule+That+Acts+as+a+Dual+Inhibitor+of+HDAC+and+PDE5%2C+and+That+Rescues+Hippocampal+Synaptic+Impairment+in+Alzheimer%E2%80%99s+Disease+Mice&doi=10.1038%2Fnpp.2016.163"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.163%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DMederos%26aufirst%3DS.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DSegura%26aufirst%3DV.%26aulast%3DPerea%26aufirst%3DG.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DA%2520First-in-Class%2520Small-Molecule%2520That%2520Acts%2520as%2520a%2520Dual%2520Inhibitor%2520of%2520HDAC%2520and%2520PDE5%252C%2520and%2520That%2520Rescues%2520Hippocampal%2520Synaptic%2520Impairment%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mice%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26doi%3D10.1038%2Fnpp.2016.163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Konsoula, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span> </span><span class="NLM_article-title">In Vitro Plasma Stability, Permeability and Solubility of Mercaptoacetamide Histone Deacetylase Inhibitors</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.ijpharm.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=18562136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2008&pages=19-25&author=R.+Konsoulaauthor=M.+Jung&title=In+Vitro+Plasma+Stability%2C+Permeability+and+Solubility+of+Mercaptoacetamide+Histone+Deacetylase+Inhibitors&doi=10.1016%2Fj.ijpharm.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span></div><div class="casAuthors">Konsoula, Roula; Jung, Mira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers.  In this study, the in vitro plasma stability, permeability, soly., and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA).  The results demonstrated that the compds. manifested high soly. in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA.  Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA.  The permeability of these compds. was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa.  The Caco-2 studies revealed that the compds. S2 and W2 are highly permeable with apparent permeability coeffs. (Papp) in the apical to basolateral direction of 7.33 × 10-6 and 15.0 × 10-6 cm/s, resp.  The in vitro stability was detd. in human, mouse, porcine and rat plasma.  Data showed that the compd. W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA.  Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable soly., lipophilicity, permeability and plasma stability features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ60NiaoIn6bVg90H21EOLACvtfcHk0ljYLdpZv5EoMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D&md5=32a5ec87e4d150d373a325b3ee296dc7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKonsoula%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Plasma%2520Stability%252C%2520Permeability%2520and%2520Solubility%2520of%2520Mercaptoacetamide%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D361%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.ijpharm.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inks, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3324</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1021/jm401877m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401877m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3324-3341&author=X.+Liauthor=E.+S.+Inksauthor=X.+Liauthor=J.+Houauthor=C.+J.+Chouauthor=J.+Zhangauthor=Y.+Jiangauthor=Y.+Zhangauthor=W.+Xu&title=Discovery+of+the+First+N-Hydroxycinnamamide-Based+Histone+Deacetylase+1%2F3+Dual+Inhibitors+with+Potent+Oral+Antitumor+Activity&doi=10.1021%2Fjm401877m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span></div><div class="casAuthors">Li, Xiaoyang; Inks, Elizabeth S.; Li, Xiaoguang; Hou, Jinning; Chou, C. James; Zhang, Jian; Jiang, Yuqi; Zhang, Yingjie; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3324-3341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our previous study, we designed and synthesized a novel series of N-hydroxycinnamamide-based histone deacetylase inhibitors (HDACIs), among which the representative compd. I exhibited promising HDACs inhibition and antitumor activity.  In this current study, we report the development of a more potent class of N-hydroxycinnamamide-based HDACIs, using I as lead, among which, compd. II gave IC50 values of 11.8, 498.1, 3.9, 2000.8, 5700.4, 308.2, and 900.4 nM for the inhibition of HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC6, and HDAC11, exhibiting dual HDAC1/3 selectivity.  Several of these compds. showed excellent growth inhibition in multiple tumor cell lines.  In vivo antitumor assay in U937 xenograft model identified compd. II as a potent, orally active HDACI.  To the best of our knowledge, this work constitutes the first report of oral active N-hydroxycinnamamide-based HDACIs with dual HDAC1/3 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrBGqCPWPO2rVg90H21EOLACvtfcHk0ljYLdpZv5EoMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D&md5=4e86a4e7c9fda199bdd3cb12730db1da</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401877m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401877m%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520the%2520First%2520N-Hydroxycinnamamide-Based%2520Histone%2520Deacetylase%25201%252F3%2520Dual%2520Inhibitors%2520with%2520Potent%2520Oral%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3324%26epage%3D3341%26doi%3D10.1021%2Fjm401877m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Palmieri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockman, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega-Valle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taskar, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudraraju, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittapalli, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaasch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohn, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsheim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liewehr, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronder, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feigenbaum, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, Q. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span> </span><span class="NLM_article-title">Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6148</span><span class="NLM_x">–</span> <span class="NLM_lpage">6157</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1158%2F1078-0432.CCR-09-1039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19789319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2lurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6148-6157&author=D.+Palmieriauthor=P.+R.+Lockmanauthor=F.+C.+Thomasauthor=E.+Huaauthor=J.+Herringauthor=E.+Hargraveauthor=M.+Johnsonauthor=N.+Floresauthor=Y.+Qianauthor=E.+Vega-Valleauthor=K.+S.+Taskarauthor=V.+Rudrarajuauthor=R.+K.+Mittapalliauthor=J.+A.+Gaaschauthor=K.+A.+Bohnauthor=H.+R.+Thorsheimauthor=D.+J.+Liewehrauthor=S.+Davisauthor=J.+F.+Reillyauthor=R.+Walkerauthor=J.+L.+Bronderauthor=L.+Feigenbaumauthor=S.+M.+Steinbergauthor=K.+Camphausenauthor=P.+S.+Meltzerauthor=V.+M.+Richonauthor=Q.+R.+Smithauthor=P.+S.+Steeg&title=Vorinostat+Inhibits+Brain+Metastatic+Colonization+in+a+Model+of+Triple-Negative+Breast+Cancer+and+Induces+DNA+Double-Strand+Breaks&doi=10.1158%2F1078-0432.CCR-09-1039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks</span></div><div class="casAuthors">Palmieri, Diane; Lockman, Paul R.; Thomas, Fancy C.; Hua, Emily; Herring, Jeanne; Hargrave, Elizabeth; Johnson, Matthew; Flores, Natasha; Qian, Yongzhen; Vega-Valle, Eleazar; Taskar, Kunal S.; Rudraraju, Vinay; Mittapalli, Rajendar K.; Gaasch, Julie A.; Bohn, Kaci A.; Thorsheim, Helen R.; Liewehr, David J.; Davis, Sean; Reilly, John F.; Walker, Robert; Bronder, Julie L.; Feigenbaum, Lionel; Steinberg, Seth M.; Camphausen, Kevin; Meltzer, Paul S.; Richon, Victoria M.; Smith, Quentin R.; Steeg, Patricia S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6148-6157</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: As chemotherapy and mol. therapy improve the systemic survival of breast cancer patients, the incidence of brain metastases increases.  Few therapeutic strategies exist for the treatment of brain metastases because the blood-brain barrier severely limits drug access.  We report the pharmacokinetic, efficacy, and mechanism of action studies for the histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclin. model of brain metastasis of triple-neg. breast cancer.  Exptl. Design: The 231-BR brain trophic subline of the MDA-MB-231 human breast cancer cell line was injected into immunocompromised mice for pharmacokinetic and metastasis studies.  Pharmacodynamic studies compared histone acetylation, apoptosis, proliferation, and DNA damage in vitro and in vivo.  Results: Following systemic administration, uptake of [14C]vorinostat was significant into normal rodent brain and accumulation was up to 3-fold higher in a proportion of metastases formed by 231-BR cells.  Vorinostat prevented the development of 231-BR micrometastases by 28% (P = 0.017) and large metastases by 62% (P < 0.0001) compared with vehicle-treated mice when treatment was initiated on day 3 post-injection.  The inhibitory activity of vorinostat as a single agent was linked to a novel function in vivo: induction of DNA double-strand breaks assocd. with the down-regulation of the DNA repair gene Rad52.  Conclusions: We report the first preclin. data for the prevention of brain metastasis of triple-neg. breast cancer.  Vorinostat is brain permeable and can prevent the formation of brain metastases by 62%.  Its mechanism of action involves the induction of DNA double-strand breaks, suggesting rational combinations with DNA active drugs or radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z2K-TIM7nrVg90H21EOLACvtfcHk0liJuYeDl7ogLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2lurzF&md5=9fc1a8b610d29417c74c943b6d892518</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1039%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DD.%26aulast%3DLockman%26aufirst%3DP.%2BR.%26aulast%3DThomas%26aufirst%3DF.%2BC.%26aulast%3DHua%26aufirst%3DE.%26aulast%3DHerring%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DFlores%26aufirst%3DN.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DVega-Valle%26aufirst%3DE.%26aulast%3DTaskar%26aufirst%3DK.%2BS.%26aulast%3DRudraraju%26aufirst%3DV.%26aulast%3DMittapalli%26aufirst%3DR.%2BK.%26aulast%3DGaasch%26aufirst%3DJ.%2BA.%26aulast%3DBohn%26aufirst%3DK.%2BA.%26aulast%3DThorsheim%26aufirst%3DH.%2BR.%26aulast%3DLiewehr%26aufirst%3DD.%2BJ.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DWalker%26aufirst%3DR.%26aulast%3DBronder%26aufirst%3DJ.%2BL.%26aulast%3DFeigenbaum%26aufirst%3DL.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DCamphausen%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DSmith%26aufirst%3DQ.%2BR.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26atitle%3DVorinostat%2520Inhibits%2520Brain%2520Metastatic%2520Colonization%2520in%2520a%2520Model%2520of%2520Triple-Negative%2520Breast%2520Cancer%2520and%2520Induces%2520DNA%2520Double-Strand%2520Breaks%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6148%26epage%3D6157%26doi%3D10.1158%2F1078-0432.CCR-09-1039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehár, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C. T.</span><span> </span><span class="NLM_article-title">Multi-Target Therapeutics: When the Whole Is Greater than the Sum of the Parts</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-Target+Therapeutics%3A+When+the+Whole+Is+Greater+than+the+Sum+of+the+Parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eZtY-OlrovaIbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-Target%2520Therapeutics%253A%2520When%2520the%2520Whole%2520Is%2520Greater%2520than%2520the%2520Sum%2520of%2520the%2520Parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Bischoff, E.</span><span> </span><span class="NLM_article-title">Potency, Selectivity, and Consequences of Nonselectivity of PDE Inhibition</span> <span class="citation_source-journal">Int. J. Impotence Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S11</span><span class="NLM_x">–</span> <span class="NLM_lpage">S14</span><span class="refDoi"> DOI: 10.1038/sj.ijir.3901208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fsj.ijir.3901208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=15224129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=S11-S14&issue=Suppl+1&author=E.+Bischoff&title=Potency%2C+Selectivity%2C+and+Consequences+of+Nonselectivity+of+PDE+Inhibition&doi=10.1038%2Fsj.ijir.3901208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Potency, selectivity, and consequences of nonselectivity of PDE inhibition</span></div><div class="casAuthors">Bischoff, E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Impotence Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S11-S14</span>CODEN:
                <span class="NLM_cas:coden">IJIRFB</span>;
        ISSN:<span class="NLM_cas:issn">0955-9930</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterases (PDEs) play a decisive role in cyclic nucleotide-mediated intracellular signaling.  As PDEs are expressed in a variety of tissues, selectivity is a prerequisite for a therapeutically applicable PDE inhibitor.  Sildenafil, vardenafil, and tadalafil are selective for PDE5, with vardenafil exhibiting the highest potency and minimal inhibition of other PDEs, with the exception of PDE6.  Tadalafil is extremely selective for PDE5, but also potently inhibits PDE11, an enzyme with unknown physiol. function.  As PDE1 is expressed in the brain, myocardium, and vascular smooth muscle cells, nonselectivity with respect to this enzyme (selectivity: tadalafil > vardenafil > sildenafil) may result in vasodilation and tachycardia.  Inhibition of PDE6 (selectivity: tadalafil > vardenafil ≃ sildenafil), which is expressed only in retina and functions in visual transduction, can transiently disturb vision.  PDE5 inhibitors may also indirectly inhibit PDE3 by increasing cyclic guanosine monophospate levels, thereby elevating heart rate and vasodilation while inhibiting platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbqbZmAdPM7Vg90H21EOLACvtfcHk0liJuYeDl7ogLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsb8%253D&md5=48ad9f175e05fd5c2f4b540f5f1ac367</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijir.3901208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijir.3901208%26sid%3Dliteratum%253Aachs%26aulast%3DBischoff%26aufirst%3DE.%26atitle%3DPotency%252C%2520Selectivity%252C%2520and%2520Consequences%2520of%2520Nonselectivity%2520of%2520PDE%2520Inhibition%26jtitle%3DInt.%2520J.%2520Impotence%2520Res.%26date%3D2004%26volume%3D16%26issue%3DSuppl%25201%26spage%3DS11%26epage%3DS14%26doi%3D10.1038%2Fsj.ijir.3901208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimer’s Disease</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5545</span><span class="NLM_x">–</span> <span class="NLM_lpage">5553</span><span class="refDoi"> DOI: 10.2174/092986711798347315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.2174%2F092986711798347315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22172064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=5545-5553&author=M.+Cuadrado-Tejedorauthor=A.+Garc%C3%ADa-Ostaauthor=A.+Ricobarazaauthor=J.+Oyarzabalauthor=R.+Franco&title=Defining+the+Mechanism+of+Action+of+4-Phenylbutyrate+to+Develop+a+Small-Molecule-Based+Therapy+for+Alzheimer%E2%80%99s+Disease&doi=10.2174%2F092986711798347315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, M.; Garcia-Osta, A.; Ricobaraza, A.; Oyarzabal, J.; Franco, R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5545-5553</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  4-Phenylbutyrate (PBA) is a small mol. that restores cognitive deficits in animal models of Alzheimer's disease (AD).  Although the mol. basis of the cognitive benefits of PBA remains unknown, a multi-modal/multi-target mechanism has been proposed.  Putative targets of this drug are different from those of drugs that are now used in clin. trials.  As PBA is already administered to patients with congenital defects affecting enzymes in the urea cycle, it can be rapidly tested in AD clin. trials.  However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day).  Thus, deciphering the precise mechanism(s) of action of this drug may enable novel drugs with similar therapeutic effects to PBA to be developed that can be used at more manageable doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosAevZlfyhp7Vg90H21EOLACvtfcHk0lhlEKzXCXZ0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbL&md5=0703163333de9afce25c352e4ef98df5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F092986711798347315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711798347315%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DDefining%2520the%2520Mechanism%2520of%2520Action%2520of%25204-Phenylbutyrate%2520to%2520Develop%2520a%2520Small-Molecule-Based%2520Therapy%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D5545%26epage%3D5553%26doi%3D10.2174%2F092986711798347315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Atadja, P.</span><span> </span><span class="NLM_article-title">Development of the Pan-DAC Inhibitor Panobinostat (LBH589): Successes and Challenges</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1016/j.canlet.2009.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.canlet.2009.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19344997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=233-241&author=P.+Atadja&title=Development+of+the+Pan-DAC+Inhibitor+Panobinostat+%28LBH589%29%3A+Successes+and+Challenges&doi=10.1016%2Fj.canlet.2009.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges</span></div><div class="casAuthors">Atadja, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins.  The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition of all HDAC enzymes implicated in cancer and has demonstrated potent anti-tumor activity in preclin. models and promising clin. efficacy in cancer patients.  In this review we discuss the successes and challenges surrounding the development of panobinostat, focusing on its proposed mechanism of action, preclin. anti-tumor activity, and early clin. efficacy in hematol. and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSTYxNKUMt7bVg90H21EOLACvtfcHk0lhlEKzXCXZ0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D&md5=4c487a2f8dc13f72cecf105d9fae97d9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DAtadja%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520the%2520Pan-DAC%2520Inhibitor%2520Panobinostat%2520%2528LBH589%2529%253A%2520Successes%2520and%2520Challenges%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D233%26epage%3D241%26doi%3D10.1016%2Fj.canlet.2009.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beliën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vreys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talloen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goris, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span> </span><span class="NLM_article-title">JNJ-26481585, a Novel “second-Generation” oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6841</span><span class="NLM_x">–</span> <span class="NLM_lpage">6851</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1158%2F1078-0432.CCR-09-0547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19861438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6841-6851&author=J.+Artsauthor=P.+Kingauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=A.+Beli%C3%ABnauthor=L.+Janssenauthor=I.+Pilatteauthor=B.+Rouxauthor=L.+Decraneauthor=R.+Gilissenauthor=I.+Hicksonauthor=V.+Vreysauthor=E.+Coxauthor=K.+Bolauthor=W.+Talloenauthor=I.+Gorisauthor=L.+Andriesauthor=M.+Du+Jardinauthor=M.+Janicotauthor=M.+Pageauthor=K.+van+Emelenauthor=P.+Angibaud&title=JNJ-26481585%2C+a+Novel+%E2%80%9Csecond-Generation%E2%80%9D+oral+Histone+Deacetylase+Inhibitor%2C+Shows+Broad-Spectrum+Preclinical+Antitumoral+Activity&doi=10.1158%2F1078-0432.CCR-09-0547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span></div><div class="casAuthors">Arts, Janine; King, Peter; Marien, Ann; Floren, Wim; Belien, Ann; Janssen, Lut; Pilatte, Isabelle; Roux, Bruno; Decrane, Laurence; Gilissen, Ron; Hickson, Ian; Vreys, Veronique; Cox, Eugene; Bol, Kees; Talloen, Willem; Goris, Ilse; Andries, Luc; Du Jardin, Marc; Janicot, Michel; Page, Martin; van Emelen, Kristof; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6841-6851</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clin. activity in the treatment of hematol. malignancies, but their activity in solid tumor indications has been limited.  Most HDAC inhibitors in clin. development only transiently induce histone acetylation in tumor tissue.  Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy.  Exptl. Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclin. in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors.  Results: In vivo pharmacodynamic anal. of 140 potent pyrimidyl-hydroxamic acid analogs resulted in the identification of JNJ-26481585.  Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation.  The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active.  JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.  Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L).  Conclusions: The potent antitumor activity as a single agent in preclin. models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising "second-generation" HDAC inhibitor.  The compd. is currently in clin. studies, to evaluate its potential applicability in a broad spectrum of both solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKc9hyMiADZrVg90H21EOLACvtfcHk0lhlEKzXCXZ0iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE&md5=8f199c25c92c967a76f273d879d6c577</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0547%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DBeli%25C3%25ABn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DVreys%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DGoris%26aufirst%3DI.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DJNJ-26481585%252C%2520a%2520Novel%2520%25E2%2580%259Csecond-Generation%25E2%2580%259D%2520oral%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Shows%2520Broad-Spectrum%2520Preclinical%2520Antitumoral%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6841%26epage%3D6851%26doi%3D10.1158%2F1078-0432.CCR-09-0547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Papavassiliou, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papavassiliou, A. G.</span><span> </span><span class="NLM_article-title">Histone Deacetylases Inhibitors: Conjugation to Other Anti-Tumour Pharmacophores Provides Novel Tools for Cancer Treatment</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1517/13543784.2014.857401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1517%2F13543784.2014.857401" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=291-294&author=K.+A.+Papavassiliouauthor=A.+G.+Papavassiliou&title=Histone+Deacetylases+Inhibitors%3A+Conjugation+to+Other+Anti-Tumour+Pharmacophores+Provides+Novel+Tools+for+Cancer+Treatment&doi=10.1517%2F13543784.2014.857401"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.857401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.857401%26sid%3Dliteratum%253Aachs%26aulast%3DPapavassiliou%26aufirst%3DK.%2BA.%26aulast%3DPapavassiliou%26aufirst%3DA.%2BG.%26atitle%3DHistone%2520Deacetylases%2520Inhibitors%253A%2520Conjugation%2520to%2520Other%2520Anti-Tumour%2520Pharmacophores%2520Provides%2520Novel%2520Tools%2520for%2520Cancer%2520Treatment%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D291%26epage%3D294%26doi%3D10.1517%2F13543784.2014.857401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Paris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelloni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: From Bench to Clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span><span class="refDoi"> DOI: 10.1021/jm7011408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+Deacetylase+Inhibitors%3A+From+Bench+to+Clinic&doi=10.1021%2Fjm7011408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0lg3wwvTd0PsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520From%2520Bench%2520to%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529%26doi%3D10.1021%2Fjm7011408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Thaler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span> </span><span class="NLM_article-title">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1002/cmdc.201300413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1002%2Fcmdc.201300413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24730063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=523-526&author=F.+Thalerauthor=C.+Mercurio&title=Towards+Selective+Inhibition+of+Histone+Deacetylase+Isoforms%3A+What+Has+Been+Achieved%2C+Where+We+Are+and+What+Will+Be+Next&doi=10.1002%2Fcmdc.201300413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span></div><div class="casAuthors">Thaler, Florian; Mercurio, Ciro</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are widely studied targets for the treatment of cancer and other diseases.  Up to now, over twenty HDAC inhibitors have entered clin. studies and two of them have already reached the market, namely the hydroxamic acid deriv. SAHA (vorinostat, Zolinza) and the cyclic depsipeptide FK228 (romidepsin, Istodax) that have been approved for the treatment of cutaneous T-cell lymphoma (CTCL).  A common aspect of the first HDAC inhibitors is the absence of any particular selectivity towards specific isoenzymes.  Some of mols. resulted to be "pan"-HDAC inhibitors, while others are class I selective.  In the meantime, the knowledge of HDAC biol. has continuously progressed.  Key advances in the structural biol. of various isoenzymes, reliable mol. homol. models as well as suitable biol. assays have provided new tools for drug discovery activities.  This Minireview aims at surveying these recent developments as well as the design, synthesis and biol. characterization of isoform-selective derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKncV8XbSHkrVg90H21EOLACvtfcHk0lg3wwvTd0PsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP&md5=72626d372ef5d953be388f3513c87e0b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300413%26sid%3Dliteratum%253Aachs%26aulast%3DThaler%26aufirst%3DF.%26aulast%3DMercurio%26aufirst%3DC.%26atitle%3DTowards%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%2520Isoforms%253A%2520What%2520Has%2520Been%2520Achieved%252C%2520Where%2520We%2520Are%2520and%2520What%2520Will%2520Be%2520Next%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D523%26epage%3D526%26doi%3D10.1002%2Fcmdc.201300413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">A Glutamine Switch Mechanism for Nucleotide Selectivity by Phosphodiesterases</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=15260978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=279-286&author=K.+Y.+J.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+Glutamine+Switch+Mechanism+for+Nucleotide+Selectivity+by+Phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span></div><div class="casAuthors">Zhang, Kam Y. J.; Card, Graeme L.; Suzuki, Yoshihisa; Artis, D. Richard; Fong, Daniel; Gillette, Sam; Hsieh, Davin; Neiman, Joshua; West, Brian L.; Zhang, Chao; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-286</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the immune response, inflammation, and memory, among many other functions.  There are three types of PDEs: cAMP-specific, cGMP-specific, and dual-specific.  Here we describe the mechanism of nucleotide selectivity on the basis of high-resoln. co-crystal structures of the cAMP-specific PDE4B and PDE4D with AMP, the cGMP-specific PDE5A with GMP, and the apo-structure of the dual-specific PDE1B.  These structures show that an invariant glutamine functions as the key specificity determinant by a "glutamine switch" mechanism for recognizing the purine moiety in cAMP or cGMP.  The surrounding residues anchor the glutamine residue in different orientations for cAMP and for cGMP.  The PDE1B structure shows that in dual-specific PDEs a key histidine residue may enable the invariant glutamine to toggle between cAMP and cGMP.  The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a crit. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRXGTDdAa1bVg90H21EOLACvtfcHk0lg3wwvTd0PsGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D&md5=32fab6a75031a67290ec5eda2c3e080b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520Glutamine%2520Switch%2520Mechanism%2520for%2520Nucleotide%2520Selectivity%2520by%2520Phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Lauffer, B. E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mintzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritscher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorowicz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koth, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminker, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, P.</span><span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">26926</span><span class="NLM_x">–</span> <span class="NLM_lpage">26943</span><span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+L.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+Deacetylase+%28HDAC%29+Inhibitor+Kinetic+Rate+Constants+Correlate+with+Cellular+Histone+Acetylation+but+Not+Transcription+and+Cell+Viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0lh2UrlOhRHDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%2BL.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitor%2520Kinetic%2520Rate%2520Constants%2520Correlate%2520with%2520Cellular%2520Histone%2520Acetylation%2520but%2520Not%2520Transcription%2520and%2520Cell%2520Viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Angibaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Brandt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Holte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speybrouck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queguiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaurrand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gompel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hijfte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span> </span><span class="NLM_article-title">Identification of a Series of Substituted 2-Piperazinyl-5-Pyrimidylhydroxamic Acids as Potent Histone Deacetylase Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.bmcl.2009.10.118" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=294-298&author=P.+Angibaudauthor=K.+Van+Emelenauthor=L.+Decraneauthor=S.+van+Brandtauthor=P.+Ten+Holteauthor=I.+Pilatteauthor=B.+Rouxauthor=V.+Ponceletauthor=D.+Speybrouckauthor=L.+Queguinerauthor=S.+Gaurrandauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=L.+Janssenauthor=M.+Verdonckauthor=J.+van+Dunauthor=J.+van+Gompelauthor=R.+Gilissenauthor=C.+Mackieauthor=M.+Du+Jardinauthor=J.+Peetersauthor=M.+Noppeauthor=L.+Van+Hijfteauthor=E.+Freyneauthor=M.+Pageauthor=M.+Janicotauthor=J.+Arts&title=Identification+of+a+Series+of+Substituted+2-Piperazinyl-5-Pyrimidylhydroxamic+Acids+as+Potent+Histone+Deacetylase+Inhibitors&doi=10.1016%2Fj.bmcl.2009.10.118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3Dvan%2BBrandt%26aufirst%3DS.%26aulast%3DTen%2BHolte%26aufirst%3DP.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DPoncelet%26aufirst%3DV.%26aulast%3DSpeybrouck%26aufirst%3DD.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DVerdonck%26aufirst%3DM.%26aulast%3Dvan%2BDun%26aufirst%3DJ.%26aulast%3Dvan%2BGompel%26aufirst%3DJ.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DJ.%26aulast%3DNoppe%26aufirst%3DM.%26aulast%3DVan%2BHijfte%26aufirst%3DL.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DArts%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520Series%2520of%2520Substituted%25202-Piperazinyl-5-Pyrimidylhydroxamic%2520Acids%2520as%2520Potent%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D294%26epage%3D298%26doi%3D10.1016%2Fj.bmcl.2009.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span>BPS Bioscience Home Page. <a href="https://bpsbioscience.com" class="extLink">https://bpsbioscience.com</a> (accessed Jul 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BPS+Bioscience+Home+Page.+https%3A%2F%2Fbpsbioscience.com+%28accessed+Jul+1%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2584</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span><span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+Drug+Design%3A+Balancing+Physicochemical+Properties+for+Optimal+Brain+Exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0lh2UrlOhRHDqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520Drug%2520Design%253A%2520Balancing%2520Physicochemical%2520Properties%2520for%2520Optimal%2520Brain%2520Exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Mensch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustijns, P.</span><span> </span><span class="NLM_article-title">In Vivo, in Vitro and in Silico Methods for Small Molecule Transfer across the BBB</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">4429</span><span class="NLM_x">–</span> <span class="NLM_lpage">4468</span><span class="refDoi"> DOI: 10.1002/jps.21745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1002%2Fjps.21745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2009&pages=4429-4468&author=J.+Menschauthor=J.+Oyarzabalauthor=C.+Mackieauthor=P.+Augustijns&title=In+Vivo%2C+in+Vitro+and+in+Silico+Methods+for+Small+Molecule+Transfer+across+the+BBB&doi=10.1002%2Fjps.21745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjps.21745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21745%26sid%3Dliteratum%253Aachs%26aulast%3DMensch%26aufirst%3DJ.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DAugustijns%26aufirst%3DP.%26atitle%3DIn%2520Vivo%252C%2520in%2520Vitro%2520and%2520in%2520Silico%2520Methods%2520for%2520Small%2520Molecule%2520Transfer%2520across%2520the%2520BBB%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D98%26spage%3D4429%26epage%3D4468%26doi%3D10.1002%2Fjps.21745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Terrett, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P.</span><span> </span><span class="NLM_article-title">Sildenafil (Viagra TM), a Potent and Selective Inhibitor of Type 5 CGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1819</span><span class="NLM_x">–</span> <span class="NLM_lpage">1824</span><span class="refDoi"> DOI: 10.1016/0960-894X(96)00323-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2F0960-894X%2896%2900323-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=1819-1824&author=N.+K.+Terrettauthor=A.+S.+Bellauthor=D.+Brownauthor=P.+Ellis&title=Sildenafil+%28Viagra+TM%29%2C+a+Potent+and+Selective+Inhibitor+of+Type+5+CGMP+Phosphodiesterase+with+Utility+for+the+Treatment+of+Male+Erectile+Dysfunction&doi=10.1016%2F0960-894X%2896%2900323-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900323-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900323-X%26sid%3Dliteratum%253Aachs%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DEllis%26aufirst%3DP.%26atitle%3DSildenafil%2520%2528Viagra%2520TM%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Type%25205%2520CGMP%2520Phosphodiesterase%2520with%2520Utility%2520for%2520the%2520Treatment%2520of%2520Male%2520Erectile%2520Dysfunction%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D1819%26epage%3D1824%26doi%3D10.1016%2F0960-894X%2896%2900323-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Sung, B.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyun, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eum, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. M.</span><span> </span><span class="NLM_article-title">Structure of the Catalytic Domain of Human Phosphodiesterase 5 with Bound Drug Molecules</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">425</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1038/nature01914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnature01914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=12955149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=98-102&author=B.-J.+Sungauthor=K.+Y.+Hwangauthor=Y.+H.+Jeonauthor=J.+I.+Leeauthor=Y.-S.+Heoauthor=J.+H.+Kimauthor=J.+Moonauthor=J.+M.+Yoonauthor=Y.-L.+Hyunauthor=E.+Kimauthor=S.+J.+Eumauthor=S.-Y.+Parkauthor=J.-O.+Leeauthor=T.+G.+Leeauthor=S.+Roauthor=J.+M.+Cho&title=Structure+of+the+Catalytic+Domain+of+Human+Phosphodiesterase+5+with+Bound+Drug+Molecules&doi=10.1038%2Fnature01914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules</span></div><div class="casAuthors">Sung, Byung-Je; Hwang, Kwang Yeon; Jeon, Young Ho; Lee, Jae Il; Heo, Yong-Seok; Kim, Jin Hwan; Moon, Jinho; Yoon, Jung Min; Hyun, Young-Lan; Kim, Eunmi; Eum, Sung Jin; Park, Sam-Yong; Lee, Jie-Oh; Lee, Tae Gyu; Ro, Seonggu; Cho, Joong Myung</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6953</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cAMP and cGMP.  As essential regulators of cyclic nucleotide signaling with diverse physiol. functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction.  Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolyzing activity in human corpus cavernosum tissue.  It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction.  Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available.  Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug mols. sildenafil, tadalafil (Cialis) and vardenafil (Levitra).  These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr5pTrMfa72rVg90H21EOLACvtfcHk0lhl8ZGi23mGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D&md5=8459333ee12ed3469f7b48d6e7f9fd5d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01914%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DB.-J.%26aulast%3DHwang%26aufirst%3DK.%2BY.%26aulast%3DJeon%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BI.%26aulast%3DHeo%26aufirst%3DY.-S.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DMoon%26aufirst%3DJ.%26aulast%3DYoon%26aufirst%3DJ.%2BM.%26aulast%3DHyun%26aufirst%3DY.-L.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DEum%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DS.-Y.%26aulast%3DLee%26aufirst%3DJ.-O.%26aulast%3DLee%26aufirst%3DT.%2BG.%26aulast%3DRo%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DJ.%2BM.%26atitle%3DStructure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520Human%2520Phosphodiesterase%25205%2520with%2520Bound%2520Drug%2520Molecules%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D98%26epage%3D102%26doi%3D10.1038%2Fnature01914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoraghi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Multiple Conformations of Phosphodiesterase-5: Implications for Enzyme Function and Drug Development</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">21469</span><span class="NLM_x">–</span> <span class="NLM_lpage">21479</span><span class="refDoi"> DOI: 10.1074/jbc.M512527200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1074%2Fjbc.M512527200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=16735511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1KjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=21469-21479&author=H.+Wangauthor=Y.+Liuauthor=Q.+Huaiauthor=J.+Caiauthor=R.+Zoraghiauthor=S.+H.+Francisauthor=J.+D.+Corbinauthor=H.+Robinsonauthor=Z.+Xinauthor=G.+Linauthor=H.+Ke&title=Multiple+Conformations+of+Phosphodiesterase-5%3A+Implications+for+Enzyme+Function+and+Drug+Development&doi=10.1074%2Fjbc.M512527200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development</span></div><div class="casAuthors">Wang, Huanchen; Liu, Yudong; Huai, Qing; Cai, Jiwen; Zoraghi, Roya; Francis, Sharron H.; Corbin, Jackie D.; Robinson, Howard; Xin, Zhongcheng; Lin, Guiting; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">21469-21479</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension.  We report here the crystal structures of a fully active catalytic domain of unliganded PDE5A1 and its complexes with sildenafil or icarisid II.  These structures together with the PDE5A1-isobutyl-1-methylxanthine complex show that the H-loop (residues 660-683) at the active site of PDE5A1 has four different conformations and migrates 7-35 Å upon inhibitor binding.  In addn., the conformation of sildenafil reported herein differs significantly from those in the previous structures of chimerically hybridized or almost inactive PDE5.  Mutagenesis and kinetic analyses confirm that the H-loop is particularly important for substrate recognition and that invariant Gly659, which immediately precedes the H-loop, is crit. for optimal substrate affinity and catalytic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplF9ohkT9ogLVg90H21EOLACvtfcHk0lhl8ZGi23mGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1KjsLs%253D&md5=3a5ac86273a74da4a559bc6efc647181</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M512527200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M512527200%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DZoraghi%26aufirst%3DR.%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DCorbin%26aufirst%3DJ.%2BD.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DMultiple%2520Conformations%2520of%2520Phosphodiesterase-5%253A%2520Implications%2520for%2520Enzyme%2520Function%2520and%2520Drug%2520Development%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D21469%26epage%3D21479%26doi%3D10.1074%2Fjbc.M512527200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1124/mol.107.040212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1124%2Fmol.107.040212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=17959709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslCrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=104-110&author=H.+Wangauthor=M.+Yeauthor=H.+Robinsonauthor=S.+H.+Francisauthor=H.+Ke&title=Conformational+Variations+of+Both+Phosphodiesterase-5+and+Inhibitors+Provide+the+Structural+Basis+for+the+Physiological+Effects+of+Vardenafil+and+Sildenafil&doi=10.1124%2Fmol.107.040212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil</span></div><div class="casAuthors">Wang, Huanchen; Ye, Mengchun; Robinson, Howard; Francis, Sharron H.; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-110</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.  However, the mol. basis for these differences is puzzling because two drugs have similar chem. structures.  Reported here is a crystal structure of the fully active and nonmutated PDE5A1 catalytic domain in complex with vardenafil.  The structure shows that the conformation of the H-loop in the PDE5A1-vardenafil complex is different from those of any known structures of the unliganded PDE5 and its complexes with the inhibitors.  In addn., the mol. configuration of vardenafil differs from that of sildenafil when bound to PDE5.  It is noteworthy that the binding of vardenafil causes loss of the divalent metal ions that have been obsd. in all the previously published PDE structures.  The conformational variation of both PDE5 and the inhibitors provides structural insight into the different potencies of the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGricnXGND9IjLVg90H21EOLACvtfcHk0lhl8ZGi23mGFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslCrtw%253D%253D&md5=6ee464e0f2f85a3bfe195b6070d923dd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.040212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.040212%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DConformational%2520Variations%2520of%2520Both%2520Phosphodiesterase-5%2520and%2520Inhibitors%2520Provide%2520the%2520Structural%2520Basis%2520for%2520the%2520Physiological%2520Effects%2520of%2520Vardenafil%2520and%2520Sildenafil%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D104%26epage%3D110%26doi%3D10.1124%2Fmol.107.040212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span>Pipeline Pilot, version 8.5; <span class="NLM_publisher-name">Accelrys</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pipeline+Pilot%2C+version+8.5%3B+Accelrys%3A+San+Diego%2C+CA%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPipeline%2520Pilot%26pub%3DAccelrys%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helquist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span> </span><span class="NLM_article-title">Zinc Binding in HDAC Inhibitors: A DFT Study</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5446</span><span class="NLM_x">–</span> <span class="NLM_lpage">5449</span><span class="refDoi"> DOI: 10.1021/jo070739s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070739s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFGgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=5446-5449&author=D.+Wangauthor=P.+Helquistauthor=O.+Wiest&title=Zinc+Binding+in+HDAC+Inhibitors%3A+A+DFT+Study&doi=10.1021%2Fjo070739s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc Binding in HDAC Inhibitors: A DFT Study</span></div><div class="casAuthors">Wang, Difei; Helquist, Paul; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5446-5449</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are attractive targets for the treatment of cancers and a variety of other diseases.  Most currently studied HDAC inhibitors contain hydroxamic acids, which are potentially problematic in the development of practical drugs.  DFT calcns. of the binding modes and free energies of binding for a variety of other functionalities in a model active site of HDAC are described.  The protonation state of hydroxamic acids in the active site and the origin of the high affinity are discussed.  These results emphasize the importance of a carefully chosen pKa for zinc binding and provide guidance for the design of novel, non-hydroxamic acid HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor2ZrvcCc2BLVg90H21EOLACvtfcHk0liR4DEKDAu5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFGgsLw%253D&md5=a5990dc23dca00224af44c2cde058ba3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjo070739s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070739s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DZinc%2520Binding%2520in%2520HDAC%2520Inhibitors%253A%2520A%2520DFT%2520Study%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D5446%26epage%3D5449%26doi%3D10.1021%2Fjo070739s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="NLM_x">–</span> <span class="NLM_lpage">10846</span><span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0liR4DEKDAu5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Witt, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deubzer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehme, I.</span><span> </span><span class="NLM_article-title">HDAC Family: What Are the Cancer Relevant Targets?</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=HDAC+Family%3A+What+Are+the+Cancer+Relevant+Targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0liR4DEKDAu5Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520Family%253A%2520What%2520Are%2520the%2520Cancer%2520Relevant%2520Targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Gómez-Vallejo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczupak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dopeso-Reyes, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Pharmacokinetic Investigation of Sildenafil Using Positron Emission Tomography and Determination of Its Effect on Cerebrospinal Fluid cGMP Levels</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">415</span><span class="refDoi"> DOI: 10.1111/jnc.13454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fjnc.13454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26641206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2016&pages=403-415&author=V.+G%C3%B3mez-Vallejoauthor=A.+Ugarteauthor=C.+Garc%C3%ADa-Barrosoauthor=M.+Cuadrado-Tejedorauthor=B.+Szczupakauthor=I.+G.+Dopeso-Reyesauthor=J.+L.+Lanciegoauthor=A.+Garc%C3%ADa-Ostaauthor=J.+Llopauthor=J.+Oyarzabalauthor=R.+Franco&title=Pharmacokinetic+Investigation+of+Sildenafil+Using+Positron+Emission+Tomography+and+Determination+of+Its+Effect+on+Cerebrospinal+Fluid+cGMP+Levels&doi=10.1111%2Fjnc.13454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels</span></div><div class="casAuthors">Gomez-Vallejo, Vanessa; Ugarte, Ana; Garcia-Barroso, Carolina; Cuadrado-Tejedor, Mar; Szczupak, Boguslaw; Dopeso-Reyes, Iria G.; Lanciego, Jose L.; Garcia-Osta, Ana; Llop, Jordi; Oyarzabal, Julen; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">403-415</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Sildenafil (Viagra) is a selective inhibitor of phosphodiesterase type 5 (PDE5), which degrades cGMP to the linear nucleotide.  Sildenafil is acutely used in erectile dysfunction and chronically in pulmonary hypertension.  Evidence in the last decade shows that sildenafil may have potential as a therapeutic option for Alzheimer's disease or other neurodegenerative disorders.  The purpose of this work was to explore whether sildenafil crosses the blood-brain barrier.  Pharmacokinetic properties of sildenafil in rodents were investigated using 11C-radiolabeling followed by in vivo positron emission tomog. (PET) and ex vivo tissue dissection and gamma counting.  PET results in rats suggest penetration into the central nervous system.  Ex vivo data in perfused animals suggest that trapping of [11C]sildenafil within the cerebral vascular endothelium limits accumulation in the central nervous system parenchyma.  Peroral sildenafil administration to Macaca fascicularis and subsequent chem. anal. of plasma and cerebrospinal fluid (CSF) using liq. chromatog. coupled with tandem mass spectrometry showed that drug content in the CSF was high enough to achieve PDE5 inhibition, which was also demonstrated by the significant increases in CSF cGMP levels.  Central actions of sildenafil include both relaxation of the cerebral vasculature and inhibition of PDE5 in neurons and glia.  This central action of sildenafil may underlie its efficacy in neuroprotection models, and may justify the continued search for a PDE5 ligand suitable for PET imaging.  Sildenafil interacts with phosphodiesterase type 5 (PDE5) expressed in the endothelium and/or smooth muscle cells of brain vessels and also crosses the blood-brain barrier to interact with PDE5 expressed in brain cells.  At therapeutic doses, the concn. of sildenafil in the cerebrospinal fluid (CSF) is high enough to inhibit PDE5 in the neural cells (neurons and glia).  In turn, the concn. of cGMP likely increases in parenchymal cells and, as shown in the CSF.  Read the Editorial Highlight for this article on page 220.  Cover Image for this issue: doi: 10.1111/jnc.13302.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrNfPXruaaALVg90H21EOLACvtfcHk0lj35iYoMGXN5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVKitw%253D%253D&md5=6de24b35db0c575431eabc500fc87fbd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13454%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Vallejo%26aufirst%3DV.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DSzczupak%26aufirst%3DB.%26aulast%3DDopeso-Reyes%26aufirst%3DI.%2BG.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPharmacokinetic%2520Investigation%2520of%2520Sildenafil%2520Using%2520Positron%2520Emission%2520Tomography%2520and%2520Determination%2520of%2520Its%2520Effect%2520on%2520Cerebrospinal%2520Fluid%2520cGMP%2520Levels%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D136%26spage%3D403%26epage%3D415%26doi%3D10.1111%2Fjnc.13454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, G. T.</span><span> </span><span class="NLM_article-title">High Throughput Artificial Membrane Permeability Assay for Blood-Brain Barrier</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/S0223-5234(03)00012-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2FS0223-5234%2803%2900012-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=12667689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=223-232&author=L.+Diauthor=E.+H.+Kernsauthor=K.+Fanauthor=O.+J.+McConnellauthor=G.+T.+Carter&title=High+Throughput+Artificial+Membrane+Permeability+Assay+for+Blood-Brain+Barrier&doi=10.1016%2FS0223-5234%2803%2900012-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput artificial membrane permeability assay for blood-brain barrier</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Fan, Kristi; McConnell, Oliver J.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The recent advances in high throughput screening for biol. activities and combinatorial chem. have greatly expanded the no. of drug candidates.  Rapid screening for BBB penetration potential early in drug discovery programs provides important information for compd. selection and guidance of synthesis for desirable CNS properties.  In this paper, we discuss a modification of the parallel artificial membrane permeation assay (PAMPA) for the prediction of blood-brain barrier penetration (PAMPA-BBB).  The assay was developed with 30 structurally diverse com. drugs and validated with 14 Wyeth Research compds.  The PAMPA-BBB assay has the advantages of: predicting passive blood-brain barrier penetration with high success, high throughput, low cost, and reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCg9Ka4mziLVg90H21EOLACvtfcHk0lj35iYoMGXN5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D&md5=d228d5808ba8df23deed92c5e2bf3863</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900012-6%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DFan%26aufirst%3DK.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DHigh%2520Throughput%2520Artificial%2520Membrane%2520Permeability%2520Assay%2520for%2520Blood-Brain%2520Barrier%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D223%26epage%3D232%26doi%3D10.1016%2FS0223-5234%2803%2900012-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span> </span><span class="NLM_article-title">Generation of a Set of Simple, Interpretable ADMET Rules of Thumb</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">834</span><span class="refDoi"> DOI: 10.1021/jm701122q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701122q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=817-834&author=M.+P.+Gleeson&title=Generation+of+a+Set+of+Simple%2C+Interpretable+ADMET+Rules+of+Thumb&doi=10.1021%2Fjm701122q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Set of Simple, Interpretable ADMET Rules of Thumb</span></div><div class="casAuthors">Gleeson, M. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">817-834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A set of simple, consistent structure-property guides have been detd. from an anal. of a no. of key ADMET assays run within GSK: soly., permeability, bioavailability, vol. of distribution, plasma protein binding, CNS penetration, brain tissue binding, P-gp efflux, hERG inhibition, and cytochrome P 450 1A2/2C9/2C19/2D6/3A4 inhibition.  The rules have been formulated using mol. properties that chemists intuitively know how to alter in a mol., namely, mol. wt., logP, and ionization state.  The rules supplement the more predictive black-box models available to us by clearly illustrating the key underlying trends, which are in line with reports in the literature.  It is clear from the analyses reported herein that almost all ADMET parameters deteriorate with either increasing mol. wt., logP, or both, with ionization state playing either a beneficial or detrimental affect depending on the parameter in question.  This study reemphasizes the need to focus on a lower mol. wt. and logP area of physicochem. property space to obtain improved ADMET parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PTdPHoD-c7Vg90H21EOLACvtfcHk0lj35iYoMGXN5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D&md5=42db5918ad8e9ea3ecf3a13846b3a434</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm701122q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701122q%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26atitle%3DGeneration%2520of%2520a%2520Set%2520of%2520Simple%252C%2520Interpretable%2520ADMET%2520Rules%2520of%2520Thumb%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D817%26epage%3D834%26doi%3D10.1021%2Fjm701122q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Beca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polidovitch, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Movsesian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manganiello, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backx, P. H.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility through Interacting with Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1161/CIRCRESAHA.111.300003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1161%2FCIRCRESAHA.111.300003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=289-297&author=S.+Becaauthor=F.+Ahmadauthor=W.+Shenauthor=J.+Liuauthor=S.+Makaryauthor=N.+Polidovitchauthor=J.+Sunauthor=S.+Hockmanauthor=Y.+W.+Chungauthor=M.+Movsesianauthor=E.+Murphyauthor=V.+Manganielloauthor=P.+H.+Backx&title=Phosphodiesterase+Type+3A+Regulates+Basal+Myocardial+Contractility+through+Interacting+with+Sarcoplasmic+Reticulum+Calcium+ATPase+Type+2a+Signaling+Complexes+in+Mouse+Heart&doi=10.1161%2FCIRCRESAHA.111.300003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.111.300003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.111.300003%26sid%3Dliteratum%253Aachs%26aulast%3DBeca%26aufirst%3DS.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMakary%26aufirst%3DS.%26aulast%3DPolidovitch%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHockman%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DY.%2BW.%26aulast%3DMovsesian%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DManganiello%26aufirst%3DV.%26aulast%3DBackx%26aufirst%3DP.%2BH.%26atitle%3DPhosphodiesterase%2520Type%25203A%2520Regulates%2520Basal%2520Myocardial%2520Contractility%2520through%2520Interacting%2520with%2520Sarcoplasmic%2520Reticulum%2520Calcium%2520ATPase%2520Type%25202a%2520Signaling%2520Complexes%2520in%2520Mouse%2520Heart%26jtitle%3DCirc.%2520Res.%26date%3D2013%26volume%3D112%26spage%3D289%26epage%3D297%26doi%3D10.1161%2FCIRCRESAHA.111.300003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span> </span><span class="NLM_article-title">Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1021/acschemneuro.6b00029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=767-775&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Central+Nervous+System+Multiparameter+Optimization+Desirability%3A+Application+in+Drug+Discovery&doi=10.1021%2Facschemneuro.6b00029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">767-775</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant progress has been made in prospectively designing mols. using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the anal. reported herein of a second wave of drug candidates that originated after the development and implementation of this tool.  This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochem. properties.  The CNS MPO tool has helped to increase the percentage of compds. nominated for clin. development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA).  The use of this tool has played a role in reducing the no. of compds. submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicol. into First in Human studies.  Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compds. nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46WD7qMaX6bVg90H21EOLACvtfcHk0lhhugi-f2CnKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D&md5=061c3aef6c88758cbaee1a2abb34796a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00029%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DCentral%2520Nervous%2520System%2520Multiparameter%2520Optimization%2520Desirability%253A%2520Application%2520in%2520Drug%2520Discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D767%26epage%3D775%26doi%3D10.1021%2Facschemneuro.6b00029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Mediavilla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frechilla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Río, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer’s Disease Mouse Model</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1732</span><span class="refDoi"> DOI: 10.1038/npp.2008.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnpp.2008.229" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1721-1732&author=A.+Ricobarazaauthor=M.+Cuadrado-Tejedorauthor=A.+P%C3%A9rez-Mediavillaauthor=D.+Frechillaauthor=J.+Del+R%C3%ADoauthor=A.+Garc%C3%ADa-Osta&title=Phenylbutyrate+Ameliorates+Cognitive+Deficit+and+Reduces+Tau+Pathology+in+an+Alzheimer%E2%80%99s+Disease+Mouse+Model&doi=10.1038%2Fnpp.2008.229"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.229%26sid%3Dliteratum%253Aachs%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez-Mediavilla%26aufirst%3DA.%26aulast%3DFrechilla%26aufirst%3DD.%26aulast%3DDel%2BR%25C3%25ADo%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DPhenylbutyrate%2520Ameliorates%2520Cognitive%2520Deficit%2520and%2520Reduces%2520Tau%2520Pathology%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mouse%2520Model%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D1721%26epage%3D1732%26doi%3D10.1038%2Fnpp.2008.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 50 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Feng He, C. James Chou, Matthias Scheiner, Eleonora Poeta, Natalia Yuan Chen, Sandra Gunesch, Matthias Hoffmann, Christoph Sotriffer, Barbara Monti, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3794-3812. <a href="https://doi.org/10.1021/acs.jmedchem.0c01940" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01940%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMelatonin-%252Band%252BFerulic%252BAcid-Based%252BHDAC6%252BSelective%252BInhibitors%252BExhibit%252BPronounced%252BImmunomodulatory%252BEffects%252BIn%252BVitro%252Band%252BNeuroprotective%252BEffects%252Bin%252Ba%252BPharmacological%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BMouse%252BModel%26aulast%3DHe%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D26032021%26volume%3D64%26issue%3D7%26spage%3D3794%26epage%3D3812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Obdulia Rabal, Edurne San José-Enériz, Xabier Agirre, Juan Antonio Sánchez-Arias, Irene de Miguel, Raquel Ordoñez, Leire Garate, Estíbaliz Miranda, Elena Sáez, Amaia Vilas-Zornoza, Antonio Pineda-Lucena, Ander Estella, Feifei Zhang, Wei Wu, Musheng Xu, Felipe Prosper, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with In Vivo Efficacy in Multiple Myeloma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 3392-3426. <a href="https://doi.org/10.1021/acs.jmedchem.0c02255" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02255%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BNovel%252BEpigenetic%252BInhibitors%252BTargeting%252BHistone%252BDeacetylases%25252C%252BDNA%252BMethyltransferase%252B1%25252C%252Band%252BLysine%252BMethyltransferase%252BG9a%252Bwith%252BIn%252BVivo%252BEfficacy%252Bin%252BMultiple%252BMyeloma%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29122020%26date%3D04032021%26volume%3D64%26issue%3D6%26spage%3D3392%26epage%3D3426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria Dichiara, Benedetto Amata, Rita Turnaturi, Agostino Marrazzo, <span class="NLM_string-name hlFld-ContribAuthor">Emanuele Amata</span>. </span><span class="cited-content_cbyCitation_article-title">Tuning Properties for Blood–Brain Barrier Permeation: A Statistics-Based Analysis. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (1)
                                     , 34-44. <a href="https://doi.org/10.1021/acschemneuro.9b00541" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00541</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00541%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DTuning%252BProperties%252Bfor%252BBlood%2525E2%252580%252593Brain%252BBarrier%252BPermeation%25253A%252BA%252BStatistics-Based%252BAnalysis%26aulast%3DDichiara%26aufirst%3DMaria%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D07102019%26date%3D03122019%26date%3D18122019%26date%3D03122019%26volume%3D11%26issue%3D1%26spage%3D34%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Obdulia Rabal, Juan A. Sánchez-Arias, Mar Cuadrado-Tejedor, Irene de Miguel, Marta Pérez-González, Carolina García-Barroso, Ana Ugarte, Ander Estella-Hermoso de Mendoza, Elena Sáez, Maria Espelosin, Susana Ursua, Haizhong Tan, Wei Wu, Musheng Xu, Antonio Pineda-Lucena, Ana Garcia-Osta, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Multitarget Approach for the Treatment of Alzheimer’s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2019,</strong> <em>10 </em>
                                    (9)
                                     , 4076-4101. <a href="https://doi.org/10.1021/acschemneuro.9b00303" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00303</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00303%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DMultitarget%252BApproach%252Bfor%252Bthe%252BTreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BInhibition%252Bof%252BPhosphodiesterase%252B9%252B%252528PDE9%252529%252Band%252BHistone%252BDeacetylases%252B%252528HDACs%252529%252BCovering%252BDiverse%252BSelectivity%252BProfiles%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D24052019%26date%3D23082019%26date%3D04092019%26date%3D23082019%26volume%3D10%26issue%3D9%26spage%3D4076%26epage%3D4101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Obdulia Rabal, Juan A. Sánchez-Arias, Mar Cuadrado-Tejedor, Irene de Miguel, Marta Pérez-González, Carolina García-Barroso, Ana Ugarte, Ander Estella-Hermoso de Mendoza, Elena Sáez, Maria Espelosin, Susana Ursua, Tan Haizhong, Wu Wei, Xu Musheng, Ana Garcia-Osta, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of in Vivo Chemical Probes for Treating Alzheimer’s Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2019,</strong> <em>10 </em>
                                    (3)
                                     , 1765-1782. <a href="https://doi.org/10.1021/acschemneuro.8b00648" title="DOI URL">https://doi.org/10.1021/acschemneuro.8b00648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.8b00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.8b00648%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDiscovery%252Bof%252Bin%252BVivo%252BChemical%252BProbes%252Bfor%252BTreating%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BDual%252BPhosphodiesterase%252B5%252B%252528PDE5%252529%252Band%252BClass%252BI%252BHistone%252BDeacetylase%252BSelective%252BInhibitors%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D22112018%26date%3D10122018%26date%3D21122018%26date%3D10122018%26volume%3D10%26issue%3D3%26spage%3D1765%26epage%3D1782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Masha
G. Savelieff, Geewoo Nam, Juhye Kang, Hyuck Jin Lee, Misun Lee, <span class="NLM_string-name hlFld-ContribAuthor">Mi Hee Lim</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (2)
                                     , 1221-1322. <a href="https://doi.org/10.1021/acs.chemrev.8b00138" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00138</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00138%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DDevelopment%252Bof%252BMultifunctional%252BMolecules%252Bas%252BPotential%252BTherapeutic%252BCandidates%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%25252C%252BParkinson%2525E2%252580%252599s%252BDisease%25252C%252Band%252BAmyotrophic%252BLateral%252BSclerosis%252Bin%252Bthe%252BLast%252BDecade%26aulast%3DSavelieff%26aufirst%3DMasha%2BG.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D02032018%26date%3D10082018%26volume%3D119%26issue%3D2%26spage%3D1221%26epage%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Obdulia Rabal, Juan Antonio Sánchez-Arias, Edurne San José-Enériz, Xabier Agirre, Irene de Miguel, Leire Garate, Estibaliz Miranda, Elena Sáez, Sergio Roa, José Angel Martínez-Climent, Yingying Liu, Wei Wu, Musheng Xu, Felipe Prosper, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6546-6573. <a href="https://doi.org/10.1021/acs.jmedchem.7b01925" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01925</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01925%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDetailed%252BExploration%252Baround%252B4-Aminoquinolines%252BChemical%252BSpace%252Bto%252BNavigate%252Bthe%252BLysine%252BMethyltransferase%252BG9a%252Band%252BDNA%252BMethyltransferase%252BBiological%252BSpaces%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D19072018%26date%3D11062018%26volume%3D61%26issue%3D15%26spage%3D6546%26epage%3D6573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Obdulia Rabal, Edurne San José-Enériz, Xabier Agirre, Juan Antonio Sánchez-Arias, Amaia Vilas-Zornoza, Ana Ugarte, Irene de Miguel, Estíbaliz Miranda, Leire Garate, Mario Fraga, Pablo Santamarina, Raul Fernandez Perez, Raquel Ordoñez, Elena Sáez, Sergio Roa, María José García-Barchino, José Angel Martínez-Climent, Yingying Liu, Wei Wu, Musheng Xu, Felipe Prosper, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6518-6545. <a href="https://doi.org/10.1021/acs.jmedchem.7b01926" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01926</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01926&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01926%26sid%3Dliteratum%253Aachs%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D15424%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BReversible%252BDNA%252BMethyltransferase%252Band%252BLysine%252BMethyltransferase%252BG9a%252BInhibitors%252Bwith%252BAntitumoral%252Bin%252BVivo%252BEfficacy%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D19072018%26date%3D28062018%26volume%3D61%26issue%3D15%26spage%3D6518%26epage%3D6545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yinuo Wu, Zhe Li, Yi-You Huang, Deyan Wu, <span class="NLM_string-name hlFld-ContribAuthor">Hai-Bin Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5467-5483. <a href="https://doi.org/10.1021/acs.jmedchem.7b01370" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01370%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BPhosphodiesterase%252BInhibitors%252Bfor%252BCognitive%252BImprovement%252Bin%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DWu%26aufirst%3DYinuo%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D15092017%26date%3D05022018%26date%3D24012018%26volume%3D61%26issue%3D13%26spage%3D5467%26epage%3D5483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Irene de Miguel, Josune Orbe, Juan A. Sánchez-Arias, José A. Rodríguez, Agustina Salicio, Obdulia Rabal, Miriam Belzunce, Elena Sáez, Musheng Xu, Wei Wu, Haizhong Tan, Hongyu Ma, José A. Páramo, <span class="NLM_string-name hlFld-ContribAuthor">Julen Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Phenotypic Screening To Discover Novel Chemical Series as Efficient Antihemorrhagic Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>9 </em>
                                    (5)
                                     , 428-433. <a href="https://doi.org/10.1021/acsmedchemlett.7b00549" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00549</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00549&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00549%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPhenotypic%252BScreening%252BTo%252BDiscover%252BNovel%252BChemical%252BSeries%252Bas%252BEfficient%252BAntihemorrhagic%252BAgents%26aulast%3Dde%2BMiguel%26aufirst%3DIrene%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30122017%26date%3D16042018%26date%3D23042018%26date%3D16042018%26volume%3D9%26issue%3D5%26spage%3D428%26epage%3D433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan A.  Sánchez-Arias</span>, <span class="hlFld-ContribAuthor ">Obdulia  Rabal</span>, <span class="hlFld-ContribAuthor ">Mar  Cuadrado-Tejedor</span>, <span class="hlFld-ContribAuthor ">Irene  de Miguel</span>, <span class="hlFld-ContribAuthor ">Marta  Pérez-González</span>, <span class="hlFld-ContribAuthor ">Ana  Ugarte</span>, <span class="hlFld-ContribAuthor ">Elena  Sáez</span>, <span class="hlFld-ContribAuthor ">Maria  Espelosin</span>, <span class="hlFld-ContribAuthor ">Susana  Ursua</span>, <span class="hlFld-ContribAuthor ">Tan  Haizhong</span>, <span class="hlFld-ContribAuthor ">Wu  Wei</span>, <span class="hlFld-ContribAuthor ">Xu  Musheng</span>, <span class="hlFld-ContribAuthor ">Ana  Garcia-Osta</span>, and <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>  . </span><span class="cited-content_cbyCitation_article-title">Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2017,</strong> <em>8 </em>
                                    (3)
                                     , 638-661. <a href="https://doi.org/10.1021/acschemneuro.6b00370" title="DOI URL">https://doi.org/10.1021/acschemneuro.6b00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.6b00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.6b00370%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DImpact%252Bof%252BScaffold%252BExploration%252Bon%252BNovel%252BDual-Acting%252BHistone%252BDeacetylases%252Band%252BPhosphodiesterase%252B5%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DS%25C3%25A1nchez-Arias%26aufirst%3DJuan%2BA.%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D31102016%26date%3D12122016%26date%3D27122016%26date%3D15032017%26date%3D12122016%26volume%3D8%26issue%3D3%26spage%3D638%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcin  Janowski</span>, <span class="hlFld-ContribAuthor ">Małgorzata  Milewska</span>, <span class="hlFld-ContribAuthor ">Peyman  Zare</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Pękowska</span>. </span><span class="cited-content_cbyCitation_article-title">Chromatin Alterations in Neurological Disorders and Strategies of (Epi)Genome Rescue. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2021,</strong> <em>14 </em>
                                    (8)
                                     , 765. <a href="https://doi.org/10.3390/ph14080765" title="DOI URL">https://doi.org/10.3390/ph14080765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph14080765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph14080765%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DChromatin%252BAlterations%252Bin%252BNeurological%252BDisorders%252Band%252BStrategies%252Bof%252B%252528Epi%252529Genome%252BRescue%26aulast%3DJanowski%26aufirst%3DMarcin%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D8%26spage%3D765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ma  Su</span>, <span class="hlFld-ContribAuthor ">Xingyu  Gong</span>, <span class="hlFld-ContribAuthor ">Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 745-761. <a href="https://doi.org/10.1080/17460441.2021.1877656" title="DOI URL">https://doi.org/10.1080/17460441.2021.1877656</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1877656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1877656%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DAn%252Bupdate%252Bon%252Bthe%252Bemerging%252Bapproaches%252Bfor%252Bhistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitor%252Bdrug%252Bdiscovery%252Band%252Bfuture%252Bperspectives%26aulast%3DSu%26aufirst%3DMa%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D745%26epage%3D761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wisanee  Wisanwattana</span>, <span class="hlFld-ContribAuthor ">Kanjana  Wongkrajang</span>, <span class="hlFld-ContribAuthor ">Dong-yi  Cao</span>, <span class="hlFld-ContribAuthor ">Xiao-ke  Shi</span>, <span class="hlFld-ContribAuthor ">Zhong-hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Zong-yuan  Zhou</span>, <span class="hlFld-ContribAuthor ">Fu  Li</span>, <span class="hlFld-ContribAuthor ">Qing-gang  Mei</span>, <span class="hlFld-ContribAuthor ">Chun  Wang</span>, <span class="hlFld-ContribAuthor ">Apichart  Suksamrarn</span>, <span class="hlFld-ContribAuthor ">Guo-lin  Zhang</span>, <span class="hlFld-ContribAuthor ">Fei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Phosphodiesterase 5 Promotes the Aromatase-Mediated Estrogen Biosynthesis in Osteoblastic Cells by Activation of cGMP/PKG/SHP2 Pathway. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Endocrinology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fendo.2021.636784" title="DOI URL">https://doi.org/10.3389/fendo.2021.636784</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fendo.2021.636784&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffendo.2021.636784%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Endocrinology%26atitle%3DInhibition%252Bof%252BPhosphodiesterase%252B5%252BPromotes%252Bthe%252BAromatase-Mediated%252BEstrogen%252BBiosynthesis%252Bin%252BOsteoblastic%252BCells%252Bby%252BActivation%252Bof%252BcGMP%25252FPKG%25252FSHP2%252BPathway%26aulast%3DWisanwattana%26aufirst%3DWisanee%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nathalia Fonseca  Nadur</span>, <span class="hlFld-ContribAuthor ">Luciana Luiz  de Azevedo</span>, <span class="hlFld-ContribAuthor ">Lucas  Caruso</span>, <span class="hlFld-ContribAuthor ">Cedric Stephan  Graebin</span>, <span class="hlFld-ContribAuthor ">Renata Barbosa  Lacerda</span>, <span class="hlFld-ContribAuthor ">Arthur Eugen  Kümmerle</span>. </span><span class="cited-content_cbyCitation_article-title">The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>212 </em>, 113123. <a href="https://doi.org/10.1016/j.ejmech.2020.113123" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113123</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113123%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Blong%252Band%252Bwinding%252Broad%252Bof%252Bdesigning%252Bphosphodiesterase%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bheart%252Bfailure%26aulast%3DNadur%26aufirst%3DNathalia%2BFonseca%26date%3D2021%26volume%3D212%26spage%3D113123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alex  Claveria-Cabello</span>, <span class="hlFld-ContribAuthor ">Leticia  Colyn</span>, <span class="hlFld-ContribAuthor ">Iker  Uriarte</span>, <span class="hlFld-ContribAuthor ">Maria Ujue  Latasa</span>, <span class="hlFld-ContribAuthor ">Maria  Arechederra</span>, <span class="hlFld-ContribAuthor ">Jose M.  Herranz</span>, <span class="hlFld-ContribAuthor ">Laura  Alvarez</span>, <span class="hlFld-ContribAuthor ">Jesus M.  Urman</span>, <span class="hlFld-ContribAuthor ">Maria L.  Martinez-Chantar</span>, <span class="hlFld-ContribAuthor ">Jesus M.  Banales</span>, <span class="hlFld-ContribAuthor ">Bruno  Sangro</span>, <span class="hlFld-ContribAuthor ">Krista  Rombouts</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>, <span class="hlFld-ContribAuthor ">Jose J. G.  Marin</span>, <span class="hlFld-ContribAuthor ">Carmen  Berasain</span>, <span class="hlFld-ContribAuthor ">Matias A.  Avila</span>, <span class="hlFld-ContribAuthor ">Maite G.  Fernandez-Barrena</span>. </span><span class="cited-content_cbyCitation_article-title">Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (12)
                                     , 3748. <a href="https://doi.org/10.3390/cancers12123748" title="DOI URL">https://doi.org/10.3390/cancers12123748</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12123748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12123748%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDual%252BPharmacological%252BTargeting%252Bof%252BHDACs%252Band%252BPDE5%252BInhibits%252BLiver%252BDisease%252BProgression%252Bin%252Ba%252BMouse%252BModel%252Bof%252BBiliary%252BInflammation%252Band%252BFibrosis%26aulast%3DClaveria-Cabello%26aufirst%3DAlex%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D12%26spage%3D3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel A.  Rodrigues</span>, <span class="hlFld-ContribAuthor ">Pedro de S. M.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Fernanda S.  Sagrillo</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>, <span class="hlFld-ContribAuthor ">Carlos A. M.  Fraga</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (6)
                                     , 2177-2211. <a href="https://doi.org/10.1002/med.21701" title="DOI URL">https://doi.org/10.1002/med.21701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21701%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DHistone%252Bdeacetylases%252Bas%252Btargets%252Bfor%252Bthe%252Btreatment%252Bof%252Bneurodegenerative%252Bdisorders%25253A%252BChallenges%252Band%252Bfuture%252Bopportunities%26aulast%3DRodrigues%26aufirst%3DDaniel%2BA.%26date%3D2020%26date%3D2020%26volume%3D40%26issue%3D6%26spage%3D2177%26epage%3D2211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  He</span>, <span class="hlFld-ContribAuthor ">Yingying  Ran</span>, <span class="hlFld-ContribAuthor ">Xiaoyang  Li</span>, <span class="hlFld-ContribAuthor ">Defeng  Wang</span>, <span class="hlFld-ContribAuthor ">Qiuqiong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiahui  Lv</span>, <span class="hlFld-ContribAuthor ">Chenggong  Yu</span>, <span class="hlFld-ContribAuthor ">Ying  Qu</span>, <span class="hlFld-ContribAuthor ">Xiangna  Zhang</span>, <span class="hlFld-ContribAuthor ">Ana  Xu</span>, <span class="hlFld-ContribAuthor ">Chao  Wei</span>, <span class="hlFld-ContribAuthor ">C. James  Chou</span>, <span class="hlFld-ContribAuthor ">Jingde  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of dual-function inhibitors targeting NMDAR and HDAC for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>103 </em>, 104109. <a href="https://doi.org/10.1016/j.bioorg.2020.104109" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104109%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bdual-function%252Binhibitors%252Btargeting%252BNMDAR%252Band%252BHDAC%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DHe%26aufirst%3DFeng%26date%3D2020%26volume%3D103%26spage%3D104109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhidong  Xu</span>, <span class="hlFld-ContribAuthor ">Limeng  Jia</span>, <span class="hlFld-ContribAuthor ">Wenqing  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Ying  Song</span>, <span class="hlFld-ContribAuthor ">Qi-Huang  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Radiosynthesis of a carbon-11 labeled PDE5 inhibitor [11C]TPN171 as a new potential PET heart imaging agent. </span><span class="cited-content_cbyCitation_journal-name">Applied Radiation and Isotopes</span><span> <strong>2020,</strong> <em>162 </em>, 109190. <a href="https://doi.org/10.1016/j.apradiso.2020.109190" title="DOI URL">https://doi.org/10.1016/j.apradiso.2020.109190</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apradiso.2020.109190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apradiso.2020.109190%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Radiation%2520and%2520Isotopes%26atitle%3DRadiosynthesis%252Bof%252Ba%252Bcarbon-11%252Blabeled%252BPDE5%252Binhibitor%252B%25255B11C%25255DTPN171%252Bas%252Ba%252Bnew%252Bpotential%252BPET%252Bheart%252Bimaging%252Bagent%26aulast%3DXu%26aufirst%3DZhidong%26date%3D2020%26volume%3D162%26spage%3D109190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Morgen</span>, <span class="hlFld-ContribAuthor ">Raphael R.  Steimbach</span>, <span class="hlFld-ContribAuthor ">Magalie  Géraldy</span>, <span class="hlFld-ContribAuthor ">Lars  Hellweg</span>, <span class="hlFld-ContribAuthor ">Peter  Sehr</span>, <span class="hlFld-ContribAuthor ">Johannes  Ridinger</span>, <span class="hlFld-ContribAuthor ">Olaf  Witt</span>, <span class="hlFld-ContribAuthor ">Ina  Oehme</span>, <span class="hlFld-ContribAuthor ">Corey J.  Herbst‐Gervasoni</span>, <span class="hlFld-ContribAuthor ">Jeremy D.  Osko</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Porter</span>, <span class="hlFld-ContribAuthor ">David W.  Christianson</span>, <span class="hlFld-ContribAuthor ">Nikolas  Gunkel</span>, <span class="hlFld-ContribAuthor ">Aubry K.  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (13)
                                     , 1163-1174. <a href="https://doi.org/10.1002/cmdc.202000149" title="DOI URL">https://doi.org/10.1002/cmdc.202000149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000149%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BDihydroxamic%252BAcids%252Bas%252BHDAC6%25252F8%25252F10%252BInhibitors%26aulast%3DMorgen%26aufirst%3DMichael%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D13%26spage%3D1163%26epage%3D1174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Esther P.  Jane</span>, <span class="hlFld-ContribAuthor ">Daniel R.  Premkumar</span>, <span class="hlFld-ContribAuthor ">Swetha  Thambireddy</span>, <span class="hlFld-ContribAuthor ">Brian  Golbourn</span>, <span class="hlFld-ContribAuthor ">Sameer  Agnihotri</span>, <span class="hlFld-ContribAuthor ">Kelsey C.  Bertrand</span>, <span class="hlFld-ContribAuthor ">Stephen C.  Mack</span>, <span class="hlFld-ContribAuthor ">Max I.  Myers</span>, <span class="hlFld-ContribAuthor ">Ansuman  Chattopadhyay</span>, <span class="hlFld-ContribAuthor ">D. Lansing  Taylor</span>, <span class="hlFld-ContribAuthor ">Mark E.  Schurdak</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Stern</span>, <span class="hlFld-ContribAuthor ">Ian F.  Pollack</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting NAD
              +
              Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2020,</strong> <em>18 </em>
                                    (7)
                                     , 1004-1017. <a href="https://doi.org/10.1158/1541-7786.MCR-19-0669" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-19-0669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-19-0669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-19-0669%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DTargeting%252BNAD%252B%25252B%252BBiosynthesis%252BOvercomes%252BPanobinostat%252Band%252BBortezomib-Induced%252BMalignant%252BGlioma%252BResistance%26aulast%3DJane%26aufirst%3DEsther%2BP.%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D7%26spage%3D1004%26epage%3D1017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Albertini</span>, <span class="hlFld-ContribAuthor ">Alessandra  Salerno</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena Murteira Pinheiro</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.1002/med.21699" title="DOI URL">https://doi.org/10.1002/med.21699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21699%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DFrom%252Bcombinations%252Bto%252Bmultitarget%2525E2%252580%252590directed%252Bligands%25253A%252BA%252Bcontinuum%252Bin%252BAlzheimer%252527s%252Bdisease%252Bpolypharmacology%26aulast%3DAlbertini%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed K.  ElHady</span>, <span class="hlFld-ContribAuthor ">Shou-Ping  Shih</span>, <span class="hlFld-ContribAuthor ">Yu-Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Yi-Chang  Liu</span>, <span class="hlFld-ContribAuthor ">Nermin S.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Adam B.  Keeton</span>, <span class="hlFld-ContribAuthor ">Gary A.  Piazza</span>, <span class="hlFld-ContribAuthor ">Matthias  Engel</span>, <span class="hlFld-ContribAuthor ">Ashraf H.  Abadi</span>, <span class="hlFld-ContribAuthor ">Mohammad  Abdel-Halim</span>. </span><span class="cited-content_cbyCitation_article-title">Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>98 </em>, 103742. <a href="https://doi.org/10.1016/j.bioorg.2020.103742" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103742%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DExtending%252Bthe%252Buse%252Bof%252Btadalafil%252Bscaffold%25253A%252BDevelopment%252Bof%252Bnovel%252Bselective%252Bphosphodiesterase%252B5%252Binhibitors%252Band%252Bhistone%252Bdeacetylase%252Binhibitors%26aulast%3DElHady%26aufirst%3DAhmed%2BK.%26date%3D2020%26volume%3D98%26spage%3D103742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Surabhi  Shukla</span>, <span class="hlFld-ContribAuthor ">Babu L.  Tekwani</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00537" title="DOI URL">https://doi.org/10.3389/fphar.2020.00537</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00537%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DHistone%252BDeacetylases%252BInhibitors%252Bin%252BNeurodegenerative%252BDiseases%25252C%252BNeuroprotection%252Band%252BNeuronal%252BDifferentiation%26aulast%3DShukla%26aufirst%3DSurabhi%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (4)
                                     , 263-274. <a href="https://doi.org/10.1080/13543776.2020.1725470" title="DOI URL">https://doi.org/10.1080/13543776.2020.1725470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1725470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1725470%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DHistone%252Bdeacetylase%252B%252528HDAC%252529%252Binhibitors%252Bin%252Bcancer%25253A%252Ba%252Bpatent%252Breview%252B%2525282017-present%252529%26aulast%3DZhao%26aufirst%3DChunlong%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D4%26spage%3D263%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pooja  Patil</span>, <span class="hlFld-ContribAuthor ">Ashima  Thakur</span>, <span class="hlFld-ContribAuthor ">Abha  Sharma</span>, <span class="hlFld-ContribAuthor ">Swaran Jeet Singh  Flora</span>. </span><span class="cited-content_cbyCitation_article-title">Natural products and their derivatives as multifunctional ligands against Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2020,</strong> <em>81 </em>
                                    (2)
                                     , 165-183. <a href="https://doi.org/10.1002/ddr.21587" title="DOI URL">https://doi.org/10.1002/ddr.21587</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21587&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21587%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DNatural%252Bproducts%252Band%252Btheir%252Bderivatives%252Bas%252Bmultifunctional%252Bligands%252Bagainst%252BAlzheimer%252527s%252Bdisease%26aulast%3DPatil%26aufirst%3DPooja%26date%3D2020%26volume%3D81%26issue%3D2%26spage%3D165%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rohan  Gupta</span>, <span class="hlFld-ContribAuthor ">Rashmi K.  Ambasta</span>, <span class="hlFld-ContribAuthor ">Pravir  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2020,</strong> <em>243 </em>, 117278. <a href="https://doi.org/10.1016/j.lfs.2020.117278" title="DOI URL">https://doi.org/10.1016/j.lfs.2020.117278</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2020.117278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2020.117278%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DPharmacological%252Bintervention%252Bof%252Bhistone%252Bdeacetylase%252Benzymes%252Bin%252Bthe%252Bneurodegenerative%252Bdisorders%26aulast%3DGupta%26aufirst%3DRohan%26date%3D2020%26volume%3D243%26spage%3D117278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Tomaselli</span>, <span class="hlFld-ContribAuthor ">Alessia  Lucidi</span>, <span class="hlFld-ContribAuthor ">Dante  Rotili</span>, <span class="hlFld-ContribAuthor ">Antonello  Mai</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic polypharmacology: A new frontier for epi‐drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>40 </em>
                                    (1)
                                     , 190-244. <a href="https://doi.org/10.1002/med.21600" title="DOI URL">https://doi.org/10.1002/med.21600</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21600%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEpigenetic%252Bpolypharmacology%25253A%252BA%252Bnew%252Bfrontier%252Bfor%252Bepi%2525E2%252580%252590drug%252Bdiscovery%26aulast%3DTomaselli%26aufirst%3DDaniela%26date%3D2020%26date%3D2019%26volume%3D40%26issue%3D1%26spage%3D190%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Garcia-Osta</span>, <span class="hlFld-ContribAuthor ">Mar  Cuadrado-Tejedor</span>. </span><span class="cited-content_cbyCitation_article-title">Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 213-226. <a href="https://doi.org/10.1016/B978-0-12-815868-5.00014-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-815868-5.00014-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-815868-5.00014-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-815868-5.00014-1%26sid%3Dliteratum%253Aachs%26atitle%3DLinking%252Bhistone%252Bdeacetylases%252Band%252Bphosphodiesterase%252B5%252Bin%252Bnovel%252Btreatments%252Bfor%252BAlzheimer%252527s%252Bdisease%26aulast%3DGarcia-Osta%26aufirst%3DAna%26date%3D2020%26spage%3D213%26epage%3D226%26pub%3DElsevier%26atitle%3DGenetics%25252C%252BNeurology%25252C%252BBehavior%25252C%252Band%252BDiet%252Bin%252BDementia%26date%3D2020%26volume%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rohan  Gupta</span>, <span class="hlFld-ContribAuthor ">Rashmi K.  Ambasta</span>, <span class="hlFld-ContribAuthor ">Pravir  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Histone deacetylase in neuropathology. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/bs.acc.2020.09.004" title="DOI URL">https://doi.org/10.1016/bs.acc.2020.09.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.acc.2020.09.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.acc.2020.09.004%26sid%3Dliteratum%253Aachs%26atitle%3DHistone%252Bdeacetylase%252Bin%252Bneuropathology%26aulast%3DGupta%26aufirst%3DRohan%26date%3D2020%26pub%3DElsevier%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Xu</span>, <span class="hlFld-ContribAuthor ">Feng  He</span>, <span class="hlFld-ContribAuthor ">Chenggong  Yu</span>, <span class="hlFld-ContribAuthor ">Ying  Qu</span>, <span class="hlFld-ContribAuthor ">Qiuqiong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jiahui  Lv</span>, <span class="hlFld-ContribAuthor ">Xiangna  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingying  Ran</span>, <span class="hlFld-ContribAuthor ">Chao  Wei</span>, <span class="hlFld-ContribAuthor ">Jingde  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">The Development of Small Molecule Inhibitors of Glutaminyl Cyclase and Isoglutaminyl Cyclase for Alzheimer's Disease. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (35)
                                     , 10591-10600. <a href="https://doi.org/10.1002/slct.201902852" title="DOI URL">https://doi.org/10.1002/slct.201902852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201902852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201902852%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DThe%252BDevelopment%252Bof%252BSmall%252BMolecule%252BInhibitors%252Bof%252BGlutaminyl%252BCyclase%252Band%252BIsoglutaminyl%252BCyclase%252Bfor%252BAlzheimer%252527s%252BDisease%26aulast%3DXu%26aufirst%3DAna%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D35%26spage%3D10591%26epage%3D10600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mar  Cuadrado-Tejedor</span>, <span class="hlFld-ContribAuthor ">Marta  Pérez-González</span>, <span class="hlFld-ContribAuthor ">Cristina  García-Muñoz</span>, <span class="hlFld-ContribAuthor ">Damián  Muruzabal</span>, <span class="hlFld-ContribAuthor ">Carolina  García-Barroso</span>, <span class="hlFld-ContribAuthor ">Obdulia  Rabal</span>, <span class="hlFld-ContribAuthor ">Víctor  Segura</span>, <span class="hlFld-ContribAuthor ">Juan A.  Sánchez-Arias</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>, <span class="hlFld-ContribAuthor ">Ana  Garcia-Osta</span>. </span><span class="cited-content_cbyCitation_article-title">Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Aging Neuroscience</span><span> <strong>2019,</strong> <em>11 </em><a href="https://doi.org/10.3389/fnagi.2019.00149" title="DOI URL">https://doi.org/10.3389/fnagi.2019.00149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnagi.2019.00149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnagi.2019.00149%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Aging%2520Neuroscience%26atitle%3DTaking%252BAdvantage%252Bof%252Bthe%252BSelectivity%252Bof%252BHistone%252BDeacetylases%252Band%252BPhosphodiesterase%252BInhibitors%252Bto%252BDesign%252BBetter%252BTherapeutic%252BStrategies%252Bto%252BTreat%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DCuadrado-Tejedor%26aufirst%3DMar%26date%3D2019%26date%3D2019%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Angela  De Simone</span>, <span class="hlFld-ContribAuthor ">Andrea  Milelli</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (11)
                                     , 1067-1073. <a href="https://doi.org/10.1002/cmdc.201900174" title="DOI URL">https://doi.org/10.1002/cmdc.201900174</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900174%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DHistone%252BDeacetylase%252BInhibitors%252Bas%252BMultitarget%252BLigands%25253A%252BNew%252BPlayers%252Bin%252BAlzheimer%252527s%252BDisease%252BDrug%252BDiscovery%25253F%26aulast%3DDe%25E2%2580%2585Simone%26aufirst%3DAngela%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D11%26spage%3D1067%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  Muthuraja</span>, <span class="hlFld-ContribAuthor ">V.  Veeramani</span>, <span class="hlFld-ContribAuthor ">S.  Prakash</span>, <span class="hlFld-ContribAuthor ">M.  Himesh</span>, <span class="hlFld-ContribAuthor ">U.  Venkatasubramanian</span>, <span class="hlFld-ContribAuthor ">P.  Manisankar</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>, 493-504. <a href="https://doi.org/10.1016/j.bioorg.2018.12.014" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.12.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.12.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DStructure-activity%252Brelationship%252Bof%252Bpyrazolo%252Bpyrimidine%252Bderivatives%252Bas%252Binhibitors%252Bof%252Bmitotic%252Bkinesin%252BEg5%252Band%252Banticancer%252Bagents%26aulast%3DMuthuraja%26aufirst%3DP.%26date%3D2019%26volume%3D84%26spage%3D493%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manish  Bodas</span>, <span class="hlFld-ContribAuthor ">Neeraj  Vij</span>. </span><span class="cited-content_cbyCitation_article-title">Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.00020" title="DOI URL">https://doi.org/10.3389/fphar.2019.00020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.00020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.00020%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DAdapting%252BProteostasis%252Band%252BAutophagy%252Bfor%252BControlling%252Bthe%252BPathogenesis%252Bof%252BCystic%252BFibrosis%252BLung%252BDisease%26aulast%3DBodas%26aufirst%3DManish%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael A.  Hollas</span>, <span class="hlFld-ContribAuthor ">Manel  Ben Aissa</span>, <span class="hlFld-ContribAuthor ">Sue H.  Lee</span>, <span class="hlFld-ContribAuthor ">Jesse M.  Gordon-Blake</span>, <span class="hlFld-ContribAuthor ">Gregory R.J.  Thatcher</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological manipulation of cGMP and NO/cGMP in CNS drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Nitric Oxide</span><span> <strong>2019,</strong> <em>82 </em>, 59-74. <a href="https://doi.org/10.1016/j.niox.2018.10.006" title="DOI URL">https://doi.org/10.1016/j.niox.2018.10.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.niox.2018.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.niox.2018.10.006%26sid%3Dliteratum%253Aachs%26jtitle%3DNitric%2520Oxide%26atitle%3DPharmacological%252Bmanipulation%252Bof%252BcGMP%252Band%252BNO%25252FcGMP%252Bin%252BCNS%252Bdrug%252Bdiscovery%26aulast%3DHollas%26aufirst%3DMichael%2BA.%26date%3D2019%26volume%3D82%26spage%3D59%26epage%3D74" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinhui  Hu</span>, <span class="hlFld-ContribAuthor ">Baijiao  An</span>, <span class="hlFld-ContribAuthor ">Tingting  Pan</span>, <span class="hlFld-ContribAuthor ">Zhengcunxiao  Li</span>, <span class="hlFld-ContribAuthor ">Ling  Huang</span>, <span class="hlFld-ContribAuthor ">Xingshu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (21)
                                     , 5718-5729. <a href="https://doi.org/10.1016/j.bmc.2018.10.022" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.10.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.10.022%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bhistone%252Bdeacetylase%252Binhibitors%252Bpossessing%252Bglutathione%252Bperoxidase-like%252Band%252Bantioxidant%252Bactivities%252Bagainst%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DHu%26aufirst%3DJinhui%26date%3D2018%26volume%3D26%26issue%3D21%26spage%3D5718%26epage%3D5729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Fenoglio</span>, <span class="hlFld-ContribAuthor ">Elio  Scarpini</span>, <span class="hlFld-ContribAuthor ">Daniela  Galimberti</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetic regulatory modifications in genetic and sporadic frontotemporal dementia. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Neurotherapeutics</span><span> <strong>2018,</strong> <em>18 </em>
                                    (6)
                                     , 469-475. <a href="https://doi.org/10.1080/14737175.2018.1481389" title="DOI URL">https://doi.org/10.1080/14737175.2018.1481389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14737175.2018.1481389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14737175.2018.1481389%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Neurotherapeutics%26atitle%3DEpigenetic%252Bregulatory%252Bmodifications%252Bin%252Bgenetic%252Band%252Bsporadic%252Bfrontotemporal%252Bdementia%26aulast%3DFenoglio%26aufirst%3DChiara%26date%3D2018%26date%3D2018%26volume%3D18%26issue%3D6%26spage%3D469%26epage%3D475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongbo  Zheng</span>, <span class="hlFld-ContribAuthor ">Lin  Li</span>, <span class="hlFld-ContribAuthor ">Bin  Sun</span>, <span class="hlFld-ContribAuthor ">Yun  Gao</span>, <span class="hlFld-ContribAuthor ">Wei  Song</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Zhao</span>, <span class="hlFld-ContribAuthor ">Yanhui  Gao</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Xie</span>, <span class="hlFld-ContribAuthor ">Nianzhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianbo  Ji</span>, <span class="hlFld-ContribAuthor ">Huiqing  Yuan</span>, <span class="hlFld-ContribAuthor ">Hongxiang  Lou</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of furyl/thineyl pyrroloquinolones based on natural alkaloid perlolyrine, lead to the discovery of potent and selective PDE5 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 30-38. <a href="https://doi.org/10.1016/j.ejmech.2018.02.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bfuryl%25252Fthineyl%252Bpyrroloquinolones%252Bbased%252Bon%252Bnatural%252Balkaloid%252Bperlolyrine%25252C%252Blead%252Bto%252Bthe%252Bdiscovery%252Bof%252Bpotent%252Band%252Bselective%252BPDE5%252Binhibitors%26aulast%3DZheng%26aufirst%3DHongbo%26date%3D2018%26volume%3D150%26spage%3D30%26epage%3D38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Obdulia  Rabal</span>, <span class="hlFld-ContribAuthor ">Juan A.  Sánchez-Arias</span>, <span class="hlFld-ContribAuthor ">Mar  Cuadrado-Tejedor</span>, <span class="hlFld-ContribAuthor ">Irene  de Miguel</span>, <span class="hlFld-ContribAuthor ">Marta  Pérez-González</span>, <span class="hlFld-ContribAuthor ">Carolina  García-Barroso</span>, <span class="hlFld-ContribAuthor ">Ana  Ugarte</span>, <span class="hlFld-ContribAuthor ">Ander  Estella-Hermoso de Mendoza</span>, <span class="hlFld-ContribAuthor ">Elena  Sáez</span>, <span class="hlFld-ContribAuthor ">Maria  Espelosin</span>, <span class="hlFld-ContribAuthor ">Susana  Ursua</span>, <span class="hlFld-ContribAuthor ">Tan  Haizhong</span>, <span class="hlFld-ContribAuthor ">Wu  Wei</span>, <span class="hlFld-ContribAuthor ">Xu  Musheng</span>, <span class="hlFld-ContribAuthor ">Ana  Garcia-Osta</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>150 </em>, 506-524. <a href="https://doi.org/10.1016/j.ejmech.2018.03.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bin%2525C2%2525A0vivo%252Btesting%252Bof%252Bdual%252Bphosphodiesterase%252B5%252B%252528PDE5%252529%252Band%252Bhistone%252Bdeacetylase%252B6%252B%252528HDAC6%252529-selective%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DRabal%26aufirst%3DObdulia%26date%3D2018%26volume%3D150%26spage%3D506%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuela  Basso</span>, <span class="hlFld-ContribAuthor ">Huan Huan  Chen</span>, <span class="hlFld-ContribAuthor ">Debasmita  Tripathy</span>, <span class="hlFld-ContribAuthor ">Mariarosaria  Conte</span>, <span class="hlFld-ContribAuthor ">Kim Y. P.  Apperley</span>, <span class="hlFld-ContribAuthor ">Angela  De Simone</span>, <span class="hlFld-ContribAuthor ">Jeffrey W.  Keillor</span>, <span class="hlFld-ContribAuthor ">Rajiv  Ratan</span>, <span class="hlFld-ContribAuthor ">Angela  Nebbioso</span>, <span class="hlFld-ContribAuthor ">Federica  Sarno</span>, <span class="hlFld-ContribAuthor ">Lucia  Altucci</span>, <span class="hlFld-ContribAuthor ">Andrea  Milelli</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (3)
                                     , 227-230. <a href="https://doi.org/10.1002/cmdc.201700601" title="DOI URL">https://doi.org/10.1002/cmdc.201700601</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700601%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesigning%252BDual%252BTransglutaminase%2525E2%252580%2525852%25252FHistone%252BDeacetylase%252BInhibitors%252BEffective%252Bat%252BHalting%252BNeuronal%252BDeath%26aulast%3DBasso%26aufirst%3DManuela%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D3%26spage%3D227%26epage%3D230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahima  Sharma</span>, <span class="hlFld-ContribAuthor ">Radha  Raghuraman</span>, <span class="hlFld-ContribAuthor ">Sreedharan  Sajikumar</span>. </span><span class="cited-content_cbyCitation_article-title">Epigenetics: the panacea for cognitive decline?. </span><span class="cited-content_cbyCitation_journal-name">Aging</span><span> <strong>2018,</strong> <em>10 </em>
                                    (1)
                                     , 1-2. <a href="https://doi.org/10.18632/aging.101366" title="DOI URL">https://doi.org/10.18632/aging.101366</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/aging.101366&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Faging.101366%26sid%3Dliteratum%253Aachs%26jtitle%3DAging%26atitle%3DEpigenetics%25253A%252Bthe%252Bpanacea%252Bfor%252Bcognitive%252Bdecline%25253F%26aulast%3DSharma%26aufirst%3DMahima%26date%3D2018%26date%3D2018%26volume%3D10%26issue%3D1%26spage%3D1%26epage%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srinivasulu  Cherukupalli</span>, <span class="hlFld-ContribAuthor ">Girish A.  Hampannavar</span>, <span class="hlFld-ContribAuthor ">Sampath  Chinnam</span>, <span class="hlFld-ContribAuthor ">Balakumar  Chandrasekaran</span>, <span class="hlFld-ContribAuthor ">Nisar  Sayyad</span>, <span class="hlFld-ContribAuthor ">Francis  Kayamba</span>, <span class="hlFld-ContribAuthor ">Rajeshwar  Reddy Aleti</span>, <span class="hlFld-ContribAuthor ">Rajshekhar  Karpoormath</span>. </span><span class="cited-content_cbyCitation_article-title">An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (2)
                                     , 309-339. <a href="https://doi.org/10.1016/j.bmc.2017.10.012" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.10.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.10.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.10.012%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DAn%252Bappraisal%252Bon%252Bsynthetic%252Band%252Bpharmaceutical%252Bperspectives%252Bof%252Bpyrazolo%25255B4%25252C3-d%25255Dpyrimidine%252Bscaffold%26aulast%3DCherukupalli%26aufirst%3DSrinivasulu%26date%3D2018%26volume%3D26%26issue%3D2%26spage%3D309%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xianfeng  Huang</span>, <span class="hlFld-ContribAuthor ">Peng  Xu</span>, <span class="hlFld-ContribAuthor ">Yijing  Cao</span>, <span class="hlFld-ContribAuthor ">Li  Liu</span>, <span class="hlFld-ContribAuthor ">Guoqiang  Song</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the binding mechanisms of PDE5 with chromeno[2,3-
              c
              ]pyrrol-9(2
              H
              )-one by theoretical approaches. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (53)
                                     , 30481-30490. <a href="https://doi.org/10.1039/C8RA06405A" title="DOI URL">https://doi.org/10.1039/C8RA06405A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA06405A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA06405A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DExploring%252Bthe%252Bbinding%252Bmechanisms%252Bof%252BPDE5%252Bwith%252Bchromeno%25255B2%25252C3-%252Bc%252B%25255Dpyrrol-9%2525282%252BH%252B%252529-one%252Bby%252Btheoretical%252Bapproaches%26aulast%3DHuang%26aufirst%3DXianfeng%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D53%26spage%3D30481%26epage%3D30490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nguyen Quoc  Thai</span>, <span class="hlFld-ContribAuthor ">Hoang Linh  Nguyen</span>, <span class="hlFld-ContribAuthor ">Huynh Quang  Linh</span>, <span class="hlFld-ContribAuthor ">Mai Suan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Protocol for fast screening of multi-target drug candidates: Application to Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2017,</strong> <em>77 </em>, 121-129. <a href="https://doi.org/10.1016/j.jmgm.2017.08.002" title="DOI URL">https://doi.org/10.1016/j.jmgm.2017.08.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2017.08.002%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DProtocol%252Bfor%252Bfast%252Bscreening%252Bof%252Bmulti-target%252Bdrug%252Bcandidates%25253A%252BApplication%252Bto%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DThai%26aufirst%3DNguyen%2BQuoc%26date%3D2017%26volume%3D77%26spage%3D121%26epage%3D129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Celorrio</span>, <span class="hlFld-ContribAuthor ">Estefanía  Rojo-Bustamante</span>, <span class="hlFld-ContribAuthor ">Diana  Fernández-Suárez</span>, <span class="hlFld-ContribAuthor ">Elena  Sáez</span>, <span class="hlFld-ContribAuthor ">Ander  Estella-Hermoso de Mendoza</span>, <span class="hlFld-ContribAuthor ">Christa E.  Müller</span>, <span class="hlFld-ContribAuthor ">María J.  Ramírez</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzábal</span>, <span class="hlFld-ContribAuthor ">Rafael  Franco</span>, <span class="hlFld-ContribAuthor ">María S.  Aymerich</span>. </span><span class="cited-content_cbyCitation_article-title">GPR55: A therapeutic target for Parkinson's disease?. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2017,</strong> <em>125 </em>, 319-332. <a href="https://doi.org/10.1016/j.neuropharm.2017.08.017" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2017.08.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2017.08.017%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DGPR55%25253A%252BA%252Btherapeutic%252Btarget%252Bfor%252BParkinson%252527s%252Bdisease%25253F%26aulast%3DCelorrio%26aufirst%3DMarta%26date%3D2017%26volume%3D125%26spage%3D319%26epage%3D332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li-yun  Zhou</span>, <span class="hlFld-ContribAuthor ">Yao  Zhu</span>, <span class="hlFld-ContribAuthor ">Yu-ren  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiong-jie  Zhao</span>, <span class="hlFld-ContribAuthor ">Dong  Guo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (17)
                                     , 4180-4184. <a href="https://doi.org/10.1016/j.bmcl.2017.07.013" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.07.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.07.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.07.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bdual%252Bacetylcholinesterase%252Band%252Bphosphodiesterase%252B5A%252Binhibitors%252Bin%252Btreatment%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DZhou%26aufirst%3DLi-yun%26date%3D2017%26volume%3D27%26issue%3D17%26spage%3D4180%26epage%3D4184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Grasso</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Santoro</span>, <span class="hlFld-ContribAuthor ">Valeria  Lanza</span>, <span class="hlFld-ContribAuthor ">Diego  Sbardella</span>, <span class="hlFld-ContribAuthor ">Grazia Raffaella  Tundo</span>, <span class="hlFld-ContribAuthor ">Chiara  Ciaccio</span>, <span class="hlFld-ContribAuthor ">Stefano  Marini</span>, <span class="hlFld-ContribAuthor ">Massimo  Coletta</span>, <span class="hlFld-ContribAuthor ">Danilo  Milardi</span>. </span><span class="cited-content_cbyCitation_article-title">The double faced role of copper in Aβ homeostasis: A survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration. </span><span class="cited-content_cbyCitation_journal-name">Coordination Chemistry Reviews</span><span> <strong>2017,</strong> <em>347 </em>, 1-22. <a href="https://doi.org/10.1016/j.ccr.2017.06.004" title="DOI URL">https://doi.org/10.1016/j.ccr.2017.06.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ccr.2017.06.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ccr.2017.06.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCoordination%2520Chemistry%2520Reviews%26atitle%3DThe%252Bdouble%252Bfaced%252Brole%252Bof%252Bcopper%252Bin%252BA%2525CE%2525B2%252Bhomeostasis%25253A%252BA%252Bsurvey%252Bon%252Bthe%252Binterrelationship%252Bbetween%252Bmetal%252Bdyshomeostasis%25252C%252BUPS%252Bfunctioning%252Band%252Bautophagy%252Bin%252Bneurodegeneration%26aulast%3DGrasso%26aufirst%3DGiuseppe%26date%3D2017%26volume%3D347%26spage%3D1%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mikel  Allende</span>, <span class="hlFld-ContribAuthor ">Eva  Molina</span>, <span class="hlFld-ContribAuthor ">Ramón  Lecumberri</span>, <span class="hlFld-ContribAuthor ">Juan  Sánchez-Arias</span>, <span class="hlFld-ContribAuthor ">Ana  Ugarte</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Guruceaga</span>, <span class="hlFld-ContribAuthor ">Julen  Oyarzabal</span>, <span class="hlFld-ContribAuthor ">José  Hermida</span>. </span><span class="cited-content_cbyCitation_article-title">Inducing heat shock protein 70 expression provides a robust anti-thrombotic effect with minimal bleeding risk. </span><span class="cited-content_cbyCitation_journal-name">Thrombosis and Haemostasis</span><span> <strong>2017,</strong> <em>117 </em>
                                    (09)
                                     , 1722-1729. <a href="https://doi.org/10.1160/TH17-02-0108" title="DOI URL">https://doi.org/10.1160/TH17-02-0108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1160/TH17-02-0108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1160%2FTH17-02-0108%26sid%3Dliteratum%253Aachs%26jtitle%3DThrombosis%2520and%2520Haemostasis%26atitle%3DInducing%252Bheat%252Bshock%252Bprotein%252B70%252Bexpression%252Bprovides%252Ba%252Brobust%252Banti-thrombotic%252Beffect%252Bwith%252Bminimal%252Bbleeding%252Brisk%26aulast%3DAllende%26aufirst%3DMikel%26date%3D2017%26date%3D2017%26volume%3D117%26issue%3D09%26spage%3D1722%26epage%3D1729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Chart 1. Known PDE5 Inhibitors Shown to Improve Memory (<b>1</b>, <b>2</b>, and <b>3</b>), HDAC Inhibitors (<b>4</b>, <b>5</b>, and <b>6</b>), and the Structure of a Novel Therapeutic Tool <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Chart a</span>PDE5 IC<sub>50</sub> inhibition values were taken from ref <a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">28</a> for <b>1</b>, <b>2</b>, and <b>3</b>. HDAC inhibition IC<sub>50</sub> values for <b>4</b> were extracted from ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">29</a>, values for <b>5</b> extracted from ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">30</a>, and values for <b>6</b> extracted from ref <a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">31</a>.</p></p></figure><figure data-id="fig1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Detection of AcH3K9 assayed using SH-SY5Y cells and AlphaLisa technology. SH-SY5Y cells were treated with <b>4</b> and <b>1</b> for 2 h (** <i>p</i> ≤ 0.01, ***<i>p</i> ≤ 0.001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0004.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Crystal structure of <b>1</b> in the PDE5 cavity (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TBF">1TBF</a><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>). The pyrazolopyrimidinone group of <b>1</b> makes bidentate H-bonds with the conserved Q817. The piperidinylsulfonamide group is solvent-oriented toward the H-loop region (residues 660–683). (B) Complex of <b>4</b> and HDAC2 (PDB entry <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>). The NH of the amide group of <b>4</b> makes an H-bond contact with the well-conserved residue Asp104 of HDAC2 (Asp99 for HDAC1 and Asp567 for HDAC6).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) ClSO<sub>3</sub>H, rt, 2 h; (ii) corresponding amine, Et<sub>3</sub>N (optional), EtOH, MW, 100 °C, 1–2 h; (iii) ethyl 3-bromopropanoate or ethyl 4-bromobutanoate, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, MW, 100 °C, 2 h; (iv) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (10:1:5), rt, overnight; (v) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (vi) HCl/1,4-dioxane (2.0 M), 1,4-dioxane or CH<sub>2</sub>Cl<sub>2</sub> (optional) rt, 3 h.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) H<sub>2</sub>SO<sub>4</sub>, KNO<sub>3</sub>, 0 °C, 20 min; (ii) Pd/C, H<sub>2</sub> (1 atm), MeOH, rt, overnight; (iii) corresponding carbonyl compound, AcOH, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (iv) 3,3-dimethoxypropanoate, TFA, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (v) paraformaldehyde, AcOH, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 60 °C, overnight; (vi) HCl/EtOAc (1.0 or 4.0 M), rt, 1–4 h; (vii) K<sub>2</sub>CO<sub>3</sub>, ethyl 2-chloropyrimidine-5-carboxylate, CH<sub>3</sub>CN, 40 °C, overnight; (viii) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2 or 3:1:1), 25–40 °C, overnight; (ix) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions (i) NIS, TFA, 0 °C, then rt, overnight; (ii) <i>t</i>-BuOK, Pd<sub>2</sub>(dba)<sub>3</sub>, 1,4-dioxa-8-azaspiro[4.5]decane, xantphos, toluene, 120 °C, MW, 1 h; (iii) HCl/THF (6.0 M), 70 °C, overnight; (iv) methyl 2-diethoxyphosphorylacetate, NaH, THF, 0 °C, 1 h, then <b>24</b>, rt, overnight; (v) Pd/C, MeOH, H<sub>2</sub> (1 atm), rt, 3 h; (vi) 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi-1,3,2-dioxaborolane, PdCl<sub>2</sub>(dppf), KOAc, 1,4-dioxane, 80–100 °C, 48 h; (vii) NaIO<sub>4</sub>, NH<sub>4</sub>OAc, acetone, 25 °C, 16 h; (viii) corresponding alcohol or amine, Cu(OAc)<sub>2</sub>, Et<sub>3</sub>N, DMAP (optional), 4 Å MS, CH<sub>2</sub>Cl<sub>2</sub>, O<sub>2</sub> (1 atm), rt, 2–12 h; (ix) HCl/EtOAc (1.0, 2.0, or 4.0 M), rt, 1–2 h; (x) K<sub>2</sub>CO<sub>3</sub>, ethyl 2-chloropyrimidine-5-carboxylate, CH<sub>3</sub>CN, 60 °C, overnight; (xi) LiOH·H<sub>2</sub>O, MeOH/THF/H<sub>2</sub>O (3:1:3, 1:3:1, 3:3:2), rt, overnight; (xii) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0009.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) NaOH (aq, 4.0 M), H<sub>2</sub>O<sub>2</sub>, H<sub>2</sub>O, rt, overnight; (ii) <i>tert</i>-butyl 4-hydroxypiperidine-1-carboxylate, PPh<sub>3</sub>, DEAD, toluene, 110 °C, 1 h; (iii) HCl/1,4-dioxane (4.0 M), rt, 1–2 h; (iv) ethyl 2-chloropyrimidine-5-carboxylate, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, rt, 3 h; (v) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (10:1:3), rt, overnight; (vi) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) Br<sub>2</sub>, AcOH, rt, overnight; (ii) Pd(dppf)Cl<sub>2</sub>, Et<sub>3</sub>N, EtOH, CO (atm), 80 °C, overnight; (iii) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:1:1), 40 °C, overnight; (iv) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (v) HCl/EtOAc (4.0 M), rt, 1 h.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 6. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) bromo-(2-ethoxy-2-oxo-ethyl)zinc, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, THF, 80 °C, overnight; (ii) corresponding borane reagent, xantphos, Na<sub>2</sub>CO<sub>3</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (10:1, 6:1 or 5:1), reflux, overnight; (iii) HCl/EtOAc (0.2, 1.0, 2.0, or 4.0 M), 0–25 °C, 1–3 h; (iv) corresponding chloride, K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, 40–100 °C, overnight; (v) CAN, ethyl prop-2-enoate, DIEA, 80 °C, overnight; (vi) (4-methoxycarbonylphenyl)boronic acid, Cu(OAc)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, O<sub>2</sub> (1 atm), rt, overnight; (vii) ethyl acrylate, POT, Et<sub>3</sub>N, DMF, 100 °C, overnight; (viii) Pd/C, H<sub>2</sub> (1 atm), MeOH, rt, overnight; (ix) <i>n</i>-BuLi, THF, −70 °C, 10 min, then −40 °C, 1 h, then ethyl 2-formylcyclopropanecarboxylate, rt, 15 h; (x) TFA, Et<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then rt, 10 h; (xi) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 80 °C, overnight; (xii) DIBAL-H, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, then rt, overnight; (xiii) <i>tert</i>-butyl piperazine-1-carboxylate, Ti[OCH(CH<sub>3</sub>)<sub>2</sub>]<sub>4</sub>, toluene, rt, 90 min, then NaBH(OAc)<sub>3</sub>, rt, overnight; (xiv) corresponding amine, AcOH, NaBH(OAc)<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight; (xv) ethyl 2-diethoxyphosphorylacetate, NaH, THF, 0 °C, 1 h, then <b>45</b>, rt, overnight; (xvi) trimethyloxosulfonium iodide, NaH, DMSO, 40 °C, 12 h; (xvii) LiOH·H<sub>2</sub>O, MeOH/THF/H<sub>2</sub>O (1:3:1 or 3:3:2), rt or 40 °C, overnight; (xviii) <i>n</i>-BuLi, THF, −70 °C, then −40 °C, 1 h, then <i>tert</i>-butyl 3-oxocyclobutanecarboxylate, rt, 15 h; (xix) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (xx) BOP, DIEA, NH<sub>2</sub>OH·HCl, DMF, 80 °C, overnight; (xxi) SFC separation.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0012.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 7. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (i) corresponding bromide, chloride or triflate, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (5:2) or 1,4-dioxane, 85 °C, MW, 1 h, or conventional heating, 80 °C, overnight; (ii) Pd/C, H<sub>2</sub> (1 atm), MeOH, rt, 1 h; (iii) LiOH·H<sub>2</sub>O, THF/MeOH/H<sub>2</sub>O (3:3:2 or 3:1:1), rt, overnight; (iv) EDC·HCl, HOBt, THPONH<sub>2</sub>, NMM, DMF, rt, overnight; (v) HCl/EtOAc (2.0 or 4.0 M) or HCl/1,4-dioxane (4.0 M), rt, 1 h.</p></p></figure><figure data-id="fig3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/medium/jm-2016-009085_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0005.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Description of the proposed binding modes, represented by the selected chemical probe <b>7</b>, and key interacting features according to each target binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-19/acs.jmedchem.6b00908/20161007/images/large/jm-2016-009085_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00908&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i226">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50701" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50701" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 54 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Zheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridkin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youdim, M.</span><span> </span><span class="NLM_article-title">New Approaches to Treating Alzheimer’s Disease</span> <span class="citation_source-journal">Perspect. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">8</span><span class="refDoi"> DOI: 10.4137/PMC.S13210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.4137%2FPMC.S13210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25733799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BC2MngsF2ntA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=1-8&author=H.+Zhengauthor=M.+Fridkinauthor=M.+Youdim&title=New+Approaches+to+Treating+Alzheimer%E2%80%99s+Disease&doi=10.4137%2FPMC.S13210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">New approaches to treating Alzheimer's disease</span></div><div class="casAuthors">Zheng Hailin; Fridkin Mati; Youdim Moussa</div><div class="citationInfo"><span class="NLM_cas:title">Perspectives in medicinal chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">To date, no truly efficacious drugs for Alzheimer's disease (AD) have been developed; moreover, all new anti-AD drugs developed since 2003 have failed.  To succeed where previous ones have failed in drug development, new approaches for AD therapy are needed.  Here we discuss the potential application of network medicine as a new approach to AD treatment.  Unlike traditional approaches focused on a single target/pathway, network medicine targets and restores disease-disrupted networks through simultaneous modulation of numerous proteins (targets)/pathways involved in AD pathogenesis.  We consider several drug candidates under development for AD therapy, including Keap1-Nrf2 regulators, endogenous neurogenic agents, and hypoxia-inducible factor 1 (HIF-1) activators.  These drug candidates are multi-target ligands with the potential to further develop as network medicines, since they act as master regulators to initiate a broad range of cellular defense mechanisms/cytoprotective genes that exert their efficacy in a holistic way.  We also explore their diverse mechanisms of action and potential disease-modifying effects, which may have profound implications for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ124YrbIuB24YPsCkJIw00fW6udTcc2eaXgul65Weof7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MngsF2ntA%253D%253D&md5=d6641b1444233a80e69dfe0c74515da0</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.4137%2FPMC.S13210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FPMC.S13210%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DFridkin%26aufirst%3DM.%26aulast%3DYoudim%26aufirst%3DM.%26atitle%3DNew%2520Approaches%2520to%2520Treating%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DPerspect.%2520Med.%2520Chem.%26date%3D2015%26volume%3D7%26spage%3D1%26epage%3D8%26doi%3D10.4137%2FPMC.S13210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzábal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Phosphodiesterases as Therapeutic Targets for Alzheimer’s Disease</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">832</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1021/cn3000907</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn3000907" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=832-844&author=A.+Garc%C3%ADa-Ostaauthor=M.+Cuadrado-Tejedorauthor=C.+Garc%C3%ADa-Barrosoauthor=J.+Oyarz%C3%A1balauthor=R.+Franco&title=Phosphodiesterases+as+Therapeutic+Targets+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Fcn3000907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterases as Therapeutic Targets for Alzheimer's Disease</span></div><div class="casAuthors">Garcia-Osta, Ana; Cuadrado-Tejedor, Mar; Garcia-Barroso, Carolina; Oyarzabal, Julen; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">832-844</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is the most common form of dementia among the elderly.  In AD patients, memory loss is accompanied by the formation of beta-amyloid plaques and the appearance of tau in a pathol. form.  Given the lack of effective treatments for AD, the development of new management strategies for these patients is crit.  The continued failure to find effective therapies using mols. aimed at addressing the anti-beta amyloid pathol. has led researchers to focus on other non-amyloid-based approaches to restore memory function.  Promising non-amyloid related candidate targets include phosphosdiesterases (PDEs), and indeed, Rolipram, a specific PDE4 inhibitor, was the first compd. found to effectively restore cognitive deficits in animal models of AD.  More recently, PDE5 inhibitors have also been shown to effectively restore memory function.  Accordingly, inhibitors of other members of the PDE family may also improve memory performance in AD and non-AD animal models.  Hence, in this review, we will summarize the data supporting the use of PDE inhibitors as cognitive enhancers and we will discuss the possible mechanisms of action underlying these effects.  We shall also adopt a medicinal chem. perspective that leads us to propose the most promising PDE candidates on the basis of inhibitor selectivity, brain distribution, and mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppeOP4NskdvrVg90H21EOLACvtfcHk0liorD3T4WMAmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejs7nK&md5=53c6dfed22bb240b17132672b13fdcf1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fcn3000907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn3000907%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DOyarz%25C3%25A1bal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPhosphodiesterases%2520as%2520Therapeutic%2520Targets%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2012%26volume%3D3%26spage%3D832%26epage%3D844%26doi%3D10.1021%2Fcn3000907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Epigenetic Drugs in Alzheimer’s Disease</span> <span class="citation_source-journal">Biomol. Concepts</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">445</span><span class="refDoi"> DOI: 10.1515/bmc-2013-0012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1515%2Fbmc-2013-0012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25436752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVWltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=433-445&author=M.+Cuadrado-Tejedorauthor=J.+Oyarzabalauthor=M.+P.+Lucasauthor=R.+Francoauthor=A.+Garc%C3%ADa-Osta&title=Epigenetic+Drugs+in+Alzheimer%E2%80%99s+Disease&doi=10.1515%2Fbmc-2013-0012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetic drugs in Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, Mar; Oyarzabal, Julen; Lucas, Maria Pascual; Franco, Rafael; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Biomolecular Concepts</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">433-445</span>CODEN:
                <span class="NLM_cas:coden">BCIOB8</span>;
        ISSN:<span class="NLM_cas:issn">1868-5021</span>.
    
            (<span class="NLM_cas:orgname">Walter de Gruyter GmbH</span>)
        </div><div class="casAbstract">A review.  Epigenetic processes, such as DNA methylation and histone acetylation, regulate the genome-environment interactions that may play important roles in a wide range of brain disorders, including Alzheimer's disease (AD).  Indeed, the role of epigenetic machinery in learning and memory processes is well documented.  In this review, we will focus on the most recent literature on tools that target epigenetic mechanisms, particularly on histone acetylation, and we will discuss the use of chem. probes to validate these targets in therapeutic strategies for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0IfwPOTWKkbVg90H21EOLACvtfcHk0lhbv9CxhDyuvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVWltrw%253D&md5=8e337544ac4fbd673b7086254fc07fb1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1515%2Fbmc-2013-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252Fbmc-2013-0012%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DM.%2BP.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DEpigenetic%2520Drugs%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBiomol.%2520Concepts%26date%3D2013%26volume%3D4%26spage%3D433%26epage%3D445%26doi%3D10.1515%2Fbmc-2013-0012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Gräff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">The Potential of HDAC Inhibitors as Cognitive Enhancers</span> <span class="citation_source-journal">Annu. Rev. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span><span class="refDoi"> DOI: 10.1146/annurev-pharmtox-011112-140216</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1146%2Fannurev-pharmtox-011112-140216" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2013&pages=311-330&author=J.+Gr%C3%A4ffauthor=L.-H.+Tsai&title=The+Potential+of+HDAC+Inhibitors+as+Cognitive+Enhancers&doi=10.1146%2Fannurev-pharmtox-011112-140216"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-011112-140216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-011112-140216%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A4ff%26aufirst%3DJ.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DThe%2520Potential%2520of%2520HDAC%2520Inhibitors%2520as%2520Cognitive%2520Enhancers%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2013%26volume%3D53%26spage%3D311%26epage%3D330%26doi%3D10.1146%2Fannurev-pharmtox-011112-140216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Benito, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urbanke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramachandran, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halder, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Awasthi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capece, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhardt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navarro-Sala, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagarajan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schütz, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnsen, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lührmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, A.</span><span> </span><span class="NLM_article-title">HDAC Inhibitor-Dependent Transcriptome and Memory Reinstatement in Cognitive Decline Models</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">3572</span><span class="NLM_x">–</span> <span class="NLM_lpage">3584</span><span class="refDoi"> DOI: 10.1172/JCI79942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1172%2FJCI79942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26280576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=3572-3584&author=E.+Benitoauthor=H.+Urbankeauthor=B.+Ramachandranauthor=J.+Barthauthor=R.+Halderauthor=A.+Awasthiauthor=G.+Jainauthor=V.+Capeceauthor=S.+Burkhardtauthor=M.+Navarro-Salaauthor=S.+Nagarajanauthor=A.-L.+Sch%C3%BCtzauthor=S.+A.+Johnsenauthor=S.+Bonnauthor=R.+L%C3%BChrmannauthor=C.+Deanauthor=A.+Fischer&title=HDAC+Inhibitor-Dependent+Transcriptome+and+Memory+Reinstatement+in+Cognitive+Decline+Models&doi=10.1172%2FJCI79942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models</span></div><div class="casAuthors">Benito Eva; Urbanke Hendrik; Ramachandran Binu; Barth Jonas; Halder Rashi; Awasthi Ankit; Jain Gaurav; Capece Vincenzo; Burkhardt Susanne; Navarro-Sala Magdalena; Nagarajan Sankari; Schutz Anna-Lena; Johnsen Steven A; Bonn Stefan; Luhrmann Reinhardt; Dean Camin; Fischer Andre</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3572-84</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aging and increased amyloid burden are major risk factors for cognitive diseases such as Alzheimer's disease (AD).  Effective therapies for these diseases are lacking.  Here, we evaluated mouse models of age-associated memory impairment and amyloid deposition to study transcriptome and cell type-specific epigenome plasticity in the brain and peripheral organs.  We determined that aging and amyloid pathology are associated with inflammation and impaired synaptic function in the hippocampal CA1 region as the result of epigenetic-dependent alterations in gene expression.  In both amyloid and aging models, inflammation was associated with increased gene expression linked to a subset of transcription factors, while plasticity gene deregulation was differentially mediated.  Amyloid pathology impaired histone acetylation and decreased expression of plasticity genes, while aging altered H4K12 acetylation-linked differential splicing at the intron-exon junction in neurons, but not nonneuronal cells.  Furthermore, oral administration of the clinically approved histone deacetylase inhibitor vorinostat not only restored spatial memory, but also exerted antiinflammatory action and reinstated epigenetic balance and transcriptional homeostasis at the level of gene expression and exon usage.  This study provides a systems-level investigation of transcriptome plasticity in the hippocampal CA1 region in aging and AD models and suggests that histone deacetylase inhibitors should be further explored as a cost-effective therapeutic strategy against age-associated cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTaDMtpB5WPpwyMywPm6HgQfW6udTcc2ebAH66MNTcM1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC287js12iuw%253D%253D&md5=e30caf3ba1aaddf0a149c514d23640b8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1172%2FJCI79942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI79942%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DE.%26aulast%3DUrbanke%26aufirst%3DH.%26aulast%3DRamachandran%26aufirst%3DB.%26aulast%3DBarth%26aufirst%3DJ.%26aulast%3DHalder%26aufirst%3DR.%26aulast%3DAwasthi%26aufirst%3DA.%26aulast%3DJain%26aufirst%3DG.%26aulast%3DCapece%26aufirst%3DV.%26aulast%3DBurkhardt%26aufirst%3DS.%26aulast%3DNavarro-Sala%26aufirst%3DM.%26aulast%3DNagarajan%26aufirst%3DS.%26aulast%3DSch%25C3%25BCtz%26aufirst%3DA.-L.%26aulast%3DJohnsen%26aufirst%3DS.%2BA.%26aulast%3DBonn%26aufirst%3DS.%26aulast%3DL%25C3%25BChrmann%26aufirst%3DR.%26aulast%3DDean%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DA.%26atitle%3DHDAC%2520Inhibitor-Dependent%2520Transcriptome%2520and%2520Memory%2520Reinstatement%2520in%2520Cognitive%2520Decline%2520Models%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2015%26volume%3D125%26spage%3D3572%26epage%3D3584%26doi%3D10.1172%2FJCI79942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kilgore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fass, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennig, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweatt, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rumbaugh, G.</span><span> </span><span class="NLM_article-title">Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">870</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span><span class="refDoi"> DOI: 10.1038/npp.2009.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnpp.2009.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=20010553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhslOisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2010&pages=870-880&author=M.+Kilgoreauthor=C.+A.+Millerauthor=D.+M.+Fassauthor=K.+M.+Hennigauthor=S.+J.+Haggartyauthor=J.+D.+Sweattauthor=G.+Rumbaugh&title=Inhibitors+of+Class+1+Histone+Deacetylases+Reverse+Contextual+Memory+Deficits+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1038%2Fnpp.2009.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Kilgore, Mark; Miller, Courtney A.; Fass, Daniel M.; Hennig, Krista M.; Haggarty, Stephen J.; Sweatt, J. David; Rumbaugh, Gavin</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">870-880</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative disorder characterized clin. by cognitive impairments that progress to dementia and death.  The earliest symptoms of AD present as a relatively pure deficit in memory retrieval.  Therefore, drug treatments that intervene in the early stages of AD by rescuing memory deficits could be promising therapies to slow, or even reverse progression of the disease.  In this study, we tested the potential of systemic histone deacetylase inhibitor (HDACi) treatment to rescue cognitive deficits in a mouse model of AD.  APPswe/PS1dE9 mice showed pronounced contextual memory impairments beginning at 6 mo of age.  Chronic HDACi injections (2-3 wk) did not alter contextual memory formation in normal mice, but had profound effects in transgenic animals.  Injections of sodium valproate, sodium butyrate, or vorinostat (suberoylanilide hydroxamic acid; Zolinza) completely restored contextual memory in these mutant mice.  Further behavioral testing of the HDACi-treated transgenic mice showed that the newly consolidated memories were stably maintained over a 2-wk period.  Measurement of the HDAC isoform selectivity profile of sodium valproate, sodium butyrate, and vorinostat revealed the common inhibition of class I HDACs (HDAC1, 2, 3, 8) with little effect on the class IIa HDAC family members (HDAC4, 5, 7, 9) and inhibition of HDAC6 only by vorinostat.  These preclin. results indicate that targeted inhibition of class I HDAC isoforms is a promising avenue for treating the cognitive deficits assocd. with early stage AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRmqbpy-Ssz7Vg90H21EOLACvtfcHk0lgdsrfW9NrPsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhslOisrk%253D&md5=d1054975a9a53f305d1ea257b92a62ec</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2009.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2009.197%26sid%3Dliteratum%253Aachs%26aulast%3DKilgore%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DC.%2BA.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DSweatt%26aufirst%3DJ.%2BD.%26aulast%3DRumbaugh%26aufirst%3DG.%26atitle%3DInhibitors%2520of%2520Class%25201%2520Histone%2520Deacetylases%2520Reverse%2520Contextual%2520Memory%2520Deficits%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeuropsychopharmacology%26date%3D2010%26volume%3D35%26spage%3D870%26epage%3D880%26doi%3D10.1038%2Fnpp.2009.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Maurice, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manganiello, V. C.</span><span> </span><span class="NLM_article-title">Advances in Targeting Cyclic Nucleotide Phosphodiesterases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">–</span> <span class="NLM_lpage">314</span><span class="refDoi"> DOI: 10.1038/nrd4228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnrd4228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24687066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=290-314&author=D.+H.+Mauriceauthor=H.+Keauthor=F.+Ahmadauthor=Y.+Wangauthor=J.+Chungauthor=V.+C.+Manganiello&title=Advances+in+Targeting+Cyclic+Nucleotide+Phosphodiesterases&doi=10.1038%2Fnrd4228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in targeting cyclic nucleotide phosphodiesterases</span></div><div class="casAuthors">Maurice, Donald H.; Ke, Hengming; Ahmad, Faiyaz; Wang, Yousheng; Chung, Jay; Manganiello, Vincent C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">290-314</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cyclic nucleotide phosphodiesterases (PDEs) catalyze the hydrolysis of cAMP and cyclic GMP, thereby regulating the intracellular concns. of these cyclic nucleotides, their signalling pathways and, consequently, myriad biol. responses in health and disease.  Currently, a small no. of PDE inhibitors are used clin. for treating the pathophysiol. dysregulation of cyclic nucleotide signalling in several disorders, including erectile dysfunction, pulmonary hypertension, acute refractory cardiac failure, intermittent claudication and chronic obstructive pulmonary disease.  However, pharmaceutical interest in PDEs has been reignited by the increasing understanding of the roles of individual PDEs in regulating the subcellular compartmentalization of specific cyclic nucleotide signalling pathways, by the structure-based design of novel specific inhibitors and by the development of more sophisticated strategies to target individual PDE variants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwMRfUs-zUmLVg90H21EOLACvtfcHk0lgdsrfW9NrPsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltFOiu7s%253D&md5=410c8d5bb5fbd7d2906e30dc1b5f2876</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd4228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4228%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DD.%2BH.%26aulast%3DKe%26aufirst%3DH.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DChung%26aufirst%3DJ.%26aulast%3DManganiello%26aufirst%3DV.%2BC.%26atitle%3DAdvances%2520in%2520Targeting%2520Cyclic%2520Nucleotide%2520Phosphodiesterases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D290%26epage%3D314%26doi%3D10.1038%2Fnrd4228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil-Bea, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cedazo-Minguez, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramírez, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span> </span><span class="NLM_article-title">Decreased Levels of Guanosine 3′, 5′-monophosphate (cGMP) in Cerebrospinal Fluid (CSF) Are Associated with Cognitive Decline and Amyloid Pathology in Alzheimer’s Disease</span> <span class="citation_source-journal">Neuropathol. Appl. Neurobiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">482</span><span class="refDoi"> DOI: 10.1111/nan.12203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fnan.12203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25488891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2015&pages=471-482&author=A.+Ugarteauthor=F.+Gil-Beaauthor=C.+Garc%C3%ADa-Barrosoauthor=%C3%81.+Cedazo-Minguezauthor=M.+J.+Ram%C3%ADrezauthor=R.+Francoauthor=A.+Garc%C3%ADa-Ostaauthor=J.+Oyarzabalauthor=M.+Cuadrado-Tejedor&title=Decreased+Levels+of+Guanosine+3%E2%80%B2%2C+5%E2%80%B2-monophosphate+%28cGMP%29+in+Cerebrospinal+Fluid+%28CSF%29+Are+Associated+with+Cognitive+Decline+and+Amyloid+Pathology+in+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fnan.12203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease</span></div><div class="casAuthors">Ugarte, Ana; Gil-Bea, Francisco; Garcia-Barroso, Carolina; Cedazo-Minguez, Angel; Ramirez, M. Javier; Franco, Rafael; Garcia-Osta, Ana; Oyarzabal, Julen; Cuadrado-Tejedor, Mar</div><div class="citationInfo"><span class="NLM_cas:title">Neuropathology and Applied Neurobiology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">471-482</span>CODEN:
                <span class="NLM_cas:coden">NANEDL</span>;
        ISSN:<span class="NLM_cas:issn">0305-1846</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aims : Levels of the cyclic nucleotides guanosine 3', 5'-monophosphate (cGMP) or adenosine 3', 5'-monophosphate (cAMP) that play important roles in memory processes are not characterized in Alzheimer's disease (AD).  The aim of this study was to analyze the levels of these nucleotides in cerebrospinal fluid (CSF) samples from patients diagnosed with clin. and prodromal stages of AD and study the expression level of the enzymes that hydrolyzed them [phosphodiesterases (PDEs)] in the brain of AD patients vs. controls.  Methods : For cGMP and cAMP CSF anal., the cohort (n = 79) included cognitively normal participants (subjective cognitive impairment), individuals with stable mild cognitive impairment or AD converters (sMCI and cMCI), and mild AD patients.  A high throughput liq. chromatog.-tandem mass spectrometry method was used.  Interactions between CSF cGMP or cAMP with mini-mental state examn. (MMSE) score, CSF Aβ(1-42) and CSF p-tau were analyzed.  For PDE4, 5, 9 and 10 expression anal., brains of AD patients vs. controls (n = 7 and n = 8) were used.  Results : cGMP, and not cAMP levels, were significantly lower in the CSF of patients diagnosed with mild AD when compared with nondemented controls.  CSF levels of cGMP showed a significant assocn. with MMSE-diagnosed clin. dementia and with CSF biomarker Aβ42 in AD patients.  Significant increase in PDE5 expression was detected in temporal cortex of AD patients compared with that of age-matched healthy control subjects.  No changes in the expression of others PDEs were detected.  Conclusions : These results support the potential involvement of cGMP in the pathol. and clin. development of AD.  The cGMP redn. in early stages of AD might participate in the aggravation of amyloid pathol. and cognitive decline.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDfphh1a73krVg90H21EOLACvtfcHk0lgdsrfW9NrPsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlCgs7s%253D&md5=4aabb42e396d12b9a74e64bd42abb064</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1111%2Fnan.12203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fnan.12203%26sid%3Dliteratum%253Aachs%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DGil-Bea%26aufirst%3DF.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DCedazo-Minguez%26aufirst%3D%25C3%2581.%26aulast%3DRam%25C3%25ADrez%26aufirst%3DM.%2BJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26atitle%3DDecreased%2520Levels%2520of%2520Guanosine%25203%25E2%2580%25B2%252C%25205%25E2%2580%25B2-monophosphate%2520%2528cGMP%2529%2520in%2520Cerebrospinal%2520Fluid%2520%2528CSF%2529%2520Are%2520Associated%2520with%2520Cognitive%2520Decline%2520and%2520Amyloid%2520Pathology%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DNeuropathol.%2520Appl.%2520Neurobiol.%26date%3D2015%26volume%3D41%26spage%3D471%26epage%3D482%26doi%3D10.1111%2Fnan.12203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hervias, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puerta, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Roldán, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Sildenafil Restores Cognitive Function without Affecting β-Amyloid Burden in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">164</span><span class="NLM_x">, </span> <span class="NLM_fpage">2029</span><span class="NLM_x">–</span> <span class="NLM_lpage">2041</span><span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01517.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fj.1476-5381.2011.01517.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=21627640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=2029-2041&author=M.+Cuadrado-Tejedorauthor=I.+Herviasauthor=A.+Ricobarazaauthor=E.+Puertaauthor=J.+M.+P%C3%A9rez-Rold%C3%A1nauthor=C.+Garc%C3%ADa-Barrosoauthor=R.+Francoauthor=N.+Aguirreauthor=A.+Garc%C3%ADa-Osta&title=Sildenafil+Restores+Cognitive+Function+without+Affecting+%CE%B2-Amyloid+Burden+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fj.1476-5381.2011.01517.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Sildenafil restores cognitive function without affecting β-amyloid burden in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, M.; Hervias, I.; Ricobaraza, A.; Puerta, E.; Perez-Roldan, J. M.; Garcia-Barroso, C.; Franco, R.; Aguirre, N.; Garcia-Osta, A.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2029-2041</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Inhibitors of phosphodiesterase 5 (PDE5) affect signalling pathways by elevating cGMP, which is a second messenger involved in processes of neuroplasticity.  In the present study, the effects of the PDE5 inhibitor, sildenafil, on the pathol. features of Alzheimer's disease and on memory-related behavior were investigated.  Exptl. Approach Sildenafil was administered to the Tg2576 transgenic mouse model of Alzheimer's disease and to age-matched neg. littermates (controls).  Memory function was analyzed using the Morris water maze test and fear conditioning tasks.  Biochem. analyses were performed in brain lysates from animals treated with saline or with sildenafil.  Key Results Treatment of aged Tg2576 animals with sildenafil completely reversed their cognitive impairment.  Such changes were accompanied in the hippocampus by a redn. of tau hyperphosphorylation and a decrease in the activity of glycogen synthase kinase 3β (GSK3β) and of cyclin-dependent kinase 5 (CDK5) (p25/p35 ratio).  Moreover, sildenafil also increased levels of brain-derived neurotrophic factor (BDNF) and the activity-regulated cytoskeletal-assocd. protein (Arc) in the hippocampus without any detectable modification of brain amyloid burden.  Conclusions and Implications Sildenafil improved cognitive functions in Tg2576 mice and the effect was not related to changes in the amyloid burden.  These data further strengthen the potential of sildenafil as a therapeutic agent for Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSIHZg2HFLZbVg90H21EOLACvtfcHk0ljZt0Q5eg9MeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFyqsL3F&md5=5bda5d02186b430428a2d7ce8c354696</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01517.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01517.x%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DHervias%26aufirst%3DI.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DPuerta%26aufirst%3DE.%26aulast%3DP%25C3%25A9rez-Rold%25C3%25A1n%26aufirst%3DJ.%2BM.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DAguirre%26aufirst%3DN.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DSildenafil%2520Restores%2520Cognitive%2520Function%2520without%2520Affecting%2520%25CE%25B2-Amyloid%2520Burden%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D164%26spage%3D2029%26epage%3D2041%26doi%3D10.1111%2Fj.1476-5381.2011.01517.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unceta, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rico, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goicolea, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sallés, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Tadalafil Crosses the Blood-Brain Barrier and Reverses Cognitive Dysfunction in a Mouse Model of AD</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">114</span><span class="NLM_x">–</span> <span class="NLM_lpage">123</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.06.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.neuropharm.2012.06.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22776546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=114-123&author=C.+Garc%C3%ADa-Barrosoauthor=A.+Ricobarazaauthor=M.+Pascual-Lucasauthor=N.+Uncetaauthor=A.+J.+Ricoauthor=M.+A.+Goicoleaauthor=J.+Sall%C3%A9sauthor=J.+L.+Lanciegoauthor=J.+Oyarzabalauthor=R.+Francoauthor=M.+Cuadrado-Tejedorauthor=A.+Garc%C3%ADa-Osta&title=Tadalafil+Crosses+the+Blood-Brain+Barrier+and+Reverses+Cognitive+Dysfunction+in+a+Mouse+Model+of+AD&doi=10.1016%2Fj.neuropharm.2012.06.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD</span></div><div class="casAuthors">Garcia-Barroso, Carolina; Ricobaraza, Ana; Pascual-Lucas, Maria; Unceta, Nora; Rico, Alberto J.; Goicolea, Maria Aranzazu; Salles, Joan; Lanciego, Jose Luis; Oyarzabal, Julen; Franco, Rafael; Cuadrado-Tejedor, Mar; Garcia-Osta, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">114-123</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Previous studies have demonstrated that cognitive function can be restored in mouse models of Alzheimer's disease (AD) following administration of sildenafil, a specific PDE5 inhibitor (Puzzo et al., 2009; Cuadrado-Tejedor et al.).  Another very potent PDE5 inhibitor with a longer half-life and safe in chronic treatments, tadalafil, may represent a better alternative candidate for AD therapy.  However, tadalafil was proven unable to achieve similar benefits than those of sildenafil in AD animal models (Puzzo et al., 2009).  The lack of efficacy was attributed to inability to cross the blood-brain barrier (BBB).  In this paper we first measured the blood and brain levels of tadalafil to prove that the compd. crosses BBB and that chronic treatment leads to accumulation in the brain of the J20 transgenic mouse model of AD.  We demonstrated the presence of PDE5 mRNA in the brain of the mice and also in the human brain.  After a 10 wk treatment with either of these PDE5 inhibitors, the performance of the J20 mice in the Morris water maze test improved when compared with the transgenic mice that received vehicle.  Biochem. anal. revealed that neither sildenafil nor tadalafil altered the amyloid burden, although both compds. reduced Tau phosphorylation in the mouse hippocampus.  This study provides evidence of the potential benefits of a chronic tadalafil treatment in AD therapy.This article is part of a Special Issue entitled 'Cognitive Enhancers'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfkrxYqIGt7LVg90H21EOLACvtfcHk0ljZt0Q5eg9MeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtV2nu77O&md5=aafb7dacec3ffd9d8ef4abc38c08e0f6</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.06.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.06.052%26sid%3Dliteratum%253Aachs%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DPascual-Lucas%26aufirst%3DM.%26aulast%3DUnceta%26aufirst%3DN.%26aulast%3DRico%26aufirst%3DA.%2BJ.%26aulast%3DGoicolea%26aufirst%3DM.%2BA.%26aulast%3DSall%25C3%25A9s%26aufirst%3DJ.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DTadalafil%2520Crosses%2520the%2520Blood-Brain%2520Barrier%2520and%2520Reverses%2520Cognitive%2520Dysfunction%2520in%2520a%2520Mouse%2520Model%2520of%2520AD%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D64%26spage%3D114%26epage%3D123%26doi%3D10.1016%2Fj.neuropharm.2012.06.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Reneerkens, O. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutten, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akkerman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blokland, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menniti, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinbusch, H. W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prickaerts, J.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Type 5 (PDE5) Inhibition Improves Object Recognition Memory: Indications for Central and Peripheral Mechanisms</span> <span class="citation_source-journal">Neurobiol. Learn. Mem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">–</span> <span class="NLM_lpage">379</span><span class="refDoi"> DOI: 10.1016/j.nlm.2012.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.nlm.2012.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22426465" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt12lt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=370-379&author=O.+A.+H.+Reneerkensauthor=K.+Ruttenauthor=S.+Akkermanauthor=A.+Bloklandauthor=C.+L.+Shafferauthor=F.+S.+Mennitiauthor=H.+W.+M.+Steinbuschauthor=J.+Prickaerts&title=Phosphodiesterase+Type+5+%28PDE5%29+Inhibition+Improves+Object+Recognition+Memory%3A+Indications+for+Central+and+Peripheral+Mechanisms&doi=10.1016%2Fj.nlm.2012.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms</span></div><div class="casAuthors">Reneerkens, Olga A. H.; Rutten, Kris; Akkerman, Sven; Blokland, Arjan; Shaffer, Christopher L.; Menniti, Frank S.; Steinbusch, Harry W. M.; Prickaerts, Jos</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Learning and Memory</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">370-379</span>CODEN:
                <span class="NLM_cas:coden">NLMEFR</span>;
        ISSN:<span class="NLM_cas:issn">1074-7427</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A promising target for memory improvement is phosphodiesterase type 5 (PDE5), which selectively hydrolyzes cyclic guanosine monophosphate (cGMP).  In rodents, PDE5 inhibitors (PDE5-Is) have been shown to improve memory performance in many behavioral paradigms.  However, it is questioned whether the pos. effects in animal studies result from PDE5 inhibition in the central nervous system or the periphery.  Therefore, we studied the effects of PDE5 inhibition on memory and detd. whether compd. penetration of the blood-brain barrier (BBB) is required for this activity.  Two selective PDE5-Is, vardenafil and UK-343,664, were tested in the object recognition task (ORT) in both a MK-801- and scopolamine-induced memory deficit model, and a time-delay model without pharmacol. intervention.  Compds. were dosed 30 min before the learning trial of the task.  To det. if the PDE5-Is crossed the BBB, their concns. were detd. in plasma and brain tissue collected 30 min after oral administration.  Vardenafil improved object recognition memory in all three variants of the ORT.  UK-343,664 was ineffective at either preventing MK-801-induced memory disruption or time-dependent memory decay.  However, UK-343,664 attenuated the memory impairment of scopolamine.  Vardenafil crossed the BBB whereas UK-343,664 did not.  Further, co-administration of UK-343,664 and scopolamine did not alter the brain partitioning of either mol.  This suggests that the pos. effect of UK-343,664 on scopolamine-induced memory decay might arise from peripheral PDE5 inhibition.  The results herein suggest that there may be multiple mechanisms that mediate the efficacy of PDE5 inhibition to improve memory performance in tasks such as the ORT and that these involve PDE5 located both within and outside of the brain.  To further elucidate the underlying mechanisms, the cellular and subcellular localization of PDE5 needs to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBHK-AKR-M6bVg90H21EOLACvtfcHk0lipkag4vw3Xpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt12lt7s%253D&md5=b57ecbaeb7529e71b4edc10aa2f78956</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.nlm.2012.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nlm.2012.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DReneerkens%26aufirst%3DO.%2BA.%2BH.%26aulast%3DRutten%26aufirst%3DK.%26aulast%3DAkkerman%26aufirst%3DS.%26aulast%3DBlokland%26aufirst%3DA.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DMenniti%26aufirst%3DF.%2BS.%26aulast%3DSteinbusch%26aufirst%3DH.%2BW.%2BM.%26aulast%3DPrickaerts%26aufirst%3DJ.%26atitle%3DPhosphodiesterase%2520Type%25205%2520%2528PDE5%2529%2520Inhibition%2520Improves%2520Object%2520Recognition%2520Memory%253A%2520Indications%2520for%2520Central%2520and%2520Peripheral%2520Mechanisms%26jtitle%3DNeurobiol.%2520Learn.%2520Mem.%26date%3D2012%26volume%3D97%26spage%3D370%26epage%3D379%26doi%3D10.1016%2Fj.nlm.2012.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Falkenberg, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">673</span><span class="NLM_x">–</span> <span class="NLM_lpage">691</span><span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lipkag4vw3Xpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Guan, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacometti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dannenberg, J.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieland, T. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePinho, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenisch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">HDAC2 Negatively Regulates Memory Formation and Synaptic Plasticity</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">459</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">60</span><span class="refDoi"> DOI: 10.1038/nature07925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnature07925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19424149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=459&publication_year=2009&pages=55-60&author=J.-S.+Guanauthor=S.+J.+Haggartyauthor=E.+Giacomettiauthor=J.-H.+Dannenbergauthor=N.+Josephauthor=J.+Gaoauthor=T.+J.+F.+Nielandauthor=Y.+Zhouauthor=X.+Wangauthor=R.+Mazitschekauthor=J.+E.+Bradnerauthor=R.+A.+DePinhoauthor=R.+Jaenischauthor=L.-H.+Tsai&title=HDAC2+Negatively+Regulates+Memory+Formation+and+Synaptic+Plasticity&doi=10.1038%2Fnature07925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC2 negatively regulates memory formation and synaptic plasticity</span></div><div class="casAuthors">Guan, Ji-Song; Haggarty, Stephen J.; Giacometti, Emanuela; Dannenberg, Jan-Hermen; Joseph, Nadine; Gao, Jun; Nieland, Thomas J. F.; Zhou, Ying; Wang, Xinyu; Mazitschek, Ralph; Bradner, James E.; DePinho, Ronald A.; Jaenisch, Rudolf; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">459</span>
        (<span class="NLM_cas:issue">7243</span>),
    <span class="NLM_cas:pages">55-60</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chromatin modifications, esp. histone-tail acetylation, have been implicated in memory formation.  Increased histone-tail acetylation induced by histone deacetylases inhibitors (HDACis) facilitates learning and memory in wild-type mice as well as in mouse models of neurodegeneration.  Harnessing the therapeutic potential of HDACis requires knowledge of the specific HDAC family member(s) linked to cognitive enhancement.  Here, the authors show that neuron-specific overexpression of HDAC2, but not that of HDAC1, decreased dendritic spine d., synapse no., synaptic plasticity and memory formation.  Conversely, gene Hdac2 deficiency resulted in increased synapse no. and memory facilitation, similar to chronic treatment with HDACis in mice.  Notably, reduced synapse no. and learning impairment of HDAC2-overexpressing mice were ameliorated by chronic treatment with HDACis.  Correspondingly, treatment with HDACis failed to further facilitate memory formation in gene Hdac2-deficient mice.  Furthermore, anal. of promoter occupancy revealed an assocn. of HDAC2 with the promoters of genes implicated in synaptic plasticity and memory formation.  Taken together, these results suggest that HDAC2 functions in modulating synaptic plasticity and long-lasting changes of neural circuits, which in turn neg. regulates learning and memory.  These observations encourage the development and testing of HDAC2-selective inhibitors for human diseases assocd. with memory impairment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0MzAlmmDwLLVg90H21EOLACvtfcHk0lipkag4vw3Xpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsF2ltro%253D&md5=bbd00accb8b6992f9c109114e8818388</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnature07925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07925%26sid%3Dliteratum%253Aachs%26aulast%3DGuan%26aufirst%3DJ.-S.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DGiacometti%26aufirst%3DE.%26aulast%3DDannenberg%26aufirst%3DJ.-H.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DNieland%26aufirst%3DT.%2BJ.%2BF.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DDePinho%26aufirst%3DR.%2BA.%26aulast%3DJaenisch%26aufirst%3DR.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DHDAC2%2520Negatively%2520Regulates%2520Memory%2520Formation%2520and%2520Synaptic%2520Plasticity%26jtitle%3DNature%26date%3D2009%26volume%3D459%26spage%3D55%26epage%3D60%26doi%3D10.1038%2Fnature07925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Gräff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hennig, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nieland, T. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fass, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samiei, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joseph, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delalle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">An Epigenetic Blockade of Cognitive Functions in the Neurodegenerating Brain</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">483</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">–</span> <span class="NLM_lpage">226</span><span class="refDoi"> DOI: 10.1038/nature10849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnature10849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22388814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BC383ptlCjtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=483&publication_year=2012&pages=222-226&author=J.+Gr%C3%A4ffauthor=D.+Reiauthor=J.-S.+Guanauthor=W.-Y.+Wangauthor=J.+Seoauthor=K.+M.+Hennigauthor=T.+J.+F.+Nielandauthor=D.+M.+Fassauthor=P.+F.+Kaoauthor=M.+Kahnauthor=S.+C.+Suauthor=A.+Samieiauthor=N.+Josephauthor=S.+J.+Haggartyauthor=I.+Delalleauthor=L.-H.+Tsai&title=An+Epigenetic+Blockade+of+Cognitive+Functions+in+the+Neurodegenerating+Brain&doi=10.1038%2Fnature10849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">An epigenetic blockade of cognitive functions in the neurodegenerating brain</span></div><div class="casAuthors">Graff Johannes; Rei Damien; Guan Ji-Song; Wang Wen-Yuan; Seo Jinsoo; Hennig Krista M; Nieland Thomas J F; Fass Daniel M; Kao Patricia F; Kahn Martin; Su Susan C; Samiei Alireza; Joseph Nadine; Haggarty Stephen J; Delalle Ivana; Tsai Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Nature</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">483</span>
        (<span class="NLM_cas:issue">7388</span>),
    <span class="NLM_cas:pages">222-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cognitive decline is a debilitating feature of most neurodegenerative diseases of the central nervous system, including Alzheimer's disease.  The causes leading to such impairment are only poorly understood and effective treatments are slow to emerge.  Here we show that cognitive capacities in the neurodegenerating brain are constrained by an epigenetic blockade of gene transcription that is potentially reversible.  This blockade is mediated by histone deacetylase 2, which is increased by Alzheimer's-disease-related neurotoxic insults in vitro, in two mouse models of neurodegeneration and in patients with Alzheimer's disease.  Histone deacetylase 2 associates with and reduces the histone acetylation of genes important for learning and memory, which show a concomitant decrease in expression.  Importantly, reversing the build-up of histone deacetylase 2 by short-hairpin-RNA-mediated knockdown unlocks the repression of these genes, reinstates structural and synaptic plasticity, and abolishes neurodegeneration-associated memory impairments.  These findings advocate for the development of selective inhibitors of histone deacetylase 2 and suggest that cognitive capacities following neurodegeneration are not entirely lost, but merely impaired by this epigenetic blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_TBTrhihJh3WEEzDrymxmfW6udTcc2eb9um2M5_Qs4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ptlCjtw%253D%253D&md5=6e567f82c587972acbdf75fbb06d2954</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature10849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature10849%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25A4ff%26aufirst%3DJ.%26aulast%3DRei%26aufirst%3DD.%26aulast%3DGuan%26aufirst%3DJ.-S.%26aulast%3DWang%26aufirst%3DW.-Y.%26aulast%3DSeo%26aufirst%3DJ.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DNieland%26aufirst%3DT.%2BJ.%2BF.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DKao%26aufirst%3DP.%2BF.%26aulast%3DKahn%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%2BC.%26aulast%3DSamiei%26aufirst%3DA.%26aulast%3DJoseph%26aufirst%3DN.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DDelalle%26aufirst%3DI.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DAn%2520Epigenetic%2520Blockade%2520of%2520Cognitive%2520Functions%2520in%2520the%2520Neurodegenerating%2520Brain%26jtitle%3DNature%26date%3D2012%26volume%3D483%26spage%3D222%26epage%3D226%26doi%3D10.1038%2Fnature10849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobbin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsunemoto, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guan, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giusti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broodie, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazitschek, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delalle, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haggarty, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neve, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, L.-H.</span><span> </span><span class="NLM_article-title">Deregulation of HDAC1 by p25/Cdk5 in Neurotoxicity</span> <span class="citation_source-journal">Neuron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">803</span><span class="NLM_x">–</span> <span class="NLM_lpage">817</span><span class="refDoi"> DOI: 10.1016/j.neuron.2008.10.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.neuron.2008.10.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19081376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFahs7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2008&pages=803-817&author=D.+Kimauthor=C.+L.+Frankauthor=M.+M.+Dobbinauthor=R.+K.+Tsunemotoauthor=W.+Tuauthor=P.+L.+Pengauthor=J.-S.+Guanauthor=B.-H.+Leeauthor=L.+Y.+Moyauthor=P.+Giustiauthor=N.+Broodieauthor=R.+Mazitschekauthor=I.+Delalleauthor=S.+J.+Haggartyauthor=R.+L.+Neveauthor=Y.+Luauthor=L.-H.+Tsai&title=Deregulation+of+HDAC1+by+p25%2FCdk5+in+Neurotoxicity&doi=10.1016%2Fj.neuron.2008.10.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity</span></div><div class="casAuthors">Kim, Dohoon; Frank, Christopher L.; Dobbin, Matthew M.; Tsunemoto, Rachel K.; Tu, Weihong; Peng, Peter L.; Guan, Ji-Song; Lee, Byung-Hoon; Moy, Lily Y.; Giusti, Paola; Broodie, Nisha; Mazitschek, Ralph; Delalle, Ivanna; Haggarty, Stephen J.; Neve, Rachael L.; Lu, YouMing; Tsai, Li-Huei</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">803-817</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Aberrant cell-cycle activity and DNA damage are emerging as important pathol. components in various neurodegenerative conditions.  However, their underlying mechanisms are poorly understood.  Here, it is shown that deregulation of histone deacetylase 1 (HDAC1) activity by p25/Cdk5 induces aberrant cell-cycle activity and double-strand DNA breaks leading to neurotoxicity.  In a transgenic model for neurodegeneration, p25/Cdk5 activity elicited cell-cycle activity and double-strand DNA breaks that preceded neuronal death.  Inhibition of HDAC1 activity by p25/Cdk5 was identified as an underlying mechanism for these events, and HDAC1 gain of function provided potent protection against DNA damage and neurotoxicity in cultured neurons and an in vivo model for ischemia.  These findings outline a pathol. signaling pathway illustrating the importance of maintaining HDAC1 activity in the adult neuron.  This pathway constitutes a mol. link between aberrant cell-cycle activity and DNA damage and is a potential target for therapeutics against diseases and conditions involving neuronal death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFpYueKsA8XbVg90H21EOLACvtfcHk0lgbH5NVDiTZOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFahs7rE&md5=12d9ecc3fe53ea6fcee61f149e5ffae3</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.neuron.2008.10.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuron.2008.10.015%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DD.%26aulast%3DFrank%26aufirst%3DC.%2BL.%26aulast%3DDobbin%26aufirst%3DM.%2BM.%26aulast%3DTsunemoto%26aufirst%3DR.%2BK.%26aulast%3DTu%26aufirst%3DW.%26aulast%3DPeng%26aufirst%3DP.%2BL.%26aulast%3DGuan%26aufirst%3DJ.-S.%26aulast%3DLee%26aufirst%3DB.-H.%26aulast%3DMoy%26aufirst%3DL.%2BY.%26aulast%3DGiusti%26aufirst%3DP.%26aulast%3DBroodie%26aufirst%3DN.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DDelalle%26aufirst%3DI.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DNeve%26aufirst%3DR.%2BL.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DTsai%26aufirst%3DL.-H.%26atitle%3DDeregulation%2520of%2520HDAC1%2520by%2520p25%252FCdk5%2520in%2520Neurotoxicity%26jtitle%3DNeuron%26date%3D2008%26volume%3D60%26spage%3D803%26epage%3D817%26doi%3D10.1016%2Fj.neuron.2008.10.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ding, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dolan, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, G. V. W.</span><span> </span><span class="NLM_article-title">Histone Deacetylase 6 Interacts with the Microtubule-Associated Protein Tau</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">106</span><span class="NLM_x">, </span> <span class="NLM_fpage">2119</span><span class="NLM_x">–</span> <span class="NLM_lpage">2130</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2008.05564.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fj.1471-4159.2008.05564.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=18636984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2008&pages=2119-2130&author=H.+Dingauthor=P.+J.+Dolanauthor=G.+V.+W.+Johnson&title=Histone+Deacetylase+6+Interacts+with+the+Microtubule-Associated+Protein+Tau&doi=10.1111%2Fj.1471-4159.2008.05564.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 interacts with the microtubule-associated protein tau</span></div><div class="casAuthors">Ding, Huiping; Dolan, Philip J.; Johnson, Gail V. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2119-2130</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a unique cytoplasmic deacetylase, likely plays a role in neurodegeneration by coordinating cell responses to abnormal protein aggregation.  Here, we provide in vitro and in vivo evidence that HDAC6 interacts with tau, a microtubule-assocd. protein that forms neurofibrillary tangles in Alzheimer's disease.  This interaction is mediated by the microtubule-binding domain on tau and the Ser/Glu tetradecapeptide domain on HDAC6.  Treatment with tubacin, a selective inhibitor of tubulin deacetylation activity of HDAC6, did not disrupt HDAC6-tau interaction.  Nonetheless tubacin treatment attenuated site-specific tau phosphorylation, as did shRNA-mediated knockdown of HDAC6.  Proteasome inhibition potentiated HDAC6-tau interactions and facilitated the concn. and co-localization of HDAC6 and tau in a perinuclear aggresome-like compartment, independent of HDAC6 tubulin deacetylase activity.  Furthermore, we obsd. that in Alzheimer's disease brains the protein level of HDAC6 was significantly increased.  These findings establish HDAC6 as a tau-interacting protein and as a potential modulator of tau phosphorylation and accumulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OtxbhpBU9LVg90H21EOLACvtfcHk0lgZKcpMwuKYJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtV2rt7fM&md5=cf63da19f8f887459227b620d9a0898b</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2008.05564.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2008.05564.x%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DH.%26aulast%3DDolan%26aufirst%3DP.%2BJ.%26aulast%3DJohnson%26aufirst%3DG.%2BV.%2BW.%26atitle%3DHistone%2520Deacetylase%25206%2520Interacts%2520with%2520the%2520Microtubule-Associated%2520Protein%2520Tau%26jtitle%3DJ.%2520Neurochem.%26date%3D2008%26volume%3D106%26spage%3D2119%26epage%3D2130%26doi%3D10.1111%2Fj.1471-4159.2008.05564.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Selenica, M.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Housley, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manchec, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nash, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gordon, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, D.</span><span> </span><span class="NLM_article-title">Histone Deacetylase 6 Inhibition Improves Memory and Reduces Total Tau Levels in a Mouse Model of Tau Deposition</span> <span class="citation_source-journal">Alzheimer's Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">12</span><span class="refDoi"> DOI: 10.1186/alzrt241</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1186%2Falzrt241" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24576665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjsVyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2014&pages=12&author=M.-L.+Selenicaauthor=L.+Bennerauthor=S.+B.+Housleyauthor=B.+Manchecauthor=D.+C.+Leeauthor=K.+R.+Nashauthor=J.+Kalinauthor=J.+A.+Bergmanauthor=A.+Kozikowskiauthor=M.+N.+Gordonauthor=D.+Morgan&title=Histone+Deacetylase+6+Inhibition+Improves+Memory+and+Reduces+Total+Tau+Levels+in+a+Mouse+Model+of+Tau+Deposition&doi=10.1186%2Falzrt241"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition</span></div><div class="casAuthors">Selenica, Maj-Linda; Benner, Leif; Housley, Steven B.; Manchec, Barbara; Lee, Daniel C.; Nash, Kevin R.; Kalin, Jay; Bergman, Joel A.; Kozikowski, Alan; Gordon, Marcia N.; Morgan, Dave</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's Research & Therapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">12/1-12/12, 12</span>CODEN:
                <span class="NLM_cas:coden">ARTLCD</span>;
        ISSN:<span class="NLM_cas:issn">1758-9193</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Tau pathol. is assocd. with a no. of age-related neurodegenerative disorders.  Few treatments have been demonstrated to diminish the impact of tau pathol. in mouse models and none are yet effective in humans.  Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from cytoplasmic proteins, rather than nuclear histones.  Its substrates include tubulin, heat shock protein 90 and cortactin.  Tubastatin A is a selective inhibitor of HDAC6.  Modification of tau pathol. by specific inhibition of HDAC6 presents a potential therapeutic approach in tauopathy.  Methods: We treated rTg4510 mouse models of tau deposition and non-transgenic mice with tubastatin (25 mg/kg) or saline (0.9%) from 5 to 7 mo of age.  Cognitive behavior anal., histol. and biochem. anal. were applied to access the effect of tubastatin on memory, tau pathol. and neurodegeneration (hippocampal vol.).  Results: We present data showing that tubastatin restored memory function in rTg4510 mice and reversed a hyperactivity phenotype.  We further found that tubastatin reduced the levels of total tau, both histol. and by western anal.  Redn. in total tau levels was pos. correlated with memory improvement in these mice.  However, there was no impact on phosphorylated forms of tau, either by histol. or western anal., nor was there an impact on silver pos. inclusions histol.  Conclusion: Potential mechanisms by which HDAC6 inhibitors might benefit the rTg4510 mouse include stabilization of microtubules secondary to increased tubulin acetylation, increased degrdn. of tau secondary to increased acetylation of HSP90 or both.  These data support the use of HDAC6 inhibitors as potential therapeutic agents against tau pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYGE6Rou8uVrVg90H21EOLACvtfcHk0lgZKcpMwuKYJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjsVyms78%253D&md5=d0e234d073b768649c60284711685155</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1186%2Falzrt241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Falzrt241%26sid%3Dliteratum%253Aachs%26aulast%3DSelenica%26aufirst%3DM.-L.%26aulast%3DBenner%26aufirst%3DL.%26aulast%3DHousley%26aufirst%3DS.%2BB.%26aulast%3DManchec%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DD.%2BC.%26aulast%3DNash%26aufirst%3DK.%2BR.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DGordon%26aufirst%3DM.%2BN.%26aulast%3DMorgan%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylase%25206%2520Inhibition%2520Improves%2520Memory%2520and%2520Reduces%2520Total%2520Tau%2520Levels%2520in%2520a%2520Mouse%2520Model%2520of%2520Tau%2520Deposition%26jtitle%3DAlzheimer%2527s%2520Res.%2520Ther.%26date%3D2014%26volume%3D6%26spage%3D12%26doi%3D10.1186%2Falzrt241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Xiong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Q.</span><span> </span><span class="NLM_article-title">HDAC6Mutations Rescue Human Tau-Induced Microtubule Defects in Drosophila</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">4604</span><span class="NLM_x">–</span> <span class="NLM_lpage">4609</span><span class="refDoi"> DOI: 10.1073/pnas.1207586110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1073%2Fpnas.1207586110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=4604-4609&author=Y.+Xiongauthor=K.+Zhaoauthor=J.+Wuauthor=Z.+Xuauthor=S.+Jinauthor=Y.+Q.+Zhang&title=HDAC6Mutations+Rescue+Human+Tau-Induced+Microtubule+Defects+in+Drosophila&doi=10.1073%2Fpnas.1207586110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1207586110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1207586110%26sid%3Dliteratum%253Aachs%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%2BQ.%26atitle%3DHDAC6Mutations%2520Rescue%2520Human%2520Tau-Induced%2520Microtubule%2520Defects%2520in%2520Drosophila%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D4604%26epage%3D4609%26doi%3D10.1073%2Fpnas.1207586110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sung, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiBattista, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moffat, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoe, H.-S.</span><span> </span><span class="NLM_article-title">Mercaptoacetamide-Based Class II HDAC Inhibitor Lowers Aβ Levels and Improves Learning and Memory in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Exp. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">239</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1016/j.expneurol.2012.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.expneurol.2012.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=23063601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=239&publication_year=2013&pages=192-201&author=Y.+M.+Sungauthor=T.+Leeauthor=H.+Yoonauthor=A.+M.+DiBattistaauthor=J.+M.+Songauthor=Y.+Sohnauthor=E.+I.+Moffatauthor=R.+S.+Turnerauthor=M.+Jungauthor=J.+Kimauthor=H.-S.+Hoe&title=Mercaptoacetamide-Based+Class+II+HDAC+Inhibitor+Lowers+A%CE%B2+Levels+and+Improves+Learning+and+Memory+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.expneurol.2012.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mercaptoacetamide-based class II HDAC inhibitor lowers Aβ levels and improves learning and memory in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Sung, You Me; Lee, Taehee; Yoon, Hyejin; DiBattista, Amanda Marie; Song, Jung Min; Sohn, Yoojin; Moffat, Emily Isabella; Turner, R. Scott; Jung, Mira; Kim, Jungsu; Hoe, Hyang-Sook</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">239</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-201</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) alter gene expression epigenetically by interfering with the normal functions of HDAC.  Given their ability to decrease Aβ levels, HDACIs are a potential treatment for Alzheimer's disease (AD).  However, it is unclear how HDACIs alter Aβ levels.  We developed two novel HDAC inhibitors with improved pharmacol. properties, such as a longer half-life and greater penetration of the blood-brain barrier: mercaptoacetamide-based class II HDACI (coded as W2) and hydroxamide-based class I and IIHDACI (coded as I2) and investigated how they affect Aβ levels and cognition.  HDACI W2 decreased Aβ40 and Aβ42 in vitro.  HDACI I2 also decreased Aβ40, but not Aβ42.  We systematically examd. the mol. mechanisms by which HDACIs W2 and I2 can decrease Aβ levels.  HDACI W2 decreased gene expression of γ-secretase components and increased the Aβ degrdn. enzyme Mmp2.  Similarly, HDACI I2 decreased expression of β- and γ-secretase components and increased mRNA levels of Aβ degrdn. enzymes.  HDACI W2 also significantly decreased Aβ levels and rescued learning and memory deficits in aged hAPP 3xTg AD mice.  Furthermore, we found that the novel HDACI W2 decreased tau phosphorylation at Thr181, an effect previously unknown for HDACIs.  Collectively, these data suggest that class II HDACls may serve as a novel therapeutic strategy for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgE2jeS-UuA7Vg90H21EOLACvtfcHk0ljwMCHWGxT_Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWisw%253D%253D&md5=11db4f9ac4e0f6f541b2441e4316b6e8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2012.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2012.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DY.%2BM.%26aulast%3DLee%26aufirst%3DT.%26aulast%3DYoon%26aufirst%3DH.%26aulast%3DDiBattista%26aufirst%3DA.%2BM.%26aulast%3DSong%26aufirst%3DJ.%2BM.%26aulast%3DSohn%26aufirst%3DY.%26aulast%3DMoffat%26aufirst%3DE.%2BI.%26aulast%3DTurner%26aufirst%3DR.%2BS.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHoe%26aufirst%3DH.-S.%26atitle%3DMercaptoacetamide-Based%2520Class%2520II%2520HDAC%2520Inhibitor%2520Lowers%2520A%25CE%25B2%2520Levels%2520and%2520Improves%2520Learning%2520and%2520Memory%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DExp.%2520Neurol.%26date%3D2013%26volume%3D239%26spage%3D192%26epage%3D201%26doi%3D10.1016%2Fj.expneurol.2012.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, J.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sui, X.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Z.-G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, S.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, C.</span><span> </span><span class="NLM_article-title">Tubastatin A/ACY-1215 Improves Cognition in Alzheimer’s Disease Transgenic Mice</span> <span class="citation_source-journal">J. Alzheimer’s Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">1193</span><span class="NLM_x">–</span> <span class="NLM_lpage">1205</span><span class="refDoi"> DOI: 10.3233/JAD-140066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.3233%2FJAD-140066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24844691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1Wisb3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2014&pages=1193-1205&author=L.+Zhangauthor=C.+Liuauthor=J.+Wuauthor=J.-J.+Taoauthor=X.-L.+Suiauthor=Z.-G.+Yaoauthor=Y.-F.+Xuauthor=L.+Huangauthor=H.+Zhuauthor=S.-L.+Shengauthor=C.+Qin&title=Tubastatin+A%2FACY-1215+Improves+Cognition+in+Alzheimer%E2%80%99s+Disease+Transgenic+Mice&doi=10.3233%2FJAD-140066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin A/ACY-1215 Improves Cognition in Alzheimer's Disease Transgenic Mice</span></div><div class="casAuthors">Zhang, Ling; Liu, Cui; Wu, Jie; Tao, Jing-jing; Sui, Xiao-long; Yao, Zhi-gang; Xu, Yan-feng; Huang, Lan; Zhu, Hua; Sheng, Shu-li; Qin, Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1193-1205</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is currently being discussed as a promising therapeutic target for the treatment of Alzheimer's disease (AD).  Mounting evidence indicates that increased HDAC6 expression may contribute to AD-assocd. neurodegeneration, although beneficial effects have also been identified.  In the present study, we tested the potential of two selective HDAC6 inhibitors, tubastatin A and ACY-1215, to rescue cognitive deficits in a mouse model of AD.  We found that both tubastatin A and ACY-1215 alleviated behavioral deficits, altered amyloid-β (Aβ) load, and reduced tau hyperphosphorylation in AD mice without obvious adverse effects.  Our data suggested that tubastatin A and ACY-1215 not only promoted tubulin acetylation, but also reduced prodn. and facilitated autophagic clearance of Aβ and hyperphosphorylated tau.  Further, the decreased hyperphosphorylated tau and increased tubulin acetylation may account for the improved microtubule stability in AD mice after tubastatin A/ACY-1215 treatment.  These preclin. results support the detrimental role of HDAC6 in AD, and offer prospective approaches for using tubastatin A/ACY-1215 as potential therapeutic strategy for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMqSzA-9TiiLVg90H21EOLACvtfcHk0ljwMCHWGxT_Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1Wisb3N&md5=4bd700182b457a81cfc688511aead426</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3233%2FJAD-140066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-140066%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DTao%26aufirst%3DJ.-J.%26aulast%3DSui%26aufirst%3DX.-L.%26aulast%3DYao%26aufirst%3DZ.-G.%26aulast%3DXu%26aufirst%3DY.-F.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DH.%26aulast%3DSheng%26aufirst%3DS.-L.%26aulast%3DQin%26aufirst%3DC.%26atitle%3DTubastatin%2520A%252FACY-1215%2520Improves%2520Cognition%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Transgenic%2520Mice%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2014%26volume%3D41%26spage%3D1193%26epage%3D1205%26doi%3D10.3233%2FJAD-140066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanzhez-Arias, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mederos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Lucas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Osta, A.</span><span> </span><span class="NLM_article-title">Concomitant Histone Deacetylase and Phosphodiesterase 5 Inhibition Synergistically Prevents the Disruption in Synaptic Plasticity and It Reverses Cognitive Impairment in a Mouse Model of Alzheimer’s Disease</span> <span class="citation_source-journal">Clin. Epigenet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">108</span><span class="refDoi"> DOI: 10.1186/s13148-015-0142-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1186%2Fs13148-015-0142-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26457123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVOksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=108&author=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+Sanzhez-Ariasauthor=S.+Mederosauthor=O.+Rabalauthor=A.+Ugarteauthor=R.+Francoauthor=M.+Pascual-Lucasauthor=V.+Seguraauthor=G.+Pereaauthor=J.+Oyarzabalauthor=A.+Garcia-Osta&title=Concomitant+Histone+Deacetylase+and+Phosphodiesterase+5+Inhibition+Synergistically+Prevents+the+Disruption+in+Synaptic+Plasticity+and+It+Reverses+Cognitive+Impairment+in+a+Mouse+Model+of+Alzheimer%E2%80%99s+Disease&doi=10.1186%2Fs13148-015-0142-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sanzhez-Arias, J.; Mederos, S.; Rabal, O.; Ugarte, A.; Franco, R.; Pascual-Lucas, M.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Epigenetics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108/1-108/11</span>CODEN:
                <span class="NLM_cas:coden">CELPCI</span>;
        ISSN:<span class="NLM_cas:issn">1868-7083</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Given the implication of histone acetylation in memory processes, histone deacetylase inhibitors (HDACIs) have been postulated as potential modulators of cognitive impairment in Alzheimer's disease (AD).  However, dose-dependent side effects have been described in patients with the currently available broad-spectrum HDACIs, explaining why their therapeutic potential has not been realized for chronic diseases.  Here, by simultaneously targeting two independent enzyme activities, histone deacetylase (HDAC) and phosphodiesterase-5 (PDE5), we propose a novel mode of inhibitory action that might increase the therapeutic specificity of HDACIs.  Results: The combination of vorinostat, a pan-HDACI, and tadalafil, a PDE5 inhibitor, rescued the long-term potentiation impaired in slices from APP/PS1 mice.  When administered in vivo, the combination of these drugs alleviated the cognitive deficits in AD mice, as well as the amyloid and tau pathol., and it reversed the reduced dendritic spine d. on hippocampal neurons.  Significantly, the combination of vorinostat and tadalafil was more effective than each drug alone, both against the symptoms and in terms of disease modification, and importantly, these effects persisted after a 4-wk washout period.  Conclusions: The results highlight the pharmacol. potential of a combination of mols. that inhibit HDAC and PDE5 as a therapeutic approach for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMSYuXPnR9SLVg90H21EOLACvtfcHk0lhbcwvCFAB6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVOksbw%253D&md5=bb0f0702afbc1ac3fe7867bd037ca09e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2Fs13148-015-0142-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13148-015-0142-9%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DSanzhez-Arias%26aufirst%3DJ.%26aulast%3DMederos%26aufirst%3DS.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DPascual-Lucas%26aufirst%3DM.%26aulast%3DSegura%26aufirst%3DV.%26aulast%3DPerea%26aufirst%3DG.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DConcomitant%2520Histone%2520Deacetylase%2520and%2520Phosphodiesterase%25205%2520Inhibition%2520Synergistically%2520Prevents%2520the%2520Disruption%2520in%2520Synaptic%2520Plasticity%2520and%2520It%2520Reverses%2520Cognitive%2520Impairment%2520in%2520a%2520Mouse%2520Model%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DClin.%2520Epigenet.%26date%3D2015%26volume%3D7%26spage%3D108%26doi%3D10.1186%2Fs13148-015-0142-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Robers, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dart, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodroofe, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimprich, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkland, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machleidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kupcho, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartnett, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmerman, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niles, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohana, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniels, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slater, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Y.-Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, K. V.</span><span> </span><span class="NLM_article-title">Target Engagement and Drug Residence Time Can Be Observed in Living Cells with BRET</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">10091</span><span class="refDoi"> DOI: 10.1038/ncomms10091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fncomms10091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26631872" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=10091&author=M.+B.+Robersauthor=M.+L.+Dartauthor=C.+C.+Woodroofeauthor=C.+A.+Zimprichauthor=T.+A.+Kirklandauthor=T.+Machleidtauthor=K.+R.+Kupchoauthor=S.+Levinauthor=J.+R.+Hartnettauthor=K.+Zimmermanauthor=A.+L.+Nilesauthor=R.+F.+Ohanaauthor=D.+L.+Danielsauthor=M.+Slaterauthor=M.+G.+Woodauthor=M.+Congauthor=Y.-Q.+Chengauthor=K.+V.+Wood&title=Target+Engagement+and+Drug+Residence+Time+Can+Be+Observed+in+Living+Cells+with+BRET&doi=10.1038%2Fncomms10091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Target engagement and drug residence time can be observed in living cells with BRET</span></div><div class="casAuthors">Robers, Matthew B.; Dart, Melanie L.; Woodroofe, Carolyn C.; Zimprich, Chad A.; Kirkland, Thomas A.; Machleidt, Thomas; Kupcho, Kevin R.; Levin, Sergiy; Hartnett, James R.; Zimmerman, Kristopher; Niles, Andrew L.; Ohana, Rachel Friedman; Daniels, Danette L.; Slater, Michael; Wood, Monika G.; Cong, Mei; Cheng, Yi-Qiang; Wood, Keith V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10091</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The therapeutic action of drugs is predicated on their phys. engagement with cellular targets.  Here we describe a broadly applicable method using bioluminescence resonance energy transfer (BRET) to reveal the binding characteristics of a drug with selected targets within intact cells.  Cell-permeable fluorescent tracers are used in a competitive binding format to quantify drug engagement with the target proteins fused to Nanoluc luciferase.  The approach enabled us to profile isoenzyme-specific engagement and binding kinetics for a panel of histone deacetylase (HDAC) inhibitors.  Our anal. was directed particularly to the clin. approved prodrug FK228 (Istodax/Romidepsin) because of its unique and largely unexplained mechanism of sustained intracellular action.  Anal. of the binding kinetics by BRET revealed remarkably long intracellular residence times for FK228 at HDAC1, explaining the protracted intracellular behavior of this prodrug.  Our results demonstrate a novel application of BRET for assessing target engagement within the complex milieu of the intracellular environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRFFk0LNiL_LVg90H21EOLACvtfcHk0lhbcwvCFAB6AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGmtrnO&md5=723cc5dd7d229b1115da4c2c9d75c913</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fncomms10091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10091%26sid%3Dliteratum%253Aachs%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DDart%26aufirst%3DM.%2BL.%26aulast%3DWoodroofe%26aufirst%3DC.%2BC.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKirkland%26aufirst%3DT.%2BA.%26aulast%3DMachleidt%26aufirst%3DT.%26aulast%3DKupcho%26aufirst%3DK.%2BR.%26aulast%3DLevin%26aufirst%3DS.%26aulast%3DHartnett%26aufirst%3DJ.%2BR.%26aulast%3DZimmerman%26aufirst%3DK.%26aulast%3DNiles%26aufirst%3DA.%2BL.%26aulast%3DOhana%26aufirst%3DR.%2BF.%26aulast%3DDaniels%26aufirst%3DD.%2BL.%26aulast%3DSlater%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DM.%2BG.%26aulast%3DCong%26aufirst%3DM.%26aulast%3DCheng%26aufirst%3DY.-Q.%26aulast%3DWood%26aufirst%3DK.%2BV.%26atitle%3DTarget%2520Engagement%2520and%2520Drug%2520Residence%2520Time%2520Can%2520Be%2520Observed%2520in%2520Living%2520Cells%2520with%2520BRET%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26spage%3D10091%26doi%3D10.1038%2Fncomms10091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez-Arias, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabal, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mederos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segura, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garcia-Osta, A.</span><span> </span><span class="NLM_article-title">A First-in-Class Small-Molecule That Acts as a Dual Inhibitor of HDAC and PDE5, and That Rescues Hippocampal Synaptic Impairment in Alzheimer’s Disease Mice</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span><span class="NLM_elocation-id"></span><span class="refDoi"> DOI: 10.1038/npp.2016.163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnpp.2016.163" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=M.+Cuadrado-Tejedorauthor=C.+Garcia-Barrosoauthor=J.+A.+S%C3%A1nchez-Ariasauthor=O.+Rabalauthor=S.+Mederosauthor=A.+Ugarteauthor=R.+Francoauthor=V.+Seguraauthor=G.+Pereaauthor=J.+Oyarzabalauthor=A.+Garcia-Osta&title=A+First-in-Class+Small-Molecule+That+Acts+as+a+Dual+Inhibitor+of+HDAC+and+PDE5%2C+and+That+Rescues+Hippocampal+Synaptic+Impairment+in+Alzheimer%E2%80%99s+Disease+Mice&doi=10.1038%2Fnpp.2016.163"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2016.163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2016.163%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DMederos%26aufirst%3DS.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DSegura%26aufirst%3DV.%26aulast%3DPerea%26aufirst%3DG.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26atitle%3DA%2520First-in-Class%2520Small-Molecule%2520That%2520Acts%2520as%2520a%2520Dual%2520Inhibitor%2520of%2520HDAC%2520and%2520PDE5%252C%2520and%2520That%2520Rescues%2520Hippocampal%2520Synaptic%2520Impairment%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mice%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26doi%3D10.1038%2Fnpp.2016.163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Konsoula, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, M.</span><span> </span><span class="NLM_article-title">In Vitro Plasma Stability, Permeability and Solubility of Mercaptoacetamide Histone Deacetylase Inhibitors</span> <span class="citation_source-journal">Int. J. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">361</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.ijpharm.2008.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=18562136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2008&pages=19-25&author=R.+Konsoulaauthor=M.+Jung&title=In+Vitro+Plasma+Stability%2C+Permeability+and+Solubility+of+Mercaptoacetamide+Histone+Deacetylase+Inhibitors&doi=10.1016%2Fj.ijpharm.2008.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors</span></div><div class="casAuthors">Konsoula, Roula; Jung, Mira</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACIs) are emerging as a new class of therapeutic agents with potent antitumor activities in a broad spectrum of human cancers.  In this study, the in vitro plasma stability, permeability, soly., and lipophilicity (log D) of two mercaptoacetamide-based HDACIs (coded as W2 and S2) were evaluated and compared to Vorinostat (SAHA).  The results demonstrated that the compds. manifested high soly. in HCl (pH 1.2) but lower in PBS (pH 7.4) than SAHA.  Moreover, mercaptoacetamide-based HDACIs exhibited higher lipophilicity values compared to SAHA.  The permeability of these compds. was evaluated using the Caco-2 cell monolayer as a model of the intestinal mucosa.  The Caco-2 studies revealed that the compds. S2 and W2 are highly permeable with apparent permeability coeffs. (Papp) in the apical to basolateral direction of 7.33 × 10-6 and 15.0 × 10-6 cm/s, resp.  The in vitro stability was detd. in human, mouse, porcine and rat plasma.  Data showed that the compd. W2 is more stable in human and rat plasma and the S2 is more stable in all plasma species than SAHA.  Taken together, these results indicate that the mercaptoacetamide-based HDACIs possess favorable soly., lipophilicity, permeability and plasma stability features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ60NiaoIn6bVg90H21EOLACvtfcHk0ljVuWFYlq0MkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpt1alsr0%253D&md5=32a5ec87e4d150d373a325b3ee296dc7</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DKonsoula%26aufirst%3DR.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520Plasma%2520Stability%252C%2520Permeability%2520and%2520Solubility%2520of%2520Mercaptoacetamide%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D361%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.ijpharm.2008.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inks, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">3324</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1021/jm401877m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401877m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=3324-3341&author=X.+Liauthor=E.+S.+Inksauthor=X.+Liauthor=J.+Houauthor=C.+J.+Chouauthor=J.+Zhangauthor=Y.+Jiangauthor=Y.+Zhangauthor=W.+Xu&title=Discovery+of+the+First+N-Hydroxycinnamamide-Based+Histone+Deacetylase+1%2F3+Dual+Inhibitors+with+Potent+Oral+Antitumor+Activity&doi=10.1021%2Fjm401877m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First N-Hydroxycinnamamide-Based Histone Deacetylase 1/3 Dual Inhibitors with Potent Oral Antitumor Activity</span></div><div class="casAuthors">Li, Xiaoyang; Inks, Elizabeth S.; Li, Xiaoguang; Hou, Jinning; Chou, C. James; Zhang, Jian; Jiang, Yuqi; Zhang, Yingjie; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3324-3341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our previous study, we designed and synthesized a novel series of N-hydroxycinnamamide-based histone deacetylase inhibitors (HDACIs), among which the representative compd. I exhibited promising HDACs inhibition and antitumor activity.  In this current study, we report the development of a more potent class of N-hydroxycinnamamide-based HDACIs, using I as lead, among which, compd. II gave IC50 values of 11.8, 498.1, 3.9, 2000.8, 5700.4, 308.2, and 900.4 nM for the inhibition of HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC6, and HDAC11, exhibiting dual HDAC1/3 selectivity.  Several of these compds. showed excellent growth inhibition in multiple tumor cell lines.  In vivo antitumor assay in U937 xenograft model identified compd. II as a potent, orally active HDACI.  To the best of our knowledge, this work constitutes the first report of oral active N-hydroxycinnamamide-based HDACIs with dual HDAC1/3 selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrBGqCPWPO2rVg90H21EOLACvtfcHk0ljcpjdit39Bvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsFOjsr4%253D&md5=4e86a4e7c9fda199bdd3cb12730db1da</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm401877m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401877m%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DInks%26aufirst%3DE.%2BS.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DDiscovery%2520of%2520the%2520First%2520N-Hydroxycinnamamide-Based%2520Histone%2520Deacetylase%25201%252F3%2520Dual%2520Inhibitors%2520with%2520Potent%2520Oral%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D3324%26epage%3D3341%26doi%3D10.1021%2Fjm401877m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Palmieri, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockman, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, F. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herring, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flores, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega-Valle, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taskar, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudraraju, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittapalli, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaasch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohn, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorsheim, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liewehr, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bronder, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feigenbaum, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camphausen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meltzer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, Q. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeg, P. S.</span><span> </span><span class="NLM_article-title">Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6148</span><span class="NLM_x">–</span> <span class="NLM_lpage">6157</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1158%2F1078-0432.CCR-09-1039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19789319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtF2lurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6148-6157&author=D.+Palmieriauthor=P.+R.+Lockmanauthor=F.+C.+Thomasauthor=E.+Huaauthor=J.+Herringauthor=E.+Hargraveauthor=M.+Johnsonauthor=N.+Floresauthor=Y.+Qianauthor=E.+Vega-Valleauthor=K.+S.+Taskarauthor=V.+Rudrarajuauthor=R.+K.+Mittapalliauthor=J.+A.+Gaaschauthor=K.+A.+Bohnauthor=H.+R.+Thorsheimauthor=D.+J.+Liewehrauthor=S.+Davisauthor=J.+F.+Reillyauthor=R.+Walkerauthor=J.+L.+Bronderauthor=L.+Feigenbaumauthor=S.+M.+Steinbergauthor=K.+Camphausenauthor=P.+S.+Meltzerauthor=V.+M.+Richonauthor=Q.+R.+Smithauthor=P.+S.+Steeg&title=Vorinostat+Inhibits+Brain+Metastatic+Colonization+in+a+Model+of+Triple-Negative+Breast+Cancer+and+Induces+DNA+Double-Strand+Breaks&doi=10.1158%2F1078-0432.CCR-09-1039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks</span></div><div class="casAuthors">Palmieri, Diane; Lockman, Paul R.; Thomas, Fancy C.; Hua, Emily; Herring, Jeanne; Hargrave, Elizabeth; Johnson, Matthew; Flores, Natasha; Qian, Yongzhen; Vega-Valle, Eleazar; Taskar, Kunal S.; Rudraraju, Vinay; Mittapalli, Rajendar K.; Gaasch, Julie A.; Bohn, Kaci A.; Thorsheim, Helen R.; Liewehr, David J.; Davis, Sean; Reilly, John F.; Walker, Robert; Bronder, Julie L.; Feigenbaum, Lionel; Steinberg, Seth M.; Camphausen, Kevin; Meltzer, Paul S.; Richon, Victoria M.; Smith, Quentin R.; Steeg, Patricia S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6148-6157</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: As chemotherapy and mol. therapy improve the systemic survival of breast cancer patients, the incidence of brain metastases increases.  Few therapeutic strategies exist for the treatment of brain metastases because the blood-brain barrier severely limits drug access.  We report the pharmacokinetic, efficacy, and mechanism of action studies for the histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclin. model of brain metastasis of triple-neg. breast cancer.  Exptl. Design: The 231-BR brain trophic subline of the MDA-MB-231 human breast cancer cell line was injected into immunocompromised mice for pharmacokinetic and metastasis studies.  Pharmacodynamic studies compared histone acetylation, apoptosis, proliferation, and DNA damage in vitro and in vivo.  Results: Following systemic administration, uptake of [14C]vorinostat was significant into normal rodent brain and accumulation was up to 3-fold higher in a proportion of metastases formed by 231-BR cells.  Vorinostat prevented the development of 231-BR micrometastases by 28% (P = 0.017) and large metastases by 62% (P < 0.0001) compared with vehicle-treated mice when treatment was initiated on day 3 post-injection.  The inhibitory activity of vorinostat as a single agent was linked to a novel function in vivo: induction of DNA double-strand breaks assocd. with the down-regulation of the DNA repair gene Rad52.  Conclusions: We report the first preclin. data for the prevention of brain metastasis of triple-neg. breast cancer.  Vorinostat is brain permeable and can prevent the formation of brain metastases by 62%.  Its mechanism of action involves the induction of DNA double-strand breaks, suggesting rational combinations with DNA active drugs or radiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z2K-TIM7nrVg90H21EOLACvtfcHk0ljcpjdit39Bvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtF2lurzF&md5=9fc1a8b610d29417c74c943b6d892518</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1039%26sid%3Dliteratum%253Aachs%26aulast%3DPalmieri%26aufirst%3DD.%26aulast%3DLockman%26aufirst%3DP.%2BR.%26aulast%3DThomas%26aufirst%3DF.%2BC.%26aulast%3DHua%26aufirst%3DE.%26aulast%3DHerring%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DE.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DFlores%26aufirst%3DN.%26aulast%3DQian%26aufirst%3DY.%26aulast%3DVega-Valle%26aufirst%3DE.%26aulast%3DTaskar%26aufirst%3DK.%2BS.%26aulast%3DRudraraju%26aufirst%3DV.%26aulast%3DMittapalli%26aufirst%3DR.%2BK.%26aulast%3DGaasch%26aufirst%3DJ.%2BA.%26aulast%3DBohn%26aufirst%3DK.%2BA.%26aulast%3DThorsheim%26aufirst%3DH.%2BR.%26aulast%3DLiewehr%26aufirst%3DD.%2BJ.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DWalker%26aufirst%3DR.%26aulast%3DBronder%26aufirst%3DJ.%2BL.%26aulast%3DFeigenbaum%26aufirst%3DL.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DCamphausen%26aufirst%3DK.%26aulast%3DMeltzer%26aufirst%3DP.%2BS.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DSmith%26aufirst%3DQ.%2BR.%26aulast%3DSteeg%26aufirst%3DP.%2BS.%26atitle%3DVorinostat%2520Inhibits%2520Brain%2520Metastatic%2520Colonization%2520in%2520a%2520Model%2520of%2520Triple-Negative%2520Breast%2520Cancer%2520and%2520Induces%2520DNA%2520Double-Strand%2520Breaks%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6148%26epage%3D6157%26doi%3D10.1158%2F1078-0432.CCR-09-1039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Zimmermann, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehár, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C. T.</span><span> </span><span class="NLM_article-title">Multi-Target Therapeutics: When the Whole Is Greater than the Sum of the Parts</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span><span class="refDoi"> DOI: 10.1016/j.drudis.2006.11.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.drudis.2006.11.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=17198971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=34-42&author=G.+R.+Zimmermannauthor=J.+Leh%C3%A1rauthor=C.+T.+Keith&title=Multi-Target+Therapeutics%3A+When+the+Whole+Is+Greater+than+the+Sum+of+the+Parts&doi=10.1016%2Fj.drudis.2006.11.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target therapeutics: when the whole is greater than the sum of the parts</span></div><div class="casAuthors">Zimmermann Grant R; Lehar Joseph; Keith Curtis T</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">34-42</span>
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    </div><div class="casAbstract">Drugs designed to act against individual molecular targets cannot usually combat multigenic diseases such as cancer, or diseases that affect multiple tissues or cell types such as diabetes and immunoinflammatory disorders.  Combination drugs that impact multiple targets simultaneously are better at controlling complex disease systems, are less prone to drug resistance and are the standard of care in many important therapeutic areas.  The combination drugs currently employed are primarily of rational design, but the increased efficacy they provide justifies in vitro discovery efforts for identifying novel multi-target mechanisms.  In this review, we discuss the biological rationale for combination therapeutics, review some existing combination drugs and present a systematic approach to identify interactions between molecular pathways that could be leveraged for therapeutic benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI14vYK2Q1LENHe_gFldTbfW6udTcc2eb1hoDTCRuYk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2s%252Fgt1ygtQ%253D%253D&md5=66715499ce21c2855dc6c477aa87f161</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2006.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2006.11.008%26sid%3Dliteratum%253Aachs%26aulast%3DZimmermann%26aufirst%3DG.%2BR.%26aulast%3DLeh%25C3%25A1r%26aufirst%3DJ.%26aulast%3DKeith%26aufirst%3DC.%2BT.%26atitle%3DMulti-Target%2520Therapeutics%253A%2520When%2520the%2520Whole%2520Is%2520Greater%2520than%2520the%2520Sum%2520of%2520the%2520Parts%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2007%26volume%3D12%26spage%3D34%26epage%3D42%26doi%3D10.1016%2Fj.drudis.2006.11.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Bischoff, E.</span><span> </span><span class="NLM_article-title">Potency, Selectivity, and Consequences of Nonselectivity of PDE Inhibition</span> <span class="citation_source-journal">Int. J. Impotence Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 1</span><span class="NLM_x">) </span> <span class="NLM_fpage">S11</span><span class="NLM_x">–</span> <span class="NLM_lpage">S14</span><span class="refDoi"> DOI: 10.1038/sj.ijir.3901208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fsj.ijir.3901208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=15224129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2004&pages=S11-S14&issue=Suppl+1&author=E.+Bischoff&title=Potency%2C+Selectivity%2C+and+Consequences+of+Nonselectivity+of+PDE+Inhibition&doi=10.1038%2Fsj.ijir.3901208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Potency, selectivity, and consequences of nonselectivity of PDE inhibition</span></div><div class="casAuthors">Bischoff, E.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Impotence Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S11-S14</span>CODEN:
                <span class="NLM_cas:coden">IJIRFB</span>;
        ISSN:<span class="NLM_cas:issn">0955-9930</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phosphodiesterases (PDEs) play a decisive role in cyclic nucleotide-mediated intracellular signaling.  As PDEs are expressed in a variety of tissues, selectivity is a prerequisite for a therapeutically applicable PDE inhibitor.  Sildenafil, vardenafil, and tadalafil are selective for PDE5, with vardenafil exhibiting the highest potency and minimal inhibition of other PDEs, with the exception of PDE6.  Tadalafil is extremely selective for PDE5, but also potently inhibits PDE11, an enzyme with unknown physiol. function.  As PDE1 is expressed in the brain, myocardium, and vascular smooth muscle cells, nonselectivity with respect to this enzyme (selectivity: tadalafil > vardenafil > sildenafil) may result in vasodilation and tachycardia.  Inhibition of PDE6 (selectivity: tadalafil > vardenafil ≃ sildenafil), which is expressed only in retina and functions in visual transduction, can transiently disturb vision.  PDE5 inhibitors may also indirectly inhibit PDE3 by increasing cyclic guanosine monophospate levels, thereby elevating heart rate and vasodilation while inhibiting platelet aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGbqbZmAdPM7Vg90H21EOLACvtfcHk0liFEDXE4CLOBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlt1Sjsb8%253D&md5=48ad9f175e05fd5c2f4b540f5f1ac367</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fsj.ijir.3901208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ijir.3901208%26sid%3Dliteratum%253Aachs%26aulast%3DBischoff%26aufirst%3DE.%26atitle%3DPotency%252C%2520Selectivity%252C%2520and%2520Consequences%2520of%2520Nonselectivity%2520of%2520PDE%2520Inhibition%26jtitle%3DInt.%2520J.%2520Impotence%2520Res.%26date%3D2004%26volume%3D16%26issue%3DSuppl%25201%26spage%3DS11%26epage%3DS14%26doi%3D10.1038%2Fsj.ijir.3901208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimer’s Disease</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5545</span><span class="NLM_x">–</span> <span class="NLM_lpage">5553</span><span class="refDoi"> DOI: 10.2174/092986711798347315</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.2174%2F092986711798347315" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=22172064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=5545-5553&author=M.+Cuadrado-Tejedorauthor=A.+Garc%C3%ADa-Ostaauthor=A.+Ricobarazaauthor=J.+Oyarzabalauthor=R.+Franco&title=Defining+the+Mechanism+of+Action+of+4-Phenylbutyrate+to+Develop+a+Small-Molecule-Based+Therapy+for+Alzheimer%E2%80%99s+Disease&doi=10.2174%2F092986711798347315"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease</span></div><div class="casAuthors">Cuadrado-Tejedor, M.; Garcia-Osta, A.; Ricobaraza, A.; Oyarzabal, J.; Franco, R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5545-5553</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  4-Phenylbutyrate (PBA) is a small mol. that restores cognitive deficits in animal models of Alzheimer's disease (AD).  Although the mol. basis of the cognitive benefits of PBA remains unknown, a multi-modal/multi-target mechanism has been proposed.  Putative targets of this drug are different from those of drugs that are now used in clin. trials.  As PBA is already administered to patients with congenital defects affecting enzymes in the urea cycle, it can be rapidly tested in AD clin. trials.  However, the main drawback to its therapeutic use is the high dosage required (up to 15 g/day).  Thus, deciphering the precise mechanism(s) of action of this drug may enable novel drugs with similar therapeutic effects to PBA to be developed that can be used at more manageable doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosAevZlfyhp7Vg90H21EOLACvtfcHk0lhs2_d0jVu57Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12ntbbL&md5=0703163333de9afce25c352e4ef98df5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2174%2F092986711798347315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711798347315%26sid%3Dliteratum%253Aachs%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DDefining%2520the%2520Mechanism%2520of%2520Action%2520of%25204-Phenylbutyrate%2520to%2520Develop%2520a%2520Small-Molecule-Based%2520Therapy%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D5545%26epage%3D5553%26doi%3D10.2174%2F092986711798347315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Atadja, P.</span><span> </span><span class="NLM_article-title">Development of the Pan-DAC Inhibitor Panobinostat (LBH589): Successes and Challenges</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">280</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.1016/j.canlet.2009.02.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.canlet.2009.02.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19344997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=280&publication_year=2009&pages=233-241&author=P.+Atadja&title=Development+of+the+Pan-DAC+Inhibitor+Panobinostat+%28LBH589%29%3A+Successes+and+Challenges&doi=10.1016%2Fj.canlet.2009.02.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges</span></div><div class="casAuthors">Atadja, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">280</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins.  The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition of all HDAC enzymes implicated in cancer and has demonstrated potent anti-tumor activity in preclin. models and promising clin. efficacy in cancer patients.  In this review we discuss the successes and challenges surrounding the development of panobinostat, focusing on its proposed mechanism of action, preclin. anti-tumor activity, and early clin. efficacy in hematol. and solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSTYxNKUMt7bVg90H21EOLACvtfcHk0lhs2_d0jVu57Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmsF2jtL4%253D&md5=4c487a2f8dc13f72cecf105d9fae97d9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.02.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.02.019%26sid%3Dliteratum%253Aachs%26aulast%3DAtadja%26aufirst%3DP.%26atitle%3DDevelopment%2520of%2520the%2520Pan-DAC%2520Inhibitor%2520Panobinostat%2520%2528LBH589%2529%253A%2520Successes%2520and%2520Challenges%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D280%26spage%3D233%26epage%3D241%26doi%3D10.1016%2Fj.canlet.2009.02.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Arts, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beliën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vreys, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bol, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talloen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goris, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andries, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angibaud, P.</span><span> </span><span class="NLM_article-title">JNJ-26481585, a Novel “second-Generation” oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">6841</span><span class="NLM_x">–</span> <span class="NLM_lpage">6851</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-0547</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1158%2F1078-0432.CCR-09-0547" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=19861438" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=6841-6851&author=J.+Artsauthor=P.+Kingauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=A.+Beli%C3%ABnauthor=L.+Janssenauthor=I.+Pilatteauthor=B.+Rouxauthor=L.+Decraneauthor=R.+Gilissenauthor=I.+Hicksonauthor=V.+Vreysauthor=E.+Coxauthor=K.+Bolauthor=W.+Talloenauthor=I.+Gorisauthor=L.+Andriesauthor=M.+Du+Jardinauthor=M.+Janicotauthor=M.+Pageauthor=K.+van+Emelenauthor=P.+Angibaud&title=JNJ-26481585%2C+a+Novel+%E2%80%9Csecond-Generation%E2%80%9D+oral+Histone+Deacetylase+Inhibitor%2C+Shows+Broad-Spectrum+Preclinical+Antitumoral+Activity&doi=10.1158%2F1078-0432.CCR-09-0547"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity</span></div><div class="casAuthors">Arts, Janine; King, Peter; Marien, Ann; Floren, Wim; Belien, Ann; Janssen, Lut; Pilatte, Isabelle; Roux, Bruno; Decrane, Laurence; Gilissen, Ron; Hickson, Ian; Vreys, Veronique; Cox, Eugene; Bol, Kees; Talloen, Willem; Goris, Ilse; Andries, Luc; Du Jardin, Marc; Janicot, Michel; Page, Martin; van Emelen, Kristof; Angibaud, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">6841-6851</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Histone deacetylase (HDAC) inhibitors have shown promising clin. activity in the treatment of hematol. malignancies, but their activity in solid tumor indications has been limited.  Most HDAC inhibitors in clin. development only transiently induce histone acetylation in tumor tissue.  Here, we sought to identify a "second-generation" class I HDAC inhibitor with prolonged pharmacodynamic response in vivo, to assess whether this results in superior antitumoral efficacy.  Exptl. Design: To identify novel HDAC inhibitors with superior pharmacodynamic properties, we developed a preclin. in vivo tumor model, in which tumor cells have been engineered to express fluorescent protein dependent on HDAC1 inhibition, thereby allowing noninvasive real-time evaluation of the tumor response to HDAC inhibitors.  Results: In vivo pharmacodynamic anal. of 140 potent pyrimidyl-hydroxamic acid analogs resulted in the identification of JNJ-26481585.  Once daily oral administration of JNJ-26481585 induced continuous histone H3 acetylation.  The prolonged pharmacodynamic response translated into complete tumor growth inhibition in Ras mutant HCT116 colon carcinoma xenografts, whereas 5-fluorouracil was less active.  JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.  Further characterization revealed that JNJ-26481585 is a pan-HDAC inhibitor with marked potency toward HDAC1 (IC50, 0.16 nmol/L).  Conclusions: The potent antitumor activity as a single agent in preclin. models combined with its favorable pharmacodynamic profile makes JNJ-26481585 a promising "second-generation" HDAC inhibitor.  The compd. is currently in clin. studies, to evaluate its potential applicability in a broad spectrum of both solid and hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKc9hyMiADZrVg90H21EOLACvtfcHk0lhs2_d0jVu57Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtl2ktLzE&md5=8f199c25c92c967a76f273d879d6c577</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0547&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0547%26sid%3Dliteratum%253Aachs%26aulast%3DArts%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DP.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DBeli%25C3%25ABn%26aufirst%3DA.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DHickson%26aufirst%3DI.%26aulast%3DVreys%26aufirst%3DV.%26aulast%3DCox%26aufirst%3DE.%26aulast%3DBol%26aufirst%3DK.%26aulast%3DTalloen%26aufirst%3DW.%26aulast%3DGoris%26aufirst%3DI.%26aulast%3DAndries%26aufirst%3DL.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DPage%26aufirst%3DM.%26aulast%3Dvan%2BEmelen%26aufirst%3DK.%26aulast%3DAngibaud%26aufirst%3DP.%26atitle%3DJNJ-26481585%252C%2520a%2520Novel%2520%25E2%2580%259Csecond-Generation%25E2%2580%259D%2520oral%2520Histone%2520Deacetylase%2520Inhibitor%252C%2520Shows%2520Broad-Spectrum%2520Preclinical%2520Antitumoral%2520Activity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D6841%26epage%3D6851%26doi%3D10.1158%2F1078-0432.CCR-09-0547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Papavassiliou, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papavassiliou, A. G.</span><span> </span><span class="NLM_article-title">Histone Deacetylases Inhibitors: Conjugation to Other Anti-Tumour Pharmacophores Provides Novel Tools for Cancer Treatment</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">291</span><span class="NLM_x">–</span> <span class="NLM_lpage">294</span><span class="refDoi"> DOI: 10.1517/13543784.2014.857401</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1517%2F13543784.2014.857401" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=291-294&author=K.+A.+Papavassiliouauthor=A.+G.+Papavassiliou&title=Histone+Deacetylases+Inhibitors%3A+Conjugation+to+Other+Anti-Tumour+Pharmacophores+Provides+Novel+Tools+for+Cancer+Treatment&doi=10.1517%2F13543784.2014.857401"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1517%2F13543784.2014.857401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2014.857401%26sid%3Dliteratum%253Aachs%26aulast%3DPapavassiliou%26aufirst%3DK.%2BA.%26aulast%3DPapavassiliou%26aufirst%3DA.%2BG.%26atitle%3DHistone%2520Deacetylases%2520Inhibitors%253A%2520Conjugation%2520to%2520Other%2520Anti-Tumour%2520Pharmacophores%2520Provides%2520Novel%2520Tools%2520for%2520Cancer%2520Treatment%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2014%26volume%3D23%26spage%3D291%26epage%3D294%26doi%3D10.1517%2F13543784.2014.857401" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Paris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porcelloni, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binaschi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fattori, D.</span><span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: From Bench to Clinic</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">1505</span><span class="NLM_x">–</span> <span class="NLM_lpage">1529</span><span class="refDoi"> DOI: 10.1021/jm7011408</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7011408" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1505-1529&author=M.+Parisauthor=M.+Porcelloniauthor=M.+Binaschiauthor=D.+Fattori&title=Histone+Deacetylase+Inhibitors%3A+From+Bench+to+Clinic&doi=10.1021%2Fjm7011408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase Inhibitors: From Bench to Clinic</span></div><div class="casAuthors">Paris, Marielle; Porcelloni, Marina; Binaschi, Monica; Fattori, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1505-1529</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Advances in the design and pharmacol. of Histone deacetylase inhibitors is discussed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcMej4R03jKbVg90H21EOLACvtfcHk0ljenqLczJUfeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKksbs%253D&md5=fd5e8c74c510835517fe5255c5c7dc5b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm7011408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7011408%26sid%3Dliteratum%253Aachs%26aulast%3DParis%26aufirst%3DM.%26aulast%3DPorcelloni%26aufirst%3DM.%26aulast%3DBinaschi%26aufirst%3DM.%26aulast%3DFattori%26aufirst%3DD.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520From%2520Bench%2520to%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1505%26epage%3D1529%26doi%3D10.1021%2Fjm7011408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Thaler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mercurio, C.</span><span> </span><span class="NLM_article-title">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">523</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span><span class="refDoi"> DOI: 10.1002/cmdc.201300413</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1002%2Fcmdc.201300413" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=24730063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=523-526&author=F.+Thalerauthor=C.+Mercurio&title=Towards+Selective+Inhibition+of+Histone+Deacetylase+Isoforms%3A+What+Has+Been+Achieved%2C+Where+We+Are+and+What+Will+Be+Next&doi=10.1002%2Fcmdc.201300413"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Towards Selective Inhibition of Histone Deacetylase Isoforms: What Has Been Achieved, Where We Are and What Will Be Next</span></div><div class="casAuthors">Thaler, Florian; Mercurio, Ciro</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">523-536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) are widely studied targets for the treatment of cancer and other diseases.  Up to now, over twenty HDAC inhibitors have entered clin. studies and two of them have already reached the market, namely the hydroxamic acid deriv. SAHA (vorinostat, Zolinza) and the cyclic depsipeptide FK228 (romidepsin, Istodax) that have been approved for the treatment of cutaneous T-cell lymphoma (CTCL).  A common aspect of the first HDAC inhibitors is the absence of any particular selectivity towards specific isoenzymes.  Some of mols. resulted to be "pan"-HDAC inhibitors, while others are class I selective.  In the meantime, the knowledge of HDAC biol. has continuously progressed.  Key advances in the structural biol. of various isoenzymes, reliable mol. homol. models as well as suitable biol. assays have provided new tools for drug discovery activities.  This Minireview aims at surveying these recent developments as well as the design, synthesis and biol. characterization of isoform-selective derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKncV8XbSHkrVg90H21EOLACvtfcHk0ljenqLczJUfeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFentrnP&md5=72626d372ef5d953be388f3513c87e0b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300413%26sid%3Dliteratum%253Aachs%26aulast%3DThaler%26aufirst%3DF.%26aulast%3DMercurio%26aufirst%3DC.%26atitle%3DTowards%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%2520Isoforms%253A%2520What%2520Has%2520Been%2520Achieved%252C%2520Where%2520We%2520Are%2520and%2520What%2520Will%2520Be%2520Next%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D523%26epage%3D526%26doi%3D10.1002%2Fcmdc.201300413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Card, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillette, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neiman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milburn, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span> </span><span class="NLM_article-title">A Glutamine Switch Mechanism for Nucleotide Selectivity by Phosphodiesterases</span> <span class="citation_source-journal">Mol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span><span class="refDoi"> DOI: 10.1016/j.molcel.2004.07.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.molcel.2004.07.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=15260978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=279-286&author=K.+Y.+J.+Zhangauthor=G.+L.+Cardauthor=Y.+Suzukiauthor=D.+R.+Artisauthor=D.+Fongauthor=S.+Gilletteauthor=D.+Hsiehauthor=J.+Neimanauthor=B.+L.+Westauthor=C.+Zhangauthor=M.+V.+Milburnauthor=S.-H.+Kimauthor=J.+Schlessingerauthor=G.+Bollag&title=A+Glutamine+Switch+Mechanism+for+Nucleotide+Selectivity+by+Phosphodiesterases&doi=10.1016%2Fj.molcel.2004.07.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases</span></div><div class="casAuthors">Zhang, Kam Y. J.; Card, Graeme L.; Suzuki, Yoshihisa; Artis, D. Richard; Fong, Daniel; Gillette, Sam; Hsieh, Davin; Neiman, Joshua; West, Brian L.; Zhang, Chao; Milburn, Michael V.; Kim, Sung-Hou; Schlessinger, Joseph; Bollag, Gideon</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-286</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) comprise a family of enzymes that modulate the immune response, inflammation, and memory, among many other functions.  There are three types of PDEs: cAMP-specific, cGMP-specific, and dual-specific.  Here we describe the mechanism of nucleotide selectivity on the basis of high-resoln. co-crystal structures of the cAMP-specific PDE4B and PDE4D with AMP, the cGMP-specific PDE5A with GMP, and the apo-structure of the dual-specific PDE1B.  These structures show that an invariant glutamine functions as the key specificity determinant by a "glutamine switch" mechanism for recognizing the purine moiety in cAMP or cGMP.  The surrounding residues anchor the glutamine residue in different orientations for cAMP and for cGMP.  The PDE1B structure shows that in dual-specific PDEs a key histidine residue may enable the invariant glutamine to toggle between cAMP and cGMP.  The structural understanding of nucleotide binding enables the design of new PDE inhibitors that may treat diseases in which cyclic nucleotides play a crit. role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGorRXGTDdAa1bVg90H21EOLACvtfcHk0ljenqLczJUfeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1ektLs%253D&md5=32fab6a75031a67290ec5eda2c3e080b</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2004.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2004.07.005%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DCard%26aufirst%3DG.%2BL.%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DFong%26aufirst%3DD.%26aulast%3DGillette%26aufirst%3DS.%26aulast%3DHsieh%26aufirst%3DD.%26aulast%3DNeiman%26aufirst%3DJ.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DMilburn%26aufirst%3DM.%2BV.%26aulast%3DKim%26aufirst%3DS.-H.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DBollag%26aufirst%3DG.%26atitle%3DA%2520Glutamine%2520Switch%2520Mechanism%2520for%2520Nucleotide%2520Selectivity%2520by%2520Phosphodiesterases%26jtitle%3DMol.%2520Cell%26date%3D2004%26volume%3D15%26spage%3D279%26epage%3D286%26doi%3D10.1016%2Fj.molcel.2004.07.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Lauffer, B. E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mintzer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fong, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zilberleyb, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flicke, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ritscher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorowicz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vallero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunzner, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modrusan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neumann, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koth, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupardus, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminker, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, P.</span><span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">288</span><span class="NLM_x">, </span> <span class="NLM_fpage">26926</span><span class="NLM_x">–</span> <span class="NLM_lpage">26943</span><span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+L.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+Deacetylase+%28HDAC%29+Inhibitor+Kinetic+Rate+Constants+Correlate+with+Cellular+Histone+Acetylation+but+Not+Transcription+and+Cell+Viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0ljoz_Kdlnuwzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%2BL.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitor%2520Kinetic%2520Rate%2520Constants%2520Correlate%2520with%2520Cellular%2520Histone%2520Acetylation%2520but%2520Not%2520Transcription%2520and%2520Cell%2520Viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Angibaud, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Emelen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decrane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Brandt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Holte, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pilatte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roux, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poncelet, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speybrouck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Queguiner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaurrand, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariën, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floren, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verdonck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Dun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Gompel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilissen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du Jardin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peeters, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noppe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hijfte, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freyne, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janicot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arts, J.</span><span> </span><span class="NLM_article-title">Identification of a Series of Substituted 2-Piperazinyl-5-Pyrimidylhydroxamic Acids as Potent Histone Deacetylase Inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">298</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.bmcl.2009.10.118" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=294-298&author=P.+Angibaudauthor=K.+Van+Emelenauthor=L.+Decraneauthor=S.+van+Brandtauthor=P.+Ten+Holteauthor=I.+Pilatteauthor=B.+Rouxauthor=V.+Ponceletauthor=D.+Speybrouckauthor=L.+Queguinerauthor=S.+Gaurrandauthor=A.+Mari%C3%ABnauthor=W.+Florenauthor=L.+Janssenauthor=M.+Verdonckauthor=J.+van+Dunauthor=J.+van+Gompelauthor=R.+Gilissenauthor=C.+Mackieauthor=M.+Du+Jardinauthor=J.+Peetersauthor=M.+Noppeauthor=L.+Van+Hijfteauthor=E.+Freyneauthor=M.+Pageauthor=M.+Janicotauthor=J.+Arts&title=Identification+of+a+Series+of+Substituted+2-Piperazinyl-5-Pyrimidylhydroxamic+Acids+as+Potent+Histone+Deacetylase+Inhibitors&doi=10.1016%2Fj.bmcl.2009.10.118"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DAngibaud%26aufirst%3DP.%26aulast%3DVan%2BEmelen%26aufirst%3DK.%26aulast%3DDecrane%26aufirst%3DL.%26aulast%3Dvan%2BBrandt%26aufirst%3DS.%26aulast%3DTen%2BHolte%26aufirst%3DP.%26aulast%3DPilatte%26aufirst%3DI.%26aulast%3DRoux%26aufirst%3DB.%26aulast%3DPoncelet%26aufirst%3DV.%26aulast%3DSpeybrouck%26aufirst%3DD.%26aulast%3DQueguiner%26aufirst%3DL.%26aulast%3DGaurrand%26aufirst%3DS.%26aulast%3DMari%25C3%25ABn%26aufirst%3DA.%26aulast%3DFloren%26aufirst%3DW.%26aulast%3DJanssen%26aufirst%3DL.%26aulast%3DVerdonck%26aufirst%3DM.%26aulast%3Dvan%2BDun%26aufirst%3DJ.%26aulast%3Dvan%2BGompel%26aufirst%3DJ.%26aulast%3DGilissen%26aufirst%3DR.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DDu%2BJardin%26aufirst%3DM.%26aulast%3DPeeters%26aufirst%3DJ.%26aulast%3DNoppe%26aufirst%3DM.%26aulast%3DVan%2BHijfte%26aufirst%3DL.%26aulast%3DFreyne%26aufirst%3DE.%26aulast%3DPage%26aufirst%3DM.%26aulast%3DJanicot%26aufirst%3DM.%26aulast%3DArts%26aufirst%3DJ.%26atitle%3DIdentification%2520of%2520a%2520Series%2520of%2520Substituted%25202-Piperazinyl-5-Pyrimidylhydroxamic%2520Acids%2520as%2520Potent%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D294%26epage%3D298%26doi%3D10.1016%2Fj.bmcl.2009.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>BPS Bioscience Home Page. <a href="https://bpsbioscience.com" class="extLink">https://bpsbioscience.com</a> (accessed Jul 1,<span class="NLM_x"> </span><span class="NLM_year">2016</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=BPS+Bioscience+Home+Page.+https%3A%2F%2Fbpsbioscience.com+%28accessed+Jul+1%2C+2016%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Rankovic, Z.</span><span> </span><span class="NLM_article-title">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">2584</span><span class="NLM_x">–</span> <span class="NLM_lpage">2608</span><span class="refDoi"> DOI: 10.1021/jm501535r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501535r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2584-2608&author=Z.+Rankovic&title=CNS+Drug+Design%3A+Balancing+Physicochemical+Properties+for+Optimal+Brain+Exposure&doi=10.1021%2Fjm501535r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure</span></div><div class="casAuthors">Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2584-2608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The human brain is a uniquely complex organ, which has evolved a sophisticated protection system to prevent injury from external insults and toxins.  Designing mols. that can overcome this protection system and achieve optimal concn. at the desired therapeutic target in the brain is a specific and major challenge for medicinal chemists working in CNS drug discovery.  Analogous to the now widely accepted rule of 5 in the design of oral drugs, the physicochem. properties required for optimal brain exposure have been extensively studied in an attempt to similarly define the attributes of successful CNS drugs and drug candidates.  This body of work is systematically reviewed here, with a particular emphasis on the interplay between the most crit. physicochem. and pharmacokinetic parameters of CNS drugs as well as their impact on medicinal chem. strategies toward mols. with optimal brain exposure.  A summary of modern CNS pharmacokinetic concepts and methods is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8V0N1j49uuLVg90H21EOLACvtfcHk0lhTR7lorGE_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVyhsrrP&md5=f01e3f2dc4e2eff7b0618124277a5cf8</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501535r%26sid%3Dliteratum%253Aachs%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DCNS%2520Drug%2520Design%253A%2520Balancing%2520Physicochemical%2520Properties%2520for%2520Optimal%2520Brain%2520Exposure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2584%26epage%3D2608%26doi%3D10.1021%2Fjm501535r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Mensch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustijns, P.</span><span> </span><span class="NLM_article-title">In Vivo, in Vitro and in Silico Methods for Small Molecule Transfer across the BBB</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">98</span><span class="NLM_x">, </span> <span class="NLM_fpage">4429</span><span class="NLM_x">–</span> <span class="NLM_lpage">4468</span><span class="refDoi"> DOI: 10.1002/jps.21745</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1002%2Fjps.21745" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2009&pages=4429-4468&author=J.+Menschauthor=J.+Oyarzabalauthor=C.+Mackieauthor=P.+Augustijns&title=In+Vivo%2C+in+Vitro+and+in+Silico+Methods+for+Small+Molecule+Transfer+across+the+BBB&doi=10.1002%2Fjps.21745"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fjps.21745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21745%26sid%3Dliteratum%253Aachs%26aulast%3DMensch%26aufirst%3DJ.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DMackie%26aufirst%3DC.%26aulast%3DAugustijns%26aufirst%3DP.%26atitle%3DIn%2520Vivo%252C%2520in%2520Vitro%2520and%2520in%2520Silico%2520Methods%2520for%2520Small%2520Molecule%2520Transfer%2520across%2520the%2520BBB%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2009%26volume%3D98%26spage%3D4429%26epage%3D4468%26doi%3D10.1002%2Fjps.21745" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Terrett, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P.</span><span> </span><span class="NLM_article-title">Sildenafil (Viagra TM), a Potent and Selective Inhibitor of Type 5 CGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1819</span><span class="NLM_x">–</span> <span class="NLM_lpage">1824</span><span class="refDoi"> DOI: 10.1016/0960-894X(96)00323-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2F0960-894X%2896%2900323-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=1819-1824&author=N.+K.+Terrettauthor=A.+S.+Bellauthor=D.+Brownauthor=P.+Ellis&title=Sildenafil+%28Viagra+TM%29%2C+a+Potent+and+Selective+Inhibitor+of+Type+5+CGMP+Phosphodiesterase+with+Utility+for+the+Treatment+of+Male+Erectile+Dysfunction&doi=10.1016%2F0960-894X%2896%2900323-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900323-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900323-X%26sid%3Dliteratum%253Aachs%26aulast%3DTerrett%26aufirst%3DN.%2BK.%26aulast%3DBell%26aufirst%3DA.%2BS.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DEllis%26aufirst%3DP.%26atitle%3DSildenafil%2520%2528Viagra%2520TM%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Inhibitor%2520of%2520Type%25205%2520CGMP%2520Phosphodiesterase%2520with%2520Utility%2520for%2520the%2520Treatment%2520of%2520Male%2520Erectile%2520Dysfunction%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D1819%26epage%3D1824%26doi%3D10.1016%2F0960-894X%2896%2900323-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Sung, B.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hwang, K. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeon, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyun, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eum, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, J. M.</span><span> </span><span class="NLM_article-title">Structure of the Catalytic Domain of Human Phosphodiesterase 5 with Bound Drug Molecules</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">425</span><span class="NLM_x">, </span> <span class="NLM_fpage">98</span><span class="NLM_x">–</span> <span class="NLM_lpage">102</span><span class="refDoi"> DOI: 10.1038/nature01914</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnature01914" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=12955149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=425&publication_year=2003&pages=98-102&author=B.-J.+Sungauthor=K.+Y.+Hwangauthor=Y.+H.+Jeonauthor=J.+I.+Leeauthor=Y.-S.+Heoauthor=J.+H.+Kimauthor=J.+Moonauthor=J.+M.+Yoonauthor=Y.-L.+Hyunauthor=E.+Kimauthor=S.+J.+Eumauthor=S.-Y.+Parkauthor=J.-O.+Leeauthor=T.+G.+Leeauthor=S.+Roauthor=J.+M.+Cho&title=Structure+of+the+Catalytic+Domain+of+Human+Phosphodiesterase+5+with+Bound+Drug+Molecules&doi=10.1038%2Fnature01914"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules</span></div><div class="casAuthors">Sung, Byung-Je; Hwang, Kwang Yeon; Jeon, Young Ho; Lee, Jae Il; Heo, Yong-Seok; Kim, Jin Hwan; Moon, Jinho; Yoon, Jung Min; Hyun, Young-Lan; Kim, Eunmi; Eum, Sung Jin; Park, Sam-Yong; Lee, Jie-Oh; Lee, Tae Gyu; Ro, Seonggu; Cho, Joong Myung</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">425</span>
        (<span class="NLM_cas:issue">6953</span>),
    <span class="NLM_cas:pages">98-102</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cAMP and cGMP.  As essential regulators of cyclic nucleotide signaling with diverse physiol. functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction.  Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolyzing activity in human corpus cavernosum tissue.  It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction.  Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available.  Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug mols. sildenafil, tadalafil (Cialis) and vardenafil (Levitra).  These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacol. profiles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr5pTrMfa72rVg90H21EOLACvtfcHk0lhTR7lorGE_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFansrg%253D&md5=8459333ee12ed3469f7b48d6e7f9fd5d</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature01914&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01914%26sid%3Dliteratum%253Aachs%26aulast%3DSung%26aufirst%3DB.-J.%26aulast%3DHwang%26aufirst%3DK.%2BY.%26aulast%3DJeon%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BI.%26aulast%3DHeo%26aufirst%3DY.-S.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DMoon%26aufirst%3DJ.%26aulast%3DYoon%26aufirst%3DJ.%2BM.%26aulast%3DHyun%26aufirst%3DY.-L.%26aulast%3DKim%26aufirst%3DE.%26aulast%3DEum%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DS.-Y.%26aulast%3DLee%26aufirst%3DJ.-O.%26aulast%3DLee%26aufirst%3DT.%2BG.%26aulast%3DRo%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DJ.%2BM.%26atitle%3DStructure%2520of%2520the%2520Catalytic%2520Domain%2520of%2520Human%2520Phosphodiesterase%25205%2520with%2520Bound%2520Drug%2520Molecules%26jtitle%3DNature%26date%3D2003%26volume%3D425%26spage%3D98%26epage%3D102%26doi%3D10.1038%2Fnature01914" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoraghi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xin, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Multiple Conformations of Phosphodiesterase-5: Implications for Enzyme Function and Drug Development</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">21469</span><span class="NLM_x">–</span> <span class="NLM_lpage">21479</span><span class="refDoi"> DOI: 10.1074/jbc.M512527200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1074%2Fjbc.M512527200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=16735511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD28Xnt1KjsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2006&pages=21469-21479&author=H.+Wangauthor=Y.+Liuauthor=Q.+Huaiauthor=J.+Caiauthor=R.+Zoraghiauthor=S.+H.+Francisauthor=J.+D.+Corbinauthor=H.+Robinsonauthor=Z.+Xinauthor=G.+Linauthor=H.+Ke&title=Multiple+Conformations+of+Phosphodiesterase-5%3A+Implications+for+Enzyme+Function+and+Drug+Development&doi=10.1074%2Fjbc.M512527200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple Conformations of Phosphodiesterase-5: implications for enzyme function and drug development</span></div><div class="casAuthors">Wang, Huanchen; Liu, Yudong; Huai, Qing; Cai, Jiwen; Zoraghi, Roya; Francis, Sharron H.; Corbin, Jackie D.; Robinson, Howard; Xin, Zhongcheng; Lin, Guiting; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">21469-21479</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Phosphodiesterase-5 (PDE5) is the target for sildenafil, vardenafil, and tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension.  We report here the crystal structures of a fully active catalytic domain of unliganded PDE5A1 and its complexes with sildenafil or icarisid II.  These structures together with the PDE5A1-isobutyl-1-methylxanthine complex show that the H-loop (residues 660-683) at the active site of PDE5A1 has four different conformations and migrates 7-35 Å upon inhibitor binding.  In addn., the conformation of sildenafil reported herein differs significantly from those in the previous structures of chimerically hybridized or almost inactive PDE5.  Mutagenesis and kinetic analyses confirm that the H-loop is particularly important for substrate recognition and that invariant Gly659, which immediately precedes the H-loop, is crit. for optimal substrate affinity and catalytic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplF9ohkT9ogLVg90H21EOLACvtfcHk0liTCvNXfIEuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xnt1KjsLs%253D&md5=3a5ac86273a74da4a559bc6efc647181</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M512527200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M512527200%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHuai%26aufirst%3DQ.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DZoraghi%26aufirst%3DR.%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DCorbin%26aufirst%3DJ.%2BD.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DXin%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DG.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DMultiple%2520Conformations%2520of%2520Phosphodiesterase-5%253A%2520Implications%2520for%2520Enzyme%2520Function%2520and%2520Drug%2520Development%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2006%26volume%3D281%26spage%3D21469%26epage%3D21479%26doi%3D10.1074%2Fjbc.M512527200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ke, H.</span><span> </span><span class="NLM_article-title">Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">104</span><span class="NLM_x">–</span> <span class="NLM_lpage">110</span><span class="refDoi"> DOI: 10.1124/mol.107.040212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1124%2Fmol.107.040212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=17959709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslCrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=104-110&author=H.+Wangauthor=M.+Yeauthor=H.+Robinsonauthor=S.+H.+Francisauthor=H.+Ke&title=Conformational+Variations+of+Both+Phosphodiesterase-5+and+Inhibitors+Provide+the+Structural+Basis+for+the+Physiological+Effects+of+Vardenafil+and+Sildenafil&doi=10.1124%2Fmol.107.040212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil</span></div><div class="casAuthors">Wang, Huanchen; Ye, Mengchun; Robinson, Howard; Francis, Sharron H.; Ke, Hengming</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-110</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.  However, the mol. basis for these differences is puzzling because two drugs have similar chem. structures.  Reported here is a crystal structure of the fully active and nonmutated PDE5A1 catalytic domain in complex with vardenafil.  The structure shows that the conformation of the H-loop in the PDE5A1-vardenafil complex is different from those of any known structures of the unliganded PDE5 and its complexes with the inhibitors.  In addn., the mol. configuration of vardenafil differs from that of sildenafil when bound to PDE5.  It is noteworthy that the binding of vardenafil causes loss of the divalent metal ions that have been obsd. in all the previously published PDE structures.  The conformational variation of both PDE5 and the inhibitors provides structural insight into the different potencies of the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGricnXGND9IjLVg90H21EOLACvtfcHk0liTCvNXfIEuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslCrtw%253D%253D&md5=6ee464e0f2f85a3bfe195b6070d923dd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.040212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.040212%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DRobinson%26aufirst%3DH.%26aulast%3DFrancis%26aufirst%3DS.%2BH.%26aulast%3DKe%26aufirst%3DH.%26atitle%3DConformational%2520Variations%2520of%2520Both%2520Phosphodiesterase-5%2520and%2520Inhibitors%2520Provide%2520the%2520Structural%2520Basis%2520for%2520the%2520Physiological%2520Effects%2520of%2520Vardenafil%2520and%2520Sildenafil%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D104%26epage%3D110%26doi%3D10.1124%2Fmol.107.040212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span>Pipeline Pilot, version 8.5; <span class="NLM_publisher-name">Accelrys</span>: <span class="NLM_publisher-loc">San Diego, CA</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pipeline+Pilot%2C+version+8.5%3B+Accelrys%3A+San+Diego%2C+CA%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DPipeline%2520Pilot%26pub%3DAccelrys%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helquist, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiest, O.</span><span> </span><span class="NLM_article-title">Zinc Binding in HDAC Inhibitors: A DFT Study</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">5446</span><span class="NLM_x">–</span> <span class="NLM_lpage">5449</span><span class="refDoi"> DOI: 10.1021/jo070739s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070739s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmsFGgsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=5446-5449&author=D.+Wangauthor=P.+Helquistauthor=O.+Wiest&title=Zinc+Binding+in+HDAC+Inhibitors%3A+A+DFT+Study&doi=10.1021%2Fjo070739s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Zinc Binding in HDAC Inhibitors: A DFT Study</span></div><div class="casAuthors">Wang, Difei; Helquist, Paul; Wiest, Olaf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5446-5449</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are attractive targets for the treatment of cancers and a variety of other diseases.  Most currently studied HDAC inhibitors contain hydroxamic acids, which are potentially problematic in the development of practical drugs.  DFT calcns. of the binding modes and free energies of binding for a variety of other functionalities in a model active site of HDAC are described.  The protonation state of hydroxamic acids in the active site and the origin of the high affinity are discussed.  These results emphasize the importance of a carefully chosen pKa for zinc binding and provide guidance for the design of novel, non-hydroxamic acid HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGor2ZrvcCc2BLVg90H21EOLACvtfcHk0liTCvNXfIEuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmsFGgsLw%253D&md5=a5990dc23dca00224af44c2cde058ba3</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjo070739s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070739s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DWiest%26aufirst%3DO.%26atitle%3DZinc%2520Binding%2520in%2520HDAC%2520Inhibitors%253A%2520A%2520DFT%2520Study%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D5446%26epage%3D5449%26doi%3D10.1021%2Fjo070739s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kalin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brochier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistoli, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">132</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="NLM_x">–</span> <span class="NLM_lpage">10846</span><span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0limk9Zt-F6JxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Witt, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deubzer, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milde, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oehme, I.</span><span> </span><span class="NLM_article-title">HDAC Family: What Are the Cancer Relevant Targets?</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">–</span> <span class="NLM_lpage">21</span><span class="refDoi"> DOI: 10.1016/j.canlet.2008.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2Fj.canlet.2008.08.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=18824292" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2009&pages=8-21&author=O.+Wittauthor=H.+E.+Deubzerauthor=T.+Mildeauthor=I.+Oehme&title=HDAC+Family%3A+What+Are+the+Cancer+Relevant+Targets%3F&doi=10.1016%2Fj.canlet.2008.08.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC family: What are the cancer relevant targets?</span></div><div class="casAuthors">Witt, Olaf; Deubzer, Hedwig E.; Milde, Till; Oehme, Ina</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">8-21</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases comprise a family of 18 genes, which are grouped into classes I-IV based on their homol. to their resp. yeast orthologues.  Classes I, II, and IV consist of 11 family members, which are referred to as "classical" HDACs, whereas the 7 class III members are called sirtuins.  Classical HDACs are a promising novel class of anti-cancer drug targets.  First HDAC inhibitors have been evaluated in clin. trials and show activity against several cancer diseases.  However, these compds. act unselectively against several or all 11 HDAC family members.  As a consequence, clin. phase I trials document a wide range of side effects.  Therefore, the current challenge in the field is to define the cancer relevant HDAC family member(s) in a given tumor type and to design selective inhibitors, which target cancer cells but leave out normal cells.  Knockout of single HDAC family members in mice produces a variety of phenotypes ranging from early embryonic death to viable animals with only discrete alterations, indicating that potential side effects of HDAC inhibitors depend on the selectivity of the compds.  Recently, several studies have shown that certain HDAC family members are aberrantly expressed in several tumors and have non-redundant function in controlling hallmarks of cancer cells.  The aim of this review is to discuss individual HDAC family members as drug targets in cancer taking into consideration their function under physiol. conditions and their oncogenic potential in malignant disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAb3q1vc1AQrVg90H21EOLACvtfcHk0limk9Zt-F6JxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFOhsL4%253D&md5=025373367edd6bcd79b689b6bcdd92d2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DDeubzer%26aufirst%3DH.%2BE.%26aulast%3DMilde%26aufirst%3DT.%26aulast%3DOehme%26aufirst%3DI.%26atitle%3DHDAC%2520Family%253A%2520What%2520Are%2520the%2520Cancer%2520Relevant%2520Targets%253F%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D277%26spage%3D8%26epage%3D21%26doi%3D10.1016%2Fj.canlet.2008.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Gómez-Vallejo, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ugarte, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Barroso, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczupak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dopeso-Reyes, I. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lanciego, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Llop, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyarzabal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franco, R.</span><span> </span><span class="NLM_article-title">Pharmacokinetic Investigation of Sildenafil Using Positron Emission Tomography and Determination of Its Effect on Cerebrospinal Fluid cGMP Levels</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">403</span><span class="NLM_x">–</span> <span class="NLM_lpage">415</span><span class="refDoi"> DOI: 10.1111/jnc.13454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1111%2Fjnc.13454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=26641206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVKitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=2016&pages=403-415&author=V.+G%C3%B3mez-Vallejoauthor=A.+Ugarteauthor=C.+Garc%C3%ADa-Barrosoauthor=M.+Cuadrado-Tejedorauthor=B.+Szczupakauthor=I.+G.+Dopeso-Reyesauthor=J.+L.+Lanciegoauthor=A.+Garc%C3%ADa-Ostaauthor=J.+Llopauthor=J.+Oyarzabalauthor=R.+Franco&title=Pharmacokinetic+Investigation+of+Sildenafil+Using+Positron+Emission+Tomography+and+Determination+of+Its+Effect+on+Cerebrospinal+Fluid+cGMP+Levels&doi=10.1111%2Fjnc.13454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels</span></div><div class="casAuthors">Gomez-Vallejo, Vanessa; Ugarte, Ana; Garcia-Barroso, Carolina; Cuadrado-Tejedor, Mar; Szczupak, Boguslaw; Dopeso-Reyes, Iria G.; Lanciego, Jose L.; Garcia-Osta, Ana; Llop, Jordi; Oyarzabal, Julen; Franco, Rafael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">403-415</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Sildenafil (Viagra) is a selective inhibitor of phosphodiesterase type 5 (PDE5), which degrades cGMP to the linear nucleotide.  Sildenafil is acutely used in erectile dysfunction and chronically in pulmonary hypertension.  Evidence in the last decade shows that sildenafil may have potential as a therapeutic option for Alzheimer's disease or other neurodegenerative disorders.  The purpose of this work was to explore whether sildenafil crosses the blood-brain barrier.  Pharmacokinetic properties of sildenafil in rodents were investigated using 11C-radiolabeling followed by in vivo positron emission tomog. (PET) and ex vivo tissue dissection and gamma counting.  PET results in rats suggest penetration into the central nervous system.  Ex vivo data in perfused animals suggest that trapping of [11C]sildenafil within the cerebral vascular endothelium limits accumulation in the central nervous system parenchyma.  Peroral sildenafil administration to Macaca fascicularis and subsequent chem. anal. of plasma and cerebrospinal fluid (CSF) using liq. chromatog. coupled with tandem mass spectrometry showed that drug content in the CSF was high enough to achieve PDE5 inhibition, which was also demonstrated by the significant increases in CSF cGMP levels.  Central actions of sildenafil include both relaxation of the cerebral vasculature and inhibition of PDE5 in neurons and glia.  This central action of sildenafil may underlie its efficacy in neuroprotection models, and may justify the continued search for a PDE5 ligand suitable for PET imaging.  Sildenafil interacts with phosphodiesterase type 5 (PDE5) expressed in the endothelium and/or smooth muscle cells of brain vessels and also crosses the blood-brain barrier to interact with PDE5 expressed in brain cells.  At therapeutic doses, the concn. of sildenafil in the cerebrospinal fluid (CSF) is high enough to inhibit PDE5 in the neural cells (neurons and glia).  In turn, the concn. of cGMP likely increases in parenchymal cells and, as shown in the CSF.  Read the Editorial Highlight for this article on page 220.  Cover Image for this issue: doi: 10.1111/jnc.13302.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrNfPXruaaALVg90H21EOLACvtfcHk0limk9Zt-F6JxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVKitw%253D%253D&md5=6de24b35db0c575431eabc500fc87fbd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13454%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Vallejo%26aufirst%3DV.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DGarc%25C3%25ADa-Barroso%26aufirst%3DC.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DSzczupak%26aufirst%3DB.%26aulast%3DDopeso-Reyes%26aufirst%3DI.%2BG.%26aulast%3DLanciego%26aufirst%3DJ.%2BL.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26aulast%3DLlop%26aufirst%3DJ.%26aulast%3DOyarzabal%26aufirst%3DJ.%26aulast%3DFranco%26aufirst%3DR.%26atitle%3DPharmacokinetic%2520Investigation%2520of%2520Sildenafil%2520Using%2520Positron%2520Emission%2520Tomography%2520and%2520Determination%2520of%2520Its%2520Effect%2520on%2520Cerebrospinal%2520Fluid%2520cGMP%2520Levels%26jtitle%3DJ.%2520Neurochem.%26date%3D2016%26volume%3D136%26spage%3D403%26epage%3D415%26doi%3D10.1111%2Fjnc.13454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerns, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, O. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, G. T.</span><span> </span><span class="NLM_article-title">High Throughput Artificial Membrane Permeability Assay for Blood-Brain Barrier</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">223</span><span class="NLM_x">–</span> <span class="NLM_lpage">232</span><span class="refDoi"> DOI: 10.1016/S0223-5234(03)00012-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1016%2FS0223-5234%2803%2900012-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=12667689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2003&pages=223-232&author=L.+Diauthor=E.+H.+Kernsauthor=K.+Fanauthor=O.+J.+McConnellauthor=G.+T.+Carter&title=High+Throughput+Artificial+Membrane+Permeability+Assay+for+Blood-Brain+Barrier&doi=10.1016%2FS0223-5234%2803%2900012-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">High throughput artificial membrane permeability assay for blood-brain barrier</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Fan, Kristi; McConnell, Oliver J.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">223-232</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">The recent advances in high throughput screening for biol. activities and combinatorial chem. have greatly expanded the no. of drug candidates.  Rapid screening for BBB penetration potential early in drug discovery programs provides important information for compd. selection and guidance of synthesis for desirable CNS properties.  In this paper, we discuss a modification of the parallel artificial membrane permeation assay (PAMPA) for the prediction of blood-brain barrier penetration (PAMPA-BBB).  The assay was developed with 30 structurally diverse com. drugs and validated with 14 Wyeth Research compds.  The PAMPA-BBB assay has the advantages of: predicting passive blood-brain barrier penetration with high success, high throughput, low cost, and reproducibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZCg9Ka4mziLVg90H21EOLACvtfcHk0lgd6Mdeajb8OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKju7c%253D&md5=d228d5808ba8df23deed92c5e2bf3863</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0223-5234%2803%2900012-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0223-5234%252803%252900012-6%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DFan%26aufirst%3DK.%26aulast%3DMcConnell%26aufirst%3DO.%2BJ.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DHigh%2520Throughput%2520Artificial%2520Membrane%2520Permeability%2520Assay%2520for%2520Blood-Brain%2520Barrier%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2003%26volume%3D38%26spage%3D223%26epage%3D232%26doi%3D10.1016%2FS0223-5234%2803%2900012-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Gleeson, M. P.</span><span> </span><span class="NLM_article-title">Generation of a Set of Simple, Interpretable ADMET Rules of Thumb</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">817</span><span class="NLM_x">–</span> <span class="NLM_lpage">834</span><span class="refDoi"> DOI: 10.1021/jm701122q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701122q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=817-834&author=M.+P.+Gleeson&title=Generation+of+a+Set+of+Simple%2C+Interpretable+ADMET+Rules+of+Thumb&doi=10.1021%2Fjm701122q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Generation of a Set of Simple, Interpretable ADMET Rules of Thumb</span></div><div class="casAuthors">Gleeson, M. Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">817-834</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A set of simple, consistent structure-property guides have been detd. from an anal. of a no. of key ADMET assays run within GSK: soly., permeability, bioavailability, vol. of distribution, plasma protein binding, CNS penetration, brain tissue binding, P-gp efflux, hERG inhibition, and cytochrome P 450 1A2/2C9/2C19/2D6/3A4 inhibition.  The rules have been formulated using mol. properties that chemists intuitively know how to alter in a mol., namely, mol. wt., logP, and ionization state.  The rules supplement the more predictive black-box models available to us by clearly illustrating the key underlying trends, which are in line with reports in the literature.  It is clear from the analyses reported herein that almost all ADMET parameters deteriorate with either increasing mol. wt., logP, or both, with ionization state playing either a beneficial or detrimental affect depending on the parameter in question.  This study reemphasizes the need to focus on a lower mol. wt. and logP area of physicochem. property space to obtain improved ADMET parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7PTdPHoD-c7Vg90H21EOLACvtfcHk0lgd6Mdeajb8OQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtl2msrk%253D&md5=42db5918ad8e9ea3ecf3a13846b3a434</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm701122q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701122q%26sid%3Dliteratum%253Aachs%26aulast%3DGleeson%26aufirst%3DM.%2BP.%26atitle%3DGeneration%2520of%2520a%2520Set%2520of%2520Simple%252C%2520Interpretable%2520ADMET%2520Rules%2520of%2520Thumb%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D817%26epage%3D834%26doi%3D10.1021%2Fjm701122q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Beca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Makary, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polidovitch, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hockman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Movsesian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manganiello, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backx, P. H.</span><span> </span><span class="NLM_article-title">Phosphodiesterase Type 3A Regulates Basal Myocardial Contractility through Interacting with Sarcoplasmic Reticulum Calcium ATPase Type 2a Signaling Complexes in Mouse Heart</span> <span class="citation_source-journal">Circ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">112</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">297</span><span class="refDoi"> DOI: 10.1161/CIRCRESAHA.111.300003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1161%2FCIRCRESAHA.111.300003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2013&pages=289-297&author=S.+Becaauthor=F.+Ahmadauthor=W.+Shenauthor=J.+Liuauthor=S.+Makaryauthor=N.+Polidovitchauthor=J.+Sunauthor=S.+Hockmanauthor=Y.+W.+Chungauthor=M.+Movsesianauthor=E.+Murphyauthor=V.+Manganielloauthor=P.+H.+Backx&title=Phosphodiesterase+Type+3A+Regulates+Basal+Myocardial+Contractility+through+Interacting+with+Sarcoplasmic+Reticulum+Calcium+ATPase+Type+2a+Signaling+Complexes+in+Mouse+Heart&doi=10.1161%2FCIRCRESAHA.111.300003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1161%2FCIRCRESAHA.111.300003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FCIRCRESAHA.111.300003%26sid%3Dliteratum%253Aachs%26aulast%3DBeca%26aufirst%3DS.%26aulast%3DAhmad%26aufirst%3DF.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMakary%26aufirst%3DS.%26aulast%3DPolidovitch%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DHockman%26aufirst%3DS.%26aulast%3DChung%26aufirst%3DY.%2BW.%26aulast%3DMovsesian%26aufirst%3DM.%26aulast%3DMurphy%26aufirst%3DE.%26aulast%3DManganiello%26aufirst%3DV.%26aulast%3DBackx%26aufirst%3DP.%2BH.%26atitle%3DPhosphodiesterase%2520Type%25203A%2520Regulates%2520Basal%2520Myocardial%2520Contractility%2520through%2520Interacting%2520with%2520Sarcoplasmic%2520Reticulum%2520Calcium%2520ATPase%2520Type%25202a%2520Signaling%2520Complexes%2520in%2520Mouse%2520Heart%26jtitle%3DCirc.%2520Res.%26date%3D2013%26volume%3D112%26spage%3D289%26epage%3D297%26doi%3D10.1161%2FCIRCRESAHA.111.300003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Wager, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verhoest, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villalobos, A.</span><span> </span><span class="NLM_article-title">Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">767</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1021/acschemneuro.6b00029</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.6b00029" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=767-775&author=T.+T.+Wagerauthor=X.+Houauthor=P.+R.+Verhoestauthor=A.+Villalobos&title=Central+Nervous+System+Multiparameter+Optimization+Desirability%3A+Application+in+Drug+Discovery&doi=10.1021%2Facschemneuro.6b00029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery</span></div><div class="casAuthors">Wager, Travis T.; Hou, Xinjun; Verhoest, Patrick R.; Villalobos, Anabella</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">767-775</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Significant progress has been made in prospectively designing mols. using the central nervous system multiparameter optimization (CNS MPO) desirability tool, as evidenced by the anal. reported herein of a second wave of drug candidates that originated after the development and implementation of this tool.  This simple-to-use design algorithm has expanded design space for CNS candidates and has further demonstrated the advantages of utilizing a flexible, multiparameter approach in drug discovery rather than individual parameters and hard cutoffs of physicochem. properties.  The CNS MPO tool has helped to increase the percentage of compds. nominated for clin. development that exhibit alignment of ADME attributes, cross the blood-brain barrier, and reside in lower-risk safety space (low ClogP and high TPSA).  The use of this tool has played a role in reducing the no. of compds. submitted to exploratory toxicity studies and increasing the survival of our drug candidates through regulatory toxicol. into First in Human studies.  Overall, the CNS MPO algorithm has helped to improve the prioritization of design ideas and the quality of the compds. nominated for clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp46WD7qMaX6bVg90H21EOLACvtfcHk0liSkMKb_Mxtyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVSktbw%253D&md5=061c3aef6c88758cbaee1a2abb34796a</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.6b00029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.6b00029%26sid%3Dliteratum%253Aachs%26aulast%3DWager%26aufirst%3DT.%2BT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DVerhoest%26aufirst%3DP.%2BR.%26aulast%3DVillalobos%26aufirst%3DA.%26atitle%3DCentral%2520Nervous%2520System%2520Multiparameter%2520Optimization%2520Desirability%253A%2520Application%2520in%2520Drug%2520Discovery%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2016%26volume%3D7%26spage%3D767%26epage%3D775%26doi%3D10.1021%2Facschemneuro.6b00029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Ricobaraza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuadrado-Tejedor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pérez-Mediavilla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frechilla, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Río, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">García-Osta, A.</span><span> </span><span class="NLM_article-title">Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer’s Disease Mouse Model</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">1721</span><span class="NLM_x">–</span> <span class="NLM_lpage">1732</span><span class="refDoi"> DOI: 10.1038/npp.2008.229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;key=10.1038%2Fnpp.2008.229" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1721-1732&author=A.+Ricobarazaauthor=M.+Cuadrado-Tejedorauthor=A.+P%C3%A9rez-Mediavillaauthor=D.+Frechillaauthor=J.+Del+R%C3%ADoauthor=A.+Garc%C3%ADa-Osta&title=Phenylbutyrate+Ameliorates+Cognitive+Deficit+and+Reduces+Tau+Pathology+in+an+Alzheimer%E2%80%99s+Disease+Mouse+Model&doi=10.1038%2Fnpp.2008.229"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.229%26sid%3Dliteratum%253Aachs%26aulast%3DRicobaraza%26aufirst%3DA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3DP%25C3%25A9rez-Mediavilla%26aufirst%3DA.%26aulast%3DFrechilla%26aufirst%3DD.%26aulast%3DDel%2BR%25C3%25ADo%26aufirst%3DJ.%26aulast%3DGarc%25C3%25ADa-Osta%26aufirst%3DA.%26atitle%3DPhenylbutyrate%2520Ameliorates%2520Cognitive%2520Deficit%2520and%2520Reduces%2520Tau%2520Pathology%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Mouse%2520Model%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D1721%26epage%3D1732%26doi%3D10.1038%2Fnpp.2008.229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TBF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1TBF','PDB','1TBF'); return false;">PDB: 1TBF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ','PDB','4LXZ'); return false;">PDB: 4LXZ</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NM_004964" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NM_004964','Genbank','NM_004964'); return false;">Genbank: NM_004964</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NM_001527" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NM_001527','Genbank','NM_001527'); return false;">Genbank: NM_001527</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NM_003883" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NM_003883','Genbank','NM_003883'); return false;">Genbank: NM_003883</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=BC069243" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=BC069243','Genbank','BC069243'); return false;">Genbank: BC069243</a></li><li><a href="http://www.ncbi.nlm.nih.gov/gquery?Term=NM_001083" onclick="trackOutboundLink('http://www.ncbi.nlm.nih.gov/gquery?Term=NM_001083','Genbank','NM_001083'); return false;">Genbank: NM_001083</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i221"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00908">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_33054"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00908">10.1021/acs.jmedchem.6b00908</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Details about purification methods, SFC methods, synthesis of intermediates, purities, HRMS data and HPLC traces for final compounds, superposition of PDE5 inhibitors extracted from crystal complexes as well as biochemical activities as pIC<sub>50</sub> values (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_001.pdf">jm6b00908_si_001.pdf (2.29 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00908/suppl_file/jm6b00908_si_002.csv">jm6b00908_si_002.csv (4.45 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00908&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00908%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-19" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00908" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799b66c381e3291","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
